Pro-fibrotic effects of all-trans retinoic acid in transforming growth factor-β1-induced fibrogenesis in renal fibroblasts by Rankin, Alexandra Catherine
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Pro-fibrotic effects of all-trans retinoic acid in transforming growth factor-1-induced




Download date: 06. Nov. 2017
Pro-fibrotic effects of all-trans retinoic 
acid in transforming growth factor-β1-
induced fibrogenesis in renal 
fibroblasts
A thesis submitted for the degree of Doctor of Philosophy
By Dr. Alexandra Catherine Rankin






Retinoids, including the prototypic vitamin A and its  main bioactive form, all-
trans retinoic acid (tRA), have both anti- and pro-fibrotic effects in renal 
disease models. To understand and prevent the pro-fibrotic effects of retinoids 
it is important to establish in vitro models. This work aimed to explore the 
mechanisms behind the fibrogenic effects of tRA in renal fibroblasts.  
A picro-Sirius red-based in vitro assay was used to determine the effects of 
retinoids on total collagen accumulation with and without transforming growth 
factor (TGF)-β1 in NRK-49F normal rat kidney fibroblasts. Individual fibrotic 
markers and nuclear receptors were investigated using molecular biology 
approaches, activity assays and chemical agonists and inhibitors.
tRA dose-dependently increased total collagen deposition with and without 
TGF-β1 in NRK-49F cells. At the level of gene expression tRA showed dual 
potential, down-regulating mRNAs encoding a range of extracellular matrix 
proteins and matrix metalloproteinases (MMPs), while up-regulating others 
including plasminogen activator inhibitor (PAI)-1 and transglutaminase 2 
(TG2). tRA alone and additively, with TGF-β1, reduced MMP activity and 
increased PAI-1 protein; the PAI-1 inhibitor tiplaxtinin reduced the increase in 
total collagen caused by tRA and TGF-β1 treatment. TG2 protein was not 
modulated by tRA and a TG2 inhibitor did not reduce tRA’s pro-fibrotic effect.
NRK-49F cells expressed retinoid nuclear receptors and PPARβ/δ and 
nuclear receptor mRNAs were differentially regulated by tRA and TGF-β1. 
RAR and RXR antagonists reduced tRA’s  pro-fibrotic effect while a pan-RXR 
agonist more than a pan-RAR or PPARβ/δ agonist increased total collagen 
deposition. RAR isotype-selective agonists had less, if any, effect on fibrosis. 
In summary, an in vitro model for the pro-fibrotic effects of retinoids has been 
established, which is associated with modulation of MMPs, PAI-1 and RAR/
RXR. Further studies of RAR isotype-selective agonists might be of merit as 
they had reduced pro-fibrotic activities compared to less selective retinoids.
2
Acknowledgements
Firstly and foremostly I would like to thank Professor Bruce Hendry and Dr. 
Qihe Xu for giving me the opportunity to do this PhD and for their generosity 
of advice, support and encouragement. In so many different ways I would not 
be writing this without them. Thank you also to the renal research team (Andi, 
Joe, Qin, Fei, Lucy and Ayesha) and in particular Dr. Claire Sharpe for inciting 
scientific discussion which has been of enormous help to me and Mazzie 
Noor for throwing me many golden nuggets of scientific information. In 
addition I am extremely grateful for the support I have received from the 
King’s Renal Research Fund and Kidney Research UK.
This  PhD thesis would not have been possible without the unwavering support 
of my husband “Gorgeous Daniel” as he is known in the renal lab. who, had 
he known how absent a wife I would be at the start of this journey, might not 
have agreed to marry me! Daniel, thank you also for listening to my 
presentations countless times and giving me your constructive criticism on 
this  thesis. In addition my very special son Oscar was born during the writing 
of this thesis. He has brought light and perspective to this work (and my life).  
Finally to my other four favourite distractions, my nieces and nephew, Kristin, 
Iona, Phoebe and William who, along with Oscar, have the ability to make me 
forget all about my work worries!
3
Publications relating to this thesis
“An in vitro model for the pro-fibrotic effects  of retinoids: Mechanisms of 
action.”
Alexandra C. Rankin, Bruce M. Hendry, Jonathan P. Corcoran  and Qihe Xu. 
Br J Pharmacol. 2013; 170(6): 1177-1189.
“Endogenous retinoic acid activity in principal cells and intercalated cells of 
mouse collecting duct system.”
Yuen Fei Wong, Jeffrey B. Kopp, Catherine Roberts, Peter J. Scambler, 
Yoshifusa Abe, Alexandra C. Rankin, Neelanjana Dutt, Bruce M. Hendry and 
Qihe Xu. PLoS One. 2011 Feb 4; 6(2): e16770.
“NRK-49F cells as  a model for studying the pro-fibrotic effects  of all-trans 
retinoic acid: Roles for retinoid nuclear receptors and carrier proteins.”
Alexandra C. Rankin, Bruce M. Hendry and Qihe Xu. J Am Soc Nephol. 2010; 
21: 614A (abstract). 
“Kidneys of Alb/TGF-beta1 transgenic mice are deficient in retinoic acid and 
exogenous retinoic acid shows dose-dependent toxicity.”
Qihe Xu, Bruce M. Hendry, Malcolm Maden, Huiyan Lu, Yuen Fei Wong, 
Alexandra C. Rankin, Mazhar Noor and Jeffrey B. Kopp. Nephron Exp 
Nephrol. 2010; 114(4): e127-32.
“All-trans retinoic acid is pro-fibrotic in a normal rat kidney fibroblast cell line: 
A role for retinoid nuclear receptors and lipid binding proteins?”




Abstract                                    
     
Acknowledgements
Publications arising from this thesis
     
Contents
        
List of figures and tables
Abbreviations used
Chapter 1. Introduction
1.1 Chronic kidney disease (CKD)
1.2 Renal tubulointerstitial fibrosis (TIF)
 1.2.1 Role of myofibroblasts
 1.2.2 Role of transforming growth factor (TGF)-β
 1.2.3 Role of extracellular matrix (ECM) remodelling
1.3 Retinoids
 1.3.1 Vitamin A metabolism
 1.3.2 Canonical retinoic acid (RA) signalling pathway
 1.3.3 Non-canonical retinoid signalling pathways
 1.3.4 Role of retinoids in proliferation, differentiation 
  and inflammation
 1.3.5 Effects of retinoids in non-renal fibrosis
 1.3.6 Effects of retinoids in renal fibrosis 
 1.3.7 In vivo evidence of possible mechanisms for 
  the effects of retinoids in renal fibrosis
 1.3.8 In vitro evidence of possible mechanisms for 
  the effects of retinoids in renal fibrosis




























Chapter 2. Materials and methods
2.1 Materials
 2.1.1 Cell culture
 2.1.2 Retinoid preparations and TGF-β1
 2.1.3 Other chemical agonists, antagonists and inhibitors
 2.1.4 Immunocytochemistry and Western blotting
 2.1.5 Real-time quantitative polymerase chain reaction 
  (qPCR)
2.2 Buffers and solutions
 2.2.1 General solutions 
 2.2.2 Solutions for the 2 dimensional (2D) in vitro model of 
  fibrosis
 2.2.3 Immunocytochemistry
 2.2.4 Protein extraction and Western blotting
2.3  Cell culture
 2.3.1 NRK-49F cell line
 2.3.2 Other primary cell cultures and cell lines
 2.3.3 2D in vitro model of fibrosis
2.4 Lactate dehydrogenase cytotoxicity assay
2.5  Immunocytochemistry
2.6 Reverse transcription qPCR
 2.6.1 RNA extraction
 2.6.2 Reverse transcription
 2.6.3 qPCR
 2.6.4 Optimisation of qPCR
2.7 Rat ECM and adhesion molecules PCR array
2.8 Protein extraction
2.9 Western blot analysis
































 2.10.1 Preparation of samples
 2.10.2 Mass spectrometry
 2.10.3 Peptide sequencing and database searching
2.11 Matrix metalloproteinase activity assay
2.12 Gene silencing techniques: Short-interfering RNA 
 transfection in NRK-49F cells
2.13 Statistical analysis
Chapter 3. Effects of all-trans retinoic acid (tRA) on 
fibrogenesis in NRK-49F cells
3.1 Effect of tRA on total collagen deposition in the 2D in vitro 
 model of fibrosis
3.2 Effects of tRA on selected fibrotic markers using a PCR array
3.3 Further evaluation of collagens and fibronectin
3.4 Further evaluation of MMPs
3.5 Evaluation of other important molecular markers
3.6 Further investigation of the association between tRA-induced 
 collagen accumulation and plasminogen activator inhibitor 
 (PAI)-1
 3.6.1 PAI-1 protein expression
 3.6.2 Effect of the PAI-1 inhibitor tiplaxtinin on tRA-induced 
  collagen accumulation
3.7 Further investigation of the association between tRA-induced 
 collagen accumulation and transglutaminase 2 (TG2)
 3.7.1 TG2 protein expression
 3.7.2 Effect of the TG2 inhibitor NTU283 on tRA-induced 























Chapter 4. Expression of retinoid nuclear receptors, PPARβ/δ 
and RA carrier proteins in NRK-49F cells
4.1 Expression of retinoid nuclear receptors and PPARβ/δ 
 4.1.1 mRNA expression of nuclear receptors
 4.1.2 Protein expression of nuclear receptors
 4.1.3 mRNA expression of nuclear receptors following 
  treatment with tRA with and without TGF-β1
4.2 Expression of RA carrier proteins in NRK-49F cells
 4.2.1 mRNA expression of RA carrier proteins
 4.2.2 Protein expression of RA carrier proteins
4.3 Discussion
Chapter 5. Effects of nuclear receptor agonists and 
antagonists on total collagen accumulation in the 2D in vitro 
model of fibrosis in NRK-49F cells
5.1 Effects of selective nuclear receptor agonists on total 
 collagen accumulation
 5.1.1 Effects of a pan-RAR and pan-RXR agonist
 5.1.2 Effects of RAR-isotype selective agonists
 5.1.3 Effect of a PPARβ/δ agonist
5.2 Effects of nuclear receptor antagonists  on tRA-induced total 
 collagen accumulation
 5.2.1 Effect of a pan-RAR and pan-RXR antagonist





















Chapter 6. Gene silencing using short-interfering RNA (siRNA) 
in NRK-49F cells
6.1 Pilot study to determine optimal settings  for electroporation 
 of siRNA into NRK-49F cells
6.2 Chemical and electrical transfection of NRK-49F cells using 
 siRNA targeting PAI-1 and TG2
6.3 Discussion
Chapter 7. Other cell models for the study of the pro-fibrotic 
effects of tRA
7.1 Effect of tRA on total collagen deposition in a human foreskin 
 fibroblast primary culture
7.2 Other fibroblast and mesangial cell cultures
 7.2.1 COS-7 kidney fibroblast cell line and the 2D in vitro 
  model of fibrosis
 7.2.2 Mesangial cells and the 2D in vitro model of fibrosis
7.3 Discussion
Chapter 8. Conclusions, perspectives and future work
8.1 Summary of findings
8.2 Relevance of this work
 8.2.1 NRK-49F cells as  a suitable in vitro model for studying 
  the effects of retinoids in renal interstitial fibrosis
 8.2.2 The 2D in vitro model of fibrosis as a suitable 
  fibrotic model for studying the effects of tRA 
 8.2.3 Effect of tRA on fibrosis in NRK-49F cells
 8.2.4 Contribution of the nuclear receptor signalling 
  pathways to the pro-fibrotic effects of tRA




















8.3 Limitations of this work
 8.3.1 Choice of cell model and the 2D in vitro model of 
  fibrosis
 8.3.2 Use of chemical agonists and inhibitors and gene 
  silencing technology
 8.3.3 Roles of the matrix degradation pathways in the 
  pro-fibrotic effects of tRA
 8.3.4 Roles for ret inoid receptor-dependent and 
  -independent pathways  in the pro-fibrotic effects  of 
  tRA
8.4 Future work
 8.4.1 in vitro work
 8.4.2 Translation of this work into an in vivo model
8.4 Concluding remarks
Chapter 9. Bibliography
Chapter 10. Appendix 
Appendix A. Supplementary figures















List of figures and tables
Figures
1.1 Signal-transduction pathways of TGF-β1
1.2 Changes in expression and activity of MMPs and TIMPs in 
 acute and chronic renal diseases
1.3 Molecular structure of retinoids
1.4 Metabolism of all-trans retinol to tRA in cells
1.5 Schematic diagram of the functional domains of RARs
2.1 Molecular structures of nuclear receptor agonists  and 
 antagonists
2.2 Molecular structures of tiplaxtinin and NTU283
2.3 NRK-49F cells in culture
2.4 Characterisation of NRK-49F cells by immunocytochemistry
2.5 αSMA protein expression in NRK-49F cells by  Western blot 
 analysis
2.6 Human foreskin fibroblasts in culture
2.7 Characterisation of human foreskin fibroblasts by 
 immunocytochemistry
2.8 Molecular structure of Sirius Red
2.9 Protocol for RNA extraction of NRK-49F cells at different time 
 points
2.10 Effect of tRA in the absence and presence of TGF-β1 on 
 Gapdh mRNA expression in NRK-49F cells
2.11 Effect of tRA in the absence and presence of TGF-β1 on 
 β-actin mRNA expression in NRK-49F cells 
2.12 Effect of tRA in the absence and presence of TGF-β1 on 




















2.13 Dissociation curves for Mmp-2 and Mmp-13 PCR products
2.14 Dissociation curves for Mmp-2 PCR product following serial 
 dilutions of primer
2.15 Dissociation curves for Mmp-13 PCR product following serial 
 dilutions of primer
2.16 Amplification curves  for Mmp-2, Mmp-13, Gapdh and 
 Rpl13a using serial dilutions of NRK-49F cDNA
2.17 Standard curves for Mmp-2, Mmp-13, Gapdh and Rpl13a
2.18 Validation of the 2-ΔΔCt method
2.19 Rat ECM and adhesion molecules PCR array layout
3.1 Effect of tRA in the absence and presence of TGF-β1 on total 
 collagen deposition in NRK-49F cells
3.2 RT-qPCR array analysis of a pilot study of the effects of tRA 
 in the absence and presence of TGF-β1 on mRNA 
 expression of selected fibrotic markers in NRK-49F cells
3.3 Effect of tRA in the absence and presence of TGF-β1 on 
 Col1a1, Col1a2, Col3a1 and Fn1 mRNA expression 
3.4 Effect of tRA in the absence and presence of TGF-β1 on 
 collagen types I and III protein expression using 
 immunocytochemistry
3.5 Effect of tRA in the absence and presence of TGF-β1 on FN 
 protein expression using Western blot analysis
3.6 Effect of tRA in the absence and presence of TGF-β1 on 
 Mmp-2, Mmp-3 and Mmp-13 mRNA expression
3.7 Effect of tRA in the absence and presence of TGF-β1 on 
 MMP activity
3.8 Effect of tRA in the absence and presence of TGF-β1 on 

















3.9    Western blot analysis of PAI-1 protein in 
NRK-49F total cell  lysate and conditioned media 
3.10 Effect of the PAI-1 inhibitor tiplaxtinin on tRA-induced total 
 collagen accumulation
3.11 Western blot analysis of TG2 protein in NRK-49F total cell 
 lysate and conditioned media using anti-TG2 CUB7402 
 mouse monoclonal antibody
3.12 Colloidal Coomassie blue-stained electrophoresis gel of 
 NRK-49F total cell lysate
3.13 Western blot analysis of TG2 protein in NRK-49F total cell 
 lysate and conditioned media using anti-TG2 IA12 mouse 
 monoclonal antibody
3.14 Effect of TG2 inhibitor NTU283 on tRA-induced total 
 collagen accumulation
4.1 Relative mRNA expression of retinoid nuclear receptors and 
 PPARβ/δ in NRK-49F cells
4.2 Western blot analysis of RARs
4.3 Western blot analysis of PPARβ/δ
4.4 Western blot analysis of retinoid X receptors
4.5 Change in mRNA expression of retinoid nuclear receptors 
 and PPARβ/δ following tRA and TGF-β1 treatment
4.6 Relative mRNA expression of RA carrier proteins CRABP-II 
 and FABP5 in NRK-49F cells
4.7 Western blot analysis of CRABP-II protein
4.8 Immunocytochemistry of CRABP-II and FABP5 proteins
4.9 Colloidal Coomassie blue-stained electrophoresis gel of 
 NRK-49F and NIH/3T3 total cell lysates
5.1 Effects of synthetic RAR, RXR and PPARβ/δ agonists on 
 total collagen deposition in the absence and presence of 


















5.2 Effect of RAR, RXR and PPARβ/δ antagonists on 
 tRA-induced total collagen accumulation in the presence of 
 TGF-β1 in NRK-49F cells
6.1 Photomicroscopy of NRK-49F cells 48 h after electroporation
6.2 A single parameter histogram showing relative fluorescence 
 of NRK-49F cells electroporated with Cy-5-labelled siRNA
6.3 Flow cytometry of NRK-49F cells electroporated with 
 Cy5-labelled siRNA under varying conditions
6.4 siRNA knockdown of PAI-1 in NRK-49F cells
6.5 siRNA knockdown of TG2 in NRK-49F cells
6.6 Effect of TG2 knockdown on tRA-induced total collagen 
 accumulation in the absence and presence of TGF-β1
7.1 Effect of tRA treatment with and without TGF-β1 on total 
 collagen deposition in human foreskin fibroblasts
7.2 Effect of TGF-β1 treatment on total collagen deposition in 
 COS-7 cells
7.3 Effect of TGF-β1 treatment on total collagen deposition in 
 mesangial cell cultures
8.1 Potential mechanisms for the RAR/RXR-dependent pro- 
 fibrotic effects of retinoids
8.2 Diagram of the proposed pathways of the pro-fibrotic effects 
 of tRA in NRK-49F cells
Supplementary figures
1 RXRγ (Y-20): sc-555 antibody datasheet from Santa Cruz 

















1.1 ECM proteins that accumulate in TIF
1.2 Effects of retinoids on fibrosis in in vivo models of renal 
 disease
1.3 Possible effects  of retinoids on molecular markers of fibrosis 
 in cellular models
2.1 Biological activity of nuclear receptor agonists used in 
 experiments
2.2 Biological activity of nuclear receptor antagonists  used in 
 experiments
2.3 Biological activity of chemical inhibitors used in experiments
2.4 List of antibodies used in experiments
2.5 Gene expression assays used in experiments
2.6 Reactions prepared for TaqMan and SYBR Green qPCR 384 
 plate formats
2.7 Sequences for Ambion’s Silencer® Select siRNAs used for 
 knockdown in NRK-49F cells
3.1 Summary of relevant molecular markers up-regulated and 
 down-regulated by tRA in the absence and presence of 
 TGF-β1 in NRK-49F cells
Supplementary tables        
1 PCR array dataset showing fold change of tRA-treated group 
 compared to vehicle
2 PCR array dataset showing fold change of TGFβ1-treated 
 group compared to vehicle
3 PCR array dataset showing fold change of the dual-treated 
 group compared to the TGFβ1-treated group
4 LC/MS/MS analysis of 1D polyacrylamide gel bands of 


















ACE-I   Angiotensin converting enzyme inhibitors
ACN   Acetonitrile
ADH   Alcohol dehydrogenase
AF   Activation function
ANOVA  Analysis of variance
ANG II  Angiotensin II
AP-1   Activating protein-1
APL   Acute promyelocytic leukaemia
ARB   Angiotensin receptor blocker
αSMA   Alpha smooth muscle actin
BSA   Bovine serum albumin
Ca2+   Calcium
CBP   CREB-binding protein
CDK   Cyclin-dependent kinase
CKD   Chronic kidney disease
COL   Collagen
COUP-TFII  Chicken ovalbumin upstream promoter- 
   transcription 2
CRABP  Cellular retinoic acid binding protein
CRBP   Cellular retinol binding protein
CREB   Cyclic AMP-regulated enhancer-binding 
   protein 
CTGF   Connective tissue growth factor
CVD   Cardiovascular disease
CYP26   Cytochrome P450 family 26
DBD   DNA-binding domain
ddH2O  Double distilled water
DMEM  Dulbecco’s Modified Eagle Medium
DNA   Deoxyribonucleic acid
DR   Direct repeat
DTT   Dithiothreitol
16
ECM   Extracellular matrix
EC50   Half maximal effective concentration
EDTA   Ethylenediaminetetraacetic acid
EMT   Epithelial-to-mesenchymal transition
ERK   Extracellular signal-regulated kinases
ESRD  End-stage renal disease
FABP5  Fatty acid binding protein 5
FCS   Foetal calf serum
FN   Fibronectin
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
GFR   Glomerular filtration rate
GOI   Gene of interest
GTP   Guanosine triphosphate
HGF   Hepatocyte growth factor
HKG   Housekeeping gene
HMC   Human mesangial cell
HPLC   high performance liquid chromatography
HRP   Horseradish peroxidase
HSC   Hepatic stellate cell
HSP   Heat shock protein
IC50   Half maximal inhibitory concentration
IM   Intramuscular
IP   Intraperitoneal
IV   Intravenous
JNK   c-Jun N-terminal kinase
Kd   Binding efficiency
Ki   Inhibitor constant
LBD   Ligand-binding domain
LC/MS/MS  L iqu id ch romatog raphy - tandem mass 
   spectrometry
LDH   Lactate dehydrogenase
LRAT   Lecithin:retinol acyltransferase
17
LRP-1   Low-density lipoprotein receptor-related protein 
   1
MAP kinase  Mitogen-activated protein kinase
MEF   Mouse embryonal fibroblast
MMP   Matrix metalloproteinase
N-CoR  Nuclear receptor co-repressor
NFκB   Nuclear factor kappa-light-chain-enhancer of 
   activated B
NRK   Normal rat kidney
NTD   N-terminal domain
PA   Plasminogen activator
PAI-1   Plasminogen activator inhibitor-1
PAR6   Partitioning defective 6
PBS   Phosphate buffered saline
PCR   Polymerase chain reaction
PDGF   Platelet-derived growth factor
PI3K   Phosphoinositide 3-kinase
PKC   Protein kinase C
PML   Promyelocytic leukaemia
PMSF   Phenylmethanesulphonylfluoride
PO   Per os
PPAR   Peroxisome proliferator-activated receptor
PPRE   Peroxisome proliferator response element
PSR   Picro-Sirius red
Q-ToF   Quadrupole time-of-flight
RA   Retinoic acid
RAAS   Renin-angiotensin-aldosterone system
RALDH  Retinaldehyde dehydrogenase
RAR    Retinoic acid receptor
RARE   Retinoic acid response element
RBP   Retinol binding protein
REH    Retinyl ester hydrolase
RhoA   Ras homolog gene family, member A 
18
RMC   Rat mesangial cell
RNA   Ribonucleic acid
ROCK1   Rho-associated protein kinase 1
ROR-β  Retinoic acid receptor-related orphan receptor 
   β
RPL13a  60S ribosomal protein L 13a
RRT   Renal replacement therapy
R-Smads  Receptor-activated Smads
RT-qPCR  Reverse transcription quantitative PCR
RXR    Retinoid X receptor
SARA   SMAD anchor for receptor activation
SC   Subcutaneous
SDR   Short-chain dehydrogenases/reductase
SDS   Sodium dodecyl sulphate
SDS-PAGE  SDS-polyacrylamide gel electrophoresis
siRNA   Short-interfering ribonucleic acid
SMRT   Silencing mediator of RA and TR
Smurf   Smad-ubiquitination-regulatory factor
SNx   Subtotal nephrectomy
SPARC  Secreted protein, acidic and rich in cysteine
STRA6  Stimulated by retinoic acid gene 6
TAK1   TGF-β activated kinase 1
TBS   Tris-buffered saline
TG2   Transglutaminase 2
TGIF   TGF β-induced factor homeobox 1
TGF-β  Transforming growth factor-β
TβRI   TGF-β receptor type I
TβRII   TGF-β receptor type II
TIMP   Tissue inhibitor of matrix metalloproteinase
TIF   Renal tubulointerstitial fibrosis
TNF   Tumour necrosis factor
tPA   Tissue-type plasminogen activator
tRA   All-trans retinoic acid
19
TSP-1  Thrombospondin-1
TTNPB  (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl- 
   2-naphthalenyl)-1-propenyl] 
   benzoic acid
TTR   Transthyretin
uPA   Urokinase-type plasminogen activator
UTI   Urinary tract infection 
UUO   Unilateral ureteric obstruction
VAD   Vitamin A deficiency
VCAM  Vascular cell adhesion molecule
VSMC  Vascular smooth muscle cell 
WSB   Western sample buffer
9cRA   9-cis retinoic acid
13cRA  13-cis retinoic acid
20
Chapter 1. Introduction
1.1 Chronic kidney disease (CKD)
Chronic kidney disease (CKD) is a major public health concern worldwide. In 
the UK, the prevalence of CKD stages 3-5 is as high as 8.5% (Stevens, 
O'Donoghue et al. 2007). It is  caused by a variety of conditions including 
hypertension, diabetes mellitus and glomerulonephritis and is  chronic and 
progressive, characterised by excessive and abnormal extracellular matrix 
(ECM) deposition leading to renal fibrosis and end-stage renal disease 
(ESRD). Patients  with CKD are at significantly increased risk of 
cardiovascular disease (CVD) and death and this risk increases as their 
glomerular filtration rate (GFR) falls (Go, Chertow et al. 2004). Once ESRD 
has developed patients need to be established on renal replacement therapy 
(RRT) and this patient group have a poor prognosis with incident over 65 year 
olds having only a 74.9% and 25.1% 1- and 5- year survival, respectively 
(Ansell, Roderick et al. 2009). 
In the general nephrology clinic management of CKD initially involves 
diagnosis  and treatment of the underlying cause of kidney injury. More 
general measures are also undertaken to maintain stable kidney function and 
prevent CVD. These include lifestyle advice (achieving a healthy weight, 
taking regular exercise and smoking abstention) and pharmacological 
interventions, such as anti-hypertensive drugs to maintain adequate blood 
pressure control, treatment of hyperlipidaemia and medication to reduce 
proteinuria (National Collaborating Centre for Chronic Conditions 2008).
Novel strategies for the treatment of CKD include more comprehensive 
blockade of the renin-angiotensin-aldosterone system (RAAS) with direct 
renin inhibitors  (Mende 2010), endothelin receptor antagonists (Turgut and 
Bolton 2010), drugs that target the transforming growth factor (TGF)-β system 
(Akhurst and Hata 2012) and connective tissue growth factor (CTGF) 
inhibitors (Reeves, Rawal et al. 2012). However, thus far, a therapy that 
directly targets renal fibrosis safely and effectively remains elusive.
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Retinoids (vitamin A derivatives) have been proposed as  potential therapies 
for the treatment of renal fibrosis  (Xu, Lucio-Cazana et al. 2004). Retinoids 
and their signalling system have been shown to interfere with pathways 
involved in fibrogenesis including ECM production (Perez, Shull et al. 1992; 
Wang, Tankersley et al. 2002), TGF-β1 signalling (Morath, Dechow et al. 
2001; Schaier, Jocks et al. 2003; Kishimoto, Kinoshita et al. 2011) and 
modulation of matrix turnover (Liu, Lu et al. 2008; Liu, Lu et al. 2011). 
However, despite evidence supporting a role for retinoids in the treatment of 
renal fibrosis, there remains a lack of consensus that they are, indeed, 
beneficial. This laboratory-based work uses a novel in vitro model to provide 
new insights into the effects of retinoids on progression of fibrosis in renal 
fibroblasts. The background of the current understanding of renal fibrosis, with 
particular focus on areas where retinoids may play a role, is reviewed here. 
1.2 Renal tubulointerstitial fibrosis
Renal tubulointerstitial fibrosis (TIF) is characterised by excessive 
accumulation of ECM in the interstitium of the kidney. Integral to this process 
is  the loss of tubules  and peritubular capillaries and infiltration of mononuclear 
cells. TIF is an important predictor of progression to ESRD (Risdon, Sloper et 
al. 1968; Schainuck, Striker et al. 1970; Mackensen-Haen, Bader et al. 1981; 
Nath 1992) and is  mediated by many different growth factors and cytokines, 
which exert pro-fibrotic effects on effector cells, particularly fibroblasts (Liu 
2011). In this section the key roles of renal myofibroblasts, TGF-β and ECM 
remodelling in TIF will be reviewed.
1.2.1 Role of myofibroblasts
Myofibroblasts have long been identified as key cellular mediators of TIF. 
They are elongated, spindle-shaped cells with large, elliptical and speckled 
nuclei, dense rough endoplasmic reticulum, extensive Golgi apparatus and an 
absence of lysosomes (Hutchison, Fligny et al. 2012). Biochemically, they are 
characterised by expression of the intermediate filaments desmin, vimentin 
and the contractile protein alpha smooth muscle actin (αSMA), which is  widely 
regarded as a myofibroblast marker, and morphologically, by the formation of 
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stress fibres (Hutchison, Fligny et al. 2012). They synthesise and secrete a 
complex array of pathological structural and non-structural ECM molecules, 
and of particular importance in fibrosis are collagen types I and III (Rodemann 
and Muller 1991; Hutchison, Fligny et al. 2012). In addition, they remodel the 
ECM through the production of proteinases, use autocrine and paracrine 
signalling systems to communicate with other cells (Jeon 2009) and contract 
matrix increasing its density (Kelynack, Hewitson et al. 2000). 
Myofibroblasts are rarely identified in normal kidneys however following injury 
they are found in increasing numbers. The origin of renal myofibroblasts is a 
hotly debated subject however there is now strong evidence from genetic fate-
mapping studies that they develop from mesenchymal precursors resident in 
the kidney as interstitial fibroblasts, perivascular fibroblasts and pericytes (Lin, 
Kisseleva et al. 2008; Humphreys, Lin et al. 2010; Asada, Takase et al. 2011). 
There are few distinguishing characteristics between these cells  but include 
differences in their tissue location and anatomical connections with 
endothelial cells; however following kidney injury they become 
indistinguishable as myofibroblasts (Lin, Kisseleva et al. 2008; Picard, Baum 
et al. 2008; Humphreys, Lin et al. 2010; Hutchison, Fligny et al. 2012). 
Although, epithelial-to-mesenchymal transition (EMT) is reportedly a potential 
source of renal myofibroblasts  and in vitro studies demonstrate that renal 
tubular cells can undergo EMT (Okada, Danoff et al. 1997), evidence for the 
biological significance of this effect in vivo is  lacking (Iwano, Plieth et al. 2002; 
Humphreys, Lin et al. 2010; Koesters, Kaissling et al. 2010). Likewise, 
evidence for endothelial-to-mesenchymal transition remains unsubstantiated 
(Zeisberg, Potenta et al. 2008). In view of the emerging importance of resident 
mesenchymal precursors as  a key source of myofibroblasts a focus on these 
fibroblastic cells  when examining the direct effects of therapies on TIF would 
seem a reasonable approach.
Trans-differentiation of resident mesenchymal precursors into renal 
myofibroblasts occurs via various different mechanisms following renal injury. 
Tubular cells, leukocytes and fibroblasts themselves all produce cytokines and 
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growth factors that contribute to (myo)fibroblast differentiation, proliferation 
and collagen synthesis (Hewitson 2009). Implicated pro-fibrotic molecules 
include angiotensin (ANG) II and platelet-derived growth factor (PDGF) as 
well as  disease-specific states such as hyperglycaemia in diabetes mellitus 
and mechanical stress (Darby and Hewitson 2007; Hewitson 2009). In 
addition, TGF-β has been identified as a group of premier cytokines involved 
in TIF.
1.2.2 Role of transforming growth factor (TGF)-β 
TGF-β belongs to the TGF-β superfamily of cytokines, of which there are over 
30 members in humans (Massague 2012). It plays important roles in 
embryogenesis and adult tissue homeostasis by regulating cell proliferation, 
differentiation and migration. TGF-β is made up of three isoforms, TGF-βs 
1-3; TGF-β1 was initially identified by its ability to induce anchorage-
independent growth of fibroblasts (Moses, Branum et al. 1981; Roberts, 
Anzano et al. 1981) and subsequently TGF-β2 was identified, cloned and 
sequenced (Hanks, Armour et al. 1988; Madisen, Webb et al. 1988) followed 
by TGF-β3 (Derynck, Lindquist et al. 1988; Jakowlew, Dillard et al. 1988; ten 
Dijke, Hansen et al. 1988).
TGF-β1 is the most broadly studied of the TGF-β isoforms and its role as a 
key mediator of renal fibrosis is well established as it increases ECM 
production and interferes with matrix turnover (Lan and Chung 2012). 
Evidence to support its importance in renal fibrogenesis  includes its  increased 
expression in virtually every animal model of CKD (Okuda, Languino et al. 
1990; Coimbra, Wiggins et al. 1991; Yamamoto, Noble et al. 1994; Cheng, 
Orikasa et al. 1995; Hamaguchi, Kim et al. 1995; Moll, Menoud et al. 1995) as 
well as in human CKD (Yoshioka, Takemura et al. 1993; Yamamoto, Noble et 
al. 1996; Sharma, Ziyadeh et al. 1997), its ability to activate fibroblasts and 
mesangial cells  and cause trans-differentiation of epithelial and endothelial 
cells into myofibroblasts in vitro (Border, Okuda et al. 1990; Fan, Ng et al. 
1999; Han, Isono et al. 1999; Oldfield, Bach et al. 2001) and exogenous TGF-
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β1 causes renal fibrosis while transgenic mice over-expressing TGF-β1 
develop renal fibrosis (Sanderson, Factor et al. 1995; Mozes, Bottinger et al. 
1999; Liu 2006). In addition TGF-β1 increases the expression of a variety of 
ECM molecules  including collagens I, III and IV, fibronectin (FN) and also 
plasminogen activator inhibitor (PAI)-1, all of which are increased in TIF 
(MacKay, Striker et al. 1989; Tomooka, Border et al. 1992; McKay, Khong et 
al. 1993; Suzuki, Ebihara et al. 1993; Hansch, Wagner et al. 1995; Bertelli, 
Valenti et al. 1998; Poncelet and Schnaper 1998; Douthwaite, Johnson et al. 
1999; Zhang, Ou et al. 2000). TGF-β1 also modulates the expression and 
activity of matrix metalloproteinases (MMPs) and their inhibitors resulting in 
reduced matrix degradation and a pro-fibrotic phenotype (Schnaper, 
Hayashida et al. 2003).
TGF-β1 is  secreted as a homodimer consisting of two 12-kDa polypeptides 
linked by disulphide bonds and associated non-covalently with a latency-
associated protein; this inactive complex may be covalently bound to a latent 
TGF-β-binding protein by disulphide bonds (Schnaper, Hayashida et al. 
2003). Latent TGF-β1 deposits in the ECM and binds to matrix proteins such 
as FN (Dallas, Sivakumar et al. 2005). In vitro, release of active TGF-β1 
occurs through a number of environmental triggers including heat, shear 
force, pH extremes and proteolysis (Munger, Harpel et al. 1997). In vivo, TGF-
β1 activation is a complex and tightly regulated process: A non-proteolytic 
activation by integrins and thrombospondin-1 (TSP-1) has been identified 
(Jenkins 2008; Hayashi and Sakai 2012) and proteolytic activation also 
occurs, with proteases exerting their actions both indirectly, via integrins and 
other activating molecules, and directly, functioning in a coordinated manner 
with other activating molecules (Jenkins 2008). 
TGF-β signalling is highly complex, context dependent and involves canonical 
and non-canonical pathways. An illustration of current knowledge of TGF-β 
signalling pathways is shown in Figure 1.1. 
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Figure 1.1. Signal-transduction pathways of TGF-β1 (adapted from Massague 2000, 
Doyle, Gerber et al. 2012 and Choi, Ding et al. 2012). Active TGF-β1 binds to TβRII causing 
phosphorylation and activation of TβRI. TβRI phosphorylates R-Smad, which binds to Smad4. 
The Smad complex is then imported into the nucleus where it binds to specific  locations within 
TGF-β1-responsive genes, co-factors are recruited and transcription of specific  genes can be 
initiated. TGF-β1 can also exert its effects via non-Smad signalling pathways. MAP kinases: 
mitogen-activated protein kinases; PAR6: partitioning defective 6; PI3K: phosphoinositide-3-
kinase; TAK1: TGF-β-activated kinase 1; TGF-β activated kinase; TβRI: TGF-β receptor type 
I; TβRII: TGF-β receptor type II.
In canonical TGF-β signalling active TGF-β binds  to a complex of two TGF-β 
receptor type I and two type II transmembrane receptors that possess 
cytoplasmic serine/threonine kinase domains (Massague 2000). On ligand 
binding, the type II receptors trans-phosphorylate the Gly-Ser (GS) domain of 
the type I receptors, which, in turn, phosphorylate carboxy-terminal serine 
























and Sapkota 2012). R-Smads can also be phosphorylated by mediators other 
than TGF-β1, for example ANGII via MAP kinases, leading to TGF-β1-
independent R-Smad signalling (Derynck and Zhang 2003). Once 
phosphorylated, R-Smads form a complex with Smad4 and enter the nucleus 
where regulation of transcription of target genes occurs (Shi and Massague 
2003; Feng and Derynck 2005; Schmierer and Hill 2007).
In renal fibrosis phosphorylated Smad3 is considered to be pathogenic while 
Smad2 may be protective (Lan and Chung 2012). Evidence for the pathogenic 
effects of Smad3 include: 1) TGF-β1/Smad3 signalling targets fibrogenic 
genes such as COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, COL6A3 and 
tissue inhibitor of matrix metalloproteinase (TIMP)-1 (Verrecchia, Chu et al. 
2001); 2) Smad3 knockout mice show reduced fibrosis  in murine models of 
renal disease (Fujimoto, Maezawa et al. 2003; Sato, Muragaki et al. 2003); 
and 3) A specific inhibitor of Smad3 reduces renal fibrosis in a mouse model 
of streptozotocin-induced diabetes (Li, Qu et al. 2010). The role of Smad2 in 
renal fibrosis requires  clarification although there is  some evidence to support 
a renoprotective role as conditional Smad2 knockout mice show increased 
renal fibrosis following unilateral ureteric obstruction (UUO) (Meng, Huang et 
al. 2010). 
The transcriptional response of cells to TGF-β varies depending on three 
contextual determinants: 1) The extra- and intra-cellular composition of the 
TGF-β signal transduction system including concentration and activity of 
ligands, receptors and regulators; 2) Transcriptional factors, histone readers 
and modifiers and chromatin remodellers  that bind to activated Smad proteins 
to regulate transcription and determine which genes are targeted; and 3) 
Epigenetic status of the cell (Massague 2012). 
Control of TGF-β/Smad signalling is  tightly regulated, occurs at multiple levels 
and has been found to be disrupted in renal diseases. For example, one of 
the inhibitory Smads, Smad7, helps maintain TGF-β homeostasis by 
increasing the degradation of the TGF-β receptor type I and R-Smads 
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(Kavsak, Rasmussen et al. 2000; Ebisawa, Fukuchi et al. 2001; Lan and 
Chung 2012) and Smad7 expression is induced by TGF-β1 resulting in a 
negative feedback mechanism (Afrakhte, Moren et al. 1998). However, in the 
pathological state of renal fibrosis, there is reduced renal Smad7 protein and 
increased degradation, which is  associated with increased renal fibrosis (Lan 
2008; Lan and Chung 2012).
It is now well established that TGF-β1 also signals via non-canonical 
pathways, which helps to explain the diverse actions of TGF-β1 that cannot 
be attributed to Smad-dependent signalling (Derynck and Zhang 2003; Zhang 
2009; Massague 2012). For example, ligand activation of the TGF-β type II 
receptor can lead to direct phosphorylation of partitioning defective 6 (PAR6) 
in cells undergoing EMT (Massague 2012); TGF-β can also modulate TGF-β-
activated kinase 1 (TAK1) activity, mitogen-activated protein (MAP) kinases, 
Rho-like guanosine triphosphatases and the phosphoinositide-3-kinase (PI3K) 
pathway independently of Smad activation (Funaba, Zimmerman et al. 2002; 
Derynck and Zhang 2003; Zhang 2009; Choi, Ding et al. 2012; Massague 
2012).
In vitro evidence for the importance of non-canonical TGF-β1 signalling in 
renal fibrosis includes the association of TGF-β1-induced p38 MAP kinase 
activation and increased Col1a1 in mesangial cells  (Chin, Mohsenin et al. 
2001) and FN expression in proximal tubular epithelial cells  (Niculescu-Duvaz, 
Phanish et al. 2007) and the association of TGF-β1-induced extracellular 
signal-regulated kinases (ERK) activation with FN accumulation and collagen 
mRNA production in mesangial cells  (Hayashida, Poncelet et al. 1999; Inoki, 
Haneda et al. 2000). More recently, TAK1 has been identified as  a major 
upstream molecule in TGF-β1-induced type I collagen and FN expression 
through activation of the MAP kinases in mesangial cells (Choi, Ding et al. 
2012). Furthermore, In vivo studies have corroborated the importance of non-
canonical TGF-β signalling in renal fibrosis (Choi, Ding et al. 2012). For 
example, conditional tak1 gene deletion in a mouse UUO model resulted in 
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suppression of interstitial myofibroblast accumulation, collagen deposition and 
expression of pro-fibrotic markers (Ma, Tesch et al. 2011).
1.2.3 Role of extracellular matrix (ECM) remodelling
In the normal kidney a balance between matrix production and degradation 
exists  resulting in homeostasis of ECM turnover. The accumulation of ECM 
proteins, primarily collagens, leads to TIF resulting in loss of kidney function 
as normal tissue is  replaced by scar tissue. Major pathological features of TIF 
include an increase in the amount of ECM protein usually present in the 
interstitium such as collagen types I, III, V and VII and FN, as well as those 
usually absent in normal interstitium such as collagen type IV and laminin 
(usually found in the tubular basement membrane) (Table 1.1) (Eddy 1996; 
Norman and Fine 1999). 
It is  generally accepted that over-production of ECM proteins leads to their 
accumulation in renal fibrosis however a reduction in matrix degradation can 
exacerbate the situation. Remodelling of the ECM occurs via two major 
degradation pathways, the serine protease plasminogen-plasmin system and 
the matrix metalloproteinases (MMPs). Together these two systems can 
degrade all components of the ECM.
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Table 1.1. ECM proteins that accumulate in TIF (Eddy 1996; Norman and Fine 1999).
Interstitial matrix proteins Collagens I, III, V, VI, VII, XV
Fibronectin
Tenascin
Basement membrane proteins Collagen IV
Laminin
Extracellular proteoglycans Large chondroitin sulfate proteoglycans 
(aggrecan, versican)
Small proteoglycans (decorin, fibromodulin, 
biglycan, fibromodulin)
Basement membrane proteoglycans (heparin 
sulfate proteoglycan, perlecan)
Polysaccharides and glycoproteins Hyaluronan
Thrombospondin
Secreted protein, acidic and rich in cysteine 
(SPARC)
Osteopontin
In the serine protease plasminogen-plasmin system activation of plasminogen 
to plasmin by tissue-type plasminogen activator (tPA) or urokinase-type 
plasminogen activator (uPA) leads to proteolysis of matrix proteins including 
FN, laminin, entactin, tenascin, thrombospondin and perlecan, and also the 
activation of several MMPs (Eddy 2009). Plasminogen activator inhibitors, of 
which PAI-1 is the primary physiological inhibitor, regulate this system. PAI-1 
has been implicated in the pathogenesis of CKD. It is  a 50-kDa glycoprotein 
that is  produced by adipocytes, and by the liver as an acute phase protein. It 
cannot be detected in normal kidney but is present in almost all human CKD 
specimens examined (Eddy and Fogo 2006; Eddy 2009) and its expression 
can be induced in fibroblasts, glomerular cells, tubular epithelial cells and 
macrophages in response to injury (Eddy 2009). Evidence of a causal role for 
PAI-1 in renal fibrosis includes: 1) Its non-inhibitory mutant inhibits  collagen 
deposition in anti-Thy1 nephritis (Huang, Haraguchi et al. 2003) and renal 
fibrosis in experimental diabetic nephropathy (Huang, Border et al. 2008), and 
its deficiency reduces TIF in UUO (Oda, Jung et al. 2001) and TGF-β1 
transgenic mice (Krag, Danielsen et al. 2005); and 2) PAI-1 transgenic mice 
30
develop more fibrosis compared to wild-type in response to UUO injury 
(Matsuo, Lopez-Guisa et al. 2005). 
The mechanisms through which PAI-1 exerts its fibrogenic effects are still not 
known. While it has been tempting to attribute its pathogenic activity to 
inhibition of plasminogen activation, studies suggest that this is  unlikely to be 
its sole mechanism of action. In fact plasmin(ogen) and its activators have not 
been proven to attenuate renal fibrosis and even have pro-fibrotic effects. For 
example, in mouse models of UUO plasmin(ogen) deficiency reduced fibrosis 
(Edgtton, Gow et al. 2004; Zhang, Kernan et al. 2007); there was no change 
in renal fibrosis in uPA-deficient compared to wild-type mice (Yamaguchi, 
Lopez-Guisa et al. 2007); and tPA-deficient mice developed less severe 
fibrosis (Yang, Shultz et al. 2002). Potential mechanisms for the pro-fibrotic 
effects of PAI-1 include cell chemoattraction as  higher levels of PAI-1 
expression are associated with an increase in renal myofibroblasts  and 
macrophages (Matsuo, Lopez-Guisa et al. 2005). In addition, PAI-1 can also 
influence integrin-dependent cell adhesion and migration via an interaction 
with the urokinase receptor and its bound ligand uPA (Zhang and Eddy 2008).  
The MMPs make up the other major ECM degradation pathway. They are a 
family of zinc-dependent endopeptidases classified into six groups based on 
substrate and sequence homology consisting of the collagenases, 
gelatinases, stromelysins, matrilysins, membrane-type MMPs and “other 
MMPs” (Catania, Chen et al. 2007). They have multiple domains including a 
pro-domain, catalytic domain, hinge region and hemopexin-like domain 
(Catania, Chen et al. 2007). They are mostly secreted as zymogens  (inactive 
enzyme precursors) and require activation by cleavage of the pro-domain by 
plasmin or other MMPs (Visse and Nagase 2003). Tissue inhibitors of matrix 
metalloproteinases (TIMPs), of which there are four members TIMPs-1-4, all 
have similar structures, which fit into the active site of the MMP catalytic 
domain to regulate MMP activity (Catania, Chen et al. 2007). Other MMP 
inhibitors also exist, for example tissue factor pathway inhibitor-2 (Herman, 
Sukhova et al. 2001).
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Renal expression of the MMPs and TIMPs is complex, likely to be species 
dependent and their localisation in the kidney has not been fully 
characterised. MMPs -2, -3, -9, -13, -14, -24, -25, -27 and -28 and TIMPs -1, 
-2 and -3 have all been identified in renal tissue and in addition MMP-7 has 
been found in pathophysiological states (Catania, Chen et al. 2007). MMPs -2 
and -9 (the gelatinases) cleave denatured collagens, laminin and some 
chemokines; MMP-3 (stromelysin) can degrade a variety of substrates 
including collagens, FN, laminin, gelatin and casein; MMP-13 (collagenase) 
cleaves collagen types I, II and III; MMPs -14, -24 and -25 are membrane-type 
MMPs; and the other MMPs are difficult to classify as they do not easily fit into 
the above categories. As well as  targeting and degrading ECM proteins, 
MMPs can cleave non-ECM substrates including cell adhesion molecules, 
growth factors and growth factor receptors and can also activate each other, 
increasing the complexity of their actions in fibrosis (Somerville, Oblander et 
al. 2003).
MMP expression and activity are altered in a variety of renal disease states 
however changes can be variable depending on the renal disease model 
studied (Figure 1.2) (Catania, Chen et al. 2007). For example, in the UUO 
model in rabbits and rats  an early increase in MMP-2 expression and activity 
(Sharma, Mauer et al. 1995; Iimura, Takahashi et al. 2004) and decreased 
MMP-1 and -9 expression (Iimura, Takahashi et al. 2004) have been 
documented as well as an increase in TIMP expression (Sharma, Mauer et al. 
1995; Iimura, Takahashi et al. 2004). Other experimental models including a 
rat model of UUO and transgenic rats with renin-dependent hypertension 
mirror these findings of increased MMP-2 expression, reduced MMP-9 
expression and increased TIMP-1 (Duymelinck, Dauwe et al. 2000; 
Bolbrinker, Markovic et al. 2006). However, levels  of cortical MMP-2 and -9 
are increased and activity of medullary MMP-7 and -9 increased in 
spontaneously hypertensive rats (Camp, Smiley et al. 2003) and in a rat 
model of diabetic nephropathy MMP-2 and -9 were down-regulated 
(McLennan, Kelly et al. 2002). Studies of human tissue have also shown 
increased TIMP-1 and -2 expression in glomerulosclerosis, increased TIMP-1 
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in the urine of CKD patients and increased MMP-2 but decreased MMP-9 
levels  in the plasma of CKD patients  (Carome, Striker et al. 1993; Horstrup, 
Gehrmann et al. 2002; Chang, Yang et al. 2006).
cleavage in tubular epithelial cells is mediated by MMPs (21),
specifically MMP-14 (22).
Recent data also suggest a role for MMPs in endothelial
injury during ischemia-reperfusion injury. Following ischemia-
reperfusion, increased MMP-9 activity was associated with
degradation of occludin in endothelial cells, which was postu-
lated to increase vascular permeability (16). This hypothesis is
supported by the finding that minocycline, a tetracycline MMP
inhibitor, and ABT-518, a specific inhibitor of MMP-2 and -9,
attenuated increased microvascular permeability following is-
chemia-reperfusion (78). Taken together, these data support the
hypothesis that MMPs mediate acute kidney injury and are
involved in changes in the vascular endothelium, glomeruli,
and tubular epithelial cells. Cell adhesion molecules have been
identified as critical targets of MMP in several of these studies,
consistent with the increased vascular and tubular permeability
characteristic of acute kidney injury.
MMPs in Chronic Kidney Disease
Glomerulosclerosis/tubulointerstitial fibrosis. The unilateral
ureteral obstruction model has provided insight into the molecular
mechanisms involved in the development of renal fibrosis,
including the role of MMPs and TIMPs (Fig. 3). In this model,
there is an early increase in MMP-2 expression and activity
(37, 72) and decreased MMP-1 and -9 activity (31). In addi-
tion, the model is characterized by an increase in TIMP
expression (72), specifically TIMP-1 (26). Interestingly,
TIMP-1!/! mice are not more susceptible to the development
of fibrosis following unilateral ureteral obstruction, possibly
due to a compensatory increase in TIMP-3 (43). A role for
MMPs in glomerulosclerosis and tubulointerstitial fibrosis is
also demonstrated in several other experimental models. De-
creased MMP-9 expression was correlated with the develop-
ment of tubulointerstitial fibrosis and glomerulosclerosis in rats
(10, 52) and mice (86, 87). Eight weeks after ischemia-
reperfusion injury in the rat, MMP-2 gene levels were in-
creased, but fell at 16 and 24 wk, when increased TIMP-1
expression was observed (40). Increased TIMP-1 expression
following ischemia-reperfusion injury was also observed by
Basile et al. (6). These results suggest increased ECM turnover
following injury, but reduced degradation favoring the devel-
opment of tubulointerstitial fibrosis at later time points. In
spontaneously hypertensive rats, levels of cortical MMP-2 and
MMP-9 are decreased, while the activity of medullary MMP-7
and -9 is increased, suggesting a role for MMPs in hyperten-
sive nephropathy (13). An exciting recent development is the
production of a transgenic model in which renal proximal
tubular cells overexpress MMP-2. These mice recapitulate
human chronic kidney disease (CKD), including tubular atro-
phy, glomerulosclerosis, and tubulointerstitial fibrosis, provid-
ing compelling evidence for a role of MMP-2 in CKD (19).
These data are interesting as most work on CKD has focused
on the relationship between decreased MMP activity and in-
creased ECM deposition; however, these data suggest that
overexpression of a single MMP may be a critical mediator of
CKD, but the critical targets of MMP-2 mediating these effects
remain undefined. The relationship between MMP activity and
inflammation remains an important component of CKD that
remains to be addressed.
Over a decade ago, increased TIMP-1 and -2 expression was
found to be associated with glomerulosclerosis in humans (15).
Urinary levels of TIMP-1 were increased in patients with CKD
(n " 54) vs. controls (n " 176) (36). The expression of
MMP-13 and -14 is elevated in chronic renal inflammation
and/or fibrosis in the human kidney (32). Plasma samples from
60 CKD patients had elevated MMP-2 and decreased MMP-9
activity compared with 40 controls; increased serum creatinine
concentrations correlated with MMP-2 expression and in-
versely correlated with MMP-9 expression (18). The relative
contribution of the kidney, as well as other cellular/organ
systems, to the altered MMP expression patterns in both the
plasma and urine is, at this time, unclear.
Chronic Allograft Nephropathy
A rat model of chronic allograft nephropathy (CAN) showed
decreased TIMP-3 and increased proMMP-2 and -9 and active
MMP-2 (39) (Fig. 3). BAY 12–956, an inhibitor of MMP-2, -3,
and -9, attenuated CAN in a rat model when administered early
(first 10 days following transplantation); however, disease
progression was exacerbated if administered late (weeks 12–20)
(50). Therefore, attention must be paid to the temporal relation-
ship between MMP inhibition and therapeutic outcome. In CAN
patients, serum proMMP-2 and -3 are increased (65); however, in
biopsies of CAN patients, MMP-2 was decreased (61).
Diabetic Nephropathy
A number of studies have demonstrated a link between
aberrant MMP expression and the progression of diabetic
nephropathy in animal models (Fig. 3). The expression of
MMP-2 is decreased before overt structural changes in a
streptozocin (STZ)-induced diabetes (type 1) model (90); how-
ever, increased expression of MMP-2, -9, and -14 was seen in
Goto-Kakizaki rats (type 2) before the development of glomer-
ulosclerosis and tubulointerstitial fibrosis (63). Diabetic ne-
Fig. 3. Role of MMPs/TIMPs in acute and chronic renal pathophysiologies.
Alterations in the expression and activity of MMPs have been linked to a
number of kidney diseases, including acute kidney injury (ARF), aging,
glomerulosclerosis/tubulointerstitial fibrosis (GS/TF), chronic allograft ne-
phropathy (CAN), diabetic nephropathy (DN), polycystic kidney disease
(PKD), and renal cell carcinoma (RCC).
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Figure 1.2. Changes in expression and activity of MMPs and TIMPs in acute and 
chronic renal diseases (C tania, Chen et al. 2007). AKI: acute kidney injury; CAN: chronic 
allograft nephropathy; DN: diabetic  nephropathy; GS/TF: glomerulosclerosis/tubulointerstitial 
fibrosis; PKD: polycystic kidney disease; RCC: renal cell carcinoma.
TGF-β1 has  been found to modulate MMPs in a variety of renal cell types 
although there are few reports of renal fibroblasts to date. For example, in 
TGF-β1-stimulated murine podocytes there was  an increase in MMP-2 and -9 
(Martin, Steadman et al. 1998; Asanuma, Shirato et al. 2002) and in TGF-β1-
stimulated tubul r epithelial cells  MMP-2 expression was increas d (Phanish, 
Wahab et al. 2006). However in mesangial cells TGF-β1 reduced MMP-2 
activation (Baricos, Cortez et al. 1999; Singh, Song et al. 2001).
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Due to their ability to degrade ECM proteins MMPs have been implicated as 
potential anti-fibrotic targets. However MMP knockout mice including those of 
MMP-2 and MMP-9 do not have a spontaneously fibrotic phenotype (Lelongt 
and Ronco 2002; Ronco and Chatziantoniou 2008; Rojiani, Alidina et al. 2010)
and transgenic mice that over-express MMP-2 in renal proximal tubular cells 
develop tubular atrophy, glomerulosclerosis and TIF (Cheng, Pollock et al. 
2006). Conversely, increasing MMP-2 activity was protective against fibrosis 
in rat models of diabetic nephropathy (Sun, Wang et al. 2006; Mankhey, Wells 
et al. 2007). The diverse effects of MMPs on fibrosis might be partly explained 
by their additional activities other than on matrix proteins. For example, 
MMP-2 accelerates macrophage infiltration following UUO possibly by 
degrading ECM components  (Nishida, Okumura et al. 2007), is capable of 
inducing EMT in renal tubular cells in vitro and mediates  EMT in a paracrine 
manner by activating TGF-β1 (Cheng and Lovett 2003). MMP-9 has been 
found to activate TGF-β (Ronco, Lelongt et al. 2007).
In addition to reduced matrix degradation, accelerated collagen deposition 
and matrix stabilisation may contribute to ECM accumulation (Fisher, Jones et 
al. 2009). Transglutaminase 2 (TG2) is an 80-kDa, calcium-dependent 
enzyme that catalyses an acyl-transfer reaction between the γ-carboxamide 
group of peptide-bound glutamine and the ε-amino group of peptide-bound 
lysine leading to a stable and proteolytic-resistant covalent dipeptide bond 
within a single peptide or between peptides. Cytosolic TG2 is unique amongst 
its family members in that a small proportion is secreted by cells. On release, 
TG2 is  activated by the high calcium and low guanosine triphosphate (GTP) 
concentration in the interstitial space causing ε-(γ-glutamyl) lysine cross-
linking of ECM proteins making them harder to degrade and increasing the 
rate of soluble collagen deposition (Fisher, Jones et al. 2009). Substrates for 
TG2 include FN, collagens, fibrinogen, oseopontin, laminin and nidogen 
(Mosher 1984; Martinez, Rich et al. 1989; Aeschlimann and Paulsson 1991; 
Kleman, Aeschlimann et al. 1995; Kaartinen, Pirhonen et al. 1999). TG2 can 
also activate TGF-β1 (Nunes, Gleizes et al. 1997; Annes, Munger et al. 2003; 
Shweke, Boulos et al. 2008) and TGF-β1 increases TG2 mRNA (Douthwaite, 
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Johnson et al. 1999). In addition, TG2 also plays diverse roles in cell 
signalling, cell adhesion, cell migration, cell-matrix interactions, cell death, 
apoptosis and autophagy (Nakaoka, Perez et al. 1994; Jones, Nicholas et al. 
1997; Verderio, Nicholas et al. 1998; Oliverio, Amendola et al. 1999; Akimov 
and Belkin 2001; D'Eletto, Farrace et al. 2009; Rossin, D'Eletto et al. 2011). 
Because of its ability to accelerate collagen deposition and stabilise matrix, 
TG2 has been identified as  a possible target for renal fibrosis. Evidence that 
TG2 is involved in renal fibrogenesis includes that ε-(γ-glutamyl) lysine cross-
links and TG2 expression are increased in numerous experimental models of 
renal disease including the streptozotocin-induced model of type 1 diabetes 
with (Huang, Haylor et al. 2009) and without uninephrectomy (Skill, Griffin et 
al. 2001) and the subtotal nephrectomy model (SNx) (Johnson, Skill et al. 
1999) as  well as in human diabetic nephropathy (El Nahas, Abo-Zenah et al. 
2004) and a variety of other human CKD specimens (Johnson, El-Koraie et al. 
2003). Furthermore, evidence supporting that TG2 is  pathogenic and targeting 
TG2 improves renal outcome include the reduction of glucose-induced ECM 
accumulation in proximal tubular epithelial cells  by TG inhibition (Skill, 
Johnson et al. 2004), the reduction in total and fibrillar collagen in TG2 
knockout mice subjected to UUO (Shweke, Boulos et al. 2008) and the 
preservation of kidney function and amelioration of histological changes by an 
irreversible TG2 inhibitor in an animal model of diabetic nephropathy (Huang, 
Haylor et al. 2009) and the SNx model (Johnson, Fisher et al. 2007). 
TG2 is also up-regulated in liver disease and fibrosis. However, following 
carbon tetrachloride-induced liver injury in wild-type and TG2 knockout mice, 
mice lacking TG2 failed to clear hepatic necrotic tissue, demonstrated 
increased ECM accumulation and inflammatory cells  and had a 60% mortality 
compared to no deaths in the wild-type group (Nardacci, Lo Iacono et al. 
2003). The same group found elevated levels of TG2 in the livers of HCV-
infected patients during the initial stages of liver fibrosis but levels had 
decreased in the more advance stages leading them to hypothesise a 
protective role for TG2 (Nardacci, Lo Iacono et al. 2003). More recent studies 
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have shown that TG2 expression and activity, although increased in liver 
fibrosis, does not appear to contribute to stabilisation of collagen matrix or 
fibrogenesis (Popov, Sverdlov et al. 2011).    
1.3 Retinoids
1.3.1 Vitamin A metabolism
Retinoids are a group of compounds related to vitamin A (retinol). They exert 
a wide range of biological effects on embryogenesis, tissue homeostasis, cell 
differentiation, proliferation and apoptosis. Retinoids can be classified into 
three groups: retinoic acid (RA) precursors (including retinol), naturally-
occurring RAs (including tRA) and synthetic retinoids (Xu, Lucio-Cazana et al. 
2004). Humans cannot synthesise retinoids and must gain their required daily 
intake from the diet as  RA precursors  that are subsequently converted to RA 
so that they may exert the majority of their biological effects. Figure 1.3 
illustrates the molecular structures  of some well-studied, naturally-occurring 
retinoids and demonstrates that they are small, lipophilic molecules with a 













Figure 1.3. Molecular structure of retinoids. A- all-trans retinol; B- all-trans retinoic  acid; C- 
13-cis retinoic acid; and D- 9-cis retinoic acid.
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Figure 1.4 demonstrates the pathway through which retinol is  converted to 
RA and its subsequent metabolism in cells. Following absorption in the 
intestine and modification in hepatocytes, retinol (predominantly all-trans 
retinol) enters the circulation, transported in plasma in a one-to-one complex 
with retinol binding protein (RBP), thereby reducing its rate of metabolism 
(Theodosiou, Laudet et al. 2010; D'Ambrosio, Clugston et al. 2011) and to 
transthyretin (TTR), reducing the renal elimination of RBP (Blomhoff and 
Blomhoff 2006). Plasma levels of retinol:RBP are maintained at a steady state 
of approximately 2 μM while other retinoids  including tRA and 13-cis RA 
(13cRA) are detectable only at around 5-10 nM bound to albumin (Blomhoff 
and Blomhoff 2006; Theodosiou, Laudet et al. 2010). Retinyl esters (most 
commonly retinyl palmitate) are also present in plasma, transported directly 
from the intestine to target tissues as chylomicron remnants (Theodosiou, 
Laudet et al. 2010). Retinyl esters and retinol:RBP, via the RBP receptor 
“stimulated by retinoic acid gene 6” (STRA6) (Kawaguchi, Yu et al. 2007), 
enter RA target cells where retinol can be stored as retinyl esters following 
esterification by microsomal lecithin:retinol acyltransferase (LRAT), or be 
converted to RA. The fatty acid binding proteins cellular retinol binding protein 
(CRBP) I, CRBPII and CRBPIII bind intracellular retinol and retinal and are 
thought to play roles in the uptake of retinol into cells, determination of 
intracellular retinol levels, facilitation of retinol esterification and protection of 
retinol from metabolism (Napoli 1999; Napoli 2000; Theodosiou, Laudet et al. 
2010; Napoli 2012). 
Retinol is converted to its active form in two steps. Firstly, it is reversibly 
oxidised to retinal by microsomal short-chain dehydrogenases/reductases 
(SDRs) with retinol dehydrogenase activity or by cytosolic alcohol 
dehydrogenases (ADHs) (Pares, Farres et al. 2008). Retinal then undergoes 
irreversible oxidation to the active RA, a reaction catalysed by retinaldehyde 




























Non-canonical tRA signalling pathways
• Activation of other nuclear receptors
• Interference with other transcription factors
• Cross-talk with non-genomic pathways
Figure 1.4. Metabolism of all-trans retinol to tRA in cells (adapted from Theodosiou, 
Laudet et al. 2010; D’Ambrosio, Clugston et al. 2011). ADH: alcohol  dehydrogenase; CRABP-
II: cellular retinoic acid binding protein-II; CRBP: cellular retinol binding protein; CYP26: 
cytochrome P450 family 26; FABP5: fatty acid binding protein 5; LRAT: lecithin:retinol 
acetyltransferase; PPAR: peroxisome proliferator activated receptor β/δ; RALDH: 
retinaldehyde dehydrogenases; RAR: retinoic acid receptor; RBP: retinol  binding protein; 
REH: retinyl ester hydrolase; RXR: rexinoid receptor; SDR: short-chain dehydrogenase/
reductase; STRA6: stimulated by retinoic  acid gene 6; tRA: all-trans retinoic  acid; tRal: all-
trans retinal; tRol: all-trans retinol; TTR: transthyretin.
Of the naturally-occurring biologically active RAs, tRA is the most abundant in 
mammalian embryos (Satre, Ugen et al. 1992; Scott, Walter et al. 1994; 
Horton and Maden 1995). Other endogenous retinoids reported to have 
biological activity include 9cRA, 13cRA, 11-cis retinaldehyde, 3,4-didehydro 
RA, 4-oxo RA and 4-oxo-retinol (Buck, Derguini et al. 1991; Achkar, Derguini 
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et al. 1996; Napoli 1996; Blaner 2001). While tRA can undergo isomerisation 
to 9cRA (Levin, Sturzenbecker et al. 1992; Blaner 2001) and 13cRA (Cullum 
and Zile 1985), isomerisation products  of tRA have not been consistently 
detected in mammalian cells and their biological significance remains unclear 
(Germain, Chambon et al. 2006; Theodosiou, Laudet et al. 2010). 
Furthermore, while 13cRA is detectable in nature it does not have potent gene 
regulatory activity but undergoes isomerisation to the biologically active tRA 
and 9cRA, which may account for at least some of its  physiological activity
(Blaner 2001). Since tRA is the predominant endogenous, biologically active 
retinoid it is  currently considered the most important (Germain, Chambon et 
al. 2006).
Once synthesised, active RA binds with high affinity to cytosolic cellular RA 
binding protein (CRABP)-I or CRABP-II. Although the distinct roles  of the two 
CRABP isoforms have not been fully elucidated, it is  proposed that they 
protect RA and aid its transport within the cell (Dong, Ruuska et al. 1999). In 
addition, CRABP-I may influence the metabolic fate of RA by increasing its 
degradation or sequestering RA (Boylan and Gudas 1991; Boylan and Gudas 
1992). In adults, the widespread expression of CRABP-I and the more limited 
expression of CRABP-II implies a more specialised function for CRABP-II 
(Dong, Ruuska et al. 1999). Specifically, CRABP-II also appears to play a role 
in delivering RA to RA receptors (RARs) (Dong, Ruuska et al. 1999). Binding 
of RA to CRABP-II results in its translocation from cytosol to nucleus where 
RA is directly delivered by CRABP-II to RARs (Dong, Ruuska et al. 1999). 
The cytosolic fatty acid binding protein 5 (FABP5) has also been postulated to 
bind RA then translocate to the nucleus to deliver RA directly to another 
nuclear receptor, peroxisome proliferator-activated receptor (PPAR) β/δ (Tan, 
Shaw et al. 2002; Schug, Berry et al. 2007). However this  proposed RA 
signalling pathway is controversial as other groups have not been able to 
confirm tRA-induced PPARβ/δ activation in cells  (Borland, Foreman et al. 
2008; Rieck, Meissner et al. 2008) even with high intracellular FABP5 and 
PPARβ/δ expression (Borland, Khozoie et al. 2011). 
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Catabolism of RA into polar metabolites for excretion is controlled by the 
cytochrome P450 family 26 (CYP26) family of enzymes and is  thought to be 
initiated by hydroxylation of the C4 or C18 position of the β-ionone ring of RA 
(Theodosiou, Laudet et al. 2010).
1.3.2 Canonical retinoic acid (RA) signalling pathway
Classical RA signalling occurs through retinoid nuclear receptors which 
function as transcriptional regulators. There are two classes of retinoid 
nuclear receptor, the retinoic acid receptors  (RARs) and the retinoid X 
receptors (RXRs). RARs bind tRA and 9cRA whereas RXRs bind 9cRA but 
not tRA. Both RARs and RXRs consist of three isotypes, α, β and γ 
(Chambon 1996). RARα and RARγ have two isoforms (α1-2 and γ1-2) and 
RARβ has five isoforms (β1-5) (Leroy, Krust et al. 1991; Zelent, Mendelsohn 
et al. 1991; Peng, Maruo et al. 2004; Germain, Chambon et al. 2006). The 
RXR isotypes also have several isoforms, RXRα1-4, RXRβ1-4 and RXRγ1-2 
(Lefebvre, Benomar et al. 2010). RAR and RXR isotypes are encoded by 
separate genes with the isoforms generated by differential promoter usage 
and alternative splicing (Chambon 1996; Pfahl and Chytil 1996).
RARs have a modular structure consisting of six well-defined regions 
designated A to F (Figure 1.5), with RXRs lacking the F region (Rochette-Egly 
and Germain 2009). The C and E regions  contain a DNA-binding domain 
(DBD) and a ligand-binding domain (LBD), respectively, and are the most 
conserved and considered the most important regions with respect to 
canonical retinoid receptor signalling (Rochette-Egly and Germain 2009). The 
DBD confers sequence-specific DNA recognition and has a dimerisation 
interface; the LBD is complex and contains a ligand-binding pocket, a 
dimerisation interface and the ligand-dependent activation function (AF)-2 
(Mader, Chen et al. 1993; Perlmann, Umesono et al. 1996; Laudet and 
Gronemeyer 2002). Regions A and B contain the N-terminal domain (NTD) 
which includes the AF-1 and region B is proline-rich with multiple 
phosphorylation sites; region D is  poorly conserved and is  thought to act as a 
hinge between the DBD and LBD; and the function of region F is still unknown 
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although it too has multiple phosphorylation sites that might alter RAR 
function (Rochette-Egly and Germain 2009).
A/B E FDC
NTD DBD LBD
Figure 1.5. Schematic diagram of the functional domains of RARs (adapted from 
Rochette-Egly and Germain 2009). RARs consist of six regions, A to F, with regions C and E 
the most conserved. Regions A and B correspond to the N-terminal domain (NTD) that 
contains a proline-rich motif with phosphorylation sites for kinases; region C corresponds to 
the DNA-binding domain (DBD); and region E corresponds to the ligand-binding domain 
(LBD) which also contains the AF-2 domain, a dimerisation domain and phosphorylation sites 
for several kinases.
Retinoid nuclear receptors function as dimers  with RXRs binding to RARs and 
RXRs (Yu, Delsert et al. 1991; Leid, Kastner et al. 1992; Germain, Chambon 
et al. 2006). RXRs also dimerise with numerous other nuclear receptors 
including PPARβ/δ, thyroid hormone and vitamin D nuclear receptors 
(Lefebvre, Benomar et al. 2010).
RXR-RAR heterodimers act as  ligand-dependent transcriptional regulators  by 
binding to specific retinoic acid response elements (RAREs) found in the 
promoter region of retinoid target genes (Germain, Chambon et al. 2006). 
RAREs are direct repeats  (DRs) of polymorphic arrangements of the 
canonical motif 5’-PuG(G/T)TCA separated by five, two or one nucleotides 
(DR5, DR2, DR1) (Leid, Kastner et al. 1992; Mangelsdorf and Evans 1995). 
Heterodimers are organised as 5’-RXR-RAR-3’ for DR5 and DR2 conferring 
activational gene activity but the polarity is  reversed in DR1 elements (5’-
RAR-RXR-3’) leading to repressive activity (Perlmann, Rangarajan et al. 
1993; Kurokawa, DiRenzo et al. 1994; Predki, Zamble et al. 1994; Zechel, 
Shen et al. 1994; Germain, Chambon et al. 2006). The unliganded RXR-RAR 
heterodimer prevents  transcription due to the presence of co-repressors 
(Glass and Rosenfeld 2000) such as nuclear receptor co-repressor (N-CoR) 
(Horlein, Naar et al. 1995) and silencing mediator of RA and TR (SMRT) 
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(Chen and Evans 1995). On ligand binding to RAR the LBD undergoes a 
conformational change causing the dissociation of co-repressors  and 
association of various co-activator complexes to initiate transcription 
(Rochette-Egly and Germain 2009). RXR LBD activation alone cannot induce 
the dissociation of co-repressors and activate transcription, a phenomenon 
referred to as RXR subordination or silencing (Chambon 2005; Germain, 
Chambon et al. 2006). 
There is evidence to suggest that the RAR and RXR isotypes may have 
distinct physiological functions in development. For example, RAR isotypes 
display differential spacio-temporal distribution in mouse embryonal 
development (Dolle, Ruberte et al. 1990) and isotype-specific RAR knockout 
mice show differential signs of the vitamin A deficiency (VAD) syndrome as 
well as other congenital abnormalities (although many of these defects  can be 
rescued with RA treatment suggesting functional redundancy among the 
RARs) (Germain, Chambon et al. 2006). In addition, different roles for 
individual RXR-RAR heterodimers have been demonstrated from experiments 
performed on F9 murine embryonal carcinoma cells. In these cells RXRα-
RARγ heterodimers are necessary for growth arrest, visceral endodermal 
differentiation and primitive endodermal differentiation whereas RXRα-RARα 
heterodimers are required for parietal endodermal differentiation (Taneja, 
Rochette-Egly et al. 1997; Germain, Chambon et al. 2006). 
In contrast, knowledge of the pathophysiological roles of the individual 
receptor isotypes  post-natally and in adulthood is lacking due, in part, to 
functional redundancies observed between the RARs and the early mortality 
of various  combinations of retinoid receptor null mutants from germline 
mutations (Germain, Chambon et al. 2006). 
42
1.3.3 Non-canonical retinoid signalling pathways
The classical ligand-activated RXR-RAR/RARE pathway is  well established 
as essential for RA signal transduction however it is becoming more apparent 
that retinoids also exert their effects via other, non-canonical pathways. For 
example, RA can bind to and activate other nuclear receptors than retinoid 
receptors such as  retinoic acid receptor-related orphan receptor β (ROR-β) 
and the chicken ovalbumin upstream promoter-transcription 2 (COUP-TFII), 
although the relevance of these receptors  in RA signalling in vivo is  not yet 
clear (Stehlin-Gaon, Willmann et al. 2003; Kruse, Suino-Powell et al. 2008). 
RA has also been found to bind and activate PPARβ/δ with nanomolar affinity 
and in so doing can activate the RXR-PPARβ/δ/peroxisome proliferator 
response element (PPRE) pathway (Shaw, Elholm et al. 2003; Berry and Noy 
2007). This alternative signalling pathway of RA was shown to be important in 
studies of the RA-resistant mouse model of breast cancer, MMTV-neu (Schug, 
Berry et al. 2008). In this model RA preferentially activates PPARβ/δ rather 
than RAR due to a high FABP5:CRABP-II ratio diverting RA to PPARβ/δ 
(Schug, Berry et al. 2008). However if this ratio of FABP5 to CRABP-II is 
reduced, thus diverting RA back to RAR, suppression of tumour growth in this 
previously RA-resistant cancer model occurred (Schug, Berry et al. 2008).
Retinoids and/or their receptors may also interfere indirectly with 
transcriptional events. A well-established effect of RARs is the repression of 
activating protein-1 (AP-1) activation via ligand-dependent and ligand-
independent mechanisms. Potential models for this repression include 
suppression of c-Fos and c-Jun expression, a direct interaction with Jun/Fos, 
disruption of Jun/Fos dimerisation and inhibition of c-Jun N-terminal kinase 
(JNK) (Fanjul, Dawson et al. 1994; Moreno-Manzano, Ishikawa et al. 1999; 
Konta, Xu et al. 2001; Rochette-Egly and Germain 2009). RA, via its  retinoid 
nuclear receptors, can also interfere with nuclear factor kappa-light-chain-
enhancer of activated B-cells (NFκB) signalling partly via a direct interaction 
and also competitive recruitment of transcription integrators between NFκB 
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and RXR (Na, Kang et al. 1999; Austenaa, Carlsen et al. 2004; Austenaa, 
Carlsen et al. 2009).
In addition retinoids can exert effects via non-genomic pathways. For 
example, RA rapidly activates MAP kinases subsequent to the activation of 
upstream kinases including phosphoinositide 3-kinase (PI3K) and protein 
kinase C δ (PKCδ) via retinoid receptor-dependent and independent 
pathways (Kambhampati, Li et al. 2003; Ochoa, Torrecillas et al. 2003; del 
Rincon, Guo et al. 2004; Pan, Kao et al. 2005; Bastien, Plassat et al. 2006; 
Masia, Alvarez et al. 2007). In line with this  concept RARs have been 
identified not only in the nucleus but also in the cytosol and membranes of 
cells (Dey, De et al. 2007; Masia, Alvarez et al. 2007; Rochette-Egly and 
Germain 2009). RARα has also been purported to have a non-genomic role 
as an RNA-binding protein: Unliganded RARα interacts  directly with mRNA in 
neurones resulting in repression of translation but on RA-binding the 
association of RARα with mRNA is  reduced relieving translational repression 
(Chen, Onisko et al. 2008). 
1.3.4 Role of retinoids in proliferation, differentiation and inflammation
The importance of a fully functioning retinoid signalling system has long been 
acknowledged in embryonic growth and patterning and much is now 
understood about the role of retinoids in embryogenesis (Niederreither and 
Dolle 2008). Likewise, the importance of retinoids, and, in particular, retinal, in 
the visual cycle is  well recognised (Palczewski 2010). The role of retinoids 
post-natally however is less well understood. Vitamin A deficiency increases 
the risk of infection, nephrolithiasis, and growth retardation whereas an 
excess can lead to toxicity of multiple organs including liver and central 
nervous system (Theodosiou, Laudet et al. 2010). However, since this  thesis 
explores the effects of pharmacological doses of exogenous  retinoids on renal 
fibrosis, the following section will focus on the effects of exogenous retinoids 
on cell proliferation, differentiation and inflammation, as these processes are 
relevant to post-natal pathological disease states including kidney diseases 
and renal fibrosis.
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Retinoids are known to be anti-proliferative, exerting their effects via different 
mechanisms including interference with cell cycle progression and apoptosis. 
RA inhibits cell cycle progression by blocking the G1 phase of the cell cycle 
with an increase in the proportion of cells  in the G0/G1 phase and a decrease 
of those in the S phase (Mongan and Gudas 2007). They are known to 
modulate cyclins  and cyclin-dependent kinases (CDKs) through a variety of 
mechanisms including changes in mRNA and protein expression (Ma, Feng et 
al. 2005) and they increase the expression and post-translational stability of 
CDK inhibitors (Tang and Gudas 2011). RARβ2 has been implicated as the 
predominant retinoid receptor mediating the inhibitory effects of RA on the cell 
cycle by targeting genes that mediate tRA-induced cell growth inhibition, for 
example the cell-cycle inhibitors p21CIP1 (Suzui, Shimizu et al. 2004) and 
p27KIP1 (Li, Faria et al. 2004). 
Retinoids also induce apoptosis in different cancer cells however the 
processes through which they exert this  effect are not fully elucidated and are 
likely to depend on cell type and environment (Tang and Gudas 2011). For 
example, RARα, RARβ and RARγ signalling pathways have all been 
identified as important in different situations  (Hatoum, El-Sabban et al. 2001; 
Chikamori, Hill et al. 2006; Altucci, Leibowitz et al. 2007; Chen, Zhang et al. 
2007; Luo, Lin et al. 2009). Conversely, retinoids are also anti-apoptotic in a 
variety of cell types and conditions via negative regulation of the AP-1 
pathway (Moreno-Manzano, Ishikawa et al. 1999). Both nuclear receptor-
dependent and independent mechanisms are important for this anti-apoptotic 
effect of retinoids (Konta, Xu et al. 2001). 
In addition, retinoids can induce cell differentiation in various  normal and 
cancer cells including breast, melanoma, neuroblastoma, squamous, 
osteosarcoma and F9 cells (Beere and Hickman 1993; Taneja, Rochette-Egly 
et al. 1997; Luo, Yang et al. 2010) with retinoid-suppressed phosphorylation of 
RARα being postulated as a potential mechanism of action (Luo, Yang et al. 
2010).
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Retinoids also play a major role in immune modulation and inflammation. 
Vitamin A deficiency (VAD) is known to have profound effects on the host 
defence against infection. RA has been implicated in regulation of thymic 
proliferation and selection processes, T-cell differentiation and behaviour and 
RA can determine the balance of Th1/Th2-type T cells and Th-17 cells  (Mora, 
Iwata et al. 2008; Pino-Lagos, Benson et al. 2008). RA is known to modulate 
antigen presentation by altering dendritic cell function (Mora, Iwata et al. 
2008; Pino-Lagos, Benson et al. 2008) and it exerts direct and indirect effects 
on B cell isotype switching and antibody production (Gudas, Sporn et al. 
1994; Pino-Lagos, Benson et al. 2008). The anti-inflammatory effects of 
retinoids occur via a variety of different mechanisms including modulation of 
inflammatory cytokines and receptor expression as well as leukocyte 
behaviour. For example, tRA prevents tumour necrosis factor α (TNFα)-
induced vascular cell adhesion molecule (VCAM)-1 expression and VCAM-1-
dependent T-cell binding to TNFα-treated human dermal microvascular 
endothelial cells via effects of tRA on the activation of NFκB-dependent 
complex formation (Gille, Paxton et al. 1997); retinoids modulate trans-
epidermal migration of polymorphonuclear leukocytes following epicutaneous 
challenge with leukotriene-B4 (Wozel, Chang et al. 1991); 9cRA reduces 
monocyte adhesion to foetal calf serum (FCS)-stimulated human mesangial 
cells (HMCs) (Manzano, Munoz et al. 2000); tRA inhibits constitutive 
expression of monocyte chemoattractant protein-1 in rat mesangial cells 
(RMCs) in a retinoid receptor-dependent manner (Lucio-Cazana, Nakayama 
et al. 2001); and tRA increases the expression of cyclooxygenases 1 and 2 
and prostaglandin E2 production in HMCs (Alique, Moreno et al. 2006) and 
RMCs (Alique, Lucio-Cazana et al. 2007). 
The diverse effects of retinoids on cell cycle progression, programmed cell 
death, cytodifferentiation, immunity and inflammation have led to retinoid-
based therapeutic strategies for the treatment of a variety of disease states. 
Furthermore, clinical trials of the effects of retinoids  in a variety of disease 
states are currently being conducted including in a variety of cancers and 
autoimmune diseases. 
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In oncology, retinoid-induced cytodifferentiation forms the basis of treatment in 
acute promyelocytic leukaemia (APL). In most APL sufferers the RARα gene 
is  rearranged and fused to the promyelocytic leukaemia (PML) gene creating 
a PML/RARα fusion protein. This causes a stoichiometric increase in the 
levels of histone deacetylases and associated DNA methyltransferase 
complexes resulting in silencing of retinoid-regulated genes including 
important regulators of myeloid differentiation (Villa, Morey et al. 2006). 
Pharmacological doses of tRA reduce the promoter occupancy of this  fusion 
protein allowing transcription of previously silenced genes (Morey, Brenner et 
al. 2008). Tazarotene, a retinoid with RARβ and RARγ specificity, has been 
identified as a potential treatment for basal cell carcinomas and bexarotene, 
an RXR agonist, is  used in the treatment of cutaneous T cell lymphomas. In 
dermatology, tazarotene is successfully used for plaque psoriasis and 13cRA 
is  used for cystic acne vulgaris (Theodosiou, Laudet et al. 2010). Finally, tRA 
has been successfully used to improve clinical symptoms and laboratory 
parameters in a case series of patients with steroid-refractory lupus nephritis 
(Kinoshita and Funauchi 2012).
1.3.5 Effects of retinoids in non-renal fibrosis
The effects of retinoids  in fibrosis have been explored in numerous fibrotic 
diseases including skin, liver and lung fibrosis. In the 1970s-1980s retinoids 
were trialled in two cutaneous disorders characterised by excessive 
deposition of collagen, namely keloid scars and hypertrophic scars. Topical 
RA treatment successfully reduced scar size in patients  suffering these 
conditions (Janssen de Limpens 1980; Panabiere-Castaings 1988). Other 
reports however opposed this view of retinoids as anti-scarring agents as they 
were shown to enhance keloid formation in patients receiving dermabrasion 
(Rubenstein, Roenigk et al. 1986).
Reports in the literature of the effects of retinoids in liver fibrosis are also 
conflicting. Some evidence suggests that VAD can damage the liver as adult 
Wistar rats fed a diet deficient in vitamin A for 3 months expressed increased 
hepatic α-SMA in sinusoidal cells and there was an increase in FN, laminin 
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and collagen type IV in hepatic extracts  (Aguilar, Genta et al. 2009). 
Furthermore, RA supplementation in liver disease can protect against liver 
fibrosis. For example, tRA-treated mice with CCl4-induced liver fibrosis 
showed reduced fibrosis, attenuation of the increase in α2(I) collagen mRNA 
(Wang, Potter et al. 2007) and survival was also improved (Hisamori, Tabata 
et al. 2008); in a rat model of liver fibrosis induced by common bile duct 
ligation tRA reduced fibrosis  and decreased the increase in collagen type I 
(Wang, Dan et al. 2008). Other reports, however, suggest that retinoids  could 
aggravate fibrosis in an already damaged liver. For example, in the CCl4 rat 
model high dietary uptake of retinoids acted as an accelerator of fibrotic liver 
disease (Vollmar, Heckmann et al. 2002) and, in liver fibrosis induced by 
peritoneal injections of porcine serum, polyprenoic acid facilitated liver fibrosis 
(Numaguchi, Okuno et al. 1994). In humans there is also evidence that 
retinoid treatment may be detrimental to the liver. In a group of 18 patients 
receiving long-term etretinate for psoriasis two suffered mild periportal 
fibrosis, one suffered chronic active hepatitis and one was diagnosed with 
cirrhosis (Camuto, Shupack et al. 1987). 
In models of pulmonary fibrosis  studies have suggested that retinoids have an 
anti-fibrotic effect. For example, tRA decreased fibrosis and α-SMA 
expression in a model of oxygen-induced lung injury in the newborn rat (Ozer, 
Kumral et al. 2005) and in a mouse model of bleomycin-induced pulmonary 
fibrosis tRA ameliorated fibrosis (Tabata, Kadokawa et al. 2006).
1.3.6 Effects of retinoids in renal fibrosis  
The role of exogenous retinoids in renal fibrosis  also remains unknown as, 
although the majority of published reports  suggest that they have anti-fibrotic 
potential, a few studies also show a pro-fibrotic effect of retinoids on kidney 
scarring. Table 1.2 summarises  the effects of different retinoids on renal 
fibrosis in various experimental renal disease models. Examples of the pro-
fibrotic effect of retinoids include: 1) In the SNx model, a model considered to 
represent CKD in humans, while low-dose 13cRA was renoprotective, high-
dose 13cRA caused an increase in glomerular sclerosis index in both sham
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Table 1.2. Effects of retinoids on fibrosis in in vivo models of renal disease. IM: 










         ✔ Vitamin A 
60 kIU IM/IV/PO




         ✔ tRA
0.5 mg IP thrice per 
week
(Kinoshita, Yoo et al. 
2003)
Acute renal allograft 
rejection
Fisher rat kidney 
grafted to Lewis rats 
         ✔ 13cRA
2 mg/kg/day PO
20 mg/kg/day PO




Fisher rat kidney 
grafted to Lewis rats 
         ✔ 13cRA
2 mg/kg/day PO
20 mg/kg/day PO





Wistar and Lewis rats
         ✔          ✔ tRA
5 mg/kg/day PO
30 mg/kg/day PO
(Datta, Reddy et al. 
2001; Oseto, 
Moriyama et al. 2003)
Puromycin-induced 
nephrosis; Wistar rats
         ✔ tRA
10 mg/kg/day PO
(Moreno-Manzano, 
Mampaso et al. 2003)
acute an t i -Thy1.1 
mesangioproliferative 
nephritis in Wistar rats
         ✔ tRA 10 mg/kg/day 
SC
13cRA 40 mg/kg/day 
SC
(Wagner, Dechow et 
al . 2000; Morath, 
Dechow et al. 2001)
chronic  anti-Thy1.1 
mesangioproliferative 
nephritis in Wistar rats
         ✔ 13cRA
2 mg/kg/day PO
10 mg/kg/day PO





         ✔ ✔ 13cRA
10 mg/kg/day PO
40 mg/kg/day PO
(Morath, Ratzlaff et 
al. 2009)
UUO
Wistar rats and 
C57BL/B6 mice
         ✔ 13cRA





(Schaier, Jocks et al. 
2003; Kishimoto, 
Kinoshita et al. 2011; 
Zhou, Qin et al. 2012)
Alb/TGF-β1 
transgenic mice




(Xu, Hendry et al. 
2010)
Age-related renal 
disease in Fisher 344 
rats






and SNx groups as well as an increase in collagen IV staining and an 
increase in the interstitial area (Morath, Ratzlaff et al. 2009); and 2) In the 
kidneys of Alb/TGF-β1 transgenic mice, a model that over-expresses active 
TGF-β1 leading to progressive renal fibrosis, medium- and high-dose tRA 
exacerbated fibrosis and increased mortality although low-dose tRA did not 
alter the severity of renal fibrosis (Xu, Hendry et al. 2010). These two studies, 
in particular, highlight three important questions that remain unanswered: 1) 
Do different retinoids play different roles in renal fibrosis; 2) What is the 
optimal therapeutic dose of RA to avoid toxic effects; and 3) How are the 
activities of retinoids affected by experimental model used?
1.3.7 In vivo evidence of possible mechanisms for the effects of 
retinoids in renal fibrosis
The endogenous retinoid signalling system is  disrupted in kidney diseases. 
Reduced levels of endogenous kidney RA occur in renal disease models, 
such as in Alb/TGF-β1 transgenic mice (Xu, Hendry et al. 2010), diabetic 
nephropathy (Starkey, Zhao et al. 2010) and anti-Thy1.1 nephritis  (Liebler, 
Uberschar et al. 2004). In addition, changes in the expression of endogenous 
retinoid signalling molecules  also occur. For example, in the acute anti-Thy1.1 
nephritis model, there was time-dependent activation of the retinoid system 
with reduced mRNA expression of RXRα, RARβ and RARγ, retinol 
dehydrogenase 1 and 2 and RALDHs 1 and 2 on day 3 but an increase of 
RXRα, RARα, RARβ and RARγ as well as RARα protein on day 7 (Liebler, 
Uberschar et al. 2004); In the chronic anti-Thy1.1 glomerulonephritis model 
there was significantly greater RARα and RXRα mRNA expression compared 
to control animals and RARγ expression was decreased (Schaier, Liebler et 
al. 2004).
Interventional studies using retinoid receptor agonists suggest that, not only 
does retinoid nuclear receptor expression alter in renal disease, but retinoid 
receptor activation modulates  fibrosis. The RAR and RXR agonists, 
Ro-137410 and Ro-257386, respectively, were found to reduce glomerular 
damage, procollagen I and FN I mRNAs and FN I protein in the acute anti-
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Thy1.1 nephritis model (Lehrke, Schaier et al. 2002) and the RARα- and 
RXR-specific agonists, AGN195183 and AGN194204, respectively, reduced 
renal injury with a reduction in mesangial matrix expansion, glomerular 
sclerosis  index and tubulointerstitial area in the chronic anti-Thy1.1 
glomerulonephritis model (Schaier, Liebler et al. 2004). 
These results demonstrate that the endogenous renal retinoid signalling 
system is altered in renal disease and suggest that it is at least partly via 
retinoid nuclear receptor signalling that modulation of renal fibrosis by 
retinoids occurs. 
There are multiple potential targets for retinoids in renal fibrosis and one such 
target had been identified as TGF-β1. In the acute anti-Thy1.1 nephritis 
model, tRA was found to reduce urinary TGF-β1 excretion and lower 
glomerular TGF-β1 and TGF receptor type II protein; furthermore, tRA and 
13cRA were found to attenuate the increase in cortical TGF-β1 and TGF-β 
receptor type II gene expression (Morath, Dechow et al. 2001). In the rat UUO 
model, 13cRA reduced the increases in TGF-β1 and TGF-β receptor type II 
mRNAs (Schaier, Jocks et al. 2003) and in the mouse UUO model  the 
increase of TGF-β1 mRNA and protein was attenuated by prophylactic and 
therapeutic administration of tRA (Kishimoto, Kinoshita et al. 2011). The 
reduction in TGF-β1 expression by retinoids could in part be nuclear receptor-
dependent as both RARα and RXR agonists  (AGN195183 and AGN194204) 
exerted similar effects in the chronic anti-Thy1.1 glomerulonephritis model 
(Schaier, Liebler et al. 2004). Although infiltrating macrophages produce 
significant amounts of TGF-β1 therefore the reduction in TGF-β1 could be 
attributed to an anti-inflammatory effect of RA, Morath et al. showed that 
glomerular cells were a significant source of TGF-β1 and could be a target for 
RA treatment (Morath, Dechow et al. 2001). 
There are also reports of retinoid-induced increases in TGF-β1 expression 
although this pro-fibrotic effect of retinoids is less well documented. 
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Glomerular TGF-β1 protein levels were increased by tRA treatment in 
experimental anti-GBM antibody-mediated glomerulonephritis (Datta, Reddy 
et al. 2001) and, in the SNx model, TGF-β1 gene and protein levels were 
increased by high-dose 13cRA associated with an increased glomerular 
sclerosis  index, interstitial area and collagen IV staining (Morath, Ratzlaff et 
al. 2009).
 
Matrix degradation systems also appear to be targets for retinoids in in vivo 
renal disease models  although again the mechanisms through which they 
exert their effects remain unclear. In a rat model of glomerulosclerosis 
induced by uninephrectomy and an injection of adriamycin, tRA reduced 
TIMP-1 mRNA and protein expression and enhanced MMP-2 and MMP-9 
expression and activity associated with a reduction in collagen IV and 
fibronectin (Qin, Lei et al. 2009; Zhou, Qin et al. 2011). In the 5/6 nephrectomy 
rat model, tRA reduced the increase in PAI-1 observed associated with a 
reduction in αSMA, and this effect was independent of plasmin (Liu, Lu et al. 
2011). 
1.3.8 In vitro evidence of possible mechanisms for the effects of 
retinoids in renal fibrosis
Further insights into possible mechanisms underlying the effects of retinoids 
on fibrosis  are available from cell models although, unfortunately, there are 
few in vitro renal cell models to refer to. Other in vitro models, however, 
suggest possible pathways through which RA might exert its effects in TIF, 
which are summarised in Table 1.3. 
Firstly, the canonical retinoid signalling system has been shown to directly 
interfere with ECM production. For example, the mouse α2(I) collagen 
promoter has  at least two RAREs (Perez, Shull et al. 1992) and tRA-induced 
suppression of α2(I) collagen in rat HSCs has been shown to be mediated by 
RARβ and RXRα via one or more RAREs (Wang, Tankersley et al. 2002; 
Wang, Tankersley et al. 2004). Another example is  laminin B1: Its promoter 
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Table 1.3. Possible effects of retinoids on molecular markers of fibrosis in cellular 
models. 
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also contains an RARE and RA-induced transcription results in a pro-fibrotic 
effect (Vasios, Gold et al. 1989).
Secondly, retinoids can interfere indirectly with ECM production via cross-talk 
with the TGF-β signalling system although they have variable and often 
opposing actions depending on cell type and environment. Evidence for 
antagonistic effects of retinoids on the TGF-β1 signalling system in vitro 
includes: 1) tRA suppresses production of TGF-β in rat HSCs (Davis, Kramer 
et al. 1990); 2) RA decreases TGF-β expression in chicken myocytes 
(Jakowlew, Cubert et al. 1992); 3) tRA reduces TGF-β1 production in 
irradiated human lung fibroblasts  (Tabata, Kadokawa et al. 2006); and 4) Low-
dose 13cRA decreases TGF-β1 gene expression in rat vascular smooth 
muscle cells (VSMCs) (Morath, Ratzlaff et al. 2009). Conversely, evidence for 
potentiation of the TGF-β signalling system by RA includes: 1) tRA induces 
TGF-β1 mRNA and protein expression in HL-60 cells (Falk, De Benedetti et 
al. 1991); 2) RA increases active TGF-β1 in bovine endothelial cells (Kojima 
and Rifkin 1993); 3) 9cRA increases the secretion and activation of TGF-β in 
rat HSCs (Okuno, Moriwaki et al. 1997); and 4) High-dose 13cRA increases 
TGF-β1 mRNAs in rat VSMCs (Morath, Ratzlaff et al. 2009). 
The RA and TGF-β1 systems communicate through a variety of different 
mechanisms both at the transcriptional and post-transcriptional levels. For 
example, retinoids can inhibit TGF-β1 gene expression through their anti-AP-1 
activity as TGF-β1 mRNA expression is largely governed by three AP-1 
binding sites located in two promoters of the gene (Salbert, Fanjul et al. 1993; 
Blomhoff 1997). Retinoids may also interfere indirectly with TGF-β1 
expression via cross-talk with the RAAS. tRA can block the ANG II-induced 
increase in TGF-β1 mRNA in rat VSMCs, the mechanism of which involves 
retinoid receptor-dependent mechanisms and anti-AP-1 activity. Specifically, 
there was abrogation of the increase in ANG II-induced c-fos mRNA by tRA 
and also down-regulation of AT1 receptor mRNA expression, the promoter of 
which contains an AP-1 consensus site (Haxsen, Adam-Stitah et al. 2001). 
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Retinoids can also increase CTGF expression, which in turn promotes TGF-
β1 signalling, as there is a conserved DR2 RARE in the CTGF gene of mouse 
embryonal fibroblasts  (MEFs) (Brigstock 2003; Leask and Abraham 2003). 
Furthermore, RA can modulate TGF-β1 signalling through the serine protease 
plasminogen-plasmin system. RA has been shown to increase PA leading to 
an increase in plasmin activity, which in turn can activate latent TGF-β1 
(Kojima and Rifkin 1993; Okuno, Moriwaki et al. 1997). 
Other postulated mechanisms through which the retinoid signalling system 
interferes with TGF-β1 signalling include: 1) RAR-dependent phosphatases 
that limit R-Smad phosphorylation therefore reducing levels of nuclear Smad 
complexes (Cao, Flanders et al. 2003); 2) Direct interactions of RARs with 
Smad proteins which, in the absence of agonists, potentiate Smad signalling 
(Pendaries, Verrecchia et al. 2003); 3) Direct regulation of Smad2 activity by 
RXRα (Hoover, Burton et al. 2008); 4) Induction of the anti-fibrotic hepatocyte 
growth factor (HGF) (Wen, Li et al. 2005); and 5) Down-regulation of the 
Smad4-targeting microRNA-146a by tRA (Zhong, Wang et al. 2010). 
Thirdly, retinoids can interfere with fibrosis  via modulation of matrix 
degradation pathways without affecting TGF-β1 activity. For example, tRA can 
reduce the increase in PAI-1 protein following TGF-β1 treatment in RMCs, 
which is associated with reduced FN accumulation (Liu, Lu et al. 2008; Liu, Lu 
et al. 2011). Conversely, tRA and 9cRA induced PAI-1 gene expression in 
human VSMCs (Watanabe, Kanai et al. 2002). MMP expression and activity is 
also modulated by retinoids. In human skin fibroblasts, tRA reduced trypsin-
activatable collagenase (Oikarinen, Oikarinen et al. 1985), in keloid-derived 
fibroblasts, tRA suppressed the increase in MMP-13 (Uchida, Yoshimura et al. 
2003) and in 3T3 L1 preadipocytes as a model of HSCs, retinoids reduced 
collagenase activity (Numaguchi, Okuno et al. 1994). 
Finally, RA also up-regulates TG2 expression as the TG2 gene promoter 
possesses an RARE providing a further mechanism for how retinoids interfere 
with renal fibrosis (Nagy, Saydak et al. 1996; Yan, Noonan et al. 1996).
55
1.4 Aims and objectives of this project
Despite numerous  reports suggesting that retinoids might constitute promising 
new treatments for kidney diseases, there is growing evidence that they also 
have a pro-fibrotic potential in certain situations. The mechanisms of the pro-
fibrotic effects of retinoids in renal diseases are poorly understood. In this 
project, the central hypothesis  that renal fibroblasts are the target of the net 
fibrogenic effects of tRA is tested. Further this project aims to elucidate 
potential mechanisms behind the pro-fibrotic effects of tRA.
More specifically, the objectives of this project are to:
1) Establish the effect of tRA on net fibrogenesis in NRK-49F normal    
rat kidney fibroblasts in the absence and presence of TGF-β1; 
2) Explore the roles of selected fibrotic markers in the effects of tRA on 
TGF-β1-induced fibrosis in NRK-49F cells;
3) Investigate the roles for retinoid nuclear receptors, tRA carrier proteins 
and retinoid nuclear receptor-independent pathways in the effects  of 
tRA on TGF-β1-induced fibrosis in NRK-49F cells. 
1.5  Experimental design
The normal rat kidney fibroblast cell line “NRK-49F” was used as a cell model 
for renal interstitial fibrosis. An in vitro assay was set up to determine the 
effects of tRA on total collagen deposition in the absence and presence of 
TGF-β1 using picro-Sirius red stain. Molecular biology techniques  including 
reverse transcription quantitative polymerase chain reaction (RT-qPCR), 
Western blot analysis, immunocytochemistry, mass spectrometry, enzyme 
activity assays and gene silencing techniques were used to explore the 
contributions of fibrotic markers  and retinoid signalling molecules to the 
effects  of tRA on fibrosis in NRK-49F cells. Chemical agonists  and 
antagonists further determined the actions of specific proteins. The effects of 
tRA on total collagen deposition in human foreskin fibroblasts was also 
determined.
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Chapter 2. Materials and Methods
2.1  Materials
2.1.1 Cell culture
Plasticware: Cell lines and primary cultures were maintained in 75 cm2 flasks 
purchased from Greiner Bio-One Ltd (Stonehouse, UK). For use in 
experiments, cell culture multi-well plates in 6, 12, and 24 well formats and 60 
and 100 mm cell culture dishes were purchased from Corning B.V. Life 
Sciences (Amsterdam, The Netherlands), 35 mm dishes were purchased from 
Greiner Bio-One Ltd and 96 well collagen type-I coated tissue culture plates 
were purchased from BD Biosciences (Oxford, UK).
Cell culture medium and supplements: Dulbecco’s Modified Eagle Medium 
(DMEM) high glucose (4.5g/L) with 584 mg/L L-glutamine and 110 mg/L 
sodium pyruvate, DMEM/Ham’s F-12 (DMEM/F12) and RPMI-1640 were 
purchased from PAA Laboratories GmbH (Pasching, Austria) and 
supplemented with penicillin/streptomycin x100 (PAA Laboratories GmbH) 
and Fungizone amphotericin B (Invitrogen, Paisley, UK) to give final 
concentrations of 100 IU/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml 
Fungizone, unless otherwise stated. Foetal calf serum (FCS; Sigma-Aldrich 
Company Ltd., Gillingham, UK), BD Nu-Serum culture supplement (BD 
Biosciences) and insulin-transferrin-sodium selenite Liquid Media Supplement 
x100 sterile-filtered (ITS; Sigma) were used to supplement culture media as 
described in methods.
2.1.2 Retinoid preparations and TGF-β1
tRA: tRA with a purity of 98% determined by high performance liquid 
chromatography (Sigma) was dissolved in 100% ethanol to a stock 
concentration of 10 mM and stored at -80OC protected from light using 
aluminium foil. Stock solution was mixed by vortexing, incubated at 37OC for 
15 min, then vortexed again before use in experiments.
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Other retinoids: AGN194204, AGN193109 (kind gifts from R.A.S. 
Chandraratna, Irvine, California, USA), HX531 (a kind gift from H. Kagechika, 
Tokyo, Japan) and CD437, CD2019 and AGN195183 (kind gifts from Dr J. 
Corcoran, London, UK) were dissolved in DMSO and stored at -80OC; please 
refer to Table 2.1 and 2.2 for references for these chemicals. (E)-4-[2-(5,6,7,8-
tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid 
(TTNPB; Enzo Life Sciences, Exeter, UK), >98% purity, was dissolved in 
100% ethanol and stored at -80OC. Retinoid preparations  were protected from 
light at all times using aluminium foil. Molecular structures and biological 
activities of retinoids are shown in Figure 2.1 and Tables 2.1 and 2.2. Binding 
efficiencies (Kd) were determined by in vitro assays and half maximal effective 
concentrations (EC50) and half maximal inhibitory concentrations (IC50) were 
determined using functional assays in a cellular context (see references in 
Tables 2.1 and 2.2 for details).
 
TGF-β1: Human platelet TGF-β1 (R&D Systems, Abingdon, UK) was 
reconstituted in a solution of 4 mM hydrochloric acid (HCl; VWR International 
Ltd, Lutterworth, UK) and 0.1% bovine serum albumin (BSA; PAA 
Laboratories GmbH) that had been filter-sterilised using a polyethersulfone 
membrane with 0.2 μm pore size. A stock solution of 10 ng/μl TGF-β1 was 
stored at -80OC until use.
2.1.3 Other chemical agonists, antagonists and inhibitors
PPARβ/δ agonist GW0742 and PPARβ/δ antagonist GSK0660 (Sigma), both 
>98% purity by HPLC, TG2 inhibitor 1,3-dimethyl-2[(2-oxo-propyl)thio]
imidazolium chloride (NTU283; Zedira, Darmstadt, Germany), >95% purity by 
HPLC, and PAI-1 inhibitor tiplaxtinin (Axon Medchem, Groningen, The 
Netherlands), purity 99%, were dissolved in DMSO and stored at -80OC. 
Molecular structures and biological activities are shown in Figures 2.1 and 2.2 
and Tables 2.1, 2.2 and 2.3. Binding efficiencies (Kd) were determined by in 
vitro assays and half maximal effective concentrations (EC50) and half 
maximal inhibitory concentrations (IC50) were determined using functional 












































































































































Figure 2.1. Molecular structures of nuclear receptor agonists and antagonists.
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Table 2.1. Biological activity of nuclear receptor agonists used in experiments. EC50 half 
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Table 2.2. Biological activity of nuclear receptor antagonists used in experiments. IC50 
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Figure 2.2. Molecular structures of tiplaxtinin and NTU283.
Table 2.3. Biological activity of chemical inhibitors used in experiments. 
Chemical 
inhibitor
Target Ki (nM) IC50 (nM) References
Tiplaxtinin PAI-1 480 2700 (Elokdah, Abou-
Gharbia et al. 
2004)
NTU283 TG2 - 50000 (Skill, Johnson 
et al. 2004)
2.1.4 Immunocytochemistry and Western blotting
Antibodies: Table 2.4 lists  the antibodies used in experiments and their 
sources. All antibodies were stored according to the recommendations of the 
supplier.
Positive controls:  A-431 nuclear extract (sc-2122), human RXRγ transfected 
293T total cell lysate (sc-177886), Sol8 nuclear extract (sc-2157), HeLa 
nuclear extract (sc-2120) and NIH/3T3 total cell lysate (sc-2210) were 
purchased from Santa Cruz biotechnology, inc. (Heidelberg, Germany). Rat 
recombinant TG2 was a kind gift from Dr T. Johnson (Sheffield, UK).
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Table 2.4. List of antibodies used in experiments. BP blocking peptide; GAPDH 
glyceraldehyde-3-phosphate dehydrogenase; HRP horseradish peroxidase; HSP heat shock 
protein.
Antibody Manufacturer
Anti-E-FABP rabbit polyclonal IgG (H-45, sc-50379) 
Anti-CRABP-II goat polyclonal IgG and BP (K-13, sc-10065) 
Anti-RARα rabbit polyclonal IgG and BP (C-20, sc-551)
Anti-RARβ rabbit polyclonal IgG and BP (C-19, sc-552) 
Anti-RARγ mouse monoclonal IgG2A (G-1, sc-7387) 
Anti-RXRα rabbit polyclonal IgG and BP (D-20, sc-553)
Anti-RXRγ rabbit polyclonal IgG and BP (Y-20, sc-555)
Anti-PPARβ rabbit polyclonal IgG (H-74, sc-7197)
Anti-FN rabbit polyclonal IgG (H-300, sc-9068)
Anti-Col4A1/3 goat polyclonal IgG (G-20, sc-9301)
Anti-HSP-70 goat polyclonal IgG (K-20, sc-1060) 
Normal rabbit IgG control IgG (sc-2027)
Normal goat IgG control IgG (sc-2028)
Normal mouse IgG control IgG (sc-2025)
Goat anti-rabbit IgG-HRP conjugated secondary antibody (sc-2004) 
Bovine anti-goat IgG-HRP conjugated secondary antibody (sc-2378) 




Anti-vimentin mouse monoclonal IgM (ab20346)
Anti-cytokeratin mouse monoclonal IgG1 (ab49779)
Anti-collagen I rabbit polyclonal IgG (ab292)
Anti-collagen III rabbit polyclonal IgG (ab7778)
Anti-PAI-1 rabbit polyclonal IgG (ab7205)
Anti-TG2 mouse monoclonal IgG1 (ab2386) 




Anti-αSMA mouse monoclonal IgG2A (A2547) Sigma 
(Gillingham, UK)
Anti-GAPDH mouse monoclonal antibody (MAB374)  Millipore
(Durham, UK)
ECL sheep anti-mouse IgG-HRP conjugated secondary antibody 
(NA931V) 
GE Healthcare 
UK Ltd (Chalfont 
St Giles, UK)
Alexa Fluor 488 goat anti-rabbit IgG secondary antibody (A11008) 
Alexa Fluor 555 donkey anti-goat IgG secondary antibody (A21432) 
Invitrogen
(Paisley, UK)
Anti-TG2 mouse monoclonal antibody IA12 A kind gift from 
Dr T. Johnson 
(Sheffield, UK)
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2.1.5 Real-time quantitative polymerase chain reaction (qPCR)
Plasticware: RNase-, DNase-, DNA- and pyrogen-free bevelled filter pipette 
tips  were purchased from Starlab (Milton Keynes, UK) and RNase-, DNase-, 
DNA- and PCR inhibitor-free 1.5 ml microcentrifuge tubes were purchased 
from Alpha Laboratories (Eastleigh, UK).
Gene expression assays: TaqMan gene expression assays were purchased 
from Applied Biosystems (Foster City, California, USA). SABiosciences RT2 
qPCR primer assays were purchased from SABiosciences (Frederick, 
Maryland, USA). Please refer to Table 2.5 for details of assays.
Table 2.5. Gene expression assays used in experiments.
TaqMan gene expression assays SABiosciences RT2 qPCR 
primer assays
Collagen type I alpha1 (col1A1; collagen_A1-I)
Collagen type I alpha 2 (col1A2; Rn01638584_m1)
Collagen type III alpha 1 (col3A1; Rn01437681_m1)
Collagen type IV alpha 1 (col4A1; collagen_A1-IV) 
Fibronectin (FN; FN1_66s)























Rat ECM and adhesion molecules PCR array: Rat ECM and adhesion 
molecules PCR arrays were purchased from SABiosciences.
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2.2 Buffers and solutions
2.2.1 General solutions
Phosphate buffered saline (PBS): To make 1 L of 10x PBS, 80 g NaCl, 2 g 
KCl, 14.4 g Na2PO4 and 2.4 g KH2PO4 (all Sigma) were dissolved in double 
distilled water (ddH2O) to a volume of 1 L and pH adjusted to 7.4 using 1 M 
sodium hydroxide (NaOH; Sigma). For use in experiments 1x PBS was made 
by adding 100 ml 10x PBS to 900 ml ddH2O.
Tris-buffered saline (TBS): To make 1 L of 10x TBS, 80 g NaCl, 2 g KCl and 
30 g Tris base (Merck, Darmstadt, Germany) were added to ddH2O to a 
volume of 1 L and the pH adjusted to 7.4 using 5 M HCl. For use in 
experiments 1x TBS was made by adding 100 ml 10x TBS to 900 ml ddH2O.
TBST (0.1%): 1 ml Tween 20 (Sigma) was added to 1 L 1xTBS.
2.2.2 Solutions for the 2 dimensional (2D) in vitro model of fibrosis
Picro-Sirius red (PSR) stain (0.1%): Approximately 1.5 g of picric acid (Sigma) 
was added to 100 ml ddH2O to make saturated picric acid then 0.1 g of Direct 
Red 80 (Sigma) was added to make 0.1% PSR. 
Acetic acid solution (0.1%): To make 1% stock solution, 5 ml of acetic acid 
(VWR International Ltd) was added to 500 ml of ddH2O. Stock solution was 
further diluted 10x to make 0.1% acetic acid solution.
NaOH solution (0.1M): To make 1 M stock solution, 20 g of NaOH was added 
to 500 ml ddH2O. Stock solution was then diluted 10x to make 0.1 M NaOH.
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2.2.3 Immunocytochemistry
Paraformaldehyde solution (3.7%): 2 ml of 37% formaldehyde solution 
(Sigma) was added to 18 ml PBS.
Triton X solution (0.1%): 10 μl Triton X-100 (Sigma) was added to 10 ml PBS.
BSA blocking agent (1%): 0.1 g BSA was added to 10ml PBS.
2.2.4 Protein extraction and Western blotting 
PBS-TDS cell lysis buffer: To make 4x stock, 40 ml 10x PBS, 4 ml Triton 
X-100, 2 g sodium deoxycholate (Sigma) and 0.4 g sodium dodecyl sulphate 
(SDS; VWR International Ltd) were added to 56 ml ddH2O. For a working 
solution of 1x PBS-TDS with protease inhibitors, 5 ml of 4x stock solution was 
added to 15 ml ddH2O and 2 μl 5 mg/ml leupeptin, 4 μl 5 mg/ml pepstatin, 40 
μl 100 mM phenylmethanesulphonylfluoride (PMSF) and 40 μl 100 mM 
ethylenediaminetetraacetic acid (EDTA) (all Sigma) were added.
SDS (10%): 10 g SDS  was added to 100 ml ddH2O.
Tris  1.0 M (pH 6.8): 121.14 g Tris  base was  added to 1 L ddH2O and the pH 
adjusted to 6.8.
Tris  1.5 M (pH 8.8): 181.71 g Tris  base was  added to 1 L ddH2O and the pH 
adjusted to 8.8.
Ammonium persulphate (10%): 0.1 g ammonium persulphate (AppliChem UK 
Ltd, Lancaster, UK) was added to 1 ml of ddH2O.
Stacking and resolving gels  for Tris-glycine SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE): ddH2O, 30% acrylamide mix (Sigma), 1.5 M Tris 
(pH 8.8), 10% SDS, 10% ammonium persulphate and TEMED (Bio-Rad 
Laboratories, Hemel Hempstead, UK) were mixed in varying proportions to 
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produce 6-15% resolving gels. Stacking gels (5%) were made as above but 
using 1.0 M Tris instead of 1.5 M Tris. 
Western sample buffer (WSB): To make 10x stock solution, 100 mg SDS and 
2 mg bromophenol blue (Sigma) were added to 1 ml 1 M Tris HCl (pH 6.8) 
and 1 ml glycerol (Invitrogen). Stock solution was filtered using a 
polyethersulfone membrane with 0.2 μm pore size and stored at -20OC until 
use.
Electrophoresis  buffer: To make 5 L of 4x electrophoresis  buffer, 60.4 g Tris 
base, 288 g glycine (Merck) and 20 g SDS were added to ddH2O to a volume 
of 5 L. For use in experiments, 250 ml 4x electrophoresis buffer was added to 
750 ml ddH2O water and stored at 4OC until use.
Towbin transfer buffer: To make 2.5 L of 4 x stock, 30.28 g Tris base and 144 
g glycine were added to ddH2O to a volume of 2.5 L. For use in experiments, 
550 ml 4x Towbin transfer buffer and 440 ml methanol were added to 1210 ml 
ddH2O and stored at 4OC before use.
Milk blocking solution (5%): 2.5 g non-fat milk was added to 50 ml 0.1% TBST.
Mild stripping buffer: Mild stripping buffer was prepared according to Abcam’s 
protocol:
http://www.abcam.com/ps/pdf/protocols/stripping%20for%20reprobing.pdf. 
To make 1 L, 15 g glycine, 1 g SDS and 10 ml Tween 20 were added to 
ddH2O to a volume of 1L and the pH adjusted to 2.2.
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2.3 Cell culture
Cell cultures  were maintained in 75 cm2 flasks in Jencons Millenium 
incubators (Leighton Buzzard, UK) under humidified conditions at 37OC and 
5% CO2. For passaging or use in experiments, cells were washed with sterile 
Dulbecco’s PBS (PAA Laboratories GmbH) then trypsinised with 0.05%/ 
0.02% trypsin-EDTA (PAA Laboratories GmbH) under humidified conditions at 
37OC and 5% CO2 for 3-5 min. Cells were then resuspended in culture 
medium supplemented with FCS and counted using a haemocytometer. 
2.3.1 NRK-49F cell line
Normal rat kidney fibroblast-like cells  (NRK-49F; LGC Standards, Teddington, 
UK) were chosen as a suitable in vitro model for the study of the effects of 
tRA on renal interstitial fibroblasts. Long-term cell cultures were originally 
established from kidneys of adult non-inbred Osborne-Mendel rats  (Huu, 
Rosenblum et al. 1966) and consisted of both fibroblastic and epithelioid cells. 
Subsequently, several independently isolated fibroblastic clones were 
developed one of which was designated “49F” (de Larco and Todaro 1978). 
The NRK-49F cell line consists of cells  that are morphologically (Figure 2.3) 
and behaviourally similar to fibroblasts  and stain positive for the fibroblast cell 
marker vimentin and negative for the epithelial cell marker cytokeratin (Figure 
2.4). They express αSMA at low levels when quiescent, however αSMA is 
induced following treatment with TGF-β1 consistent with trans-differentiation 
of fibroblasts  to myofibroblasts  (Figure 2.5). NRK-49F cells have been used 
for operational definition of TGF-β activity (Roberts, Anzano et al. 1985) and 
as they characteristically respond to TGF-β1 they were selected as an 
appropriate cell line to study the effects  of tRA in an in vitro model of fibrosis. 
Cells  were propagated in DMEM supplemented with 5% FCS and subcultured 
before becoming confluent because of the risk of transformation. Cells 
between passages 5 to 20 (as they were designated passage 0 on arrival 
from supplier) were used for experiments.
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Figure 2.3. NRK-49F cells in culture. (Phase contrast microscopy, x200 magnification).
Figure 2.4. Characterisation of NRK-49F cells by immunocytochemistry. NRK-49F cells 
were seeded in 12 well plates in DMEM supplemented with 5% FCS and incubated overnight. 
Cells were fixed and permeabilised in 100% methanol  at -20OC for 10 min, then washed with 
PBS and blocked with 1% BSA for 1 h. Cells were then incubated in primary antibody for 1 h 
at room temperature, washed with PBS then incubated with Alexa Fluor secondary antibody 
overnight at 4OC followed by further washing then finally counterstained with 4’,6-diamidino-2-
phenylindole (DAPI). Cells stained positive for vimentin (A) and negative for cytokeratin (B). 












Figure 2.5. αSMA protein expression in NRK-49F cells by Western blot analysis. 
NRK-49F cells were cultured for 3 d in DMEM supplemented with 2.5% FCS and 2.5% Nu 
then for 4 d in DMEM supplemented with ITS then treated with 5 ng/ml TGF-β1 or vehicle for 
48 h. NRK-49F total cell lysate was extracted and run on a 10% polyacrylamide gel under 
reducing and denaturing conditions then transferred onto a nitrocellulose membrane. The 
membrane was blocked with 5% milk and subjected to αSMA immunoblotting. HSP-70 was 
used as a loading control. The experiment was repeated twice. αSMA protein expression was 
induced by TGF-β1 treatment. For full protocol  of protein extraction and Western blotting 
please see below.
2.3.2 Other primary cell cultures and cell lines
Human foreskin fibroblasts (a kind gift from Dr C. Yee, Bethesda, Maryland, 
USA) were maintained in DMEM supplemented with 10% FCS. This primary 
cell culture showed typical morphological appearances of fibroblasts (Figure 
2.6) and stained positive for the (myo)fibroblast markers vimentin and αSMA 
but negative for the epithelial marker cytokeratin (Figure 2.7). Cells between 
passages 8-12 were used for experiments.
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Figure 2.7. Characterisation of human foreskin fibroblasts by immunocytochemistry. 
Human foreskin fibroblasts were seeded in 12 well plates in DMEM supplemented with 10% 
FCS and incubated overnight. Cells were then subjected to immunocytochemical  analysis as 
before. Cells stained positive for vimentin and αSMA (A and B) and negative for cytokeratin 
(B). (Fluorescence microscopy, x200 magnification).
The COS-7 kidney fibroblast cell line (a kind gift from Dr N. Bury, London, UK) 
was originally derived from the African green monkey and was established by 
transformation of CV-1 cells  by an origin-defective mutant of SV40 which 
codes for wild type T antigen (Gluzman 1981). This cell line was maintained in 
DMEM supplemented with 10% FCS. On arrival, COS-7 cells were 

















Primary rat mesangial cells isolated from the glomeruli of Wistar rats  (a kind 
gift from Prof M. Rodriguez-Puyol, Madrid, Spain) were maintained in 
RPMI-1640 supplemented with 10% FCS; a primary rat mesangial cell culture 
isolated from the glomeruli of male Sprague-Dawley rats  (Dominion 
Pharmakine, Bizkaia, Spain) was maintained in DMEM/F12 supplemented 
with 20% FCS; the SM43 rat mesangial cell line (established by Dr M. 
Kitamura, London, UK) was maintained in DMEM/F12 supplemented with 
10% FCS; and the human mesangial cell line “HMCL” (a kind gift from Dr 
Xiong Zhong Ruan, London, UK) was maintained in RPMI-1640 
supplemented with 5% FCS and ITS.
2.3.3 2D in vitro model of fibrosis
The 2D in vitro model of TGF-β1-induced fibrosis (Xu, Norman et al. 2007) 
was used to qualitatively and quantitatively determine the effects of tRA and 
other retinoids on collagen deposition in cells. This model uses the strong 
anionic dye PSR to stain and quantify total collagen, a technique that is well 
documented in other commercially available collagen quantification assays 
such as the QuickZyme collagen assays (QuickZyme Biosciences, Leiden, 
The Netherlands) and Sircol soluble collagen assay (Biocolor Ltd, 
Carrickfergus, UK). PSR consists  of the small, anionic picric acid and the 
large, hydrophobic Sirius Red (Figure 2.8) and binds to collagens via the 
interaction of its acid sulphonic groups with the basic groups of collagen 
molecules. As  collagen types I, II and III are rich in basic amino acids PSR 
reacts strongly with these collagens (Junqueira, Bignolas et al. 1979). 
NRK-49F cells  were seeded at a density of 1x104/well in 96-well collagen type 
I-coated tissue culture plates in DMEM supplemented with 2.5% FCS and 
2.5% Nu for 3 d then DMEM supplemented with ITS for 4 d, as previously 
defined (Grotendorst, Rahmanie et al. 2004). Cells, with or without 2 h pre-
treatment with chemical antagonists/inhibitors, were then treated with 
retinoids and/or 5 ng/ml TGF-β1 in DMEM supplemented with ITS for a further 
48 h protected from light with aluminium foil. Vehicle-treated cells (cells 
exposed to the same concentration of DMSO or ethanol as treated cells) were 
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included as controls. Changes in cell morphology were observed and 
captured by photomicroscopy using a Nikon Eclipse TE2000-S 
epifluorescence microscope (Nikon Instruments  Europe BV, Amstelveen, The 
Netherlands) and a DXM1200F Nikon digital camera (Nikon UK Limited, 
Kingston upon Thames, UK). Cell detachment index was also recorded. The 
cell detachment index was a qualitative method of determining toxicity of 
treatment with a score of 0 representing no cell detachment and 0.5, 1, 1.5, 2, 
2.5, 3 and 3.5 equating to cell detachment of 5%, 10%, 20%, 30%, 40%, 60% 
and 80%, respectively. A score of 4 corresponded to complete disruption of 
the cell monolayer. Some caution should be exercised when using this 
method to determine cytotoxicity as not all detached cells represent non-
viable cells. The cells  were then fixed with 100% ice-cold methanol overnight 
at -20OC, rinsed then washed twice for 5 min with PBS before staining with 
200 μl 0.1% PSR for ≥ 4 h on a rocking platform at room temperature. Excess 
PSR was removed by a rinse and two 5 min washes with 0.1% acetic acid 
after which the acetic acid was discarded and the plate air-dried overnight at 
room temperature. Cell staining for PSR was observed and captured by 
photomicroscopy then the PSR eluted with 200 μl 0.1 M sodium hydroxide for 
≥ 2 h on a rocking platform at room temperature. Following elution, PSR 
staining was quantified by spectrophotometric analysis at 540 nm using a 
spectrophotometer (Dynex Technologies, Worthing, UK). Experiments were 
repeated at least three times. 



















2.4 Lactate dehydrogenase cytotoxicity assay
The effects of tRA, TGF-β1 and tiplaxtinin on NRK-49F cell toxicity were 
further assessed by measuring lactate dehydrogenase (LDH) release from 
cells using Promega’s CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega, Southampton, UK). LDH is  a cytosolic enzyme that converts 
pyruvate to lactate with the concomitant conversion of NADH to NAD+ when 
oxygen is absent or in short supply. LDH is also released from necrotic cells 
and the amount of LDH present in conditioned medium can therefore be used 
as a measure of cytotoxicity. Promega’s CytoTox 96® Non-Radioactive 
Cytotoxicity Assay measures LDH in conditioned medium by using a 30 
minute coupled enzymatic reaction that results in the conversion of a 
tetrazolium salt into a red formazan product. This  red formazan product can 
be measured by spectrophotometry with the amount of product being directly 
proportional to the number of necrotic cells. 
NRK-49F cells were seeded in quadruplicate into 96 well collagen type I-
coated plates and treated as per the protocol for the 2D in vitro model. A 
control for culture medium background absorbance, a volume correction 
control, a cell spontaneous LDH release control and a control to determine 
maximum LDH release from cells  were included in the plate set up. Lysis 
solution at a volume of 20 μl (10 μl per 100 μl) was added to the volume 
correction control and to control cells for complete lysis  and plates incubated 
under humidified conditions at 37OC and 5% CO2 for 45 min. Conditioned 
media at a volume of 50 μl from control wells  and experimental wells were 
then transferred to 96 well flat bottom enzymatic assay plates (Nunc, 
Roskilde, Denmark) and an equal volume of substrate mix was  added. Plates 
were incubated at room temperature for 30 min protected from light then 50 μl 
of stop solution was added to halt the reaction and the absorbance recorded 
at 490 nm using a spectrophotometer. 
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Percentage cytotoxicity for the test conditions was calculated as follows:
Maximum LDH release= (cells + lysis solution) - (medium + lysis solution)
Baseline LDH release= (cells alone) - (medium alone)
Test LDH release= (cells in test conditions) - (medium alone)
% cytotoxicity= (test LDH release) - (baseline LDH release)
                          _________________________________       X 100
   Maximum LDH release
 
% cytotoxicity was presented as an average of quadruplicates and 
experiments were repeated three times.
2.5 Immunocytochemistry
NRK-49F cells  at a density of 3x104 cells/well were seeded in 35 mm cell 
culture dishes in either DMEM supplemented with 5% FCS for 24 h or, if cells 
were to be treated with retinoids  with and without TGF-β1, they were cultured 
as per the protocol for the 2D in vitro model (see above). Culture medium was 
then removed and the cells washed with PBS at room temperature before 
fixing with 3.7% paraformaldehyde on ice for 10 min. Cells were washed 
thrice with ice-cold PBS, then permeabilised with 0.1% Triton in PBS for 5 min 
at room temperature then again washed with PBS. Cells  were blocked with 
1% BSA at room temperature for 1 h followed by incubation in primary 
antibody or normal Ig (used as a negative control) in PBS for 1 h at room 
temperature. After further washes with PBS, cells were incubated in a 1 in 
1000 dilution of secondary antibody labelled with fluorescent Alexa Fluor 488 
or Alexa Fluor 555 fluorescent dyes overnight at 4OC. Finally cells were again 
washed thrice with PBS, counterstained with 1 mg/ml 4’,6-diamidino-2-
phenylindole (DAPI) in PBS at a 1 in 1000 dilution for 5 min followed by 
further washes then examined using fluorescence photomicroscopy.
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2.6 Reverse transcription qPCR 
Two-step reverse transcription (RT)-qPCR was used to determine the mRNA 
expression of retinoid nuclear receptors, PPARβ/δ and two tRA carrier 
proteins in NRK-49F cells and to investigate the effects of tRA on fibrosis-
related genes. Experiments were carried out in an area of the laboratory 
designated for nucleic acid work and RNase ZAP (Sigma) was used to clean 
benches and gloves. All pipette tips  and plasticware were commercially-
purchased free of RNase, DNase, PCR inhibitors and pyrogens. Water used 
in experiments was either commercially-purchased and free of RNases or had 
been treated with 0.1% diethylpyrocarbonate (DEPC; Sigma). 
2.6.1 RNA extraction
RNA extraction from cells- standard protocol: NRK-49F cells were seeded in 
35 mm cell culture dishes at a density of 3x104 cells/dish in DMEM 
supplemented with 2.5% FCS and 2.5% Nu for 3 d then DMEM supplemented 
with ITS for 4 d. Cells were then treated with vehicle, 2 μM tRA, 5 ng/ml TGF-
β1 or tRA and TGF-β1 at variable time points (Figure 2.9). Total RNA was 
extracted using Qiagen’s RNeasy Mini Kit according to the manufacturer’s 
guidelines (Qiagen, Crawley, UK). Briefly, cell culture medium was removed 
then the cells lysed directly with Buffer RLT and 1% β-mercaptoethanol. Cell 
lysate was collected, mixed by pipetting then transferred to a QIA shredder 
spin column placed in a 2 ml collection tube and centrifuged for 2 min at full 
speed. An equal volume of 70% ethanol was then added to the homogenised 
lysate and mixed by pipetting before transferring to an RNeasy spin column 
placed in a 2 ml collection tube and centrifuged at 21.1 x g. The flow-through 
was discarded and the spin column membrane washed once with 700 μl 
Buffer RW1 and twice with 500 μl Buffer RPE, discarding the flow-through 
following centrifugation between each wash. The RNeasy spin column was 
then transferred to a new 2 ml collection tube and centrifuged at full speed for 
1 min to eliminate any carry over of Buffer RPE. Finally, the RNeasy spin 
column was placed in a 1.5 ml collection tube, 30 μl of RNase-free water 
directly added to the spin column membrane and the spin column centrifuged 
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for 1 min at full speed. Purity of the eluted total RNA was confirmed using a 
Nanodrop ND1000 spectrophotometer (Labtech, Ringmer, UK). Total RNA 


























Figure 2.9. Protocol for RNA extraction of NRK-49F cells at different time points. 
NRK-49F cells were seeded in 35 mm dishes in DMEM supplemented with 2.5% FCS and 
2.5% Nu for 3 d then DMEM supplemented with ITS for 4 d. Cells were then treated with 2 
μM tRA and/or 5 ng/ml TGF-β1 at different time points. Total RNA was extracted at the end of 
the experiment.
RNA extraction from small samples of cells (<5x105): For extraction of total 
RNA from cells seeded in 96-well plates, the Qiagen RNeasy Micro Kit was 
used according to manufacturer’s guidelines  (Qiagen). Briefly, following 
removal of culture medium and direct cell lysis  with Buffer RLT and 1% β-
mercaptoethanol, cell lysate was collected in 1.5 ml eppendorf tubes and 
samples homogenised by vortexing for 1 min. An equal volume of 70% 
ethanol was then added to the lysates and samples were transferred to an 
RNeasy MinElute spin column, centrifuged at full speed then washed once 
with Buffer RW1. On-column DNase digestion was performed by adding 
DNase I incubation mix directly to the spin column membrane and incubating 
for 15 min at room temperature. Further washes were performed using Buffer 
RW1, Buffer RPE and 80% ethanol. The MinElute spin columns were then 
centrifuged in new 2 ml collection tubes  with their lids open at full speed for 5 
min to dry the spin columns and remove residual ethanol. Finally, RNA was 
eluted into 1.5 ml collection tubes  by adding 14 μl of RNase-free water directly 
to the centre of the spin column membrane followed by centrifugation for 1 
min at full speed. The purity of the eluted total RNA was  confirmed using a 
Nanodrop ND1000 spectrophotometer and stored at -80OC until use.
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2.6.2 Reverse transcription
Total RNA was reverse transcribed into cDNA using the Omniscript Reverse 
Transcription Kit (Qiagen). Equal amounts of RNA for comparative samples 
(50 ng-2μg) were diluted in RNase-free water to a total volume of 13 μl then 2 
μl each of Buffer RT, deoxyribonucleotide triphosphate (dNTP) mix and oligo-
dT primers and 1 μl of Omniscript reverse transcriptase were added to start 
the reaction. Samples were incubated at 37OC for 60 min then the resulting 
cDNA diluted with 80 μl water and stored until use at -20OC. 
2.6.3 qPCR
Two methodologies were used for the fluorescent identification of PCR 
product using qPCR based on the availability of pre-designed primers from 
either Applied Biosystems or SABiosciences:
1) TaqMan chemistry: TaqMan gene expression assays  (Applied Biosystems) 
consist of 2 unlabelled primers for amplification and one 6-FAM-dye-labelled 
TaqMan probe for detection of the sequence of interest. When intact, the 
probe has a reporter (6-FAM) dye at its 5’ end and a non-fluorescent quencher 
dye at the 3’ end. The proximity of the reporter and quencher dyes results  in 
suppression of the fluorescent signal from the reporter dye by fluorescence 
resonance energy transfer (FRET) through space. If the target of interest is 
present in the reaction mix then the forward and reverse primers anneal at the 
3’ end of the cDNA with the probe annealing between the forward and reverse 
primer sites. During the reaction DNA polymerase extends the primer 
sequences and, as it reaches the probe, its  5’ nuclease activity cleaves the 
probe. The reporter is  released and separates from the quencher dye 
resulting in increased fluorescent signal. The increase in fluorescence is  used 
to monitor the accumulation of PCR product. The fluorogenic probes allow the 
detection of only the target of interest thus increasing the specificity of the 
reaction. TaqMan Universal 2x PCR Master mix (Applied Biosystems) was 
used with the 20x TaqMan gene expression assays which were supplied at a 
concentration of 18 μM for each primer and 5 μM for the probe.
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2) SYBR Green chemistry: SABiosciences RT2 qPCR primer assays 
consisting of forward and reverse primers  use SYBR Green technology to 
identify PCR product. SYBR Green is a fluorogenic dye that emits  little signal 
in solution but when bound to double-stranded DNA emits a strong signal. 
Thus, as qPCR product accumulates  there is increased binding of SYBR 
Green dye and increased fluorescent signal allowing quantification of the 
amplified target sequence. As the SYBR Green dye will detect all double-
stranded DNA this  methodology is less specific than the TaqMan chemistry 
and may require optimisation. In addition, if comparison of expression 
between genes is desirable, then amplicon length between target genes 
should be considered as a longer amplicon will produce more fluorescent 
signal if the primer efficiencies are the same. RT2 SYBR Green/ROX 2x qPCR 
Master Mix (SABiosciences) was used with the RT2 qPCR primer assays 
which were supplied at a concentration of 10 μM. 
To prepare the reactions, gene expression assay, qPCR Master Mix and 
RNase-free water, in the proportions shown in Table 2.6, were mixed in a 1.5 
ml micro-centrifuge tube then transferred to a 384-well optical plate before 
adding cDNA. Each reaction was repeated in triplicate and no template 
controls (NTCs) were included in plate set up. Plates were sealed with optical 
adhesive film, centrifuged and run on an ABI7900HT PCR system using 
Sequence Detection Systems (SDS) 2.2 software (Applied Biosystems), 
which was programmed to run for 40 cycles. Each cycle consisted of 
denaturation of cDNA for 15 sec at 95OC then annealing and extension for 1 
min at 60OC. A melting curve program was also included in the cycling when 
SYBR Green technology was  used to identify any primer-dimer or non-specific 
products in the reaction.
The cycle number at which the amount of amplified target reached a fixed 
threshold (Ct) was used to calculate relative changes in gene expression 
using the 2e-ΔΔCt method (relative quantification) (Livak and Schmittgen 2001). 
This  method involves normalisation of the gene of interest (GOI) to an 
endogenous control or housekeeping gene (HKG) (ΔCt= GOI Ct - HKG Ct) 
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then comparing the normalised vehicle-treated sample to the normalised 
treated sample (ΔΔCt= ΔCt of treated sample - ΔCt of vehicle-treated 
sample). Finally, the relative expression was determined by the formula 2-ΔΔCt, 
which represents the fold change in gene expression normalised to an 
endogenous reference gene and relative to the untreated control sample.
Table 2.6. Reactions prepared for TaqMan and SYBR Green qPCR 384 plate formats.
TaqMan technology SYBR Green technology
Gene expression assay (μl) 0.875 0.5
qPCR Master Mix (μl) 6.25 5
Water (μl) 2.875 3.5
cDNA (μl) 2.5 1
Total volume 12.5 10
2.6.4 Optimisation of qPCR
Identification of suitable HKGs: HKGs are genes that are constitutively 
expressed at relatively constant levels  in cells and are often used as 
endogenous controls because their expression does not alter across 
experimental conditions. The HKGs GAPDH, β-actin and RPL13a were 
chosen for further investigation as suitable endogenous controls in NRK-49F 
cells. Therefore, their mRNA expression was determined at 0, 1, 3, 6, 24 and 
48 h following treatment of cells with 2 μM tRA and/or 5 ng/ml TGF-β1, as per 
protocol. Fold change mRNA expression compared to the 0 h time point was 
determined by taking the difference between the 0 h sample and other time 
points (ΔCt) then calculating 2-ΔCt (Figure 2.10-2.12). 
There was a significant up-regulation of β-actin mRNA at 24 h following tRA, 
TGF-β1 and dual treatment with tRA and TGF-β1 (p<0.001), which was also 
present at 48 h following tRA treatment (p<0.05) and at 6 h and 48 h following 
TGF-β1 treatment (p<0.01) (Figure 2.11). β-actin was therefore eliminated as 
a suitable endogenous control. mRNA expression of Gapdh and Rpl13a was 
also modulated by treatment, albeit less so than for β-actin, with significant 
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increases in Gapdh mRNA expression at 24 h following tRA (p<0.05) and 
TGF-β1 treatment (p<0.01) (Figure 2.10) and significant decreases in Rpl13a 
mRNA expression at 1 and 3 h following dual treatment (p<0.05 and p<0.01, 
respectively) (Figure 2.12). Gapdh and Rpl13a were thus identified as more 
suitable HKGs for use as endogenous controls and Gapdh was ultimately 
chosen for use in experiments although data generated at the 24 h time point, 
which showed statistically significant changes, were interpreted with caution. 
A B
C D
Figure 2.10. Effect of tRA in the absence and presence of TGF-β1 on Gapdh mRNA 
expression in NRK-49F cells. NRK-49F cells cultured as per protocol  were treated with 2 
μM tRA and/or 5 ng/ml TGF-β1 for 0, 1, 3, 6, 24 or 48 h. Total RNA was collected at 48 h. 
Two-step RT-qPCR using SYBR Green technology was used to determine changes in mRNA 
expression of Gapdh following treatment with tRA (A), TGF-β1 (B) and tRA and TGF-β1 (C). 
The dissociation curve is shown in D. Data represent mean ± SEM of 3 independent cell 
culture studies. Statistical analysis was performed on transformed data using repeated 




Figure 2.11. Effect of tRA in the absence and presence of TGF-β1 on β-actin mRNA 
expression in NRK-49F cells. NRK-49F cells cultured as per protocol  were treated with 2 
μM tRA and/or 5 ng/ml TGF-β1 for 0, 1, 3, 6, 24 or 48 h. Total RNA was collected at 48 h. 
Two-step RT-qPCR using SYBR Green technology was used to determine changes in mRNA 
expression of β-actin following treatment with tRA (A), TGF-β1 (B) and tRA and TGF-β1 (C). 
The dissociation curve is shown in D. Data represent mean ± SEM of 3 independent cell 
culture studies. Statistical analysis was performed on transformed data using repeated 




Figure 2.12. Effect of tRA in the absence and presence of TGF-β1 on Rpl13a mRNA 
expression in NRK-49F cells. NRK-49F cells cultured as per protocol  were treated with 2 
μM tRA and/or 5 ng/ml TGF-β1 for 0, 1, 3, 6, 24 or 48 h. Total RNA was collected at 48 h. 
Two-step RT-qPCR using SYBR Green technology was used to determine changes in mRNA 
expression of Rpl13a following treatment with tRA (A), TGF-β1 (B) and tRA and TGF-β1 (C). 
The dissociation curve is shown in D. Data represent mean ± SEM of 3 independent cell 
culture studies. Statistical analysis was performed on transformed data using repeated 
measures ANOVA. *p<0.05, **p<0.01 vs 0 h.
Optimisation of SABiosciences RT2 qPCR primer assays: TaqMan and 
SABiosciences gene expression assays are purchased with a guarantee of 
adequate specificities and efficiencies. However, as part of the quality control 
process, a melting curve program was included in instrument set up for the 
gene expression assays that used SYBR Green technology to identify the 
presence of any non-specific products formed during the PCR reaction that 
could affect data analysis. Although the dissociation curves for the majority of 
gene expression assays displayed only one peak, those for Mmp-2 and 
Mmp-13 had more than one peak suggesting the presence of either primer-
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dimer formation or non-specific product (Figure 2.13A, B). These gene 
expression assays required optimisation before use in experiments.
A B
Figure 2.13. Dissociation curves for Mmp-2 and Mmp-13 PCR products. Dissociation 
curves for Mmp-2 (A) and Mmp-13 (B) RT-qPCR revealed more than one PCR product.
Primer concentration can affect the specificity of the reaction with high 
concentrations of primers increasing the yield of non-specific products. 
Therefore serial 1 in 2 dilutions  of the 10 μM Mmp-2 and Mmp-13 stock 
primers were used to determine whether the non-specific peaks on the 
dissociation curves could be eliminated. A 1 in 4 dilution of Mmp-2 and 
Mmp-13 primers produced a single specific peak (Figures 2.14 and 2.15) and 




Figure 2.14. Dissociation curves for Mmp-2 PCR product following serial dilutions of 
primer. qPCR was performed on 1 in 2 serial dilutions of Mmp-2 primers using NRK-49F 





Figure 2.15. Dissociation curves for Mmp-13 PCR product following serial dilutions of 
primer. qPCR was performed on 1 in 2 serial  dilutions of Mmp-13 primers using NRK-49F 
cDNA as template. A- no dilution of primer, B- 1 in 2 dilution, C- 1 in 4 dilution, D- 1 in 8 
dilution.
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Since the primers for Mmp-2 and Mmp-13 were to be diluted 1 in 4 in 
experiments it was  necessary to show that they were present in excess  in 
reactions, that diluting them did not limit the reaction and that their efficiencies 
were maintained and comparable to the efficiencies of the endogenous 
controls. Therefore, qPCR experiments were run on 1 in 3 serial dilutions of 
NRK-49F cDNA template using 1 in 4 dilutions of Mmp-2 and Mmp-13 primers 
and undiluted primers of HKGs Rpl13a and Gapdh. 
The cDNA dilution series produced evenly spaced amplification curves for all 
four primers tested (Figure 2.16) and linear standard curves with coefficients 
of determination (R2) >0.980 for all primers (Figure 2.17). The slopes of the 
standard curves were close to -3.32 suggestive of efficiencies of near 100% 
for all primers tested and the efficiencies calculated from the formula 10-1/slope 
were 1.98, 2.02, 1.99 and 1.98 for Mmp-2, Mmp-13, Rpl13a and Gapdh, 
respectively. Finally, to further determine if two amplicons have the same 
efficiency, the ΔCt variation with template dilution can be compared (Livak and 
Schmittgen 2001). The Cts of the HKGs Rpl13a and Gapdh at different cDNA 
dilutions were subtracted from the corresponding Cts  of Mmp-2 and Mmp-13. 
This  showed that the ΔCts at different cDNA dilutions were comparable 
(Figure 2.18) and the absolute values  of the slopes  generated by linear 
regression were <0.1. Therefore, the Mmp-2 and Mmp-13 primers at dilutions 




Figure 2.16. Amplification curves for Mmp-2, Mmp-13, Gapdh and Rpl13a using serial 
dilutions of NRK-49F cDNA. Serial  1 in 3 dilutions of NRK-49F cDNA were subjected to 
qPCR with Mmp-2 primers diluted 1 in 4 (A), Mmp-13 primers diluted 1 in 4 (B), undiluted 
Gapdh primers (C) and undiluted Rpl13a primers (D).
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Figure 2.17. Standard curves for Mmp-2, Mmp-13, Gapdh and Rpl13a. Serial 1 in 3 
dilutions of NRK-49F cDNA were subjected to qPCR. Standard curves for Mmp-2 (A), 








Figure 2.18. Validation of the 2-ΔΔCt method. Serial 1 in 3 dilutions of NRK-49F cDNA were 
subjected to qPCR with the diluted Mmp-2 and Mmp-13 or undiluted Gapdh and Rpl13a gene 
expression assays. ΔCt was calculated by subtracting Gapdh or Rpl13a Ct from Mmp-2 or 
Mmp-13 Ct. Data were plotted as the average of triplicates and fit using linear regression 
analysis.
2.7 Rat ECM and adhesion molecules PCR array
A rat ECM and adhesion molecules PCR array (SABiosciences) was used to 
explore the changes in expression of 84 genes important in cell-cell and cell-
matrix interactions in NRK-49F cells  treated with tRA with and without TGF-
β1. The RT2 ProfilerTM PCR array uses SYBR Green technology and consists 
of a set of optimised real-time PCR primer assays on a 96-well plate format. It 
performs gene expression analysis  with real-time PCR sensitivity and the 
multi-gene profiling capability of a microarray. The layout of the PCR array is 
shown in Figure 2.19.
RNA extracted from NRK-49F cells treated with vehicle, 2 μM tRA, 5 ng/ml 
TGF-β1 or both tRA and TGF-β1 was subjected to reverse transcription using 
SABiosciences RT2 first strand kit according to the manufacturer’s guidelines
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Figure 2.19. Rat ECM and adhesion molecules PCR array layout. A1-G12= target genes 
of interest; H1-H5= HKGs; H6= rat genomic DNA contamination control (RGDC); H7-H9= 
reverse transcription controls (RTC); H10-H12= positive PCR controls (PPC). Adamts1, 5, 8 
A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 1, 
5, 8; Catna1/Ctnna2 catenin (cadherin-associated protein) α 1, 2; Cd44 CD44 antigen; 
Cdh1-4 cadherin 1-4; Cntn1 contactin 1; Col1a1 procollagen type I α 1; Col2a1 procollagen 
type II α 1; Col3a1 procollagen type III α 1; Col4a1-3 procollagen type IV α 1-3; Col5a1 
procollagen type V α 1; Col6a1 procollagen type VI α 1; Col8a1 procollagen type XIII α 1; 
Cspg chondroitin sulfate proteoglycan 2; Ctgf connective tissue growth factor; Ctnnb1 catenin 
(cadherin associated protein beta 1); Ecm1 extracellular matrix protein 1; Emilin1 elastin 
microfibril  interfacer 1; Entpd1 ectonucleoside triphosphate diphosphohydrolase 1; Fbln1 
fibulin 1; Fn1 fibronectin 1; Hapln1 hyaluronan and proteogylcan link protein 1; Icam1 
intercellular adhesion molecule 1; Itga2-5 integrin alpha2-5; Itgad integrin α D; Itgae integrin 
α E; Itgal  integrin α L; Itgam integrin α M; Itgav integrin α V; Itgb1-4 integrin β 1-4; Lama1-3 
laminin α 1-3; Lamb2-3 laminin β 2-3; Lamc1 laminin γ  1; Mmp1a, 2-3, 7-9, 10-16 matrix 
metallopeptidase 1a, 2-3, 7-9, 10-16; Ncam1-2 neural cell  adhesion molecule 1-2; Pecam 
platelet/endothelial cell  adhesion molecule; Postn periostin, osteoblast specific  factor; 
Rgd1565950 similar to A disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif 2; Sele selectin, endothelial cell; Sell selectin, lymphocyte; Selp 
selectin, platelet; Sgce sarcoglycan, epsilon; Sparc secreted acidic  cysteine rich glycoprotein; 
Spock1 sparc/osteonectin, cwcv and kazal-like domains proteogycan 1; Spp1 secreted 
phosphoprotein 1; Syt1 synaptotagmin 1; Tgfbi transforming growth factor beta induced; 
Thbs1-2 thrombospondin 1-2; Timp1-3 tissue inhibitor of metallopeptidase 1-3; Tnc  tenascin 
C; Vcam1 vascular cell  adhesion molecule 1; Vtn vitronectin; Rplp1 ribosomal  protein, large, 
P1; Hprt hypoxanthine guanine phosphoribosyl transferase; Rpl13a ribosomal  protein L13A; 
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(SABiosciences). This kit was used to  transcribe cDNA from RNA for the PCR 
array as it has been designed and optimised for use with the RT2 ProfilerTM 
PCR arrays. The kit includes a built-in external RNA control that helps monitor 
reverse transcription efficiency and also tests for enzyme inhibitors 
contaminating RNA samples. Briefly, a genomic DNA elimination mixture for 
each RNA sample was prepared by adding 2 μl 5x genomic DNA elimination 
buffer to 1 μg RNA and the volume made up to 10 μl with RNase-free water. 
The DNA elimination mixture was incubated at 42OC for 5 min then placed on 
ice for 1 min. An equal volume of the reverse transcription cocktail consisting 
of a reverse transcriptase enzyme mix, reverse transcription buffer, random 
hexamers, oligo-dT primers, an external control mix and RNase-free water 
was then added to each reaction and samples incubated at 42OC for 15 min. 
The mixture was then immediately incubated at 95OC for 5 min to stop the 
reaction. First strand cDNA samples  were diluted with RNase-free water and 
stored at -20OC until use. 
Reactions for the PCR array were prepared by adding cDNA samples to RT2 
SYBR Green/ROX 2x qPCR Master Mix and RNase-free water according to 
manufacturer’s  guidelines. Reactions were mixed thoroughly then 25 μl was 
added to each of the 96 wells of the PCR array. Included in the PCR array 
were 5 HKGs for normalisation of qPCR data, a genomic DNA control (GDC) 
that detects non-transcribed genomic DNA contamination, a reverse 
transcription control (RTC) that tests  the efficiency of the RT2 first strand kit 
reaction with a primer set that detects template synthesised from the kit’s  built 
in external RNA control, and a positive PCR control (PPC) that tests the 
efficiency of the PCR itself using a pre-dispensed artificial DNA sequence and 
the primer set that detects it. The sets of replicate control wells (RTC and 
PPC) also test for inter-well, intra-plate consistency. Once prepared the plate 
was sealed with optical thin-walled 8-cap strips, centrifuged at 1000 x g for 1 
min at room temperature then run on an ABI7900HT PCR system using SDS 
2.2 software. Data was analysed using SABiosciences PCR Array Data 
Analysis  Web portal including calculation of 2e-ΔΔCt (relative quantification). 
Each PCR array was repeated in triplicate.
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For the GDC, a Ct of 35 or more is  considered acceptable. Of the 12 plates 
run, 10 had GDC Cts of greater that 35 and 2 had GDC Cts of less than 35. 
Of the two samples that had Cts of less than 35, one sample was from the 
vehicle treated-group and had a Ct of 34.91 and one sample was from the 
tRA-treated group and had a Ct of 34.52. The efficiency of the RT2 first strand 
kit reaction is  considered acceptable if the ΔCt of RTC-PPC is 5 or less. The 
averages of the triplicate samples for all four groups passed this test. Finally, 
a PPC was used to test for the presence of different amounts of PCR 
amplification inhibitors in each sample. The average PPC Ct on each plate 
should be 20 +/- 2 and should not vary by more than two cycles between 
arrays being compared. All the plates passed this  test. In general inter-plate, 
intraplate consistency was good with ΔCt of  less than 0.5 between replicates.
2.8 Protein extraction
In order to determine protein expression of nuclear receptors and RA carrier 
proteins and changes in expression or activity of proteins involved in fibrosis 
following tRA treatment with and without TGF-β1, total protein was  extracted 
and conditioned media stored from NRK-49F cell cultures.
NRK-49F cells were seeded in 10 cm cell culture dishes at a density of 1x105 
cells/dish in DMEM supplemented with 2.5% FCS and 2.5% Nu for 3 d then 
DMEM supplemented with ITS for 4 d; phenol red-free medium was used 
when collecting conditioned media (PAA Laboratories GmbH). Cells were then 
treated with vehicle, 2 μM tRA, 5 ng/ml TGF-β1 or dual treatment for 48 h and 
conditioned media stored at -80OC until use. For extraction of total cell 
lysates, cell culture dishes  were firstly placed on ice and the medium 
discarded. Cells were washed thrice with PBS then 500 μl of ice-cold PBS-
TDS with protease inhibitors (except where the protease inhibitors would 
interfere with protein activity assays) was added to the cell monolayer to cover 
the cells. Dishes were incubated for 1 h on ice. Cell scrapers (Greiner Bio-
One Ltd) were then used to collect total cell lysates and the lysates 
transferred to 1.5 ml microcentrifuge tubes (Greiner Bio-One Ltd) on ice. 
Intact cell membranes were broken up and DNA sheared using a 25 G needle 
92
and syringe then the samples were centrifuged at full speed for 2 min. 
Supernatants were transferred to fresh microcentrifuge tubes and the protein 
concentration of samples determined by comparison with a set of protein 
standards using the bicinchoninic acid method (BCA) and BCA protein assay 
reagent (Pierce Protein Research products, Thermo Scientific, Rockford, 
USA). The BCA protein assay combines the reduction of Cu2+ to Cu1+ by 
protein in an alkaline medium with the highly sensitive and selective 
colorimetric detection of the cuprous cation (Cu1+) by BCA. The resulting 
intense purple-coloured product can be measured by spectrophotometric 
analysis at 540 nm. NRK-49F total cell lysate was stored at -80OC until use.
2.9 Western blot analysis
Immunoblotting was used for the detection and relative quantification of 
proteins of interest in samples. This technique uses gel electrophoresis to 
separate native or denatured proteins by the length of polypeptide (denatured 
protein) or by the 3-D structure of the protein (native/ non-denatured protein). 
Protein is  then transferred from gel to a nitrocellulose membrane and the 
protein of interest detected using a specific antibody.
 
2.9.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Samples consisting of total cell lysate were diluted using PBS-TDS so that 
they contained equal amounts of protein for loading. Samples consisting of 
conditioned medium contained very small amounts of protein so these 
samples were not diluted and normalisation between samples was done using 
the corresponding undiluted total cell lysate as a loading control. Samples 
were prepared by mixing them with 10x WSB and 10% beta-mercaptoethanol 
(Sigma) then they were heated to 100OC for 10 min on a heat block to 
denature the protein. The biotinylated protein ladder (Cell Signalling 
Technology, Danvers, Massachusetts, USA) was heated at 100OC for 2 min. 
Samples, biotinylated protein ladder and Amersham’s full range rainbow 
molecular weight marker (GE Healthcare, Little Chalfont, UK) were then 
loaded onto a polyacrylamide gel and run in an electrophoresis tank filled with 
pre-cooled electrophoresis  buffer at 50 V for 30 min (through the stacking gel) 
93
then at 200 V for a further 45-60 min (through the resolving gel). Protein was 
then transferred from gel to Amersham’s Hybond C-super nitrocellulose 
membrane (GE Healthcare) in a transfer tank containing ice-cold Towbin 
transfer buffer at 100 V for 45 min. Adequate transfer was confirmed by 
Ponceau S staining (Sigma). The membrane was destained by washing with 
ddH2O then blocked in 5% skimmed milk blocking solution for 2 h at room 
temperature on a rocking platform. 
2.9.2 Immunodetection
Once blocking was complete the nitrocellulose membrane was incubated in 
primary antibody in 5% milk blocking solution overnight at 4OC on a rocking 
platform (the biotinylated ladder was  incubated in milk blocking solution 
alone). The membrane was  then briefly rinsed then washed thrice for 10 min 
with 0.1% TBST before incubating with secondary antibody conjugated to 
horseradish peroxidase in milk blocking solution for 1 h at room temperature 
on a rocking platform. The membrane was again washed with 0.1% TBST 
then the membrane developed using Amersham’s ECL Plus  Western Blotting 
detection Reagents (GE Healthcare) and exposed to Amersham’s  Hyperfilm 
ECL chemiluminescence film (GE Healthcare) in a dark room. 
Band densitometry was performed using Adobe Photoshop CS version 8.0 
software (Adobe Direct, Rotterdam, The Netherlands). Films were scanned, 
converting to greyscale, inverted then the contrast and brightness of the 
image optimised. The lasso tool was used to draw around the bands and the 
mean x pixels recorded. Results were normalised to a loading control and 
presented as mean +/- SEM relative to the vehicle control of three 
independent cell culture studies. 
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2.10 Mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC/MS/MS) was used to 
further determine the protein content of bands identified by TG2 and CRABP-
II immunoblotting of NRK-49F total cell lysates. 
2.10.1 Preparation of samples
General measures to avoid keratin contamination were taken including 
conducting experiments in a dust-free environment and wearing powder-free 
latex gloves. 
Identification of protein bands of interest in polyacrylamide gels: NRK-49F 
total cell lysate and NIH/3T3 total cell lysate (used as a positive control for 
CRABP-II protein) were prepared as per the protocol for Western blot analysis 
(see above). Samples were loaded onto 8% (TG2) or 15% (CRABP-II) 
polyacrylamide gels with Amersham’s full range rainbow molecular weight 
marker and run at 50 V for 30 min then 200 V for 45-60 min. Protein in the 
gels was then fixed in a solution of 10 ml methanol, 280 μl acetic acid and 29 
ml ddH2O for 30 min followed by staining with Brilliant Blue G-colloidal 
Coomassie stain (Sigma) made up of 4 parts stain and 1 part methanol at 
room temperature overnight on a rocking platform. Destaining consisted of 
one 10 min wash with the fixing solution followed by two 45-60 min washes 
with a solution of 10 ml methanol, 80 μl acetic acid and 29 ml ddH2O until the 
bands appeared in good contrast to the background. Bands of interest were 
identified and cut out of the gels by comparison of the stained gels  with 
immunoblots of TG2 and CRABP-II then cut into ~2 mm2 pieces and 
transferred to a microcentrifuge tube. The remainder of the gels were stored 
in ddH2O at 4OC.
Tryptic digestion: Trypsin was used for protein digestion because the 
proteolytic fragments  produced contain a basic arginine and lysine amino acid 
residue which are suitable for positive ionisation mass spectrophotometric 
analysis. Gel cubes were initially washed with 100 mM ammonium 
bicarbonate (Sigma) in excess then acetonitrile (ACN; Fisher Scientific UK 
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Ltd, Loughborough, UK) was added to dehydrate the samples before drying in 
a SpeedVac vacuum concentrator for 5 min at 35OC with the lids open. 
Samples were then rehydrated and the cysteine residues  reduced with 10 mM 
dithiothreitol (DTT; Sigma) at 56OC for 30 min. DTT was then discarded and 
ACN was again added before drying the samples  as before. The gel pieces 
were then incubated in 55 mM iodoacetamide (IAA; Sigma) at room 
temperature in the dark for 20 min. IAA binds covalently to the thiol group of 
cysteine residues  forming stable carbamidomethyl derivatives and preventing 
disulfide bond formation. The supernatant was subsequently discarded and 
the gel pieces again washed twice with 100 mM ammonium bicarbonate. 
Destaining was completed by washing with a 1:1 solution of 100 mM 
ammonium bicarbonate and ACN incubating at 37OC with shaking for 30 min 
and the process repeated until all visible stain was removed. The samples 
were dehydrated once more with ACN and dried in a SpeedVac vacuum 
concentrator for 10 min. Trypsin diluted to a final concentration of 13 ng/μl in 
50 mM ammonium bicarbonate was added to the gel pieces and samples 
incubated at 4OC for 20 min. Excess trypsin was removed and a minimal 
volume of 50 mM ammonium bicarbonate added to cover the gel pieces and 
keep them moist during enzyme cleavage. The samples were incubated at 
37OC for 3-4 h then at room temperature overnight. 
Peptide extraction: Following tryptic digestion the peptide-rich supernatant 
was collected in a fresh microcentrifuge tube. The gel pieces were washed 
with 50 mM ammonium bicarbonate then dehydrated with ACN and the 
supernatant pooled with the peptide samples already collected. This process 
of rehydrating with 50 mM ammonium bicarbonate and dehydrating with ACN 
was repeated until all peptide from the gel pieces had been collected. The 
peptide samples were lyophilised and stored at -80OC until use.
2.10.2 Mass spectrometry
LC/MS/MS was performed using an Ultimate LC system (Dionex Ltd, 
Camberley, UK) where chromatographic separations  of samples occurs 
before analysis  by a quadrupole time-of-flight (Q-ToF) tandem mass 
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spectrometer (Q-Tof micro; Waters Ltd, Elstree, UK) operating under 
MassLynx v4.0 software (Waters Ltd). 
Lyophilised peptide samples were initially prepared by resuspending them in 
23 μl 50 mM ammonium bicarbonate and incubating at 37OC with shaking. 
Samples were then taken up by an autosampler and transferred to a C18 
guard (trapping) column where peptides bind and are washed with loading 
“buffer A” consisting of 0.1% formic acid and H2O to remove salts  and provide 
peptides with a positive charge. Separation of peptides was commenced by 
reversed phase chromatography on a 75 μm C18 PepMap analytical column 
(Dionex). This  column captures small peptides (<50-kDa), which are then 
resolved with an increasing mixture of “Buffer B” (80% ACN, 0.1% formic acid 
and H2O) added to “buffer A” so that the gradient of ACN increases causing 
elution of peptides at a flow rate of 200 nL/min over 60 min. The eluate then 
enters the Q-ToF mass spectrometer which consists of an ion source and ion 
optics to accelerate and focus ions  through an aperture into the quadrupole 
filter, a collision cell and a time-of-flight analyser. The mass spectrometer is 
kept in a vacuum so that the ions do not collide with air molecules. 
When the eluate initially passes through the ion source, which is held at a 
high potential (35 kV) at 200OC, it undergoes electrospray ionisation with a Z-
spray source fitted to the QTof-micro. Highly charged, vapourised ions are 
then accelerated through four parallel metal rods (a quadrupole), two of which 
are positively charged and two negatively charged, down a potential gradient. 
The applied voltages cause the ions to fly in a specific trajectory between the 
rods and peptides that are too big, too small or highly charged are thrown out 
of their original path. The quadrupole is  responsible for filtering ions based on 
their mass-to-charge ratio (m/z) and the stability of their trajectories. The 
instrument was run in automated data-dependent switching mode so that 
precursor or parent ions are detected and selected based on their intensity for 
sequencing by collision-induced fragmentation (CID). This process is  called 
the MS survey scan. Selected peptides then move to the collision cell where a 
voltage is applied that excites  argon gas, which then collides with peptide 
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fragmenting it into product or daughter ions. A small focusing lens guides the 
amino acids  into the flight tube where pusher and puller plates cause the 
amino acids  to hit channel plates and a time-to-digital converter (TDC) allows 
data acquisition (MS/MS). The mass  spectrometer then continues to cycle 
through the “duty cycle” consisting of two MS survey scans and two MS/MS 
cycles. 
2.10.3 Peptide sequencing and database searching 
Data acquired from LC/MS/MS was displayed as a mass spectrum using 
ProteinLynx Global Server v2.2.5 software (Waters  Ltd), which creates a peak 
list from the data collected. The peak lists were searched against the Swiss-
Prot and an “in-house” neuroproteins database using Mascot software v2.2 
(Matrix Science Ltd, London, UK) and sequence information was obtained for 
the peptides identified. Experiments were performed once. 
2.11 Matrix metalloproteinase activity assay
Molecular Probes EnzChek® Gelatinase/Collagenase Assay kit (Invitrogen) 
was used to determine changes  in MMP activity in NRK-49F cells treated with 
tRA in the absence or presence of TGF-β1. This kit uses fluorescent DQ™ 
gelatin, which is efficiently digested by most gelatinases and collagenases, as 
substrate for the MMPs. DQ™ gelatin is so heavily labelled with fluorescein 
that the fluorescent signal is quenched however when it is  digested by MMPs 
fluorescent peptides are produced with the fluorescent signal being 
proportional to proteolytic activity.
The kit was used according to the manufacturer’s guidelines  to assay for 
gelatinase/collagenase activity in NRK-49F total cell lysates. Stock solution of 
1 mg/ml DQ™ gelatin was prepared by adding 1 ml ddH2O to the lyophilised 
substrate and protected from light. To each assay well of a 96 well flat bottom 
enzymatic assay plate, 20 μl of DQ™ gelatin (for a final concentration of 100 
μg/ml) was added to 80 μl of 1x reaction buffer and the solution pipetted up 
and down to mix. NRK-49F total cell lysates (extracted from cells  using PBS-
TDS with protease inhibitors except EDTA as EDTA inhibits  MMPs) were then 
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added at a volume of 100 μl to the assay wells. Reaction buffer alone was 
used as a negative control and Clostridium collagenase as a positive control. 
Reactions were performed in triplicate. The plate was incubated at room 
temperature protected from light for 2 h then fluorescence intensity measured 
using a BioTek FLx800 fluorescence microplate reader (BioTek UK, Potton, 
UK) at an absorption of  485 +/- 20 nm and fluorescence emission detection of 
530 nm +/- 20 nm. Results were corrected for background fluorescence by 
subtracting the value derived from the negative control. Results were 
presented as mean of percentage change in fluorescence compared to 
vehicle-treated NRK-49F cells of three independent cell culture studies. 
2.12 Gene silencing techniques: Short-interfering RNA 
transfection in NRK-49F cells
Ambion’s Silencer® Select pre-designed short-interfering RNAs (siRNA; 
Applied Biosystems) were used to knockdown expression of TG2 and PAI-1 in 
NRK-49F cells (Table 2.7). Non-targeting Silencer® Select negative control # 
1 siRNA (Applied Biosystems) was used as a negative control. Chemical-
based transfection gave variable and inconsistent knockdown therefore a 
combination of electroporation and chemical-based transfection was used to 
attempt adequate silencing of gene expression.
Bio-Rad electroporation: A Bio-Rad Gene Pulser II electroporation system 
with the Capacitance Extender Plus accessory (Bio-Rad, Hemel Hempstead, 
UK) was used for electroporation of NRK-49F cells. This system delivers 
exponential decay pulses characterised by two parameters, the field strength 
(kV/cm) and the time constant, which can be adjusted by varying the voltage 
and capacitance. 
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Table 2.7. Sequences for Ambion’s Silencer® Select siRNAs used for knockdown in 
NRK-49F cells. 


















A pilot study was performed to determine the optimal voltage and capacitance 
for delivery of siRNA into NRK-49F cells. Cy5-labelled siRNA (Dharmacon, 
Thermo Scientific, Loughborough, UK), to give a final concentration of 100 
nM, was added to 1.5 x 106 cells/ml NRK-49F cells suspended in sterile PBS 
(without Ca2+ and Mg2+). A negative control of untreated cells was included in 
experimental set up. Cell suspensions at a volume of 0.6 ml were then 
electroporated at 0-400 V and 250 or 500 μF in sterile Gene Pulser cuvettes 
with a 0.4 cm electrode gap (Bio-Rad) at room temperature. They were 
subsequently transferred to 35 mm cell culture dishes  and cultured in 
antibiotic-free DMEM supplemented with 2.5% FCS and 2.5% Nu. Cell 
morphology was examined by photomicroscopy and transfection efficiency 
was determined by flow cytometry. 
Flow cytometry was performed by trypsinising cells then resuspending them in 
PBS supplemented with 2.5% FCS and washing them two further times with 
PBS supplemented with 1% FCS. Cells were then subjected to flow cytometry 
using a BD FACSCanto II flow cytometer (BD Biosciences) and data analysed 
using FloJo Flow Cytometry Analysis Software (Ashland, USA). 
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Chemical and electrical transfection: On the basis of the results of the pilot 
study, optimal electroporation settings were selected as 300 V and 250 μF as 
these conditions  achieved greatest transfection of Cy5-labelled siRNA while 
keeping cell death to a minimum (see Chapter 6 for further details). For 
subsequent experiments, cells were electroporated using the methods 
described above with some adaptations. Cells  were suspended in Opti-MEM 
and 7.5 μl lipofectamine RNAiMAX transfection reagent (both Invitrogen) prior 
to electroporation, and a concentration of 20 nM targeting siRNA was used as 
per manufacturer’s guidelines. Untreated cells  and those treated with negative 
control siRNA were used as controls. Following electroporation, NRK-49F 
cells were plated in collagen type-I-coated 96-well plates and cultured in 
antibiotic-free DMEM supplemented with 2.5% FCS and 2.5% Nu for 3 d then 
antibiotic-free DMEM supplemented with ITS and a further dose of 20 nM 
siRNA and lipofectamine RNAiMAX for 4 d prior to treatment with 2 μM tRA 
and/or 5 ng/ml TGF-β1. Knockdown was determined by two-step RT-qPCR of 
RNA extracted on d 7 of tissue culture and the effects of knockdown on total 
collagen deposition determined using the 2D in vitro model of fibrosis  (see 
protocol above). Experiments were repeated twice.
2.13 Statistical analysis
Data was statistically analysed using GraphPad Prism software (GraphPad 
Software, San Diego, California, USA). Parametric data was analysed using a 
paired t-test when comparing results between two groups and a repeated 
measures analysis  of variance (ANOVA) with Tukey post-test was used to test 
for statistical significance between multiple groups. Results  presented as fold 
change were logarithmically transformed before performing statistical 
analysis. P<0.05 was taken as  statistically significant. Data was only analysed 
when 3 or more independent cell culture studies  were performed. Although 
cell detachment index was analysed using the methodology described above 
the data could also be described as interval variables and statistically 
analysed as such. 
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Chapter 3. Effects of all-trans retinoic acid (tRA) on 
fibrogenesis in NRK-49F cells
3.1 Effect of tRA on total collagen deposition in the 2D in 
vitro model of fibrosis
There are few, if any, reports of the effects of retinoids on fibrosis in renal 
interstitial fibroblasts. Therefore, NRK-49F cells were used as a renal 
fibroblast cell model to determine the net effects of tRA on total collagen 
deposition using the 2D in vitro model of fibrosis. tRA at doses of 0.02-5 μM 
were chosen for initial experiments on the basis of doses of tRA used in other 
published data (Liu, Lu et al. 2008).
tRA at concentrations of 0.02-5 μM, with and without 5 ng/ml TGF-β1, dose-
dependently increased PSR staining for total collagen (Figure 3.1A, B). Up to 
5 μM tRA alone did not increase LDH release from cells, but, in the presence 
of TGF-β1, there was a significant increase in LDH release with the highest 
dose tested of 5 μM tRA (Figure 3.1C). tRA, with or without TGF-β1, did not 
significantly increase cell detachment index (Figure 3.1D). 
3.2 Effects of tRA on selected fibrotic markers using a PCR 
array
In order to study the effects of tRA on fibrosis  in more detail, a rat ECM and 
adhesion molecules PCR array was employed, which allowed the study of 84 
genes associated with fibrosis. In this pilot study, NRK-49F cells were treated 
as per protocol then RNA extracted and subjected to the RT-qPCR array. tRA 
at a concentration of 2 μM was used in this and subsequent experiments 
because it consistently caused an increase in PSR staining both with and 
without TGF-β1, without evidence of toxicity, in the 2D in vitro model of 
fibrosis. Triplicate measurements of each RNA sample from a single biological 
study were recorded.  
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Figure 3.1. Effect of tRA in the absence and presence of TGF-β1 on total collagen 
deposition in NRK-49F cells. NRK-49F cells cultured as per protocol were treated with 
0.02-5 μM tRA with and without 5 ng/ml TGF-β1 for 48 h. The effects on total  collagen 
deposition were illustrated by representative photomicroscopy of PSR staining (x100 
magnification) (A) and quantified by spectrophotometric  analysis of eluted PSR, n=5 (B). 
Cytotoxicity was assessed by LDH release, n=3 (C) and cell detachment, n=3 (D). Data 
represent mean ± SEM of 3 or more independent cell culture studies. * p<0.05, ** p<0.01, *** 
p<0.001 vs vehicle; ψ p<0.05, ψ ψ p<0.01 vs TGF-β1-treated group.
From the 84 genes in the PCR array, those known to be important in ECM 
accumulation, including collagens, MMPs and TIMPs, were selected for 
further study in this chapter. However, a summary of all results from the PCR 
array dataset generated from SABiosciences PCR Array Data Analysis Web 
portal can be found in the Appendix section of this  thesis  (Supplementary 
tables 1-3) and there are changes in expression in some genes of unknown 
significance, that may also be worth more detailed study in the future.
Table 3.1 lists  selected genes that demonstrated a two-fold or more up- or 
down-regulation by 2 μM tRA in the absence and presence of 5 ng/ml TGF-β1 
and Figure 3.2 illustrates the effects of tRA with and without TGF-β1 on 
selected genes from the PCR array. 
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Table 3.1. Summary of relevant molecular markers up-regulated and down-regulated by 
tRA in the absence and presence of TGF-β1 in NRK-49F cells. Molecular markers that 
showed a two-fold or more up- or down-regulation following treatment with 2 μM tRA with or 
without 5 ng/ml TGF-β1 in the PCR array. Red= potential  pro-fibrotic  markers of tRA; green= 
potential anti-fibrotic markers of tRA.
Markers up-regulated by tRA Markers down-regulated by 
tRA
TGF-β1 (-) Mmp-7 Ctgf, Mmp-3, Mmp-9, Mmp-10, 
Mmp-12, Mmp-13 
TGF-β1 (+) Col4a3, Mmp-7 Ctgf, Col6a1, Col8a1, Mmp-13, 
Mmp-14, Timp-1, Timp-2, Timp-3
TGF-β1 treatment of NRK-49F cells  tended to up-regulate the majority of 
collagens and Fn1 as well as Timps -1 and -3; there was a tendency towards 
down-regulation of most MMPs although the mRNA of Mmps -9 and -10 
tended to increase (Figures 3.2Ai, Aii). Overall these results are consistent 
with the concept that TGF-β1 is pro-fibrotic.
tRA treatment tended to down-regulate many collagen mRNAs as well as 
some other pro-fibrotic markers, including Col1a1, Col4a3, Col5a1, Col6a1, 
Col8a1, Ctgf and Fn1; conversely, there was evidence of up-regulation of 
other markers including Col3a1, Col4a1 and Col4a2 (Figure 3.2Bi). tRA 
tended to down-regulate the MMPs including Mmps -1a, -3, -9, -10, -12, -13, 
-15 and -16 although Mmps -2, -7 and -11 were up-regulated; there was a 
tendency towards down-regulation of Timps- 1-3 by tRA (Figure 3.2Bii).
In NRK-49F cells  treated with both tRA and TGF-β1 compared to TGF-β1-
treated cells alone there was a trend towards a down-regulation of Col3a1, 
Col4a1, Col4a2, Col5a1, Col6a1, Col8a1, Ctgf, Fn1, Timps- 1-3 and Mmps -2, 
-3, -10, -13, -14, -15 and -16 but a tendency towards up-regulation of Col4a3 





Figure 3.2. RT-qPCR array analysis of a pilot study of the effects of tRA in the absence 
and presence of TGF-β1 on mRNA expression of selected fibrotic markers in NRK-49F 
cells. NRK-49F cells cultured as per protocol were treated with 2 μM tRA with and without 5 
ng/ml TGF-β1 for 48 h. Total  RNA was extracted and subjected to an RT-qPCR array. Fold 
change in mRNA expression of collagens, Ctgf and Fn1 in TGF-β1- and tRA-treated cells vs 
vehicle-treated cells (Ai, Bi) and dual-treated cells vs TGF-β1-treated cells (Ci) are shown in 
the left panels. The right panels demonstrate fold changes in mRNA expression of the MMPs 
and TIMPs in TGF-β1- and tRA-treated cells vs vehicle-treated cells (Aii, Bii) and dual-
treated cells vs TGF-β1-treated cells (Cii). Data represent average of triplicated 
measurements of samples from one cell  culture study therefore statistical analysis was not 
performed.
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3.3 Further evaluation of collagens and fibronectin
To confirm some of the results of the RT-qPCR array Col1a1, Col3a1 and Fn1 
mRNA expression was studied using standard RT-qPCR. These molecular 
markers were chosen as they are known to be important in TIF. In addition, 
Col1a2 mRNA expression was explored as it is also important in fibrosis and 
was not included in the array. As well as the 48 h time point used in the RT-
qPCR array, changes in mRNA expression at 6 h and 24 h were also studied. 
Col1a1 mRNA expression was  significantly suppressed by tRA and dual 
treatment at 24 h; by 48 h this effect of tRA alone had disappeared although 
there was a trend towards reduced Col1a1 mRNA expression by dual 
compared to TGF-β1 treatment (Figure 3.3A). Col1a2 mRNA was significantly 
suppressed at 48 h by tRA and there was  a non-significant suppression by 
dual treatment compared to TGF-β1 treatment at this time point. There was a 
trend towards Col1a2 mRNA suppression by tRA at 24 h that reached 
significance in the dual treatment group and there was a significant 
suppression of Col1a2 mRNA by dual- versus TGF-β1 treatment at this time 
point (Figure 3.3B). Col3a1 mRNA expression was significantly suppressed at 
24 h by tRA, however at 48 h there was an induction of Col3a1 mRNA in all 
three groups. There was a non-significant reduction in Col3a1 by dual 
treatment compared to TGF-β1 treatment at the 6 h, 24 h and 48 h time points 
(Figure 3.3C). Finally, Fn1 mRNA was significantly suppressed at 24 h by tRA 
although the effect did not reach significance at 48 h. There was a significant 
suppression of Fn1 expression by dual compared to TGF-β1 treatment at 24 
h, an effect that appeared to be reversed at the 48 h time point (Figure 3.3D). 
Standard RT-qPCR results  at the 48 h time point for Col1a1 and Col3a1 were 
in agreement with results from the RT-qPCR array. However, results for Fn1 
did differ between the two techniques: While tRA tended to down-regulate Fn1 
mRNA in both standard RT-qPCR and the RT-qPCR array, there was 
evidence of Fn1 mRNA suppression following dual versus TGF-β1 treatment 





Figure 3.3. Effect of tRA in the absence and presence of TGF-β1 on Col1a1, Col1a2, 
Col3a1 and Fn1 mRNA expression. NRK-49F cells were cultured as per protocol and 
treated with 2 μM tRA with and without 5 ng/ml  TGF-β1 for 0, 6, 24 or 48 h. Total  RNA was 
extracted at 48 h and two-step RT-qPCR performed to determine changes in mRNA 
expression of Col1a1 (A), Col1a2 (B), Col3a1 (C) and Fn1 (D). Results were normalised to 
Gapdh and are presented as fold change compared to 0 h. Data represent mean ± SEM of 3 
independent cell  culture studies; clear bars= tRA-treated group, striped bars= TGF-β1-treated 
group, chequed bars= dual-treated group. Statistical  analysis was performed on transformed 
data using repeated measures ANOVA. * p<0.05, ** p<0.01, *** p<0.001 vs 0 h group; + 
p<0.05, ++ p<0.01, +++ p<0.001 between groups indicated.
Because there was evidence of a dual effect of tRA on fibrosis  at the level of 
gene expression, further analysis of collagens and FN at the protein level was 
done. Immunocytochemistry of collagen types  I, III and IV suggested that the 
increase in PSR staining by tRA with and without TGF-β1 was due, at least in 
part, to increases in collagen types I and III (Figure 3.4), but not type IV (data 
not shown). Western blot analysis showed that FN protein expression was not 
altered by tRA treatment although dual treatment with tRA and TGF-β1 














Figure 3.4. Effect of tRA in the absence and presence of TGF-β1 on collagen types I 
and III protein expression using immunocytochemistry. NRK-49F cells were cultured as 
per protocol and treated with 2 μM tRA with and without 5 ng/ml TGF-β1 for 48 h. Cells were 
fixed with 4% paraformaldehyde, permeabilised with 0.1% Triton X-100 and blocked with 1% 
BSA before the addition of primary then secondary antibodies. Staining of collagen types I 








Figure 3.5. Effect of tRA in the absence and presence of TGF-β1 on FN protein 
expression using Western blot analysis. Total cell lysate was extracted from NRK-49F 
cells cultured as per the protocol and treated with 2 μM tRA with and without 5 ng/ml TGF-β1 
for 48 h. Total  cell  lysate was loaded and run on 6% polyacrylamide gels under reducing and 
denaturing conditions then transferred onto a nitrocellulose membrane before blocking with 
5% milk blocking solution and immunoprobing. A- Representive immunoblot of FN with 
HSP-70 used as a loading control; B- fold change of FN band densitometry relative to vehicle 
and normalised to HSP-70 loading control. Data represent mean ± SEM of 3 independent cell 
culture studies. Statistical analysis was done on transformed data using repeated measures 
ANOVA. * p<0.05, ** p<0.01  vs vehicle-treated group. 
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3.4 Further evaluation of MMPs
Results from the RT-qPCR array suggested that tRA in the absence and 
presence of TGF-β1 down-regulated several MMPs. To confirm these results 
standard RT-qPCR was performed on Mmps -2, -3 and -13. These MMPs 
were chosen for further evaluation because of their biological significance in 
fibrosis and because their Ct values were less than 30 suggesting that they 
might be expressed at protein level and play a role in matrix turnover in this 
cell model. 
tRA caused a significant suppression of Mmp-2 mRNA at 24 h followed by an 
up-regulation at 48 h; dual treatment compared to TGF-β1 treatment alone 
caused a suppression of Mmp-2 at 24 h and 48 h (Figure 3.6A). Mmp-3 
mRNA expression was significantly reduced in all three treatment groups at 
24 h and 48 h and dual treatment compared to TGF-β1 treatment alone 
caused a significant suppression at 48 h (Figure 3.6B). Finally, tRA treatment 
caused a non-significant increase in Mmp-13 mRNA at 6 h followed by a 
significant suppression at 24 h in all three treatment groups (Figure 3.6C). 
These results were consistent with the RT-qPCR array data.
Although the majority of Mmps were down-regulated by tRA with and without 
TGF-β1 at the level of gene expression, the Timps were also down-regulated. 
Therefore, to determine whether tRA altered MMP activity as well as gene 
expression, NRK-49F total cell lysates were subjected to an MMP activity 
assay. The positive control of 0.025-0.2 U/ml Clostridium collagenase caused 
an increase in fluorescence confirming that the assay was working properly 
(data not shown). tRA and TGF-β1 both caused a significant reduction in 
fluorescence compared to the vehicle-treated group although no additive 





Figure 3.6. Effect of tRA in the absence and presence of TGF-β1 on Mmp-2, Mmp-3 and 
Mmp-13 mRNA expression. NRK-49F cells were cultured as per protocol and treated with 2 
μM tRA with and without 5 ng/ml TGF-β1 for 0, 6, 24 or 48 h. Total RNA was extracted at 48 h 
and two-step RT-qPCR performed to determine changes in mRNA expression of Mmp-2 (A), 
Mmp-3 (B) and Mmp-13 (C). Results were normalised to Gapdh and are presented as fold 
change compared to 0 h. Data represent mean ± SEM of 3 independent cell  culture studies; 
clear bars= tRA-treated group, striped bars= TGF-β1-treated group, chequed bars= dual-
treated group. Statistical analysis was performed on transformed data using repeated 
measures ANOVA. *p<0.05, **p<0.01, ***p<0.001 vs 0 h; + p<0.05, ++ p<0.01, +++ p<0.001 
between groups indicated. 
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Figure 3.7. Effect of tRA in the absence and presence of TGF-β1 on MMP activity. 
NRK-49F cells were cultured as per protocol and treated with 2 μM tRA with and without 5 ng/
ml TGF-β1. Total  cell lysates were subjected to Molecular Probes’ EnzChek Gelatinase/
Collagenase Assay as per manufacturer’s guidelines. The reactions were incubated at room 
temperature for 2 h and fluorescence measured using a microplate reader with excitation at 
485 +/- 20 nm and emission detection at 530 nm +/- 20 nm. Background fluorescence was 
subtracted from each value. Data represent mean +/- SEM of % change in fluorescence 
compared to vehicle-treated cells of 3 independent cell  culture studies. Statistical analysis 
was done using repeated measures ANOVA. *** p<0.001 vs vehicle-treated cells.
3.5 Evaluation of other important molecular markers
The RT-qPCR array was a catalogued item and did not include all genes 
involved in fibrogenesis therefore the expression of some additional fibrogenic 
markers were examined using standard RT-qPCR. 
The mRNA expression of Tgfbs 1-3 was examined as, although TGF-β1 is 
generally considered to be the major TGF-β isoform causing TIF, there is 
evidence that TGF-β2 and TGF-β3 also play a role (Figure 3.8A-C). TGF-β1 
treatment caused a significant increase in Tgfb1 gene expression at 6 h 
consistent with TGF-β1 auto-induction; dual treatment caused a non-
significant increase in Tgfb1 at the same time point although no additive effect 






Figure 3.8. Effect of tRA in the absence and presence of TGF-β1 on Tgfb1, Tgfb2, 
Tgfb3, Pai1 and Tg2 mRNA expression. NRK-49F cells were cultured as per protocol  and 
treated with 2 μM tRA with and without 5 ng/ml  TGF-β1 for 0, 6, 24 or 48 h. Total  RNA was 
extracted at 48 h and two-step RT-qPCR performed to determine changes in mRNA 
expression of Tgfb1 (A), Tgfb2 (B), Tgfb3 (C), Pai1 (D) and Tg2 (E). Results were normalised 
to Gapdh and are presented as fold change compared to 0 h. Data represent mean ± SEM of 
3 independent cell culture studies; clear bars= tRA-treated group, striped bars= TGF-β1-
treated group, chequed bars= dual-treated group. Statistical  analysis was performed on 
transformed data using repeated measures ANOVA. *p<0.05, **p<0.01, ***p<0.001 vs 0 h; + 
p<0.05, ++ p<0.01 between groups indicated.
 
tRA significantly suppressed Tgfb1 at 24 h with evidence of on-going non-
significant suppression at 48 h (Figure 3.8A). tRA suppressed Tgfb2 gene 
expression at 6 h with a tendency towards  ongoing suppression at 24 and 48 
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h and at 48 h following dual treatment (Figure 3.8B). In contrast, Tgfb3 gene 
expression was induced by tRA, further increased by TGF-β1 and increased 
still more by dual treatment at 6 h; tRA treatment continued to cause a 
significant increase in Tgfb3 at 24 and 48 h but this induction was only 
maintained at 24 h in the dual treatment group (Figure 3.8C).
Pai1 and Tg2 gene expression were also studied. TGF-β1 caused a 
significant increase in Pai1 that was  further increased by the addition of tRA at 
the 6 h and 24 h time points; tRA treatment alone caused a smaller, non-
significant increase in Pai1 gene expression at 6 h (Figure 3.8D). tRA and 
dual treatment both caused a significant induction of Tg2 at 6, 24 and 48 h 
(Figure 3.8E). 
3.6 Further investigation of the association between tRA-
induced collagen accumulation and plasminogen activator 
inhibitor (PAI)-1 
3.6.1 PAI-1 protein expression
As 2 μM tRA in the presence of 5 ng/ml TGF-β1 caused a significant increase 
in PAI-1 mRNA in NRK-49F cells  with a smaller increase seen with tRA 
treatment alone, Western blot analysis  was performed to determine whether 
PAI-1 protein was also modulated by tRA with and without TGF-β1. Both total 
cell lysates and conditioned media were studied as PAI-1 exerts its  effects 
extracellularly. In total cell lysates and conditioned media, the anti-PAI-1 rabbit 
polyclonal antibody recognised a single band at ~50-kDa corresponding to the 
expected molecular weight of PAI-1 (Figure 3.9). In total cell lysates, both tRA 
and TGF-β1 induced a trend towards an increase in PAI-1 protein levels and 
dual treatment significantly increased PAI-1 protein expression; in conditioned 
media, PAI-1 protein was significantly increased by tRA treatment with further 












GAPDH   
(total cell 
  lysate) 
   Vehicle     tRA  TGF-β1  Dual
Figure 3.9. Western blot analysis of PAI-1 protein in NRK-49F total cell lysate and 
conditioned media. NRK-49F cells were cultured and treated as per protocol and total cell 
lysate and conditioned media were collected. Western blot analysis was performed using 10% 
polyacrylamide gels and membranes immunoprobed with rabbit polyclonal  antibody to PAI-1. 
GAPDH was used as a loading control. A- Representative Western blot of PAI-1 protein; B- 
PAI-1 band densitometry presented as fold change compared to vehicle and normalised to 
GAPDH. Data represent mean ± SEM of 3 independent cell  culture studies. Statistical 
analysis was performed on transformed data using repeated measures ANOVA. * p<0.05, ** 
p<0.01, *** p<0.001 vs vehicle-treated group.
3.6.2 Effect of the PAI-1 inhibitor tiplaxtinin on tRA-induced collagen 
accumulation
To determine if tRA-induced total collagen accumulation could be prevented 
by PAI-1 inhibition, cells were pre-treated for 2 h with the PAI-1 inhibitor 
tiplaxtinin then treated with 2 μM tRA and/or 5 ng/ml TGF-β1 for 48 h. 
Tiplaxtinin was chosen for use in experiments  as it is the optimal PAI-1 
inhibitor currently available commercially (Professor Daniel Lawrence, Ann 
Arbor, Michigan, USA, personal communication). However its use is limited by 
cytotoxicity. This is a particular problem as  the Kd of tiplaxtinin is 480 nM and 
IC50 is  2.7 μM (Elokdah, Abou-Gharbia et al. 2004) therefore high 
concentrations are required to ensure PAI-1 inhibition.
Because of cytotoxicity at higher concentrations, doses  of 1 and 2.5 μM 
tiplaxtinin were chosen for experiments (data not shown). As expected, a 
significant increase in PSR staining was observed following treatment of cells 
with tRA with and without TGF-β1 (Figure 3.10A). Tiplaxtinin at doses of 1 and 
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2.5 μM had no effect on PSR staining in vehicle and TGF-β1-treated cells, 
however 2.5 μM tiplaxtinin significantly reduced the increase in PSR staining 
caused by tRA and dual treatment (Figure 3.10A). There was a significant 
increase in LDH release by 2.5 μM tiplaxtinin although no significant increase 
in cell detachment index was demonstrated (Figure 3.10B, C). 
A
B C
Figure 3.10. Effect of the PAI-1 inhibitor tiplaxtinin on tRA-induced total collagen 
accumulation. NRK-49F cells cultured as per protocol  were treated with 0-2.5 μM tiplaxtinin, 
2 μM tRA and/or 5 ng/ml TGF-β1 for 48 h. The effect on total collagen deposition was 
determined by spectrophotometric analysis of eluted PSR (A). Cytotoxicity was determined by 
LDH release (B) and cell detachment index (C). Data represent mean ± SEM of 3 
independent cell  culture studies. Statistical analysis was performed on transformed data using 
repeated measures ANOVA for A and using repeated measures ANOVA for B and C. * p<0.05, 
*** p<0.001 vs vehicle; ψψ p<0.01, ψψψ p<0.001 vs TGF-β1-treated group; Ω p<0.05 vs 
tRA-only treated group; Φ p<0.05 vs dual-treated group only.
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3.7 Further investigation of the association between tRA-
induced collagen accumulation and transglutaminase 2 (TG2) 
3.7.1 TG2 protein expression
tRA at a dose of 2 μM in the absence and presence of 5 ng/ml TGF-β1 
caused a significant increase in TG2 mRNA in NRK-49F cells. Therefore 
further experiments were performed to determine whether TG2 was also 
expressed at protein level and modulated by tRA.
Western blot analysis  using anti-TG2 CUB7402 mouse monoclonal antibody 
was initially employed to determine whether NRK-49F cells expressed TG2 
protein. Conditioned media was examined as well as NRK-49F total cell lysate 
as TG2 exerts its effects  both intra- and extra-cellularly. Two bands were 
identified at ~70-kDa in NRK-49F total cell lysate and one band was seen at 
~70-kDa in conditioned media (Figure 3.11). These bands were smaller than 
the expected molecular weight of TG2 of 75-85-kDa. There were also some 
smaller bands and larger bands observed at ~50-kDa and ~225-kDa, 
respectively, in NRK-49F total cell lysate (Figure 3.11). 
Figure 3.11. Western blot analysis of TG2 protein in NRK-49F total cell lysate and 
conditioned media using anti-TG2 CUB7402 mouse monoclonal antibody. NRK-49F 
cells were cultured and treated as per protocol and total cell lysate and conditioned media 
collected. Western blot analysis was performed using 8% polyacrylamide gels. Membranes 
were immunoprobed using CUB7402 mouse monoclonal antibody to TG2. GAPDH was used 
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Because it was unclear from TG2 Western blot analysis which bands, if any, 
represented TG2 protein, further determination of the effects of tRA was not 
done. Instead, LC/MS/MS analysis was performed on protein extracted from 
the ~70-kDa bands  to confirm their identity (designated AR2_1 and AR2_2). 
These bands were chosen for further analysis  because they were closest to 
the expected molecular weight of TG2. 
Gel electrophoresis of NRK-49F total cell lysate using an 8% polyacrylamide 
gel was used to separate NRK-49F protein by weight then Coomassie blue 
staining was performed to identify the bands of interest, which were then cut 
out and analysed by mass spectrometry (Figure 3.12A, B). TG2 was not 
identified in samples using LC/MS/MS although other proteins between 50.9- 
and 83-kDa were present suggesting that the correct bands had been excised 
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Figure 3.12. Colloidal Coomassie blue-stained electrophoresis gel of NRK-49F total cell 
lysate. NRK-49F total cell  lysate was run on an 8% polyacrylamide gel under reducing and 
denaturing conditions then stained with brilliant blue G-colloidal Coomassie stain. A- Colloidal 
Coomassie blue-stained gel with colour markers; B- Colloidal  Coomassie-stained gel 
following excision of the protein bands of interest (AR2_1 and AR2_2). Lanes 1 and 2- colour 
markers; Lane 3- NRK-49F total cell lysate.
Since TG2 protein was not identified in NRK-49F total cell lysates by mass 
spectrometry, Western blot analysis was revisited, this  time using a positive 
control and a different anti-TG2 mouse monoclonal antibody, IA12. A band at 
~76-kDa for both recombinant rat TG2 protein and NRK-49F total cell lysate 
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suggesting the presence of TG2 in NRK-49F total cell lysate and conditioned 
media (Figure 3.13Ai, Bi). However tRA with and without TGF-β1 did not alter 
TG2 protein expression significantly as determined by band densitometry 
although there was a trend towards an increase in dual-treated cells  in 
NRK-49F total cell lysate (Figure 3.13Aii, Bii).
NRK-49F total cell lysate
          Veh   tRA   TGF-  dual    rat recombinant
                β1      TG2  
Conditioned medium
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Figure 3.13. Western blot analysis of TG2 protein in NRK-49F total cell lysate and 
conditioned media using anti-TG2 IA12 mouse monoclonal antibody. NRK-49F cells 
were cultured and treated as per protocol and total cell  lysate and conditioned media 
collected. Western blot analysis was performed using 8% polyacrylamide gels as before. 
Membranes were immunoprobed using IA12 mouse monoclonal antibody and GAPDH was 
used as a loading control. Ai, Bi- Western blot of NRK-49F total  cell lysate (using rat 
recombinant TG2 as a positive control) and conditioned medium, respectively; Aii, Bii- TG2 
band densitometry of NRK-49F total cell lysate and conditioned medium, respectively. Band 
densitometry data was presented as mean ± SEM fold change compared to vehicle and 
normalised to GAPDH of 3 independent cell  culture studies. Statistical analysis was 
performed on transformed data using repeated measures ANOVA.
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3.7.2 Effect of the TG2 inhibitor NTU283 on tRA-induced collagen 
accumulation
Although there was no significant change in TG2 protein expression in 
NRK-49F cells treated with tRA with or without TGF-β1, the effect of reducing 
TG2 activity on tRA-induced collagen accumulation was explored to further 
rule out that TG2 was contributing to the pro-fibrotic effects of tRA.
Figure 3.14 illustrates the effects of the TG2 inhibitor NTU283 at doses of 
33-99 μM (Skill, Johnson et al. 2004) on PSR staining in NRK-49F cells 
treated with 0.2-2 μM tRA with and without 5 ng/ml TGF-β1. NTU283 alone 
had no effect on PSR staining however it caused a significant decrease in 
PSR staining in TGF-β1-treated cells (Figure 3.14Ai, Bi). There was a non-
significant increase in PSR staining in cells treated with 0.2 μM tRA, which 
was further increased by the addition of 33-99 μM NTU283; a higher dose of 2 
μM tRA did significantly increase PSR staining, which was further increased 
by NTU283 (Figure 3.14Ai). In the presence of TGF-β1, 0.2 and 2 μM tRA 
significantly increased PSR staining as expected, and PSR staining was 
increased further by NTU283 (Figure 3.14Bi). More cell detachment was 







Figure 3.14. Effect of TG2 inhibitor NTU283 on tRA-induced total collagen 
accumulation. NRK-49F cells cultured as per protocol were pre-treated with NTU283 for 2 h 
then 0.2-2 μM tRA +/- 5 ng/ml TGF-β1 for 48 h. Ai and Bi- effect of NTU283 on PSR staining 
in tRA- and dual-treated cells, respectively; Aii and Bii- effect of NTU283 on cell  detachment 
index in tRA- and dual-treated cells, respectively. Data for Ai and Bi represent mean ± SEM 
fold change relative to vehicle-treated cells and for Aii and Bii  data represent mean ± SEM of 
3 independent cell culture studies. Statistical analysis for Ai  and Bi was performed on 
transformed data using repeated measures ANOVA and for Aii and Bii a repeated measures 
ANOVA was used. ** p<0.01, *** p<0.001 vs vehicle; ψ p<0.05, ψψ p<0.01, ψψψ p<0.001 vs 
TGF-β1-treated group; + p<0.05, ++ p<0.01, +++ p<0.001 between groups indicated.
120
3.8 Discussion
In this work, a novel in vitro model for the dose-dependent, pro-fibrotic effects 
of tRA has been established in a rat kidney fibroblast cell line supporting the 
hypothesis that tRA’s fibrogenic effects are mediated through renal fibroblasts. 
Possible mechanisms through which tRA exerted its pro-fibrotic effects in this 
model included modulation of matrix degradation pathways, as there was 
evidence for reduced MMP expression and activity, and increased PAI-1 
protein expression. Increased collagen production was less  likely to play a 
role since the majority of collagen mRNAs were down-regulated by tRA with 
and without TGF-β1.
To establish the net effect of tRA on fibrosis in vitro, PSR was used to stain for 
total collagen protein. It is  well accepted that excessive collagen accumulation 
causes TIF therefore this was a relevant method to use especially as  it 
allowed quantification of collagen deposition. Since tRA can be toxic at high 
doses, which would affect the readout for the 2D in vitro model of fibrosis, two 
methods were used to determine cytotoxicity: Cell detachment index and LDH 
release from cells. There was agreement between the two assays that higher 
doses of tRA in the presence of TGF-β1 increased cytotoxicity and that 
treatment with tRA alone did not increase cell detachment or LDH release 
significantly (Figure 3.1D, E). These results suggest that the two 
methodologies for measuring cytotoxicity were comparable.
While at protein level tRA with and without TGF-β1 was pro-fibrotic, 
demonstrated by an increase in total collagen deposition and immunostaining 
for collagen types  I and III (Figures 3.1 and 3.4), an RT-qPCR array showed a 
down-regulation as well as an up-regulation of various collagen mRNAs 
(Figure 3.2). Standard RT-qPCR of Col1a1, Col1a2, Col3a1 and Fn1 also 
showed differential regulation of fibrotic markers by tRA (Figure 3.3). 
These results are important because they show that tRA can have directly 
opposing actions in the same cell model under the same conditions. Other 
published reports have also shown a dichotomous effect of RA in models  of 
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renal fibrosis. For example, Xu et al. showed that tRA treatment suppressed 
selected fibrogenic molecular markers at the mRNA level in the kidneys  of Alb/
TGF-β1 transgenic mice despite there being no evidence of improvement and 
even worsening of interstitial fibrosis with increasing doses  of tRA (Xu, Hendry 
et al. 2010). In addition, this work shows that the time points chosen for 
measurements are also important when experimenting with tRA. tRA caused 
a biphasic response of Col3a1 and Mmp-2 mRNA demonstrating a time-
dependent effect of tRA which has also been documented in other reports 
(Morath, Ratzlaff et al. 2009). Therefore, by selecting only a few molecular 
markers for experiments and variable time points to study, different biased 
conclusions could be drawn. These results also highlight the importance of 
confirming results  obtained from screening tools such as RT-qPCR arrays as, 
although the results for Col1a1 and Col3a1 were consistent between the array 
and standard RT-qPCR, the results for Fn1 differed between the two 
techniques.  
Since the RT-qPCR data did not definitively demonstrate evidence of an up-
regulation of collagens to explain the pro-fibrotic effects of tRA, it was of 
interest that the majority of Mmps were down-regulated at mRNA level 
although there was also a down-regulation of Timps (Figure 3.2 and 3.6). In 
addition, PAI-1 expression was up-regulated by tRA alone and still more in the 
presence of TGF-β1 (Figure 3.9). Furthermore, an MMP activity assay 
demonstrated an overall reduction in MMP activity (Figure 3.7) and the PAI-1 
inhibitor tiplaxtinin reduced the pro-fibrotic effects  of tRA (Figure 3.10). tRA-
induced reduced MMP activity may have been a result of reduced MMP 
expression but also decreased MMP activation as PAI-1 suppresses the 
conversion of plasminogen to plasmin, which is known to activate MMPs. 
Although caution should be applied when interpreting the effects of tiplaxtinin 
on tRA-induced collagen accumulation as tiplaxtinin caused significant 
cytotoxicity, overall, these results suggest decreased matrix degradation as a 
possible mechanism for the pro-fibrotic effect of tRA in NRK-49F cells. 
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MMP mRNA suppression by RA has been reported before as tRA suppresses 
ultraviolet irradiation-induced MMPs in human skin (Fisher and Voorhees 
1998) and reduces plasma MMP activity and MMP9/TIMP-1 in cultured 
macrophages in patients with emphysema (Mao, Tashkin et al. 2003). A 
possible mechanism for this suppression is through inhibition of AP-1 as  AP-1 
binding sites have been identified in MMP genes (Benbow and Brinckerhoff 
1997). tRA-induced PAI-1 expression has also been reported in VSMCs and 
may occur through tyrosine kinase-dependent pathways as tyrosine kinase 
inhibitors blocked retinoid-induced increase in PAI-1 mRNA in VSMCs 
(Watanabe, Kanai et al. 2002) or via retinoid receptor-dependent signalling 
through transcription factors such as Sp1 (Suzuki, Shimada et al. 1999).
tRA also caused a significant up-regulation of Tg2 mRNA in NRK-49F cells, 
which was further increased with the addition of TGF-β1 (Figure 3.8E). This 
result was not surprising because the TG2 gene has  an RARE in its  promoter 
(Nagy, Saydak et al. 1996; Yan, Noonan et al. 1996). However, TG2 protein 
was difficult to identify by both Western blot analysis and mass spectrometry 
in NRK-49F cells. Initially, TG2 immunoblotting using anti-TG2 CUB7402 
mouse monoclonal antibody was performed and demonstrated multiple bands 
in NRK-49F total cell lysates that were not at the expected molecular weight 
for TG2 of 75-85-kDa (Figure 3.11). Two bands were identified at ~70-kDa, 
which could have represented TG2 protein, however, when protein extracted 
from the bands was analysed by LC/MS/MS, TG2 protein was not identified. 
Possible reasons that LC/MS/MS failed to identify TG2 protein in samples 
include: 1) Incorrect identification of the bands of interest from the 
polyacrylamide gel; 2) Absence of TG2 in NRK-49F total cell lysate; 3) The 
TG2 antibody was very sensitive and had a lower limit of detection than the 
mass spectrometer; and 4) Technical problems with TG2 identification by LC/
MS/MS. The TG2 Western blot using anti-TG2 CUB7402 mouse monoclonal 
antibody also identified larger bands at 225-kDa, which might have consisted 
of TG2 bound to substrate and smaller bands at 50-kDa, which could have 
represented a shorter form of TG2, however it cannot be excluded that all the 
bands represented non-specific antibody binding (Figure 3.11). 
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Therefore Western blot analysis using another anti-TG2 mouse monoclonal 
antibody, IA12, was performed. This antibody recognised a band at ~76-kDa 
in NRK-49F total cell lysate and conditioned media similar to that identified in 
the positive control of recombinant rat TG2 protein and therefore was likely to 
represent TG2 protein (Figure 3.13). However, there was no evidence that 
tRA modulated TG2 protein expression either intra- or extra-cellularly using 
this  method of TG2 protein detection (Figure 3.13). Furthermore, reducing 
TG2 activity using the TG2 inhibitor NTU283 did not prevent tRA-induced total 
collagen accumulation but rather potentiated the pro-fibrotic effect of tRA 
(Figure 3.14). This finding is  consistent with some reports that TG2 might play 
a critical role in hepatic repair and a protective role in fibrosis (Nardacci, Lo 
Iacono et al. 2003). However, it may be that these fibrogenic effects of 
NTU283 were due to non-specific effects of the drug not related to TG2 
inhibition especially as very little TG2 appeared to be present in conditioned 
media and published reports suggest that the major source of TG2 is tubular 
epithelial cells with only small contributions from mesangial and interstitial 
cells (Johnson, El-Koraie et al. 2003). Interestingly, NTU283 reduced the 
increase in PSR staining caused by TGF-β1 consistent with the role of TG2 as 
an activator of TGF-β1 (Figure 3.14) (Nunes, Gleizes et al. 1997).
In summary, the results  presented in this chapter demonstrate a previously 
unreported dose-dependent, pro-fibrotic effect of tRA in an in vitro model of 
renal interstitial fibrosis and furthermore suggest possible mechanisms behind 
these detrimental effects of tRA. There are few reports of the effects of RA in 
renal fibroblast cell models to compare this  work to perhaps partly because of 
the lack of availability of renal fibroblast primary cultures and cell lines. 
However, this work is  somewhat similar to the effects of tRA in a transgenic 
mouse model of TIF caused by over-expression of TGF-β1, where high-dose 
tRA increased TIF (Xu, Hendry et al. 2010) akin to the pro-fibrotic effects  of 
tRA in this in vitro model of TGF-β1-induced fibrosis presented here. 
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Chapter 4. Expression of retinoid nuclear receptors, PPARβ/δ 
and RA carrier proteins in NRK-49F cells
 
4.1 Expression of retinoid nuclear receptors and PPARβ/δ 
4.1.1 mRNA expression of nuclear receptors
Results from the previous  chapter showed that tRA treatment with and without 
TGF-β1 was able to modulate NRK-49F cell phenotype. Since RA is known to 
primarily signal via retinoid nuclear receptors, NRK-49F cells were 
characterised for retinoid nuclear receptor expression as  a potential pathway 
through which tRA was exerting its effects. PPARβ/δ is  also postulated to be a 
target receptor of tRA therefore the expression of this  nuclear receptor was 
also studied (Shaw, Elholm et al. 2003).
mRNA expression of retinoid nuclear receptors and PPARβ/δ in NRK-49F 
cells was determined by extracting total RNA from quiescent cells then 
subjecting it to two-step RT-qPCR using pre-designed primers from 
SABiosciences and SYBR Green PCR technology. Relative quantification was 
used to compare expression of the different nuclear receptors on the 
assumption that the amplification efficiencies were similar between the targets 
(the standard curve method of absolute quantification could also have been 
used as an alternative to relative quantification). Of the tRA-binding nuclear 
receptors, Rara was the most highly expressed at mRNA level followed by 
Rarg then Pparbd; Rxrb was the most highly expressed RXR and Rxrg had 
the lowest mRNA expression relative to the other nuclear receptors (Figure 
4.1). 
4.1.2 Protein expression of nuclear receptors
Next the protein expression of the six retinoid nuclear receptors  and PPARβ/δ 
was studied by Western blot analysis of NRK-49F total cell lysates. A single 
band was identified at ~50-52-kDa by the anti-RARα and anti-RARβ rabbit 
polyclonal antibodies corresponding to the expected molecular weight of 
RARα and RARβ proteins (Figure 4.2A, B). The anti-RARγ mouse 
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monoclonal antibody recognised two bands at ~50-52-kDa but only the 50-
kDa band was present in the positive control of A431 nuclear extract, which is 
the expected molecular weight for RARγ (Figure 4.2C). 
Figure 4.1. Relative mRNA expression of retinoid nuclear receptors and PPARβ/δ in 
NRK-49F cells. Total RNA was extracted from NRK-49F cells cultured for 3 d in DMEM 
supplemented with 2.5% FCS and 2.5% Nu then for 4 d in DMEM supplemented with ITS 
then two-step RT-qPCR was performed. mRNA expression of the retinoid nuclear receptors 
relative to the lowest expressed receptor, RXRγ, was determined. Data represent mean ± 








Figure 4.2. Western blot analysis of RARs. Total cell  lysate was extracted from NRK-49F 
cells cultured as before and Western blot analysis performed using 10-12% polyacrylamide 
gels. Membranes were then subjected to immunoprobing. A- RARα immunoblot (1 in 20000 
dilution of antibody); B- RARβ immunoblot (1 in 1000 dilution of antibody); C- RARγ 
immunoblot with A431 nuclear extract as a positive control (1 in 1000 dilution of antibody). 
The rabbit polyclonal antibody to PPARβ/δ recognised multiple bands in 
NRK-49F total cell lysate, four of which were also present in the 
recommended positive control of Sol8 nuclear extract (Figure 4.3). The 
molecular weight of these bands were between 35- and 76-kDa. A blocking 
peptide was not available for this antibody.
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4.3. Western blot analysis of PPARβ/δ. Western blot analysis was performed on NRK-49F 
total  cell lysate as before using 10% polyacrylamide gels. Membranes were immunblotted 
using a rabbit polyclonal antibody to PPARβ/δ (1 in 7500 antibody). Sol8 nuclear extract was 
used as a positive control. 
Finally, RXR protein expression in NRK-49F total cell lysates was determined. 
Figure 4.4 shows relevant Ponceau S stains as well as representative RXR 
immunoblots to demonstrate equal protein loading where blocking peptides 
were used. The anti-RXRα rabbit polyclonal antibody recognised two bands at 
~50-kDa and ~60-kDa (expected molecular weight 54-kDa) in both NRK-49F 
total cell lysate and the positive control of HeLa nuclear extract; these bands 
disappeared when the membrane was incubated with blocking peptide and 
antibody (Figure 4.4A). The rabbit polyclonal antibody to RXRβ recognised 
several bands in the positive control of HeLa nuclear extract, two of which 
were also present in NRK-49F total cell lysate at ~55-kDa and ~76-kDa 
(predicted molecular weight 48-kDa) (Figure 4.4B). A blocking peptide was not 
available for this  antibody. Finally immunoprobing for RXRγ using a positive 
control of human RXRγ-transfected 293T total cell lysate revealed a cluster of 
bands with molecular weights  ranging from ~52-kDa to 102-kDa for both 
NRK-49F total cell lysate and positive control. These blots were similar to the 
immunoblot on the Santa Cruz RXRγ antibody data sheet (see Appendix, 
Supplementary figure 1). These bands disappeared when the membrane was 
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Figure 4.4. Western blot analysis of 
retinoid X receptors. Western blot analysis 
was performed on NRK-49F total cell  lysate 
as before using 10% polyacrylamide gels. 
Nitrocellulose membranes were subjected 
to Ponceau S staining then immunprobing. 
A- Ponceau S stain and RXRα immunoblot 
(1 in 5000 dilution of antibody) with HeLa 
nuclear extract as a positive control; B- 
RXRβ immunoblot (1 in 5000 dilution of 
antibody) with HeLa nuclear extract as a 
positive control; C- Ponceau S stain and 
RXRγ immunoblot (1 in 1000 dilution of 
antibody) with RXRγ-transfected 293T total 
cell lysate as a positive control.
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4.1.3 mRNA expression of nuclear receptors following treatment with 
tRA with and without TGF-β1
Since there was evidence that NRK-49F cells expressed retinoid nuclear 
receptors and possibly PPARβ/δ, change in nuclear receptor mRNA 
expression following treatment with 2 μM tRA with and without 5 ng/ml TGF-
β1 was examined by standard two-step RT-qPCR. 
tRA and dual treatment caused an early significant induction of Rara and Rarg 
mRNAs over 1-3 h and tRA also caused a later induction of Rarg mRNA at 48 
h (Figure 4.5A, C). These inductions were followed by suppression of Rara 
mRNA by dual treatment at 6, 24 and 48 h and suppression of Rarb mRNA by 
tRA and dual treatment at 24 h and 48 h, respectively (Figure 4.5A, B). There 
was a significant suppression of Pparbd mRNA at 24 h in all three treatment 
groups (Figure 4.5D). Rxra, Rxrb and Rxrg mRNAs were all significantly 
suppressed by dual treatment at the 24 or 48 h time points (Figure 4.5E-G) 
and Rxra was also suppressed by treatment with tRA or TGF-β1 at 48 h 
(Figure 4.5E).
4.2 Expression of RA carrier proteins in NRK-49F cells
4.2.1 mRNA expression of RA carrier proteins
The expression of RA carrier proteins CRABP-II and FABP5 was also 
explored in NRK-49F cells because they have previously been reported to be 
important in the regulation of RA signalling (Dong, Ruuska et al. 1999; Tan, 
Shaw et al. 2002). Crabp2 and Fabp5 mRNA expression was determined by 
extracting total RNA from quiescent cells then subjecting it to two-step RT-
qPCR using pre-designed primers and probes from Applied Biosystems and 
TaqMan technology. 
Crabp2 mRNA was present at several hundred-fold higher levels than Fabp5 
in NRK-49F cells (Figure 4.6). Fabp5 was expressed only at low levels, if at 







Figure 4.5. Change in mRNA expression of retinoid nuclear receptors and PPARβ/δ 
following tRA and TGF-β1 treatment. NRK-49F cells were cultured as per protocol  and 
treated with 2 μM tRA with and without 5 ng/ml TGF-β1 for 0, 1, 3, 6, 24 or 48 h. Total RNA 
was extracted at 48 h and two-step RT-qPCR performed to determine changes in mRNA 
expression of Rara (A), Rarb (B), Rarg (C), Pparbd (D), Rxra (E), Rxrb (F) and Rxrg (G). Data 
represent mean ± SEM of 4 independent cell  culture studies. Clear bars= tRA-treated group, 
striped bars= TGF-β1-treated group, chequed bars= dual-treated group. Statistical  analysis 
was performed on transformed data using repeated measures ANOVA. * p<0.05, ** p<0.01, 
*** p<0.001 vs 0 h group; +p<0.05, ++p<0.01 between groups indicated.
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Figure 4.6. Relative mRNA expression of RA carrier proteins CRABP-II and FABP5 in 
NRK-49F cells. Total RNA was extracted from NRK-49F cells cultured as before then two-
step RT-qPCR was performed. mRNA expression of the tRA carrier protein Crabp2 relative to 
Fabp5 was determined. Data represent mean ± SEM of 9 independent cell culture studies.
4.2.2 Protein expression of RA carrier proteins
Following the identification of CRABP-II and possibly FABP5 at mRNA level, 
their protein expression was explored by Western blot analysis of NRK-49F 
total cell lysate. A goat polyclonal antibody to CRABP-II recognised multiple 
bands in the positive control of NIH/3T3 total cell lysate and one band 
corresponded to the expected molecular weight of 15-kDa for CRABP-II 
protein (Figure 4.7). CRABP-II immunoprobing of NRK-49F total cell lysate 
also revealed multiple bands, four of which corresponded to bands seen in the 
positive control at ~20-, 31-, 35- and 80-kDa. The bands identified at 31-, 35- 
and 80-kDa disappeared with the addition of CRABP-II blocking peptide to the 
antibody (Figure 4.7). 
A rabbit polyclonal antibody to FABP5 did not recognise any bands in 
NRK-49F total cell lysate although a positive control was  not included to 
confirm that the technique had been successful (data not shown).
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4.7. Western blot analysis of CRABP-II protein. Western blot analysis was performed on 
NRK-49F total  cell  lysate as before using 15% polyacrylamide gels. Membranes were 
subjected to immunoprobing with goat polyclonal antibody to CRABP-II (1 in 2000 dilution of 
antibody). NIH/3T3 total  cell  lysate was used as a positive control  and GAPDH was used as a 
loading control. Arrows point to bands present in NRK-49F and NIH/3T3 total  cell lysates that 
disappeared with the addition of blocking peptide.
Since immunoblotting did not definitively identify CRABP-II or FABP5 protein 
in NRK-49F cells, immunocytochemistry was also performed. However, there 
was no evidence of positive staining of cells with either an anti-CRABP-II goat 
polyclonal antibody or an anti-FABP5 rabbit polyclonal antibody although a 
positive control was not included to confirm that the technique had been 
successful (Figure 4.8).
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Figure 4.8. Immunocytochemistry of CRABP-II and FABP5 proteins. NRK-49F cells were 
fixed with paraformaldehyde and permeabilised with Triton X-100 then blocked with 1% BSA. 
Cells were then incubated with goat polyclonal antibody to CRABP-II (A) or rabbit polyclonal 
antibody to FABP5 (B) at a 1 in 100 dilution. Nuclei were counterstained with DAPI. Normal Ig 
was used as a negative control. (Fluorescence microscopy, x400 magnification).
Finally, since three bands at 31-, 35- and 80-kDa were identified by CRABP-II 
immunoblotting of both NRK-49F and NIH/3T3 total cell lysates, protein from 
these bands was  extracted and further analysed by LC/MS/MS to determine 
whether CRABP-II protein was indeed present; in addition, protein from the 
15-kDa band identified in NIH/3T3 total cell lysate was analysed to confirm the 
presence of CRABP-II in this band in the positive control (Figure 4.9). 
However, LC/MS/MS analysis did not identify CRABP-II protein in any of the 
selected samples (see Appendix, Supplementary table 4 for a list of proteins 
identified). Interestingly, CRABP-I and FABP5 proteins were present in protein 
from the 15-kDa band in NIH/3T3 total cell lysate and, as these proteins have 
the same expected molecular weight as  CRABP-II, it suggests that the correct 
area of gel had been selected for analysis. 
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Figure 4.9. Colloidal Coomassie blue-stained electrophoresis gel of NRK-49F and NIH/
3T3 total cell lysates. NRK-49F and NIH/3T3 total  cell  lysates were run on 15% 
polyacrylamide gels under reducing and denaturing conditions then the gel  was stained with 
brilliant blue G-colloidal Coomassie stain. A- Colloidal  Coomassie blue-stained gel with colour 




The results presented in this chapter demonstrate the presence of key RA 
signalling machinery in NRK-49F cells. There was good evidence that 
NRK-49F cells expressed all three RAR isotypes  and RXRα although the 
evidence for PPARβ/δ, RXRβ and RXRγ protein expression was weaker. 
Nuclear receptor mRNA expression was modulated by tRA treatment with and 
without TGF-β1 suggesting a role for these receptors  in the response of 
NRK-49F cells to pro-fibrotic stimuli. However, there was little evidence that 
either CRABP-II or FABP5 were expressed at protein level and played a role 
in the pro-fibrotic effects of tRA. 
In an effort to identify potential signalling pathways for the pro-fibrotic effects 
of tRA in NRK-49F cells  retinoid receptor expression was determined as 
retinoids are known to exert their actions primarily via these receptors. All 





Rara>Rarg>Rarb (Figure 4.1). As Pparbd was present at lower levels than 
RAR, tRA signalling in NRK-49F cells  likely predominantly occurs via the 
RARs and not PPARβ/δ. RXR mRNA was also detected in NRK-49F cells  in 
order of abundance Rxrb>Rxra>Rxrg (Figure 4.1). Published data of retinoid 
receptor mRNA expression in mouse kidney by comparison shows that Rara 
is  also the highest expressed RAR at mRNA level although Rxrα is the 
highest expressed RXR (Bookout, Jeong et al. 2005). However, mouse kidney 
samples consist of numerous cell types and only a minority of these will be 
fibroblasts. Although there are no published reports of retinoid receptor 
mRNA expression in renal fibroblast cell cultures to refer to, there is data on 
fibroblast cell cultures from other organs. For example, human dermal 
fibroblasts  express RARα and RARγ but little RARβ (Redfern and Todd 1992; 
Tsou, Lee et al. 1994) and RXRα and RXRβ but not RXRγ (Tsou, Xie et al. 
1997); rabbit corneal stromal and conjunctival fibroblasts expressed all the 
RARs and RXRs except RXRγ (Bossenbroek, Sulahian et al. 1998); and rat 
HSCs expressed all the RARs (Weiner, Blaner et al. 1992) while RXRα was 
the predominant RXR followed by RXRβ with RXRγ only weakly detected 
(Ohata, Lin et al. 1997). These reports  are in agreement with the results 
presented here that Rara and Rarg are the most highly expressed RARs and 
Rxra and Rxrb are the most highly expressed RXRs at mRNA level in rat renal 
fibroblasts.
All three RARs were also identified at protein level by immunoblotting (Figure 
4.2). The antibodies to RARα and RARβ recognised a single band at the 
expected molecular weight of RARα and RARβ. Although the antibody to 
RARγ recognised two bands  at ~50-52-kDa, only the 50-kDa band was 
present in the positive control of A431 nuclear extract and was therefore likely 
to represent RARγ protein. The additional band could, however, have been an 
RARγ isoform. Although the relative expression of RAR proteins cannot be 
determined from this data as different antibodies have varying affinities  for 
their epitopes, the anti-RARα rabbit polyclonal antibody was used at only a 1 
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in 20000 dilution suggesting that RARα might be the most abundant RAR in 
NRK-49F cells, in agreement with the mRNA data. 
There was also evidence that NRK-49F cells expressed PPARβ/δ at protein 
level as the anti-PPARβ/δ rabbit polyclonal antibody recognised a band in 
both NRK-49F total cell lysate and the positive control at ~60-kDa likely to 
represent PPARβ/δ protein. However further bands were also seen at ~35-, 
65- and 76-kDa (Figure 4.3). If specific, the 35-kDa band might represent a 
smaller molecular weight PPARβ/δ, which has previously been reported 
(Lundell, Thulin et al. 2007); the larger bands are unlikely to represent 
PPARβ/δ bound to other protein as the experiment was performed under 
reducing and denaturing conditions but are likely due to non-specific antibody 
binding.
In addition, the RXR immunoblots suggested that all three RXR isotypes were 
expressed at protein level in NRK-49F cells  although the results were less 
definitive. The antibody to RXRα recognised two bands at ~50-kDa and ~60-
kDa in both NRK-49F cells and the positive control and these bands 
disappeared with the addition of blocking peptide suggesting that they were 
specific for RXRα (Figure 4.4A). Although multiple bands were recognised by 
the anti-RXRβ antibody in NRK-49F total cell lysate, only two of these bands 
were also present in the positive control, at ~55-kDa and 76-kDa. The 55-kDa 
band is close to the predicted molecular weight of RXRβ and was therefore 
most likely to represent RXRβ protein (Figure 4.4B). Finally a cluster of bands 
were identified by the antibody for RXRγ in both NRK-49F and RXRγ-
transfected 293T total cell lysate ranging from ~55-75-kDa, which compared 
to the immunoblot in the Santa Cruz RXRγ antibody data sheet (Appendix, 
Supplementary figure 1) and disappeared with the addition of blocking peptide 
suggesting these bands were specific for RXRγ antigen (Figure 4.4C).
There are several possible explanations for the multiple bands identified in the 
RXR immunoblots. Since RXRα and RXRβ have four isoforms and RXRγ has 
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two isoforms, the bands could represent different isoforms of RXRs (Lefebvre, 
Benomar et al. 2010). Post-translational modifications of protein could also 
provide an explanation for the additional bands. In addition, the bands with 
lower molecular weights might correspond to proteolytic products as  reported 
previously (Rochette-Egly, Lutz et al. 1994). However, it cannot be excluded 
that the additional bands recognised in any of the immunoblots were caused 
by non-specific antibody binding and further analysis of NRK-49F total cell 
lysate and/or the bands would be required to confirm their identity. 
Although nuclear receptor mRNA expression was modulated by tRA with and 
without TGF-β1 treatment in NRK-49F cells suggesting that these receptors 
might in some way be involved in the pro-fibrotic response, a candidate 
nuclear receptor responsible for these effects was not immediately identifiable 
(Figure 4.5). Despite this, there were some interesting and noteworthy 
findings. For example, Rara and Rarg were both up-regulated by tRA and dual 
treatment but also up-regulated more or less  by the pro-fibrotic TGF-β1. It 
could therefore be extrapolated that RARα and/or RARγ are somehow 
involved in the pro-fibrotic response of tRA and TGF-β1 in NRK-49F cells. In 
addition, all the RXRs were down-regulated by tRA and dual treatment to a 
greater or lesser degree and in particular Rxra was suppressed by tRA, TGF-
β1 and dual treatment. If this down-regulation of RXR mRNA is translated to 
reduced protein expression then the pathways through which tRA exerts  it 
effects in NRK-49F cells could change with less canonical and more non-
canonical signalling resulting in a different response of cells  to tRA. Other 
published studies also report modulation of retinoid receptor expression in 
renal disease models. Liebler et al. demonstrated suppression followed by 
activation of the RARs and RXRα in experimental glomerulonephritis  (Liebler, 
Uberschar et al. 2004) and the same group showed that in a chronic 
glomerulonephritis model RARα and RXRα mRNA were significantly 
increased (Schaier, Liebler et al. 2004). 
It might have been predicted that Rarb mRNA would be induced by tRA 
treatment as there is an RARE in its promoter region, however other cell types 
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do not consistently demonstrate an induction of RARβ following treatment 
with tRA. For example, RARβ was not induced by RA in corneal epithelial 
cells (Bossenbroek, Sulahian et al. 1998). In addition, the reduction in Rarb 
mRNA by tRA with and without TGF-β1 was consistent with other reports of a 
reduction in RARβ expression in a rat model of hepatic fibrosis (Weiner, 
Blaner et al. 1992). Furthermore, since the in vitro model of fibrosis presented 
here involves minimal fibroblast proliferation and RARβ2 has been implicated 
as the predominant retinoid receptor interfering with cell cycle progression (Li, 
Faria et al. 2004; Suzui, Shimizu et al. 2004)  it might be that RARβ has little 
role to play in this fibrogenic cell model. 
In addition to the retinoid nuclear receptors, expression of the RA carrier 
proteins CRABP-II and FABP5 was explored in NRK-49F cells as they are 
also considered important in retinoid signal transduction. Despite the 
identification of Crabp2 mRNA in NRK-49F cells (Figure 4.6) CRABP-II 
immunoblotting did not identify a band at the expected molecular weight of 15-
kDa (Figure 4.7). However multiple other bands were recognised by the anti-
CRABP-II antibody and four bands corresponded to those seen in the positive 
control of NIH/3T3 total cell lysate at ~20-, 31-, 35- and 80-kDa of which three 
(the 31-, 35- and 80-kDa bands) disappeared with the addition of blocking 
peptide (Figure 4.7). If these three bands are indeed specific then they could 
represent post-translational modifications or different splicing products  of 
CRABP-II. However they could also represent non-specific antibody binding. 
Therefore immunocytochemistry and mass spectrometry were performed to 
further determine if CRABP-II protein was present in NRK-49F total cell lysate 
but neither technique could positively identify CRABP-II protein (Figure 4.8). 
Somewhat surprisingly, LC/MS/MS did not even identify CRABP-II protein in 
the 15-kDa band in the positive control lysate that was consistent with 
CRABP-II protein. Possible explanations for this result include: 1) The wrong 
band was excised for analysis due to difficulty aligning the immunoblot with 
the gel; 2) The anti-CRABP-II antibody was  very sensitive in its detection of 
the target protein and may have a lower limit of detection than the mass 
spectrometer; 3) CRABP-II was not present in the samples (despite NIH/3T3 
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total cell lysate being a positive control); and 4) There were technical 
problems with analysis of samples  using the mass spectrometer. In addition, 
this  methodology inevitable results  in the excision of numerous proteins 
potentially reducing the sensitivity of the test.
Immunoblotting and immunocytochemistry also failed to identify FABP5 
protein in NRK-49F cells, however this was not unexpected as the Ct of 
FABP5 was generally above 35 suggesting that FABP5 was  expressed at low 
levels, if at all, in NRK-49F cells.
In summary, results presented in this  chapter demonstrate the presence of 
retinoid nuclear receptors in NRK-49F cells and the modulation of retinoid 
receptor mRNA expression in response to tRA with and without TGF-β1. 
Overall, this data suggests that retinoid nuclear receptors may be involved in 
the pro-fibrotic effects of tRA in NRK-49F cells.
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Chapter 5. Effects of nuclear receptor agonists and 
antagonists on total collagen accumulation in the 2D in vitro 
model of fibrosis in NRK-49F cells
In the previous chapters, tRA in the absence and presence of TGF-β1 caused 
a dose-dependent increase in total collagen accumulation in NRK-49F cells, 
which might be partly mediated by nuclear receptor signalling as there was 
evidence of retinoid nuclear receptor and PPARβ/δ expression in NRK-49F 
cells. In this chapter, the roles of the individual nuclear receptors in 
fibrogenesis in NRK-49F cells  were studied. Two approaches were 
undertaken: Firstly, nuclear receptor agonists were used to explore the effects 
of retinoid receptor isotype and PPARβ/δ activation on fibrogenesis and, 
secondly, nuclear receptor antagonists  were used to determine if tRA-induced 
total collagen accumulation could be prevented.
5.1 Effects of selective nuclear receptor agonists on total 
collagen accumulation
5.1.1 Effects of a pan-RAR and pan-RXR agonist 
tRA is  known to activate RAR. Therefore another pan-RAR agonist, TTNPB, 
was used to determine whether activation of RAR by TTNPB could mimic the 
effects of tRA on total collagen deposition. 
TTNPB alone caused a small but significant increase in PSR staining at the 
highest dose tested (2 μM), in contrast to tRA, which was also pro-fibrotic at 
ten-fold lower concentrations (Figure 5.1Ai). In the presence of TGF-β1, 
0.02-2 μM TTNPB caused a significant increase in PSR staining, similar to the 
effects of 0.02 μM tRA (Figure 5.1Ai), without causing significant cell 
detachment (Figure 5.1Aii). 
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Figure 5.1. Effects of synthetic RAR, RXR and PPARβ/δ agonists on total collagen 
deposition in the absence and presence of TGF-β1 in NRK-49F cells. NRK-49F cells 
were cultured as per protocol then treated with nuclear receptor agonists +/- TGF-β1 for 48 h. 
Collagen deposition was quantified by spectrophotometric analysis of eluted PSR staining 
(Ai-Di) and cytotoxicity determined by cell  detachment index (Aii-Dii). A- pan-RAR agonist 
TTNPB; B- pan-RXR agonist AGN194204; C-Isotype-selective agonists AGN195183 (RARα), 
CD2019 (RARβ) and CD437 (RARγ); D- PPARβ/δ agonist GW0742. Data represent mean ± 
SEM of three independent cell culture studies. Statistical analysis for Ai-Di was performed on 
transformed data using repeated measures ANOVA and for Aii-Dii  using repeated measures 
ANOVA. * p<0.05, ** p<0.01, *** p<0.001 vs vehicle; ψ p<0.05, ψψ p<0.01, ψψψ p<0.001 vs 









Next, the effects of the pan-RXR agonist AGN194204 were explored since, 
although tRA does not activate RXR, it could undergo isomerisation to RAs 
that do activate RXR in vitro, and thus play a role in tRA’s pro-fibrotic effects.
NRK-49F cells treated with 0.02-2 μM AGN194204 showed a dose-dependent 
increase in PSR staining both with and without TGF-β1 similar to that seen 
with tRA (Figure 5.1Bi). There was significant cell detachment caused by 2 
μM AGN194204 in the presence of TGF-β1 (Figure 5.1Bii).
5.1.2 Effects of RAR isotype-selective agonists
As pan-RAR agonist TTNPB showed a smaller pro-fibrotic effect in NRK-49F 
cells, the effects of RAR isotype-selective agonists on total collagen 
deposition were also explored. 
The RARα-selective agonist AGN195183 at a dose of 0.2 μM with and 
without TGF-β1 caused a significant increase in PSR staining (Figure 5.1Ci). 
0.2 and 2 μM RARβ-selective agonist CD2019 alone did not increase PSR 
staining however in the presence of TGF-β1 both doses mildly but significantly 
increased PSR staining (Figure 5.1Ci). Finally, the RARγ-selective agonist 
CD437 did not cause a change in PSR staining at the doses  tested of 0.2 and 
2 μM with or without TGF-β1 (Figure 5.1Ci). None of the RAR isotype-
selective agonists caused significant cell detachment (Figure 5.1Cii). 
5.1.3 Effect of a PPARβ/δ agonist
Finally, since tRA has been reported to bind and activate PPARβ/δ, the 
PPARβ/δ agonist GW0742 was used to investigate the role of this nuclear 
receptor in total collagen accumulation in NRK-49F cells. 
GW0742 caused a dose-dependent, statistically significant increase in PSR 
staining both alone and in the presence of TGF-β1 although the effect was 
milder than that seen with tRA treatment (Figure 5.1Di). GW0742 did not 
cause a significant increase in cell detachment (Figure 5.1Dii).
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5.2 Effects of nuclear receptor antagonists on tRA-induced 
total collagen accumulation
5.2.1 Effect of a pan-RAR and pan-RXR antagonist
Next, the pan-RAR antagonist AGN193109 and pan-RXR antagonist HX531 
were used to determine if the pro-fibrotic effects of tRA on total collagen 
accumulation could be prevented by blocking RAR or RXR activation. 
Because of the doses of antagonists required to block RAR and RXR 
signalling (Johnson, Klein et al. 1995; Kanayasu-Toyoda, Fujino et al. 2005), 
0.2 μM tRA was chosen for use in experiments to keep cytotoxicity to a 
minimum. This dose of tRA is the lowest dose that, in the presence of TGF-
β1, caused a consistent increase in PSR staining however in the absence of 
TGF-β1 it did not cause a consistent increase in total collagen. Therefore the 
effects of AGN193109 and HX531 on tRA-induced total collagen accumulation 
in NRK-49F cells in the presence of TGF-β1 were studied.
AGN193109 and HX531 at doses of 1 μM had no effect on TGF-β1-induced 
total collagen deposition (Figure 5.2Ai, Bi). As expected, tRA at a dose of 0.2 
μM in the presence of TGF-β1 caused a significant increase in PSR staining 
in comparison with TGF-β1-treated cells alone; however pre-treating cells  with 
either AGN193109 or HX531 significantly suppressed this increase in PSR 
staining (Figure 5.2Ai, Bi). Neither AGN193109 nor HX531 caused significant 





Figure 5.2. Effect of RAR, RXR and PPARβ/δ antagonists on tRA-induced total collagen 
accumulation in the presence of TGF-β1 in NRK-49F cells. NRK-49F cells cultured as per 
protocol were pre-treated with pan-RAR antagonist AGN193109 (A), pan-RXR antagonist 
HX531 (B) or PPARβ/δ antagonist GSK0660 (C) for 2 h then with 0.2 μM tRA and/or 5 ng/ml 
TGF-β1 for 48 h. Total  collagen deposition was quantified by spectrophotometric analysis of 
eluted PSR staining (Ai-Ci) and cytotoxicity was assessed by cell detachment index (Aii-Cii). 
Data represent mean ± SEM of three independent cell culture studies. Statistical  analysis for 
Ai-Ci was performed on transformed data using repeated measures ANOVA and for Aii-Cii 
was performed using repeated measures ANOVA.* p<0.05, ** p<0.01, *** p<0.001 vs vehicle-
treated group; ψ p<0.05, ψψψ p<0.001 vs TGF-β1-treated group; + p<0.05, ++ p<0.01 
between groups indicated.
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5.2.2 Effect of a PPARβ/δ antagonist
Finally, the effect of the PPARβ/δ antagonist GSK0660 on tRA-induced total 
collagen accumulation was investigated. GSK0660 is a PPARβ/δ antagonist 
with a half maximal inhibitory concentration (IC50) of 300 nM (Table 2.2) 
(Shearer, Steger et al. 2008) and was therefore used at a dose of 2 μM to 
ensure adequate blockade of PPARβ/δ ligand binding was achieved. This 
dose was well tolerated by NRK-49F cells  causing no increase in cell 
detachment either alone or in combination with 0.2 μM tRA and 5 ng/ml TGF-
β1 (Figure 5.2Cii). GSK0660 did not affect PSR staining in either TGF-β1-
treated cells or cells treated with both tRA and TGF-β1 (Figure 5.2Ci).
5.3 Discussion
In the results presented here, treatment of NRK-49F cells with the pan-RXR 
agonist AGN194204 increased total collagen accumulation to a similar degree 
as tRA. Furthermore, the pan-RXR antagonist HX531 partially blocked the 
pro-fibrotic effects of tRA in the presence of TGF-β1. Although the pan-RAR 
agonist TTNPB and the PPARβ/δ agonist GW0742 also increased PSR 
staining, their effects were milder than that seen with either tRA or 
AGN194204, and the isotype-selective RAR agonists caused only minor 
changes. The pan-RAR antagonist AGN193109 partially blocked tRA-induced 
total collagen accumulation in the presence of TGF-β1 however the PPARβ/δ 
antagonist GSK0660 had no effect.
The most striking findings in this chapter were the effects of the pan-RXR 
agonist AGN194204 on total collagen deposition, and the effects of the pan-
RXR antagonist HX531 on total collagen accumulation in dual-treated cells 
(Figure 5.1Bi). RXR activation mimicked the effect of tRA while blocking RXR 
signalling partially blocked the pro-fibrotic effects of tRA in the presence of 
TGF-β1 suggesting that RXRs, at least in part, play a role in the pro-fibrotic 
effects of tRA. However, since tRA cannot bind and activate RXRs, RXR 
activation by tRA must occur indirectly by conversion of tRA to metabolites, 
such as 9cRA, that can activate RXRs (Urbach and Rando 1994).
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RXRs have been implicated as modulators of fibrosis in other organ systems. 
For example, in liver fibrosis a reduction in RXR expression was found to 
convert HSCs into their active form and increasing RXR expression inhibited 
HSC activation and proliferation (Ohata, Lin et al. 1997; Hellemans, Verbuyst 
et al. 2004); and in a rat model of hepatic fibrosis induced by CCl4, increased 
expression of RXRα was associated with a decrease in α-SMA and type I 
collagen (Wang, Xu et al. 2011). Data supporting a role for RXRs in renal 
fibrosis is more scarce although there are some examples. In a rat model of 
experimental glomerulonephritis the RXR agonist Ro-257386 ameliorated 
renal damage (Lehrke, Schaier et al. 2002) and in a chronic model of 
glomerulosclerosis AGN194204 reduced glomerulosclerosis  index as well as 
other parameters of renal damage (Schaier, Liebler et al. 2004). These 
studies suggest that fibrogenesis is associated with a reduction in RXR 
expression and increasing RXR expression/activation improves fibrosis. In 
contrast, the results presented here show the opposite: RXR agonism 
increased collagen deposition, and RXR antagonism reduced the pro-fibrotic 
effect of tRA. The discrepancy in these results  are likely a demonstration of 
the variable nature of retinoids dependent on retinoid type, cell type and 
model used. 
Although AGN194204 could be exerting its pro-fibrotic effects  via canonical 
retinoid signalling there are other possible mechanisms through which it is 
functioning. For example, Hoover et al. have shown that RXR signalling can 
directly interfere with TGF-β signalling (Hoover, Burton et al. 2008); the RXR 
agonist bexarotene, in the presence of TGF-β, caused a rapid increase in 
Smad2 and Smad3 phosphorylation in MEFs and, furthermore, loss  of RXRα 
resulted in increased Smad2 phosphorylation in response to TGF-β (Hoover, 
Burton et al. 2008). Alternatively, the effects of AGN194204 might be via RXR-
independent pathways in a cell that has reduced RXR expression (although 
this  is in conflict with the RXR antagonist data). The reduction in RXR mRNA 
demonstrated in the previous  chapter could be an appropriate protective 
response in NRK-49F cells if the RXR signalling pathway is pro-fibrotic.
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The pan-RAR agonist TTNPB also caused an increase in PSR staining in 
NRK-49F cells, however the effect was not dose-dependent and much weaker 
then that for tRA. The RAR antagonist AGN193109 reduced the pro-fibrotic 
effects of dual treatment. These results suggest that the pro-fibrotic effect of 
tRA might also occur partly via RAR signalling (Figure 5.1Ai, 5.2Ai). As RARα, 
RARβ and RARγ agonists each had only minor effects on total collagen 
deposition, there was no evidence that individual RAR isotypes were 
responsible for the pro-fibrotic effect of tRA although they could each have 
had additive functions (Figure 5.1Ci). Of note, different RAR agonists had 
different fibrogenic potencies in the order tRA>TTNBP>RARα/RARβ>RARγ 
(Figure 5.1Ci).
Published literature suggests that RAR agonism in a variety of cell and animal 
renal disease models  confers protection against renal damage (Wagner, 
Dechow et al. 2000; Morath, Dechow et al. 2001; Schaier, Lehrke et al. 2001; 
Lehrke, Schaier et al. 2002; Schaier, Jocks et al. 2003; Schaier, Liebler et al. 
2004; Liu, Lu et al. 2008; Morath, Ratzlaff et al. 2009; Liu, Lu et al. 2011). 
However there are also reports  of RAR agonists exacerbating fibrosis in a 
dose-dependent (Morath, Ratzlaff et al. 2009; Xu, Hendry et al. 2010), time-
dependent (Morath, Ratzlaff et al. 2009) and environment-dependent (Liu, Lu 
et al. 2008; Morath, Ratzlaff et al. 2009) manner. Although the work here has 
not identified an anti-fibrotic potential of the retinoids tested, given that 
isotype-selective retinoids have shown promising efficacy in CKD models, the 
use of RAR isotype-selective retinoids  could be a plausible strategy to avoid 
unwanted pro-fibrotic effects of tRA.
Possible mechanisms for the pro-fibrotic effects  of RAR agonists include 
canonical signalling (Perez, Shull et al. 1992) and/or interference of the TGF-
β1 pathway (Cao, Flanders et al. 2003; Pendaries, Verrecchia et al. 2003), 
although further experiments  to deduce specific mechanisms of action in this 
cell model are required. 
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However, if the pro-fibrotic effects of tRA are mediated through RAR activation 
then it is unclear why the pan-agonist TTNPB did not have as great a 
response as tRA on total collagen deposition. TTNPB binds  RARs with 10-fold 
less efficiency than tRA, which might explain its reduced effects (Pignatello, 
Kauffman et al. 1997). In addition, tRA, as well as activating RARs directly, 
might be converted to retinoids that activate RXRs in vitro (Urbach and Rando 
1994) therefore potentiating the effect of tRA on RXR-RAR activation, an 
effect that could be particularly relevant if endogenous RA activity was present 
in NRK-49F cell culture. In addition tRA could have nuclear receptor-
independent effects as well as its RAR-dependent activities although the 
finding that an RAR antagonist reduced tRA-induced total collagen 
accumulation in the presence of TGF-β1 suggests that at least some of the 
pro-fibrotic effect of tRA is via RAR signalling (Figure 5.2Ai).
Finally, while the PPARβ/δ agonist GW0742 also caused a mild increase in 
PSR staining in NRK-49F cells, the PPARβ/δ antagonist GSK0660 could not 
prevent tRA-induced total collagen accumulation in the presence of TGF-β1 
(Figure 5.1Di, and 5.2Ci). This  suggests that activation of PPARβ/δ by tRA is 
not involved in the fibrogenic effects of tRA unless tRA binds  to PPARβ/δ in 
such a way that GSK0660 does  not prevent receptor activation. It cannot be 
excluded that a small proportion of tRA undergoes isomerisation in vitro to a 
ligand of RXRs causing RXR/PPARβ/δ activation and a pro-fibrotic response. 
In summary, there is  significant evidence for an RXR-mediated pro-fibrotic 
effect of tRA and some evidence for an RAR-mediated effect in NRK-49F 
cells. While all RAR and RXR agonists, with the exception of the RARγ-
selective agonist CD437, caused an increase collagen deposition, the RAR 
isotype-selective agonists had a minimal effect on fibrosis and might therefore 
provide a viable option for the safe use of retinoids in CKD.
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Chapter 6. Gene silencing using short-interfering RNA (siRNA) 
in NRK-49F cells 
6.1 Pilot study to determine optimal settings for 
electroporation of siRNA into NRK-49F cells
Experiments thus far have used chemical agonists and antagonists to 
investigate mechanisms behind tRA-induced total collagen accumulation. 
However chemicals may exert effects  not related to their target that cannot be 
predicted. Therefore it was important to corroborate these results use a 
different strategy and gene silencing using siRNA was  chosen for this 
purpose.
In early experiments it was established that chemical-based transfection of 
siRNA was unsuitable for gene silencing in NRK-49F cells as the knockdown 
achieved was variable and inconsistent (data not shown). Therefore a 
combination of electroporation and chemical-based transfection was used to 
attempt adequate silencing of gene expression.
 
Firstly, a pilot study was performed to determine the optimal voltage and 
capacitance for electroporation of siRNA into NRK-49F cells. Cells were 
electroporated at 0-400 V and 250 or 500 μF in the presence of 100 nM Cy5-
labelled siRNA and cell morphology examined by photomicroscopy and 
transfection efficiency determined by flow cytometry using a BD FACSCanto II 
flow cytometer. Data was analysed using FloJo Flow Cytometry Analysis 
Software.
Following electroporation, cell morphology of NRK-49F cells was altered with 
cells appearing larger and more spiculated. In addition the confluency of cells 
decreased as the voltage increased (Figure 6.1).
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Figure 6.1. Photomicroscopy of NRK-49F cells 48 h after electroporation. NRK-49F cells 
at a density of 1.5 x 106 /ml were electroporated in the presence of 100 nM Cy5-labelled 
siRNA. Cells were then cultured for 48 h in DMEM supplemented with 2.5% FCS and 2.5% 
Nu prior to photomicroscopy (phase contrast, x200 magnification). 
Figure 6.2 shows the relative fluorescence of NRK-49F cells following 
electroporation with Cy5-labelled siRNA at different voltages and 
capacitances. Negative control cells  (cells not treated with siRNA) subjected 
to electroporation at 100 V and 250 or 500 μF had less fluorescent signal 
relative to cells electroporated with Cy5-labelled siRNA; as voltage and 
capacitance increased, relative fluorescence of Cy5-labelled siRNA-treated 
NRK-49F cells increased (Figure 6.2A, B).
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Figure 6.2. A single parameter histogram showing relative fluorescence of NRK-49F 
cells electroporated with Cy-5-labelled siRNA. NRK-49F ells were el ctroporated with 
Cy-5-labelled siRNA, cultured for 3 d in DMEM supplem nted with 2.5% FCS and 2.5% Nu 
then subjected to flow cytometry. A- cells subjected to electroporation at a capacitance of 250 
μF; B- cells subjected to electroporation at a capacitance of 500 μF. Red= 100 V, negative 
control (no siRNA), blue= 0 V, green= 100 V, yellow= 200 V, turquoise= 300 V, pink= 400 V.
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70-80% of unelectroporated cells treated with Cy5-labelled siRNA gave a 
fluorescent signal and this increased to 100% when 200 V or more was 
delivered to cells (Figure 6.3A). The median intensity of signal increased as 
the voltage increased and cells exposed to a capacitance of 500 μF 
compared to 250 μF had a higher median intensity (Figure 6.3B). Although the 
percentage of cells  within the live gate was >85% in all groups, cell density 
was reduced at voltages above 100 V and was most marked in the group 
receiving 500 μF and 400 V (Figure 6.3C, D). Therefore, for future 
experiments, electroporation settings  were set at 300 V and 250 μF as these 
conditions achieved greatest transfection of Cy5-labelled siRNA while keeping 
cell death to a minimum.
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Figure 6.3. Flow cytometry of NRK-49F cells electroporated with Cy5-labelled siRNA 
under varying conditions. NRK-49F cells were electroporated with Cy-5-labelled siRNA 
then subjected to flow cytometry after 3 d culture as before. A- percentage of NRK-49F cells 
positive for Cy5-labelled siRNA; B- fluorescent intensity of NRK-49F cells following 
electroporation; C- percentage of cells within the live gate; D- percentage cell density at 
different electroporation settings.
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6.2 Chemical and electrical transfection of NRK-49F cells 
using siRNA targeting PAI-1 and TG2
Results from Chapter 3 suggested that PAI-1 was one possible mediator of 
the pro-fibrotic effects of tRA. Therefore knockdown of PAI-1 gene expression 
was attempted using a combination of electroporation and chemical 
transfection, as described in methods. A concentration of 20 nM siRNA was 
used according to manufacturer’s guidelines. Two controls were included in 
the experimental design: Cells electroporated without siRNA and those 
treated with negative control siRNA. 
Unfortunately, two different siRNAs targeting PAI-1 (designated “siRNA1” and 
“siRNA2”) achieved insufficient gene knockdown of only 29% and 44% for 
“siRNA1” and 15% and 28% for “siRNA2” in comparison with untreated cells 
in two independent cell culture studies (Figure 6.4).
A B
Figure 6.4. siRNA knockdown of PAI-1 in NRK-49F cells. NRK-49F cells were 
electroporated at 300 V and 250 μF with no siRNA (“no Rx”), 20 nM negative control siRNA 
(“NC”) or 20 nM each of two siRNAs targeting PAI-1 (“siRNA1” and ”siRNA2”). Cells were 
then seeded in collagen type-I-coated 96-well plates and cultured for 3 d in DMEM 
supplemented with 2.5% FCS and 2.5% Nu then for 4 d in DMEM supplemented with ITS and 
a further dose of 20 nM siRNA. Total  RNA was extracted from cells and subjected to two-step 
RT-qPCR. A and B show the % reduction in PAI-1 mRNA expression in comparison with the 
“no Rx” group in two independent cell culture experiments.
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Knockdown of TG2 gene expression was also attempted using two different 
siRNAs targeting TG2. “siRNA1” achieved adequate gene knockdown of 
>75% in comparison with untreated cells whereas “siRNA2” did not (Figure 
6.5). Therefore “siRNA1” was used to examine the effects  of TG2 gene 
knockdown on tRA-induced total collagen accumulation. 
Two independent cell culture studies were performed to examine the effects of 
TG2 knockdown on tRA-induced increase in PSR staining (Figure 6.6). In the 
first experiment, negative control siRNA did not have any significant effect on 
PSR staining compared to untreated cells; in addition, knockdown of TG2 
gene expression by “siRNA1” did not alter PSR staining in vehicle-, tRA- and 
TGF-β1-treated groups although there was a significant increase in PSR 
staining in the dual-treated group (Figure 6.6A). In the second independent 
cell culture study, negative control siRNA caused a reduction in PSR staining 
in comparison with the non-transfected group and “siRNA1” caused a further 
significant reduction in PSR staining in the vehicle-, tRA- and TGF-β1-treated 
groups compared cells treated with negative control siRNA (Figure 6.6B).
BA
Figure 6.5. siRNA knockdown of TG2 in NRK-49F cells. NRK-49F cells were 
electroporated then cultured as before. Total RNA was extracted from cells and subjected to 
RT-qPCR. A and B show the % reduction in TG2 mRNA expression in comparison with the 
“No Rx” group in two independent cell culture experiments. NC: cells treated with negative 
control siRNA; No Rx: untreated cells; siRNA1 and 2: cells treated with siRNAs “1” and “2”.
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Figure 6.6. Effect of TG2 knockdown on tRA-induced total collagen accumulation in the 
absence and presence of TGF-β1. NRK-49F cells were transfected as before. Cells were 
then treated with 2 μM tRA with and without 5 ng/ml TGF-β1 for 48 h. Eluted PSR stain was 
used to quantify total collagen deposition (Ai, Bi) and cell  detachment index was also 
recorded (Aii, Bii) in two independent experiments. Data for Ai and Bi represent mean ± SEM 
of quadruplicate wells; statistical analysis was performed using a one-way ANOVA. * p<0.05, 
** p<0.01, *** p<0.001 vs “no Rx” group in each of the vehicle-, tRA-, TGF-β1- and dual-
treated groups; + p<0.05, ++ p<0.01 between groups indicated.
6.3 Discussion
The results  presented here show that, despite a successful pilot study, 
NRK-49F cells were difficult to successfully transfect with targeting siRNAs. 
Furthermore, although one of the four siRNAs (“siRNA1” targeting TG2) 
tested did achieve >75% gene knockdown of TG2, experimentation with this 





The pilot study was designed to determine optimal settings for electroporation 
of NRK-49F cells and was performed as previous experiments using chemical 
transfection had been unsuccessful. As expected, increasing the voltage and 
capacitance applied to NRK-49F cells increased delivery of Cy5-labelled 
siRNA into cells, but with the consequence of more cell loss  (Figure 6.3). 
Optimal electroporation settings were therefore chosen as 300 V and 250 μF 
as these conditions achieved greatest transfection of Cy5-labelled siRNA 
while keeping cell death to a minimum.
However, despite optimising electroporation settings using fluorescent-
labelled siRNA, electroporation of NRK-49F cells with Ambion’s  Silencer® 
select pre-designed targeting siRNAs was largely unsuccessful with only one 
siRNA out of four producing adequate knockdown of gene expression. There 
are several possible reasons  for this  failure of the technique: 1) There was a 
change in the protocol from the pilot experiment with alterations in 
electroporation solution used and culture time before determining knockdown. 
Opti-MEM and lipofectamine RNAiMAX transfection reagent were used to 
suspend cells in an attempt to further encourage siRNA uptake and gene 
knockdown was  determined after 7 d culture because it was important to 
demonstrate gene knockdown at the point at which treatment of cells was to 
occur. Both these changes  may have affected the success of gene 
knockdown; 2) Cell culture conditions were generally unfavourable for 
transfection because cells were confluent as required for the 2D in vitro model 
of fibrosis; 3) There was a reduction in siRNA dose from 100 nM for the Cy5-
labelled siRNA to 20 nM for the targeting siRNAs; 4) The siRNAs may not 
have been functional or may have been of poor quality prior to use in 
experiments; 5) The RNAi pathway may not have been functioning in 
NRK-49F cells; 6) Delivery of Cy5-labelled siRNA into cells does not 
necessarily determine success  of knockdown only that siRNA has entered 
cells.
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Since “siRNA1” targeting TG2 achieved >75% knockdown, two independent 
experiments were performed to determine the effect of reducing TG2 gene 
expression on tRA-induced collagen accumulation. However these two 
studies produced very variable results and it was therefore difficult to draw 
any conclusions  from the work. The technique of electroporation is well known 
to damage cells and the higher the voltage the worse the damage that occurs 
(Wells 2010). Electroporation of NRK-49F cells  may not only have harmed 
cells but also altered their behaviour making experimentation with them and 
interpretation of results difficult. 
There are many different factors to consider when performing electroporation 
including electrode design, pulse pattern, and pulse magnitude and duration 
(Wells 2010). Amaxa Nucleofector Technology, owned by Lonza Group Ltd, is 
based on electroporation and uses cell-type-specific reagents, with optimised 
protocols  for difficult to transfect cell types including NRK-49F cells. Given the 
difficulties in transfection of NRK-49F cells  arising from this work this 
technology might be a relevant next step to take as it reportedly offers high 
efficiency, high viability transfection with maintenance of cell functionality. 
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Chapter 7. Other cell models for the study of the pro-fibrotic 
effects of tRA
7.1 Effect of tRA on total collagen deposition in a human 
foreskin fibroblast primary culture
Since NRK-49F cells  are a cell line and therefore might not represent the 
behaviour of other fibroblasts it was important to determine the effects of tRA 
on fibrosis in other fibroblast cell cultures and, in particular, primary cell 
cultures, as they are considered to more closely represent the in vivo setting. 
However primary renal fibroblast cell cultures  are not available commercially 
therefore a human foreskin fibroblast primary culture was used to determine 
the effects of tRA with and without TGF-β1 on total collagen deposition using 
the 2D in vitro model of fibrosis.
2-5 μM tRA alone and 0.02-0.2 μM tRA in the presence of TGF-β1 caused a 
dose-dependent increase in PSR staining (Figure 7.1A, B). No change in cell 
detachment index was detected in any of the treatment groups (data not 
shown).
7.2 Other fibroblast and mesangial cell cultures
7.2.1 COS-7 kidney fibroblast cell line and the 2D in vitro model of 
fibrosis
As another example of a renal fibroblast cell line, COS-7 cells were also 
considered for use in investigations of the effects of tRA with and without 
TGF-β1 on total collagen deposition. However, this  cell line had a rapid 
growth rate, produced large amounts of collagen even when quiescent, as 
demonstrated by PSR staining, and treatment with TGF-β1 did not induce an 
increase in collagen deposition (Figure 7.2). Therefore COS-7 cells were not 
suitable for further investigations of the effects of tRA on fibrosis with and 
without  TGF-β1.
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Figure 7.1. Effect of tRA treatment with and without TGF-β1 on total collagen 
deposition in human foreskin fibroblasts. Human foreskin fibroblasts cultured in collagen 
type-I-coated 96-well plates as per protocol  were treated with increasing doses of tRA in the 
absence and presence of TGF-β1 for 48 h. Total  collagen deposition was determined by 
photomicroscopy of PSR staining (x100 magnification) (A) and quantified by 
spectrophotometric analysis of eluted PSR (B). Data represent mean ± SEM of 3 independent 
cell  culture studies. Statistical analysis on B was performed on transformed data using 







Figure 7.2. Effect of TGF-β1 treatment on total collagen deposition in COS-7 cells. 
COS-7 cells cultured at a density of 1x104/well for 3 d in DMEM supplemented with 2.5% FCS 
and 2.5% Nu then for 4 d in DMEM supplemented with ITS (A) or at a density of 0.25x104/well 
for 3 d in DMEM supplemented with 2.5% FCS and 2.5% Nu then for 1 d in DMEM 
supplemented with ITS (B) were treated with 5 ng/ml TGF-β1 for 48 h. The effect on total 
collagen deposition was determined by photomicroscopy of PSR staining (x100 magnification) 
(Ai, Bi) and quantified by spectrophotometric analysis of eluted PSR (Aii, Bii). Data represent 
eight replicates of one cell culture study. 
7.2.2 Mesangial cells and the 2D in vitro model of fibrosis
Since mesangial cells  are important in the development of glomerulosclerosis, 
mesangial cell lines and primary cultures were also tested for their suitability 
for use in the 2D in vitro model of fibrosis. Two primary rat mesangial cell 
cultures isolated from the glomeruli of Sprague-Dawley and Wistar rats, 
respectively, the SM43 rat mesangial cell line and the human mesangial cell 
line “HMCL” were each treated with 5 ng/ml TGF-β1 then stained for total 
collagen as per protocol for the 2D in vitro model of fibrosis. As there was no 
significant increase in PSR staining by TGF-β1 in any of the mesangial cell 
cultures tested they did not represent appropriate fibrotic models and 






Figure 7.3. Effect of TGF-β1 treatment on total collagen deposition in mesangial cell 
cultures. Quiescent RMC primary cultures from Sprague-Dawley (A) and Wistar (B) rats and 
mesangial cell lines SM43 (C) and HMCL (D) were treated with 5 ng/ml TGF-β1 for 48 h. The 
effect on total collagen deposition was determined by photomicroscopy of PSR staining (x100 
magnification).
7.3 Discussion
The results presented here demonstrate that a human foreskin fibroblast 
primary culture responded to tRA and dual treatment similarly to NRK-49F 
cells by increasing net collagen deposition. This  result is important because it 
shows that the pro-fibrotic effect of tRA in NRK-49F cells is not idiosyncratic 
and supports the hypothesis that the pro-fibrotic effects  of tRA occur through 
fibroblast activation. 
Unfortunately, the net effect of tRA on fibrogenesis could not be tested in 
another renal fibroblast cell line, COS-7, and various mesangial cell cultures 
as they did not demonstrate increased PSR staining following TGF-β1 
treatment and therefore could not be used as appropriate in vitro models of 
TGF-β1-induced fibrosis. There are several possible explanations  why TGF-
β1 treatment did not cause an increase in total collagen deposition in these 
cell cultures. Firstly, a cell’s response to TGF-β1 can vary markedly 
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depending on a variety of factors such as confluency, serum content of media 
and whether the cells  are actively proliferating or quiescent (Sutton, Canfield 
et al. 1991). In addition, cell behaviour may alter significantly depending on 
the plastic-ware used, for example if cells  are seeded onto tissue culture-
treated plates (Lewis and Norman 1998) and further, the dose of TGF-β1 can 
determine a cell’s  response (Alvarez, Sun et al. 1992). Secondly, the 2D in 
vitro model of fibrosis may not have been sensitive enough to detect small 
changes in collagen accumulation between groups. If cells already have a 
high basal collagen secretion (which may be a particular problem if cultures 
are maintained in FCS as it contains TGF-β1) or they do not produce enough 
collagen in response to TGF-β1 to be detected by PSR staining then this 
model cannot be used.
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Chapter 8. Conclusions, perspectives and future work
8.1 Summary of findings
The work presented in this  thesis shows that tRA, in the absence and 
presence of TGF-β1, is pro-fibrotic in NRK-49F cells by causing an increase in 
total collagen accumulation determined by PSR staining. This  pro-fibrotic 
effect of tRA with and without TGF-β1 was also observed in a human foreskin 
fibroblast primary cell culture. Despite the tRA-induced increase in total 
collagen protein in NRK-49F cells, an RT-qPCR array showed there to be 
opposing actions  of tRA at the level of gene expression with evidence of anti-
fibrotic as well as pro-fibrotic potentials. Many of the MMPs were down-
regulated at mRNA level and MMP activity was also reduced providing a 
potential mechanism through which tRA is pro-fibrotic. In addition, PAI-1 
protein expression was up-regulated by tRA and further increased by dual 
treatment with tRA and TGF-β1 suggesting that it is through up-regulation of 
PAI-1 that dual treatment might cause more collagen accumulation than tRA 
alone. The PAI-1 inhibitor tiplaxtinin reduced tRA-induced collagen 
accumulation supporting the concept that PAI-1 contributes to the pro-fibrotic 
effect of tRA. There was no evidence to suggest that TG2 was involved in the 
pro-fibrotic effects of tRA as it was not up-regulated at protein level and a TG2 
inhibitor did not prevent but rather exacerbated tRA-induced total collagen 
accumulation.
The pathways through which tRA might be exerting its fibrogenic effects 
include retinoid receptor signalling as retinoid receptors  were expressed in 
NRK-49F cells and their mRNA expression was modulated by tRA and dual 
treatment. However tRA carrier proteins were less likely to be important as 
their protein expression was not detected in NRK-49F cells. A pan-RAR and 
RARα- and RARβ-selective agonists, a PPARβ/δ agonist but most of all a 
pan-RXR agonist all increased total collagen deposition; however, only a pan-
RAR and pan-RXR antagonist, and not a PPARβ/δ antagonist, decreased the 
pro-fibrotic effects of tRA in the presence of TGF-β1, implicating RXRs and 
possibly also RARs as mediators of the pro-fibrotic effects of tRA. 
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8.2  Relevance of this work
CKD is a clinically important disease in the UK causing high morbidity and 
mortality and is a financial burden on the National Health Service. Whatever 
the cause of CKD it is  renal fibrosis that is the final common pathway to 
ESRD. However there remains no direct treatment for renal fibrosis. Retinoids 
have been proposed as potential therapies for a variety of renal diseases 
because of their anti-inflammatory, anti-proliferative and possibly anti-fibrotic 
effects. Indeed, there are case reports  of the successful use of retinoids in the 
treatment of PML in a CKD patient (Yamane, Tsukamoto et al. 2009) and in 
patients with lupus nephritis (Kinoshita and Funauchi 2012). However, 
retinoids are not benign drugs. Systemic administration has been associated 
with mucocutaneous side effects, headaches, musculoskeletal abnormalities, 
hairloss, hyperlipidaemia, liver toxicity, psychiatric disturbances and 
teratogenicity. In addition, as well as reports of the favourable effects of 
retinoids in renal disease models, there is  also evidence that retinoids may 
exacerbate renal fibrosis. 
The development of less toxic, pathway specific retinoids has occurred with 
the aim of reducing the unpleasant side effects of less selective retinoids and 
to aid research into the biological actions of individual retinoid signalling 
pathways. Disease-targeted retinoids  would be particularly desirable in the 
CKD patient population because they are often asymptomatic and therefore 
will not readily accept treatments that make them feel unwell. 
There is currently a lack of understanding of the specific pathways through 
which retinoids exert their pro-fibrotic effects. This  work aimed to explore the 
mechanisms behind the fibrogenic effects of tRA in a cell model of renal 
interstitial fibrosis so that a strategy for the safe use of retinoids in renal 
diseases can be proposed.
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8.2.1 NRK-49F cells as a suitable in vitro model for studying the effects 
of retinoids in renal interstitial fibrosis
There are few reports of the effects  of retinoids on fibrosis in kidney 
fibroblasts  despite their role as key mediators of TIF. This work hypothesised 
that the pro-fibrotic effects of retinoids occurred through renal fibroblasts and 
the NRK-49F cell line was chosen as  a suitable renal fibroblast cell model to 
test this  hypothesis. NRK-49F cells are derived from normal rat kidneys and 
are morphologically and behaviourally similar to fibroblasts  (Huu, Rosenblum 
et al. 1966; de Larco and Todaro 1978). In the past, NRK-49F cells  have been 
widely used in fibrogenesis studies, especially those induced by TGF-β1 
(Roberts, Sporn et al. 1986; Grotendorst, Rahmanie et al. 2004). Furthermore, 
the NRK-49F cell culture conditions to minimise cell proliferation and 
maximise the fibrogenic response to TGF-β have already been established 
(Grotendorst, Rahmanie et al. 2004). For these reasons, NRK-49F cells were 
used to determine the effects  of retinoids  on renal fibroblasts in an in vitro 
model of TGF-β1-induced fibrosis. 
However it is  well recognised that cell lines are not recommended for 
extrapolating in vitro findings to the in vivo setting because they are 
immortalised, with the ability to proliferate indefinitely and may not retain all 
their original characteristics. However they remain useful research tools  as, in 
theory, their phenotype does not change during passaging thus  providing a 
consistent environment for the study of intracellular signalling pathways and 
they are also a continual source of cells. However, the effects of tRA on 
fibrosis were also studied in a human foreskin fibroblast primary cell culture to 
determine if the effects of tRA were reproducible in other fibroblast cell 
cultures. 
 
8.2.2 The 2D in vitro model of fibrosis as a suitable fibrotic model for 
studying the effects of tRA
It is currently common practice in research to select a few molecular markers 
of fibrosis for study in cell culture experiments. However, as demonstrated by 
the RT-qPCR array data presented here, tRA with or without TGF-β1 can 
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differentially regulate different markers of fibrosis. Therefore, if only a few 
molecular markers are chosen to study, different biased conclusions could be 
drawn. To avoid this, the 2D in vitro model of fibrosis was used in this 
research. It represents one of the only validated, reproducible cell models of 
fibrosis currently available and uses  the dye PSR to visualise total collagen 
protein deposition, which can be further quantified by spectrophotometric 
analysis of eluted stain (Xu, Norman et al. 2007). As collagens constitute a 
large component of the abnormal ECM in TIF, this model can be used to 
define changes in net fibrogenesis between treatments  and was therefore 
suitable for determining the effects of different retinoids with and without TGF-
β1 on fibrogenesis in NRK-49F cells. While there are numerous in vivo 
models  of renal fibrosis available they are not appropriate or ethical to use to 
further define mechanisms behind harmful treatments. This work therefore 
underlines the clear need for the development of fibrotic cell models  that can 
better represent the in vivo setting and can determine the effects of 
treatments on global fibrosis. 
8.2.3 Effect of tRA on fibrosis in NRK-49F cells
The work presented in this thesis  for the first time shows a net pro-fibrotic 
effect of tRA, in the absence and presence of TGF-β1, in a normal rat kidney 
fibroblast cell line (Figure 3.1). This fibrogenic effect of tRA was also observed 
in a human foreskin fibroblast primary culture (Figure 7.1) suggesting that the 
effects of tRA were not idiosyncratic to NRK-49F cells. These findings are of 
interest because there are few, if any, published reports of the effects of 
retinoids in renal fibroblasts  and much of the evidence of their effects in other 
kidney cells, such as mesangial cells, demonstrates an anti-fibrotic effect 
(Wen, Li et al. 2005; Liu, Lu et al. 2008). Possible reasons for the deficit of 
reports of the effects of retinoids  in renal fibroblasts include the lack of 
availability of renal fibroblast cultures commercially and publication bias where 
researchers and editors only seek to publish results that are favourable. In 
addition, as discussed above, if only one or two fibrogenic markers are 
selected for study then there is a risk of data being misinterpreted. 
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Despite its  net pro-fibrotic effect, with and without TGF-β1, tRA had both anti- 
and pro-fibrotic activities at the level of gene expression with a down-
regulation as well as an up-regulation of selected collagen mRNAs (Figure 
3.2). The opposing actions of retinoids  are not unique to this work. 
Suppression of collagen synthesis by retinoids has been reported in human 
keratinocytes (Chen, Goyal et al. 1997), skin fibroblasts (Shigematsu and 
Tajima 1995; Meisler, Parrelli et al. 1997), scleroderma fibroblasts (Ohta and 
Uitto 1987), lung fibroblasts (Krupsky, Fine et al. 1994; Redlich, Delisser et al. 
1995) and HSCs (Hellemans, Verbuyst et al. 2004). However an induction of 
collagen synthesis has been reported in chicken chondrocytes (Wu, Ishikawa 
et al. 1997), quail chondrocytes  (Sanchez, Gionti et al. 1993) and rat lung 
epithelial cells  (Federspiel, DiMari et al. 1990). While the opposing actions of 
tRA at the level of gene expression are of interest because strategies to 
potentiate the anti-fibrotic and reduce the pro-fibrotic actions of retinoids  might 
lead to the development of new treatments for fibrosis, mRNA changes are 
only relevant if they translate to a biologically significant effect at the 
functional level. This is exemplified by the collagen and TG2 data presented 
here where there was a down-regulation of many collagens at mRNA level 
despite collagen accumulation at protein level (Figures 3.1-3.4) and an up-
regulation of TG2 mRNA but not protein following tRA and dual treatment 
(Figures 3.8E and 3.13).
However, in agreement with the RT-qPCR data, which showed a down-
regulation of Mmp mRNAs (Figures 3.2 and 3.6), an MMP activity assay 
demonstrated that MMP activity was also reduced by tRA with and without 
TGF-β1 (Figure 3.7). This suggested that a reduction in matrix degradation by 
decreased MMP activity may contribute to the pro-fibrotic effect of tRA in 
NRK-49F cells. The published literature is  scarce on the effects  of tRA on 
MMP expression and activity in renal disease and there has tended to be 
focus on a few MMPs thought to be important in renal fibrosis despite 
evidence that at least ten isoforms are expressed in kidney tissue in health 
and disease (Catania, Chen et al. 2007). In light of the results presented here 
a review of the RT-qPCR data highlighted several individual MMPs that might 
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be of interest to explore in future studies. In particular, Mmp-13 (a 
collagenase), Mmps -3 and -10 (stromelysins) and Mmps -2 and -9 
(gelatinases) showed a marked down-regulation at mRNA level following tRA 
and/or dual treatment. Roles for MMPs -2 and -9 are well established in renal 
fibrosis (Sharma, Mauer et al. 1995; Gonzalez-Avila, Iturria et al. 1998; Ronco 
and Chatziantoniou 2008) and MMPs -3, -10 and -13 together are known to 
breakdown FN, collagens and gelatins, which are all important in TIF. In 
addition, in murine models of experimental liver fibrosis, MMP-13 was found 
to facilitate resolution of hepatic fibrosis (Fallowfield, Mizuno et al. 2007) and 
MMP-13 over-expression reduced liver fibrosis associated with an increase in 
MMPs -2 and -9 activity (Endo, Niioka et al. 2011).
One other noteworthy result from the MMP RT-qPCR array was the up-
regulation of Mmp-7 by tRA and dual treatment (Figure 3.2). While no 
conclusions can be drawn from this single result generated from a one cell 
culture study, it is intriguing that an increase in MMP-7 expression has been 
identified in diseased human kidney biopsy specimens and that it is a 
potential marker for renal Wnt/β-catenin signalling in progressive CKD 
(Surendran, Simon et al. 2004; He, Tan et al. 2011). 
PAI-1 protein was also modulated by tRA with evidence of an increase in 
protein that was further increased by dual treatment in NRK-49F cells (Figure 
3.9). Furthermore the PAI-1 inhibitor tiplaxtinin caused a reduction in tRA-
induced collagen accumulation with and without TGF-β1 (Figure 3.10). These 
results could help to explain why dual treatment caused more collagen 
accumulation than tRA alone. In addition, they could partly explain the 
reduction in MMP activity by tRA and dual treatment as plasmin is known to 
activate MMPs.
While down-regulation of MMPs by tRA has been reported before (Benbow 
and Brinckerhoff 1997; Fisher and Voorhees 1998; Mao, Tashkin et al. 2003), 
the increase in PAI-1 expression was somewhat unexpected as  a down-
regulation of PAI-1 following tRA treatment in TGF-β1-stimulated mesangial 
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cells (Wen, Li et al. 2005; Liu, Lu et al. 2008) and in the SNx model have been 
reported (Liu, Lu et al. 2011). Furthermore, RAR agonists and antagonists 
have been found to suppress  and potentiate TGF-β-induced PAI-1 promoter 
activity, respectively (Pendaries, Verrecchia et al. 2003). It is unclear whether 
these results represent true cell type specificity of tRA on PAI-1 expression 
between mesangial cells and fibroblasts, the two main effector cells in 
glomerulosclerosis and TIF, respectively. However, tRA induction of PAI-1 in 
NRK-49F cells is reminiscent of its effects in VSMCs, in which it induced PAI-1 
mRNA expression (Watanabe, Kanai et al. 2002).
Although PAI-1 is  widely reported to be pro-fibrotic the mechanisms through 
which it exerts  its  effects are complex, not fully understood and involve 
protease-independent as well as protease-dependent pathways. The primary 
role of PAI-1 is as an inhibitor of uPA and tPA, which convert plasminogen to 
plasmin. There are several mechanisms through which a decrease in renal 
plasmin might reduce fibrosis in this cell model. Firstly, plasmin is known to 
activate several latent MMPs as well as degrade fibrin (Nagase 1997), 
therefore a reduction in plasmin-induced MMP activation might exacerbate 
ECM accumulation. Secondly, if fibrinogen/fibrin is  proved to be involved in 
renal scar formation then a reduction in plasmin would exacerbate fibrosis 
(Eddy and Fogo 2006). Finally, plasmin is also known to degrade some ECM 
components such as FN (Huang, Border et al. 2006). In addition, reduction in 
uPA and tPA activity by PAI-1 could contribute to the pro-fibrotic effects  of 
PAI-1 independent of plasmin (Eddy and Fogo 2006). For example, uPA can 
degrade ECM components such as FN and activate anti-fibrotic molecules 
such as HGF. Therefore reduced uPA activity will favour development of 
fibrosis (Naldini, Vigna et al. 1995). Furthermore PAI-1 can exert its effects 
through receptor-mediated modulation of cell behaviour including cell 
detachment and migration (Eddy and Fogo 2006). 
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8.2.4 Contribution of the nuclear receptor signalling pathways to the 
pro-fibrotic effects of tRA
Results of experiments  designed to determine the roles of the retinoid nuclear 
receptors and PPARβ/δ in the pro-fibrotic effects of tRA suggested that RXRs 
were likely mediators of these effects, and RARs possible mediators, 
because: 1) NRK-49F cells  expressed retinoid nuclear receptors and their 
mRNA expression was modulated by tRA and dual treatment (Figures 4.1-4.2 
and 4.4-4.5); 2) RXR pan-agonists more than RAR pan-agonists  and RAR-
isotype-selective agonists showed pro-fibrotic effects but RAR and RXR 
antagonists did not (Figure 5.1); and 3) RAR and RXR antagonists partially 
blocked tRA-induced total collagen deposition in the presence of TGF-β1 
(Figure 5.2). 
Retinoid receptor signalling has also been shown to be relevant in other 
experimental models of renal diseases. In particular, Juergen Wagner’s group 
from the University of Heidelberg has demonstrated improvement in renal 
parameters in acute and chronic glomerulonephritis  models by RAR- and 
RXR-specific agonists (Lehrke, Schaier et al. 2002; Schaier, Liebler et al. 
2004). This work is important as it establishes that receptor-selective retinoids 
can be used successfully for the treatment of renal diseases. 
Although in these published studies no differential effects were noted between 
RAR and RXR agonists, RAR and RXR agonists have been shown to play 
different roles in matrix synthesis  in cell models of liver disease (Hellemans, 
Verbuyst et al. 2004). For example, in activated HSCs synthetic RXR agonists 
reduced collagen type I and FN synthesis however RAR agonists reduced 
collagen types I and III and FN (Hellemans, Verbuyst et al. 2004). In the work 
presented here there was also evidence that RARs and RXRs had differential 
roles in total collagen accumulation. The pan-RXR agonist HX531 caused an 
increase in PSR staining that was dose-dependent and similar in size to the 
effect seen with tRA, however the pan-RAR agonist TTNPB had only a small 
non-dose-dependent effect that was much less  comparable with that seen 
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with tRA (Figure 5.1). These results are more consistent with tRA acting 
through RXR.
However, it is difficult to relate reports of the anti-fibrotic effects of RAR and 
RXR agonists in renal disease models  to the work presented here where 
agonists  of RARs and RXRs caused a pro-fibrotic effect. But renal disease 
models  such as those of glomerulonephritis may not be directly applicable to 
TIF and more appropriate experimental models may better determine the 
effect of retinoid type in TIF, for example the Alb/TGF-β1 transgenic mouse 
model of renal fibrosis (Xu, Hendry et al. 2010). 
The receptor-selective retinoids  tested in this work had different pro-fibrotic 
potencies in the order: tRA and AGN194204 > TTNPB > AGN195183 and 
CD2019 > CD437 (Figure 5.1). Although the RARα and RARβ isotype-
selective agonists tested were less fibrogenic and the RARγ agonist had no 
fibrogenic potential, none demonstrated a net anti-fibrotic potential and it 
remains largely unknown how retinoids exert their anti-fibrotic effects. Since 
receptor-selective agonists  have already been used successfully in renal 
disease models (Schaier, Liebler et al. 2004; Zhong, Wu et al. 2011) the use 
of RAR isotype-selective retinoids  could be a plausible strategy to avoid the 
unwanted pro-fibrotic effects of tRA and deserves a focus in future research.
Thus far, there are several reported possible mechanisms through which 
retinoid receptor signalling could result in fibrosis, summarised in Figure 8.1. 
Firstly, they could be exerting their effects via RAREs by increasing the 
transcription of RA-responsive genes (Vasios, Gold et al. 1989). Secondly, 
retinoid receptors could directly interfere with TGF-β intracellular signalling. 
Hoover et al. showed that dual treatment of dispersed hearts  and NIH3T3 
cells with retinoids (particularly an RXR agonist) and TGF-β resulted in an 
increase in phosphorylated R-Smads compared to TGF-β alone and loss of 
RXRα had a similar effect (Hoover, Burton et al. 2008). This suggests a direct 
interaction between retinoid receptors and Smads where agonists/loss of 
retinoid receptors would prevent this interaction making available R-Smads for 
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phosphorylation and activation (Hoover, Burton et al. 2008). In addition, Smad 
and RXR signalling may communicate at the level of TGIF. When the TGF-β 
signalling pathway is  active TGIF binds to Smads preventing them from 
interacting with their co-activators  thus blunting Smad-mediated transcription; 
however, TGIF can also bind to RXREs therefore preventing communication 
between TGIF and Smads (Bertolino, Reimund et al. 1995; Wotton, Lo et al. 
1999). Thirdly, retinoids have been shown to increase TGF-β expression in 
some renal diseases models  (Datta, Reddy et al. 2001; Morath, Ratzlaff et al. 
2009). Finally, activation of RAR and RXR receptors can modulate other 
important intracellular signalling cascades such as the MAP kinases. These in 
turn could potentiate the effects of R-Smads leading to a heightened response 
to TGF-β1 (Rochette-Egly and Germain 2009).
Figure 8.1. Potential mechanisms for the RAR/RXR-dependent pro-fibrotic effects of 
retinoids. 1) tRA or isomers of tRA directly affect transcriptional events by binding to RXR/
RAR dimers that bind to RAREs; 2) tRA or isomers of tRA bind to retinoid receptor/ R-Smad 
complexes and R-Smad is released and made available for phosphorylation; 3) tRA activates 
MAP kinases via retinoid receptor-dependent; 4) TGIF binds RXRE making available more 










































8.2.5 Dual potential of retinoids
This  work has confirmed the complex and opposing actions that retinoids can 
have even in the same cell system. The effects  of tRA in NRK-49F cells varied 
depending on dosage, time points studied, cell culture conditions and retinoid 
type. Examples include the dose-dependent increase in total collagen 
accumulation by tRA (Figure 3.1); the opposing actions  of tRA at the level of 
gene expression with both up-regulation and down-regulation of collagen 
mRNAs (Figure 3.2); the time-dependent regulation of Mmp-2 and Mmp-13 
mRNAs with opposing actions of tRA at different time points (Figure 3.6); the 
environment-dependent regulation of FN protein following tRA treatment with 
no change seen in quiescent NRK-49F cells but a tendency towards an 
increase in TGF-β1-treated cells (Figure 3.5); and the differential effects of 
receptor-selective retinoids on total collagen accumulation (Figure 5.1). 
With respect to retinoid dose, Morath et al. have shown that dose of 13cRA 
was crucial in determining outcome in a rat SNx model of renal fibrosis 
(Morath, Ratzlaff et al. 2009). Specifically, low-dose 13cRA (10 mg/kg body 
weight) had an anti-fibrotic effect, but high doses (40 mg/kg body weight) 
aggravated kidney scarring; the low-dose group also showed reduced TGF-β1 
staining whereas high-dose treatment caused an increase in TGF-β1 mRNA 
expression (Morath, Ratzlaff et al. 2009). Another example is  the effect of tRA 
on fibrosis in the Alb/TGF-β1 transgenic mouse model of renal fibrosis (Xu, 
Hendry et al. 2010). Xu et al. showed that low-dose tRA (6-10.7 mg/kg/day) 
caused a tendency towards suppression of some fibrogenic markers including 
FN, COL1A1 and COL1A2 mRNAs although no change in interstitial fibrosis 
or glomerulosclerosis  score was seen, however high-dose tRA (20.1-27.4 mg/
kg/day) exacerbated fibrosis (Xu, Hendry et al. 2010). 
With respect to time point studied, similar to the results presented here for 
Mmp-2 and -13 mRNAs, Morath et al. showed a time-dependent effect of 
13cRA on collagen IV and TGF-β1 mRNAs in VSMC cultures with a down-
regulation of collagen IV mRNA at 4 h but an up-regulation at 24 h and a 
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down-regulation of TGF-β1 mRNA at 4 h but no change at 24 h (Morath, 
Ratzlaff et al. 2009). 
Furthermore, environmental conditions  also been found to affect the actions of 
retinoids in other studies. For example, Liu et al. showed that tRA increased 
FN protein in quiescent RMCs but reduced FN protein in TGF-β1-stimulated 
RMCs (Liu, Lu et al. 2008). A further example is the reduced procollagen 
production and type I and type III procollagen mRNA expression in 
scleroderma and normal human skin fibroblasts by tRA and 13cRA (Ohta and 
Uitto 1987) but the increase in FN, thrombospondin, laminin and collagen type 
I by tRA seen in growth-inhibited human skin fibroblasts (Varani, Mitra et al. 
1990).
Moreover, retinoid type appears to be crucial in determining outcome. For 
example, in activated HSCs, tRA inhibited synthesis of procollagen types I, II, 
and IV, as  well as FN and laminin, but 9cRA increased procollagen I mRNA 
without affecting the expression of other matrix proteins (Hellemans, Grinko et 
al. 1999). Naturally-occurring RAs and synthetic RAR/RXR-selective retinoids 
have also been shown to exert differential effects  in activated HSCs 
(Hellemans, Verbuyst et al. 2004).
Thus, given the contrary nature of retinoids, this work corroborates that extra 
care should be taken when considering dosage, time points studied, 
environmental conditions and selectivity of retinoid. 
8.3 Limitations of this work
8.3.1 Choice of cell model and the 2D in vitro model of fibrosis
NRK-49F cells were chosen as an appropriate fibroblast cell model as  they 
are derived from normal rat kidneys, are phenotypically fibroblast-like and 
they are known to respond to TGF-β1 (Roberts, Sporn et al. 1986; 
Grotendorst, Rahmanie et al. 2004). However, they are a cell line and 
therefore may not retain their original characteristics. In addition they are of 
rat origin and, while this would be advantageous for further in vivo work using 
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rat experimental models, the results may not be applicable to human renal 
fibrosis which is ultimately the target for this research. Although the effects of 
tRA on total collagen deposition were reproducible in a human foreskin 
fibroblast primary culture, these cells may not behave similarly to human renal 
fibroblasts. Therefore to strengthen this data the effects of tRA in suitable rat 
and human renal fibroblast primary cultures could be determined. However, of 
course no cell culture is ideal as the phenotype of even primary cultures will 
change following contact with plastic-ware, different growth media and the 
loss of contact with other cell types, ECM and growth factors. 
The 2D in vitro model of fibrosis  was used as a validated, reproducible and 
rapid model for determining the net effects of different retinoids on total 
collagen deposition in vitro (Xu, Norman et al. 2007). However this model has 
its limitations. Firstly, it cannot be used if TGF-β1-treated cells do not produce 
enough collagen for the change to be detected by PSR staining. Indeed this 
model proved unsuitable for a variety of cell types that are known to be 
important in TIF and glomerulosclerosis. Secondly, as PSR stains for 
collagen, relevant changes in non-collagenous ECM components will be 
overlooked in this model. Finally, this  model relies on an intact cell monolayer 
and disruption of this  monolayer or contraction of cells  could affect the 
readout. Furthermore, a confluent fibroblast monolayer does not represent the 
in vivo fibrotic setting. Thus, while the 2D in vitro model of fibrosis  represents 
a useful cell model of fibrosis, there is  a clear need for the development of 
improved in vitro fibrotic models that are applicable to a variety of cell types 
and mimic better the complex 3D environment that cells reside in in vivo.
8.3.2 Use of chemical agonists and inhibitors and gene silencing 
technology
This  work has relied heavily on the use of chemical agonists and inhibitors of 
PAI-1, TG2 and the nuclear receptors. While agonists and inhibitors are useful 
in cell culture experiments because they can be transferred into in vivo work, 
they can often have unpredictable effects not related to their expected target 
and also can cause cytotoxicity. Therefore, ideally, results obtained using 
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chemicals should be confirmed with either a second agonist/inhibitor or, better 
still, via different technologies such as gene over-expression or knockdown, 
and blocking antibodies. In this work, transient transfection was used for this 
purpose, however, despite numerous attempts  using different methodologies, 
gene knockdown using targeted siRNAs in NRK-49F cells  was  largely 
unsuccessful.
8.3.3 Roles of the matrix degradation pathways in the pro-fibrotic 
effects of tRA
The results presented in this  thesis  demonstrate an association between 
reduced MMP activity and a pro-fibrotic effect of tRA. However, interventional 
studies to further examine this  relationship have not been performed. In 
addition, which particular MMP isoforms are involved has not been 
addressed. It is relevant to identify specific MMP isoforms as it would not only 
help develop a focus on disease-specific pathways but also facilitate transfer 
of this work into the in vivo setting as targeting multiple MMPs in vivo may 
have widespread biological implications.
tRA and dual treatment also caused an increase in PAI-1 expression and 
inhibiting PAI-1 activity reduced the pro-fibrotic effect of tRA. This provided 
another mechanism through which tRA might exert its actions. However, this 
work only looked at the effects of tRA on PAI-1 in isolated fibroblast cultures. 
Since PAI-1 acts through multiple serine protease-dependent and 
independent mechanisms, its effects on fibrosis are likely to be cell-type and 
species specific and may also depend on the region of the kidney affected, 
i.e. glomerular or tubulointerstitial, where expression of modulators of PAI-1 
activity, such as cell surface receptors, may vary (Eddy and Fogo 2006). 
Therefore, in vivo experiments are necessary to further dissect the effects of 
tRA on PAI-1 in a complex setting where multiple cell types, growth factors 
and cytokines all play a role.
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8.3.4 Roles for retinoid receptor-dependent and -independent pathways 
in the pro-fibrotic effects of tRA
This  work has explored the effects  of individual nuclear receptor activation on 
fibrosis in NRK-49F cells by using the end point of total collagen accumulation 
as a read out for fibrosis. However, the actions of each of the nuclear 
receptors on specific markers of fibrosis have not been explored. This is 
relevant as different nuclear receptors  may play differential roles in fibrosis 
that remain unidentified by this work. 
In addition, the intracellular signalling pathways through which the retinoid 
receptors exert their pro-fibrotic effects  have not been elucidated and, 
furthermore, the contributions of retinoid receptor-independent pathways have 
not been explored in detail. Retinoid receptor-independent mechanisms might 
be involved in the pro-fibrotic effects of tRA as RAR and RXR antagonists did 
not fully inhibit tRA-induced total collagen accumulation suggesting that other 
pathways may also be active. Thus, future experiments could further dissect 
out the roles of individual retinoid receptors  in fibrogenesis  and the role of 
receptor-independent pathways in the pro-fibrotic effects of tRA.
8.4 Future work
8.4.1 in vitro work
To further investigate the roles of the MMPs in the pro-fibrotic effects of tRA 
protein expression of MMP isoforms could initially be performed. Zymography 
or MMP isoform-selective activity assays could subsequently be employed to 
identify which MMP isoforms are involved at the functional level. In addition, 
interventional studies using MMP inhibitors and gene silencing could be used 
to determine if the pro-fibrotic effects of tRA can be mimicked, and increasing 
MMP activity, for example by over-expression of MMPs, could be used to 
ascertain if the pro-fibrotic effects  of tRA can be prevented. It would also be 
interesting to determine if the mechanism behind the effect of tRA on MMP 
expression is AP-1-dependent, as described in other publications (Benbow 
and Brinckerhoff 1997).
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With respect to the finding that inhibiting PAI-1 activity using tiplaxtinin 
reduced the pro-fibrotic effect of tRA, this result needs to be confirmed using a 
second chemical inhibitor or a different technology, especially as  tiplaxtinin 
was toxic in NRK-49F cells. In view of the lack of suitable chemical agonists/ 
inhibitors for PAI-1, blocking antibodies designed to inhibit the function of their 
target could be used. Stable transfection of NRK-49F cells could also be 
considered or easier-to-transfect cell cultures explored. Furthermore, it would 
be interesting to investigate the pathways through which PAI-1 is up-regulated 
by tRA; for example, is the mechanism of PAI-1 up-regulation tyrosine-kinase 
dependent (Watanabe, Kanai et al. 2002)?
The results obtained using chemical agonists and antagonists to retinoid 
receptors also need to be confirmed using different chemicals or technologies. 
In addition, it would be important to determine the retinoid receptor isotype 
with the least detrimental effect on MMP and PAI-1 regulation, which could be 
done using RT-qPCR, Western blotting and functional assays, in a similar way 
to the work presented here.
8.4.2 Translation of this work into an in vivo model
This  work has focused on the effects  of retinoids on fibrosis in renal 
fibroblasts. However in reality TIF is  a highly complex process  involving 
multiple cell types, growth factors and cytokines. The MMPs are well known to 
have roles much more diverse than simply matrix degradation and the effects 
of PAI-1 depend on the multiple cell types, growth factors and cytokines 
present in the in vivo setting. Therefore, to take this work further, it would be 
important to explore the effects of different retinoids  on renal fibrosis in an 
equivalent in vivo model and there are numerous experimental models  of TIF 
that could be considered. 
The Alb/TGF-β1 transgenic mouse model is worth particular consideration 
from a mechanistic viewpoint as it is an in vivo model of TGF-β1-induced 
renal fibrosis and therefore is comparable to the in vitro model of TGF-β1-
induced fibrosis presented here. This model over-expresses active TGF-β1 in 
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the liver leading to high serum TGF-β1 levels and renal fibrosis develops 
rapidly (Mozes, Bottinger et al. 1999). tRA has been shown to exacerbate 
renal fibrosis in this mouse model therefore it constitutes an in vivo pro-fibrotic 
model of the effects of tRA (Xu, Hendry et al. 2010). Ethically, it is 
inappropriate to consider a harmful treatment for an in vivo model, however it 
would be interesting to examine the mechanisms behind the pro-fibrotic 
effects of tRA in the renal tissue preserved from previous experiments, if 
available (Xu, Hendry et al. 2010). In addition, the effects of other, more 
selective retinoids could be explored in this model once their effects on 
fibrosis have been better defined in vitro.
8.5 Concluding remarks
This  work has identified fibroblasts as a key cellular mediator of the pro-
fibrotic effects of tRA and, furthermore, potential pathways involved (Figure 
8.2). While an anti-fibrotic retinoid was not identified through this work, 
receptor-selective retinoids with no/less pro-fibrotic potential were identified, 
which may provide a safer option for use in CKD patients and reduce the side 
effect profile of less selective retinoids. The increased fibrogenic effect of tRA 
in the presence of TGF-β1 in renal fibroblasts  highlights  issues regarding the 
prescription of retinoids to CKD patients who over-express renal TGF-β1. In 
view of the emerging clinical use of retinoids in CKD there is justification to 
better define the fibrogenic effects of tRA so that the long-term safety profile of 
retinoids is improved and eventually a viable retinoid-based therapy for CKD 
devoid of the unwanted pro-fibrotic effects can be developed. 
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Figure 8.2. Diagram of the proposed pathways of the pro-fibrotic effects of tRA in 
NRK-49F cells. tRA-induced pro-fibrotic  effects in NRK-49F cells are associated with 
increased PAI-1 and reduced MMP expression. tRA-induced PAI-1 could lead to reduced 
plasminogen activation into plasmin, which in turn could lead to reduced degradation of ECM 
proteins either directly or through reduced activation of MMPs by plasmin. Thus, both PAI-1 
induction and MMP reduction could contribute to decreased degradation and increased 
accumulation of ECM. Both RXR and RAR pathways are likely involved in the pro-fibrotic 
effects of tRA, with tRA activation of RXR signalling hypothesised to occur by isomerisation of 
tRA into 9cRA. In terms of the pro-fibrotic  effects, RAR agonists had only weak effects 
however the RXR agonist AGN194204 was as potent as tRA, suggesting that RXR-activating 
metabolites might play a larger role in the pro-fibrotic effects of tRA. Solid lines represent 



















↓ degradation and ↑ accumulation 




Achkar, C. C., F. Derguini, et al. (1996). "4-Oxoretinol, a new natural ligand 
and transactivator of the retinoic acid receptors." Proc Natl Acad Sci U 
S A 93(10): 4879-4884.
Adams, J., E. Kiss, et al. (2005). "13-cis retinoic acid inhibits development and 
progression of chronic allograft nephropathy." Am J Pathol 167(1): 
285-298.
Aeschlimann, D. and M. Paulsson (1991). "Cross-linking of laminin-nidogen 
complexes by tissue transglutaminase. A novel mechanism for 
basement membrane stabilization." J Biol Chem 266(23): 
15308-15317.
Afrakhte, M., A. Moren, et al. (1998). "Induction of inhibitory Smad6 and 
Smad7 mRNA by TGF-beta family members." Biochem Biophys Res 
Commun 249(2): 505-511.
Agarwal, C., R. A. Chandraratna, et al. (1996). "AGN193109 is a highly 
effective antagonist of retinoid action in human ectocervical epithelial 
cells." J Biol Chem 271(21): 12209-12212.
Aguilar, R. P., S. Genta, et al. (2009). "Vitamin A deficiency injures liver 
parenchyma and alters the expression of hepatic extracellular matrix." 
J Appl Toxicol 29(3): 214-222.
Akhurst, R. J. and A. Hata (2012). "Targeting the TGFbeta signalling pathway 
in disease." Nat Rev Drug Discov 11(10): 790-811.
Akimov, S. S. and A. M. Belkin (2001). "Cell surface tissue transglutaminase is 
involved in adhesion and migration of monocytic cells on fibronectin." 
Blood 98(5): 1567-1576.
Alique, M., F. J. Lucio-Cazana, et al. (2007). "Upregulation of 
cyclooxygenases by retinoic acid in rat mesangial cells." Pharmacology 
79(1): 57-64.
Alique, M., V. Moreno, et al. (2006). "Kinase-dependent, retinoic acid 
receptor-independent up-regulation of cyclooxygenase-2 by all-trans 
retinoic acid in human mesangial cells." Br J Pharmacol 149(2): 
215-225.
Allegretto, E. A., M. R. McClurg, et al. (1993). "Transactivation properties of 
retinoic acid and retinoid X receptors in mammalian cells and yeast. 
Correlation with hormone binding and effects of metabolism." J Biol 
Chem 268(35): 26625-26633.
Altucci, L., M. D. Leibowitz, et al. (2007). "RAR and RXR modulation in cancer 
and metabolic disease." Nat Rev Drug Discov 6(10): 793-810.
Alvarez, R. J., M. J. Sun, et al. (1992). "Biosynthetic and proliferative 
characteristics of tubulointerstitial fibroblasts probed with paracrine 
cytokines." Kidney Int 41(1): 14-23.
Annes, J. P., J. S. Munger, et al. (2003). "Making sense of latent TGFbeta 
activation." J Cell Sci 116(Pt 2): 217-224.
Ansell, D., P. Roderick, et al. (2009). "UK Renal Registry 12th Annual Report 
(December 2009): Chapter 7: Survival and causes of death of UK adult 
patients on renal replacement therapy in 2008: national and centre-
specific analyses." Nephron Clin Pract 115 Suppl 1: c117-144.
180
Asada, N., M. Takase, et al. (2011). "Dysfunction of fibroblasts of extrarenal 
origin underlies renal fibrosis and renal anemia in mice." J Clin Invest 
121(10): 3981-3990.
Asanuma, K., I. Shirato, et al. (2002). "Selective modulation of the secretion of 
proteinases and their inhibitors by growth factors in cultured 
differentiated podocytes." Kidney Int 62(3): 822-831.
Austenaa, L. M., H. Carlsen, et al. (2004). "Vitamin A status significantly alters 
nuclear factor-kappaB activity assessed by in vivo imaging." Faseb J 
18(11): 1255-1257.
Austenaa, L. M., H. Carlsen, et al. (2009). "Retinoic acid dampens LPS-
induced NF-kappaB activity: results from human monoblasts and in 
vivo imaging of NF-kappaB reporter mice." J Nutr Biochem 20(9): 
726-734.
Baricos, W. H., S. L. Cortez, et al. (1999). "Transforming growth factor-beta is 
a potent inhibitor of extracellular matrix degradation by cultured human 
mesangial cells." J Am Soc Nephrol 10(4): 790-795.
Bastien, J., J. L. Plassat, et al. (2006). "The phosphoinositide 3-kinase/Akt 
pathway is essential for the retinoic acid-induced differentiation of F9 
cells." Oncogene 25(14): 2040-2047.
Beard, R. L., T. T. Duong, et al. (2002). "Synthesis and biological activity of 
retinoic acid receptor-alpha specific amides." Bioorg Med Chem Lett 12
(21): 3145-3148.
Beere, H. M. and J. A. Hickman (1993). "Differentiation: a suitable strategy for 
cancer chemotherapy?" Anticancer Drug Des 8(4): 299-322.
Benbow, U. and C. E. Brinckerhoff (1997). "The AP-1 site and MMP gene 
regulation: what is all the fuss about?" Matrix Biol 15(8-9): 519-526.
Bernard, B. A., J. M. Bernardon, et al. (1992). "Identification of synthetic 
retinoids with selectivity for human nuclear retinoic acid receptor 
gamma." Biochem Biophys Res Commun 186(2): 977-983.
Berry, D. C. and N. Noy (2007). "Is PPARbeta/delta a Retinoid Receptor?" 
PPAR Res 2007: 73256.
Bertelli, R., F. Valenti, et al. (1998). "Cell-specific regulation of alpha1(III) and 
alpha2(V) collagen by TGF-beta1 in tubulointerstitial cell models." 
Nephrol Dial Transplant 13(3): 573-579.
Bertolino, E., B. Reimund, et al. (1995). "A novel homeobox protein which 
recognizes a TGT core and functionally interferes with a retinoid-
responsive motif." J Biol Chem 270(52): 31178-31188.
Blaner, W. S. (2001). "Cellular metabolism and actions of 13-cis-retinoic acid." 
J Am Acad Dermatol 45(5): S129-135.
Blomhoff, R. (1997). "Retinoids may increase fibrotic potential of TGF-beta: 
crosstalk between two multi-functional effectors." Hepatology 26(4): 
1067-1068.
Blomhoff, R. and H. K. Blomhoff (2006). "Overview of retinoid metabolism and 
function." J Neurobiol 66(7): 606-630.
Bolbrinker, J., S. Markovic, et al. (2006). "Expression and response to 
angiotensin-converting enzyme inhibition of matrix metalloproteinases 
2 and 9 in renal glomerular damage in young transgenic rats with renin-
dependent hypertension." J Pharmacol Exp Ther 316(1): 8-16.
181
Bookout, A. L., Y. Jeong, et al. (2005). "www.nursa.org/10.1621/datasets.
02001."
Border, W. A., S. Okuda, et al. (1990). "Transforming growth factor-beta 
regulates production of proteoglycans by mesangial cells." Kidney Int 
37(2): 689-695.
Borland, M. G., J. E. Foreman, et al. (2008). "Ligand activation of peroxisome 
proliferator-activated receptor-beta/delta inhibits cell proliferation in 
human HaCaT keratinocytes." Mol Pharmacol 74(5): 1429-1442.
Borland, M. G., C. Khozoie, et al. (2011). "Stable over-expression of 
PPARbeta/delta and PPARgamma to examine receptor signaling in 
human HaCaT keratinocytes." Cell Signal 23(12): 2039-2050.
Bossenbroek, N. M., T. H. Sulahian, et al. (1998). "Expression of nuclear 
retinoic acid receptor and retinoid X receptor mRNA in the cornea and 
conjunctiva." Curr Eye Res 17(5): 462-469.
Boylan, J. F. and L. J. Gudas (1991). "Overexpression of the cellular retinoic 
acid binding protein-I (CRABP-I) results in a reduction in differentiation-
specific gene expression in F9 teratocarcinoma cells." J Cell Biol 112
(5): 965-979.
Boylan, J. F. and L. J. Gudas (1992). "The level of CRABP-I expression 
influences the amounts and types of all-trans-retinoic acid metabolites 
in F9 teratocarcinoma stem cells." J Biol Chem 267(30): 21486-21491.
Brigstock, D. R. (2003). "The CCN family: a new stimulus package." J 
Endocrinol 178(2): 169-175.
Bruce, D. L. and G. P. Sapkota (2012). "Phosphatases in SMAD regulation." 
FEBS Lett.
Buck, J., F. Derguini, et al. (1991). "Intracellular signaling by 14-hydroxy-4,14-
retro-retinol." Science 254(5038): 1654-1656.
Camp, T. M., L. M. Smiley, et al. (2003). "Mechanism of matrix accumulation 
and glomerulosclerosis in spontaneously hypertensive rats." J 
Hypertens 21(9): 1719-1727.
Camuto, P., J. Shupack, et al. (1987). "Long-term effects of etretinate on the 
liver in psoriasis." Am J Surg Pathol 11(1): 30-37.
Cao, Z., K. C. Flanders, et al. (2003). "Levels of phospho-Smad2/3 are 
sensors of the interplay between effects of TGF-beta and retinoic acid 
on monocytic and granulocytic differentiation of HL-60 cells." Blood 101
(2): 498-507.
Carome, M. A., L. J. Striker, et al. (1993). "Human glomeruli express TIMP-1 
mRNA and TIMP-2 protein and mRNA." Am J Physiol 264(6 Pt 2): 
F923-929.
Catania, J. M., G. Chen, et al. (2007). "Role of matrix metalloproteinases in 
renal pathophysiologies." Am J Physiol Renal Physiol 292(3): 
F905-911.
Chambon, P. (1996). "A decade of molecular biology of retinoic acid 
receptors." Faseb J 10(9): 940-954.
Chambon, P. (2005). "The nuclear receptor superfamily: a personal retrospect 
on the first two decades." Mol Endocrinol 19(6): 1418-1428.
Chang, H. R., S. F. Yang, et al. (2006). "Relationships between circulating 
matrix metalloproteinase-2 and -9 and renal function in patients with 
chronic kidney disease." Clin Chim Acta 366(1-2): 243-248.
182
Chen, H., H. Zhang, et al. (2007). "HOXA5 acts directly downstream of 
retinoic acid receptor beta and contributes to retinoic acid-induced 
apoptosis and growth inhibition." Cancer Res 67(17): 8007-8013.
Chen, J. D. and R. M. Evans (1995). "A transcriptional co-repressor that 
interacts with nuclear hormone receptors." Nature 377(6548): 454-457.
Chen, M., S. Goyal, et al. (1997). "Modulation of type VII collagen (anchoring 
fibril) expression by retinoids in human skin cells." Biochim Biophys 
Acta 1351(3): 333-340.
Chen, N., B. Onisko, et al. (2008). "The nuclear transcription factor RARalpha 
associates with neuronal RNA granules and suppresses translation." J 
Biol Chem 283(30): 20841-20847.
Cheng, Q. L., M. Orikasa, et al. (1995). "Progressive renal lesions induced by 
administration of monoclonal antibody 1-22-3 to unilaterally 
nephrectomized rats." Clin Exp Immunol 102(1): 181-185.
Cheng, S. and D. H. Lovett (2003). "Gelatinase A (MMP-2) is necessary and 
sufficient for renal tubular cell epithelial-mesenchymal transformation." 
Am J Pathol 162(6): 1937-1949.
Cheng, S., A. S. Pollock, et al. (2006). "Matrix metalloproteinase 2 and 
basement membrane integrity: a unifying mechanism for progressive 
renal injury." Faseb J 20(11): 1898-1900.
Chikamori, K., J. E. Hill, et al. (2006). "Downregulation of topoisomerase 
IIbeta in myeloid leukemia cell lines leads to activation of apoptosis 
following all-trans retinoic acid-induced differentiation/growth arrest." 
Leukemia 20(10): 1809-1818.
Chin, B. Y., A. Mohsenin, et al. (2001). "Stimulation of pro-alpha(1)(I) collagen 
by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway." Am 
J Physiol Renal Physiol 280(3): F495-504.
Choi, M. E., Y. Ding, et al. (2012). "TGF-beta signaling via TAK1 pathway: role 
in kidney fibrosis." Semin Nephrol 32(3): 244-252.
Coimbra, T., R. Wiggins, et al. (1991). "Transforming growth factor-beta 
production in anti-glomerular basement membrane disease in the 
rabbit." Am J Pathol 138(1): 223-234.
Cullum, M. E. and M. H. Zile (1985). "Metabolism of all-trans-retinoic acid and 
all-trans-retinyl acetate. Demonstration of common physiological 
metabolites in rat small intestinal mucosa and circulation." J Biol Chem 
260(19): 10590-10596.
D'Ambrosio, D. N., R. D. Clugston, et al. (2011). "Vitamin A metabolism: an 
update." Nutrients 3(1): 63-103.
D'Eletto, M., M. G. Farrace, et al. (2009). "Transglutaminase 2 is involved in 
autophagosome maturation." Autophagy 5(8): 1145-1154.
Dallas, S. L., P. Sivakumar, et al. (2005). "Fibronectin regulates latent 
transforming growth factor-beta (TGF beta) by controlling matrix 
assembly of latent TGF beta-binding protein-1." J Biol Chem 280(19): 
18871-18880.
Darby, I. A. and T. D. Hewitson (2007). "Fibroblast differentiation in wound 
healing and fibrosis." Int Rev Cytol 257: 143-179.
Datta, P. K., R. S. Reddy, et al. (2001). "Effects of all-trans-retinoic acid (atRA) 
on inducible nitric oxide synthase (iNOS) activity and transforming 
183
growth factor beta-1 production in experimental anti-GBM antibody-
mediated glomerulonephritis." Inflammation 25(6): 351-359.
Davis, B. H., R. T. Kramer, et al. (1990). "Retinoic acid modulates rat Ito cell 
proliferation, collagen, and transforming growth factor beta production." 
J Clin Invest 86(6): 2062-2070.
de Larco, J. E. and G. J. Todaro (1978). "Epithelioid and fibroblastic rat kidney 
cell clones: epidermal growth factor (EGF) receptors and the effect of 
mouse sarcoma virus transformation." J Cell Physiol 94(3): 335-342.
del Rincon, S. V., Q. Guo, et al. (2004). "Retinoic acid mediates degradation 
of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant 
mechanism." Oncogene 23(57): 9269-9279.
Derynck, R., P. B. Lindquist, et al. (1988). "A new type of transforming growth 
factor-beta, TGF-beta 3." EMBO J 7(12): 3737-3743.
Derynck, R. and Y. E. Zhang (2003). "Smad-dependent and Smad-
independent pathways in TGF-beta family signalling." Nature 425
(6958): 577-584.
Dey, N., P. K. De, et al. (2007). "CSK controls retinoic acid receptor (RAR) 
signaling: a RAR-c-SRC signaling axis is required for neuritogenic 
differentiation." Mol Cell Biol 27(11): 4179-4197.
Dolle, P., E. Ruberte, et al. (1990). "Retinoic acid receptors and cellular 
retinoid binding proteins. I. A systematic study of their differential 
pattern of transcription during mouse organogenesis." Development 
110(4): 1133-1151.
Dong, D., S. E. Ruuska, et al. (1999). "Distinct roles for cellular retinoic acid-
binding proteins I and II in regulating signaling by retinoic acid." J Biol 
Chem 274(34): 23695-23698.
Douthwaite, J. A., T. S. Johnson, et al. (1999). "Effects of transforming growth 
factor-beta1 on renal extracellular matrix components and their 
regulating proteins." J Am Soc Nephrol 10(10): 2109-2119.
Duymelinck, C., S. E. Dauwe, et al. (2000). "TIMP-1 gene expression and 
PAI-1 antigen after unilateral ureteral obstruction in the adult male rat." 
Kidney Int 58(3): 1186-1201.
Ebisawa, M., H. Umemiya, et al. (1999). "Retinoid X receptor-antagonistic 
diazepinylbenzoic acids." Chem Pharm Bull (Tokyo) 47(12): 1778-1786.
Ebisawa, T., M. Fukuchi, et al. (2001). "Smurf1 interacts with transforming 
growth factor-beta type I receptor through Smad7 and induces receptor 
degradation." J Biol Chem 276(16): 12477-12480.
Eddy, A. A. (1996). "Molecular insights into renal interstitial fibrosis." J Am Soc 
Nephrol 7(12): 2495-2508.
Eddy, A. A. (2009). "Serine proteases, inhibitors and receptors in renal 
fibrosis." Thromb Haemost 101(4): 656-664.
Eddy, A. A. and A. B. Fogo (2006). "Plasminogen activator inhibitor-1 in 
chronic kidney disease: evidence and mechanisms of action." J Am 
Soc Nephrol 17(11): 2999-3012.
Edgtton, K. L., R. M. Gow, et al. (2004). "Plasmin is not protective in 
experimental renal interstitial fibrosis." Kidney Int 66(1): 68-76.
El Nahas, A. M., H. Abo-Zenah, et al. (2004). "Elevated epsilon-(gamma-
glutamyl)lysine in human diabetic nephropathy results from increased 
184
expression and cellular release of tissue transglutaminase." Nephron 
Clin Pract 97(3): c108-117.
Elokdah, H., M. Abou-Gharbia, et al. (2004). "Tiplaxtinin, a novel, orally 
efficacious inhibitor of plasminogen activator inhibitor-1: design, 
synthesis, and preclinical characterization." J Med Chem 47(14): 
3491-3494.
Endo, H., M. Niioka, et al. (2011). "Matrix metalloproteinase-13 promotes 
recovery from experimental liver cirrhosis in rats." Pathobiology 78(5): 
239-252.
Falk, L. A., F. De Benedetti, et al. (1991). "Induction of transforming growth 
factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 
protein production in retinoic acid-treated HL-60 cells: possible TGF-
beta 1-mediated autocrine inhibition." Blood 77(6): 1248-1255.
Fallowfield, J. A., M. Mizuno, et al. (2007). "Scar-associated macrophages are 
a major source of hepatic matrix metalloproteinase-13 and facilitate the 
resolution of murine hepatic fibrosis." J Immunol 178(8): 5288-5295.
Fan, J. M., Y. Y. Ng, et al. (1999). "Transforming growth factor-beta regulates 
tubular epithelial-myofibroblast transdifferentiation in vitro." Kidney Int 
56(4): 1455-1467.
Fanjul, A., M. I. Dawson, et al. (1994). "A new class of retinoids with selective 
inhibition of AP-1 inhibits proliferation." Nature 372(6501): 107-111.
Federspiel, S. J., S. J. DiMari, et al. (1990). "Extracellular matrix biosynthesis 
by cultured fetal rat lung epithelial cells. II. Effects of acute exposure to 
epidermal growth factor and retinoic acid on collagen biosynthesis." 
Lab Invest 63(4): 455-466.
Feng, X. H. and R. Derynck (2005). "Specificity and versatility in tgf-beta 
signaling through Smads." Annu Rev Cell Dev Biol 21: 659-693.
Fisher, G. J. and J. J. Voorhees (1998). "Molecular mechanisms of photoaging 
and its prevention by retinoic acid: ultraviolet irradiation induces MAP 
kinase signal transduction cascades that induce Ap-1-regulated matrix 
metalloproteinases that degrade human skin in vivo." J Investig 
Dermatol Symp Proc 3(1): 61-68.
Fisher, M., R. A. Jones, et al. (2009). "Modulation of tissue transglutaminase 
in tubular epithelial cells alters extracellular matrix levels: a potential 
mechanism of tissue scarring." Matrix Biol 28(1): 20-31.
Fujimoto, M., Y. Maezawa, et al. (2003). "Mice lacking Smad3 are protected 
against streptozotocin-induced diabetic glomerulopathy." Biochem 
Biophys Res Commun 305(4): 1002-1007.
Funaba, M., C. M. Zimmerman, et al. (2002). "Modulation of Smad2-mediated 
signaling by extracellular signal-regulated kinase." J Biol Chem 277
(44): 41361-41368.
Germain, P., P. Chambon, et al. (2006). "International Union of Pharmacology. 
LX. Retinoic acid receptors." Pharmacol Rev 58(4): 712-725.
Gille, J., L. L. Paxton, et al. (1997). "Retinoic acid inhibits the regulated 
expression of vascular cell adhesion molecule-1 by cultured dermal 
microvascular endothelial cells." J Clin Invest 99(3): 492-500.
Glass, C. K. and M. G. Rosenfeld (2000). "The coregulator exchange in 
transcriptional functions of nuclear receptors." Genes Dev 14(2): 
121-141.
185
Gluzman, Y. (1981). "SV40-transformed simian cells support the replication of 
early SV40 mutants." Cell 23(1): 175-182.
Go, A. S., G. M. Chertow, et al. (2004). "Chronic kidney disease and the risks 
of death, cardiovascular events, and hospitalization." N Engl J Med 351
(13): 1296-1305.
Gonzalez-Avila, G., C. Iturria, et al. (1998). "Changes in matrix 
metalloproteinases during the evolution of interstitial renal fibrosis in a 
rat experimental model." Pathobiology 66(5): 196-204.
Grotendorst, G. R., H. Rahmanie, et al. (2004). "Combinatorial signaling 
pathways determine fibroblast proliferation and myofibroblast 
differentiation." FASEB J 18(3): 469-479.
Gudas, L. J., M. B. Sporn, et al. (1994). "Cellular biology and biochemistry of 
the retinods. In The Retinoids: Biology, Chemistry, and Medicine, 2nd 
Edition." Raven Press Ltd., New York, NY 443-520.
Hamaguchi, A., S. Kim, et al. (1995). "Transforming growth factor-beta 1 
expression and phenotypic modulation in the kidney of hypertensive 
rats." Hypertension 26(1): 199-207.
Han, D. C., M. Isono, et al. (1999). "High glucose stimulates proliferation and 
collagen type I synthesis in renal cortical fibroblasts: mediation by 
autocrine activation of TGF-beta." J Am Soc Nephrol 10(9): 1891-1899.
Hanks, S. K., R. Armour, et al. (1988). "Amino acid sequence of the BSC-1 
cell growth inhibitor (polyergin) deduced from the nucleotide sequence 
of the cDNA." Proc Natl Acad Sci U S A 85(1): 79-82.
Hansch, G. M., C. Wagner, et al. (1995). "Matrix protein synthesis by 
glomerular mesangial cells in culture: effects of transforming growth 
factor beta (TGF beta) and platelet-derived growth factor (PDGF) on 
fibronectin and collagen type IV mRNA." J Cell Physiol 163(3): 
451-457.
Hatoum, A., M. E. El-Sabban, et al. (2001). "Overexpression of retinoic acid 
receptors alpha and gamma into neoplastic epidermal cells causes 
retinoic acid-induced growth arrest and apoptosis." Carcinogenesis 22
(12): 1955-1963.
Haxsen, V., S. Adam-Stitah, et al. (2001). "Retinoids inhibit the actions of 
angiotensin II on vascular smooth muscle cells." Circ Res 88(6): 
637-644.
Hayashi, H. and T. Sakai (2012). "Biological Significance of Local TGF-beta 
Activation in Liver Diseases." Front Physiol 3: 12.
Hayashida, T., A. C. Poncelet, et al. (1999). "TGF-beta1 activates MAP kinase 
in human mesangial cells: a possible role in collagen expression." 
Kidney Int 56(5): 1710-1720.
He, W., R. J. Tan, et al. (2011). "Matrix Metalloproteinase-7 as a Surrogate 
Marker Predicts Renal Wnt/beta-Catenin Activity in CKD." J Am Soc 
Nephrol.
Hellemans, K., I. Grinko, et al. (1999). "All-trans and 9-cis retinoic acid alter 
rat hepatic stellate cell phenotype differentially." Gut 45(1): 134-142.
Hellemans, K., P. Verbuyst, et al. (2004). "Differential modulation of rat hepatic 
stellate phenotype by natural and synthetic retinoids." Hepatology 39
(1): 97-108.
186
Herman, M. P., G. K. Sukhova, et al. (2001). "Tissue factor pathway inhibitor-2 
is a novel inhibitor of matrix metalloproteinases with implications for 
atherosclerosis." J Clin Invest 107(9): 1117-1126.
Hewitson, T. D. (2009). "Renal tubulointerstitial fibrosis: common but never 
simple." Am J Physiol Renal Physiol 296(6): F1239-1244.
Hisamori, S., C. Tabata, et al. (2008). "All-trans-retinoic acid ameliorates 
carbon tetrachloride-induced liver fibrosis in mice through modulating 
cytokine production." Liver Int 28(9): 1217-1225.
Hoover, L. L., E. G. Burton, et al. (2008). "Retinoids regulate TGFbeta 
signaling at the level of Smad2 phosphorylation and nuclear 
accumulation." Biochim Biophys Acta 1783(12): 2279-2286.
Horlein, A. J., A. M. Naar, et al. (1995). "Ligand-independent repression by the 
thyroid hormone receptor mediated by a nuclear receptor co-
repressor." Nature 377(6548): 397-404.
Horstrup, J. H., M. Gehrmann, et al. (2002). "Elevation of serum and urine 
levels of TIMP-1 and tenascin in patients with renal disease." Nephrol 
Dial Transplant 17(6): 1005-1013.
Horton, C. and M. Maden (1995). "Endogenous distribution of retinoids during 
normal development and teratogenesis in the mouse embryo." Dev 
Dyn 202(3): 312-323.
Huang, L., J. L. Haylor, et al. (2009). "Transglutaminase inhibition ameliorates 
experimental diabetic nephropathy." Kidney Int 76(4): 383-394.
Huang, Y., W. A. Border, et al. (2006). "Noninhibitory PAI-1 enhances plasmin-
mediated matrix degradation both in vitro and in experimental 
nephritis." Kidney Int 70(3): 515-522.
Huang, Y., W. A. Border, et al. (2008). "A PAI-1 mutant, PAI-1R, slows 
progression of diabetic nephropathy." J Am Soc Nephrol 19(2): 
329-338.
Huang, Y., M. Haraguchi, et al. (2003). "A mutant, noninhibitory plasminogen 
activator inhibitor type 1 decreases matrix accumulation in 
experimental glomerulonephritis." J Clin Invest 112(3): 379-388.
Humphreys, B. D., S. L. Lin, et al. (2010). "Fate tracing reveals the pericyte 
and not epithelial origin of myofibroblasts in kidney fibrosis." Am J 
Pathol 176(1): 85-97.
Hutchison, N., C. Fligny, et al. (2012). "Resident mesenchymal cells and 
fibrosis." Biochim Biophys Acta.
Huu, D.-N., E. N. Rosenblum, et al. (1966). "Persistent infection of a rat 
kidney cell line with Rauscher murine leukemia virus." J Bacteriol 92(4): 
1133-1140.
Iimura, O., H. Takahashi, et al. (2004). "Effect of ureteral obstruction on matrix 
metalloproteinase-2 in rat renal cortex." Clin Exp Nephrol 8(3): 
223-229.
Inoki, K., M. Haneda, et al. (2000). "Role of mitogen-activated protein kinases 
as downstream effectors of transforming growth factor-beta in 
mesangial cells." Kidney Int Suppl 77: S76-80.
Iwano, M., D. Plieth, et al. (2002). "Evidence that fibroblasts derive from 
epithelium during tissue fibrosis." J Clin Invest 110(3): 341-350.
Jakowlew, S. B., J. Cubert, et al. (1992). "Differential regulation of the 
expression of transforming growth factor-beta mRNAs by growth 
187
factors and retinoic acid in chicken embryo chondrocytes, myocytes, 
and fibroblasts." J Cell Physiol 150(2): 377-385.
Jakowlew, S. B., P. J. Dillard, et al. (1988). "Complementary deoxyribonucleic 
acid cloning of a novel transforming growth factor-beta messenger 
ribonucleic acid from chick embryo chondrocytes." Mol Endocrinol 2(8): 
747-755.
Janssen de Limpens, A. M. (1980). "The local treatment of hypertrophic scars 
and keloids with topical retinoic acid." Br J Dermatol 103(3): 319-323.
Jenkins, G. (2008). "The role of proteases in transforming growth factor-beta 
activation." Int J Biochem Cell Biol 40(6-7): 1068-1078.
Jeon, K. W. (2009). "International Review of cytology (vol205)."
Johnson, A. T., E. S. Klein, et al. (1995). "Synthesis and characterization of a 
highly potent and effective antagonist of retinoic acid receptors." J Med 
Chem 38(24): 4764-4767.
Johnson, T. S., A. F. El-Koraie, et al. (2003). "Tissue transglutaminase and the 
progression of human renal scarring." J Am Soc Nephrol 14(8): 
2052-2062.
Johnson, T. S., M. Fisher, et al. (2007). "Transglutaminase inhibition reduces 
fibrosis and preserves function in experimental chronic kidney 
disease." J Am Soc Nephrol 18(12): 3078-3088.
Johnson, T. S., N. J. Skill, et al. (1999). "Transglutaminase transcription and 
antigen translocation in experimental renal scarring." J Am Soc Nephrol 
10(10): 2146-2157.
Jones, R. A., B. Nicholas, et al. (1997). "Reduced expression of tissue 
transglutaminase in a human endothelial cell line leads to changes in 
cell spreading, cell adhesion and reduced polymerisation of 
fibronectin." J Cell Sci 110 ( Pt 19): 2461-2472.
Junqueira, L. C., G. Bignolas, et al. (1979). "Picrosirius staining plus 
polarization microscopy, a specific method for collagen detection in 
tissue sections." Histochem J 11(4): 447-455.
Kaartinen, M. T., A. Pirhonen, et al. (1999). "Cross-linking of osteopontin by 
tissue transglutaminase increases its collagen binding properties." J 
Biol Chem 274(3): 1729-1735.
Kambhampati, S., Y. Li, et al. (2003). "Activation of protein kinase C delta by 
all-trans-retinoic acid." J Biol Chem 278(35): 32544-32551.
Kanayasu-Toyoda, T., T. Fujino, et al. (2005). "HX531, a retinoid X receptor 
antagonist, inhibited the 9-cis retinoic acid-induced binding with steroid 
receptor coactivator-1 as detected by surface plasmon resonance." J 
Steroid Biochem Mol Biol 94(4): 303-309.
Kavsak, P., R. K. Rasmussen, et al. (2000). "Smad7 binds to Smurf2 to form 
an E3 ubiquitin ligase that targets the TGF beta receptor for 
degradation." Mol Cell 6(6): 1365-1375.
Kavukcu, S., A. Soylu, et al. (1999). "The role of vitamin A in preventing renal 
scarring secondary to pyelonephritis." BJU Int 83(9): 1055-1059.
Kawaguchi, R., J. Yu, et al. (2007). "A membrane receptor for retinol binding 
protein mediates cellular uptake of vitamin A." Science 315(5813): 
820-825.
188
Kelynack, K. J., T. D. Hewitson, et al. (2000). "Human renal fibroblast 
contraction of collagen I lattices is an integrin-mediated process." 
Nephrol Dial Transplant 15(11): 1766-1772.
Kinoshita, K. and M. Funauchi (2012). "[Therapeutic effect of retinoic acid in 
lupus nephritis]." Nihon Rinsho Meneki Gakkai Kaishi 35(1): 1-7.
Kinoshita, K., B. S. Yoo, et al. (2003). "Retinoic acid reduces autoimmune 
renal injury and increases survival in NZB/W F1 mice." J Immunol 170
(11): 5793-5798.
Kishimoto, K., K. Kinoshita, et al. (2011). "Therapeutic Effect of Retinoic Acid 
on Unilateral Ureteral Obstruction Model." Nephron Exp Nephrol 118
(3): e69-e78.
Kiss, E., J. Adams, et al. (2003). "Isotretinoin ameliorates renal damage in 
experimental acute renal allograft rejection." Transplantation 76(3): 
480-489.
Kleman, J. P., D. Aeschlimann, et al. (1995). "Transglutaminase-catalyzed 
cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma 
cells." Biochemistry 34(42): 13768-13775.
Koesters, R., B. Kaissling, et al. (2010). "Tubular overexpression of 
transforming growth factor-beta1 induces autophagy and fibrosis but 
not mesenchymal transition of renal epithelial cells." Am J Pathol 177
(2): 632-643.
Kojima, S. and D. B. Rifkin (1993). "Mechanism of retinoid-induced activation 
of latent transforming growth factor-beta in bovine endothelial cells." J 
Cell Physiol 155(2): 323-332.
Konta, T., Q. Xu, et al. (2001). "Selective roles of retinoic acid receptor and 
retinoid x receptor in the suppression of apoptosis by all-trans-retinoic 
acid." J Biol Chem 276(16): 12697-12701.
Krag, S., C. C. Danielsen, et al. (2005). "Plasminogen activator inhibitor-1 
gene deficiency attenuates TGF-beta1-induced kidney disease." 
Kidney Int 68(6): 2651-2666.
Krupsky, M., A. Fine, et al. (1994). "Retinoic acid-induced inhibition of type I 
collagen gene expression by human lung fibroblasts." Biochim Biophys 
Acta 1219(2): 335-341.
Kruse, S. W., K. Suino-Powell, et al. (2008). "Identification of COUP-TFII 
orphan nuclear receptor as a retinoic acid-activated receptor." PLoS 
Biol 6(9): e227.
Kurokawa, R., J. DiRenzo, et al. (1994). "Regulation of retinoid signalling by 
receptor polarity and allosteric control of ligand binding." Nature 371
(6497): 528-531.
Lan, H. Y. (2008). "Smad7 as a therapeutic agent for chronic kidney 
diseases." Front Biosci 13: 4984-4992.
Lan, H. Y. and A. C. Chung (2012). "TGF-beta/Smad signaling in kidney 
disease." Semin Nephrol 32(3): 236-243.
Laudet, V. and H. Gronemeyer (2002). "The nuclear receptor facts book."
Leask, A. and D. J. Abraham (2003). "The role of connective tissue growth 
factor, a multifunctional matricellular protein, in fibroblast biology." 
Biochem Cell Biol 81(6): 355-363.
189
Lefebvre, P., Y. Benomar, et al. (2010). "Retinoid X receptors: common 
heterodimerization partners with distinct functions." Trends Endocrinol 
Metab 21(11): 676-683.
Lehrke, I., M. Schaier, et al. (2002). "Retinoid receptor-specific agonists 
alleviate experimental glomerulonephritis." Am J Physiol Renal Physiol 
282(4): F741-751.
Leid, M., P. Kastner, et al. (1992). "Multiplicity generates diversity in the 
retinoic acid signalling pathways." Trends Biochem Sci 17(10): 
427-433.
Leid, M., P. Kastner, et al. (1992). "Purification, cloning, and RXR identity of 
the HeLa cell factor with which RAR or TR heterodimerizes to bind 
target sequences efficiently." Cell 68(2): 377-395.
Lelongt, B. and P. Ronco (2002). "Role of matrix metalloproteinases in kidney 
development and glomerulopathy: lessons from transgenic mice." 
Nephrol Dial Transplant 17 Suppl 9: 28-31.
Leroy, P., A. Krust, et al. (1991). "Multiple isoforms of the mouse retinoic acid 
receptor alpha are generated by alternative splicing and differential 
induction by retinoic acid." EMBO J 10(1): 59-69.
Levin, A. A., L. J. Sturzenbecker, et al. (1992). "9-cis retinoic acid 
stereoisomer binds and activates the nuclear receptor RXR alpha." 
Nature 355(6358): 359-361.
Lewis, M. P. and J. T. Norman (1998). "Differential response of activated 
versus non-activated renal fibroblasts to tubular epithelial cells: a 
model of initiation and progression of fibrosis?" Exp Nephrol 6(2): 
132-143.
Li, J., X. Qu, et al. (2010). "Blockade of endothelial-mesenchymal transition by 
a Smad3 inhibitor delays the early development of streptozotocin-
induced diabetic nephropathy." Diabetes 59(10): 2612-2624.
Li, R., T. N. Faria, et al. (2004). "Retinoic acid causes cell growth arrest and 
an increase in p27 in F9 wild type but not in F9 retinoic acid receptor 
beta2 knockout cells." Exp Cell Res 294(1): 290-300.
Liebler, S., B. Uberschar, et al. (2004). "The renal retinoid system: time-
dependent activation in experimental glomerulonephritis." Am J Physiol 
Renal Physiol 286(3): F458-465.
Lin, S. L., T. Kisseleva, et al. (2008). "Pericytes and perivascular fibroblasts 
are the primary source of collagen-producing cells in obstructive 
fibrosis of the kidney." Am J Pathol 173(6): 1617-1627.
Liu, X., L. Lu, et al. (2011). "Amelioration of glomerulosclerosis with all-trans 
retinoic acid is linked to decreased plasminogen activator inhibitor-1 
and alpha-smooth muscle actin." Acta Pharmacol Sin 32(1): 70-78.
Liu, X., L. Lu, et al. (2008). "All-trans retinoic acid inhibits the increases in 
fibronectin and PAI-1 induced by TGF-beta1 and Ang II in rat mesangial 
cells." Acta Pharmacol Sin 29(9): 1035-1041.
Liu, Y. (2006). "Renal fibrosis: new insights into the pathogenesis and 
therapeutics." Kidney Int 69(2): 213-217.
Liu, Y. (2011). "Cellular and molecular mechanisms of renal fibrosis." Nat Rev 
Nephrol 7(12): 684-696.
190
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression 
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) 
Method." Methods 25(4): 402-408.
Lucio-Cazana, J., K. Nakayama, et al. (2001). "Suppression of constitutive but 
not Il-1beta-inducible expression of monocyte chemoattractant 
protein-1 in mesangial cells by retinoic acids: intervention in the 
activator protein-1 pathway." J Am Soc Nephrol 12(4): 688-694.
Lundell, K., P. Thulin, et al. (2007). "Alternative splicing of human peroxisome 
proliferator-activated receptor delta (PPAR delta): effects on translation 
efficiency and trans-activation ability." BMC Mol Biol 8: 70.
Luo, P., M. Lin, et al. (2009). "Function of retinoid acid receptor alpha and p21 
in all-trans-retinoic acid-induced acute T-lymphoblastic leukemia 
apoptosis." Leuk Lymphoma 50(7): 1183-1189.
Luo, P., X. Yang, et al. (2010). "Retinoid-suppressed phosphorylation of 
RARalpha mediates the differentiation pathway of osteosarcoma cells." 
Oncogene 29(19): 2772-2783.
Ma, F. Y., G. H. Tesch, et al. (2011). "TGF-beta1-activated kinase-1 regulates 
inflammation and fibrosis in the obstructed kidney." Am J Physiol Renal 
Physiol 300(6): F1410-1421.
Ma, Y., Q. Feng, et al. (2005). "Retinoid targeting of different D-type cyclins 
through distinct chemopreventive mechanisms." Cancer Res 65(14): 
6476-6483.
MacKay, K., L. J. Striker, et al. (1989). "Transforming growth factor-beta. 
Murine glomerular receptors and responses of isolated glomerular 
cells." J Clin Invest 83(4): 1160-1167.
Mackensen-Haen, S., R. Bader, et al. (1981). "Correlations between renal 
cortical interstitial fibrosis, atrophy of the proximal tubules and 
impairment of the glomerular filtration rate." Clin Nephrol 15(4): 
167-171.
Mader, S., J. Y. Chen, et al. (1993). "The patterns of binding of RAR, RXR and 
TR homo- and heterodimers to direct repeats are dictated by the 
binding specificites of the DNA binding domains." EMBO J 12(13): 
5029-5041.
Madisen, L., N. R. Webb, et al. (1988). "Transforming growth factor-beta 2: 
cDNA cloning and sequence analysis." DNA 7(1): 1-8.
Mangelsdorf, D. J. and R. M. Evans (1995). "The RXR heterodimers and 
orphan receptors." Cell 83(6): 841-850.
Mankhey, R. W., C. C. Wells, et al. (2007). "17beta-Estradiol supplementation 
reduces tubulointerstitial fibrosis by increasing MMP activity in the 
diabetic kidney." Am J Physiol Regul Integr Comp Physiol 292(2): 
R769-777.
Manzano, V. M., J. C. Munoz, et al. (2000). "Human renal mesangial cells are 
a target for the anti-inflammatory action of 9-cis retinoic acid." Br J 
Pharmacol 131(8): 1673-1683.
Mao, J. T., D. P. Tashkin, et al. (2003). "All-trans retinoic acid modulates the 
balance of matrix metalloproteinase-9 and tissue inhibitor of 
metalloproteinase-1 in patients with emphysema." Chest 124(5): 
1724-1732.
191
Martin, J., R. Steadman, et al. (1998). "Differential regulation of matrix 
metalloproteinases and their inhibitors in human glomerular epithelial 
cells in vitro." J Am Soc Nephrol 9(9): 1629-1637.
Martinez, J., E. Rich, et al. (1989). "Transglutaminase-mediated cross-linking 
of fibrinogen by human umbilical vein endothelial cells." J Biol Chem 
264(34): 20502-20508.
Masia, S., S. Alvarez, et al. (2007). "Rapid, nongenomic actions of retinoic 
acid on phosphatidylinositol-3-kinase signaling pathway mediated by 
the retinoic acid receptor." Mol Endocrinol 21(10): 2391-2402.
Massague, J. (2000). "How cells read TGF-beta signals." Nat Rev Mol Cell 
Biol 1(3): 169-178.
Massague, J. (2012). "TGFbeta signalling in context." Nat Rev Mol Cell Biol 
13(10): 616-630.
Matsuo, S., J. M. Lopez-Guisa, et al. (2005). "Multifunctionality of PAI-1 in 
fibrogenesis: evidence from obstructive nephropathy in PAI-1-
overexpressing mice." Kidney Int 67(6): 2221-2238.
McKay, N. G., T. F. Khong, et al. (1993). "The effect of transforming growth 
factor beta 1 on mesangial cell fibronectin synthesis: increased 
incorporation into the extracellular matrix and reduced pI but no effect 
on alternative splicing." Exp Mol Pathol 59(3): 211-224.
McLennan, S. V., D. J. Kelly, et al. (2002). "Decreased matrix degradation in 
diabetic nephropathy: effects of ACE inhibition on the expression and 
activities of matrix metalloproteinases." Diabetologia 45(2): 268-275.
Meisler, N. T., J. Parrelli, et al. (1997). "All-trans-retinoic acid inhibition of Pro 
alpha1(I) collagen gene expression in fetal rat skin fibroblasts: 
identification of a retinoic acid response element in the Pro alpha1(I) 
collagen gene." J Invest Dermatol 108(4): 476-481.
Mende, C. W. (2010). "Application of direct renin inhibition to chronic kidney 
disease." Cardiovasc Drugs Ther 24(2): 139-149.
Meng, X. M., X. R. Huang, et al. (2010). "Smad2 protects against TGF-beta/
Smad3-mediated renal fibrosis." J Am Soc Nephrol 21(9): 1477-1487.
Moll, S., P. A. Menoud, et al. (1995). "Induction of plasminogen activator 
inhibitor type 1 in murine lupus-like glomerulonephritis." Kidney Int 48
(5): 1459-1468.
Mongan, N. P. and L. J. Gudas (2007). "Diverse actions of retinoid receptors 
in cancer prevention and treatment." Differentiation 75(9): 853-870.
Mora, J. R., M. Iwata, et al. (2008). "Vitamin effects on the immune system: 
vitamins A and D take centre stage." Nat Rev Immunol 8(9): 685-698.
Morath, C., C. Dechow, et al. (2001). "Effects of retinoids on the TGF-beta 
system and extracellular matrix in experimental glomerulonephritis." J 
Am Soc Nephrol 12(11): 2300-2309.
Morath, C., K. Ratzlaff, et al. (2009). "Chronic low-dose isotretinoin treatment 
limits renal damage in subtotally nephrectomized rats." J Mol Med 87
(1): 53-64.
Moreno-Manzano, V., Y. Ishikawa, et al. (1999). "Suppression of apoptosis by 
all-trans-retinoic acid. Dual intervention in the c-Jun n-terminal kinase-
AP-1 pathway." J Biol Chem 274(29): 20251-20258.
192
Moreno-Manzano, V., F. Mampaso, et al. (2003). "Retinoids as a potential 
treatment for experimental puromycin-induced nephrosis." Br J 
Pharmacol 139(4): 823-831.
Moreno-Manzano, V., M. Rodriguez-Puyol, et al. (1997). "Prevention by 
tretinoin (all-trans-retinoic acid) of age-related renal changes." Int J 
Vitam Nutr Res 67(6): 427-431.
Morey, L., C. Brenner, et al. (2008). "MBD3, a component of the NuRD 
complex, facilitates chromatin alteration and deposition of epigenetic 
marks." Mol Cell Biol 28(19): 5912-5923.
Moses, H. L., E. L. Branum, et al. (1981). "Transforming growth factor 
production by chemically transformed cells." Cancer Res 41(7): 
2842-2848.
Mosher, D. F. (1984). "Cross-linking of fibronectin to collagenous proteins." 
Mol Cell Biochem 58(1-2): 63-68.
Mozes, M. M., E. P. Bottinger, et al. (1999). "Renal expression of fibrotic 
matrix proteins and of transforming growth factor-beta (TGF-beta) 
isoforms in TGF-beta transgenic mice." J Am Soc Nephrol 10(2): 
271-280.
Munger, J. S., J. G. Harpel, et al. (1997). "Latent transforming growth factor-
beta: structural features and mechanisms of activation." Kidney Int 51
(5): 1376-1382.
Na, S. Y., B. Y. Kang, et al. (1999). "Retinoids inhibit interleukin-12 production 
in macrophages through physical associations of retinoid X receptor 
and NFkappaB." J Biol Chem 274(12): 7674-7680.
Nagase, H. (1997). "Activation mechanisms of matrix metalloproteinases." 
Biol Chem 378(3-4): 151-160.
Nagy, L., M. Saydak, et al. (1996). "Identification and characterization of a 
versatile retinoid response element (retinoic acid receptor response 
element-retinoid X receptor response element) in the mouse tissue 
transglutaminase gene promoter." J Biol Chem 271(8): 4355-4365.
Nakaoka, H., D. M. Perez, et al. (1994). "Gh: a GTP-binding protein with 
transglutaminase activity and receptor signaling function." Science 264
(5165): 1593-1596.
Naldini, L., E. Vigna, et al. (1995). "Biological activation of pro-HGF 
(hepatocyte growth factor) by urokinase is controlled by a 
stoichiometric reaction." J Biol Chem 270(2): 603-611.
Napoli, J. L. (1996). "Biochemical pathways of retinoid transport, metabolism, 
and signal transduction." Clin Immunol Immunopathol 80(3 Pt 2): 
S52-62.
Napoli, J. L. (1999). "Interactions of retinoid binding proteins and enzymes in 
retinoid metabolism." Biochim Biophys Acta 1440(2-3): 139-162.
Napoli, J. L. (2000). "A gene knockout corroborates the integral function of 
cellular retinol-binding protein in retinoid metabolism." Nutr Rev 58(8): 
230-236.
Napoli, J. L. (2012). "Physiological insights into all-trans-retinoic acid 
biosynthesis." Biochim Biophys Acta 1821(1): 152-167.
Nardacci, R., O. Lo Iacono, et al. (2003). "Transglutaminase type II plays a 
protective role in hepatic injury." Am J Pathol 162(4): 1293-1303.
193
Naruhn, S., P. M. Toth, et al. (2011). "High-Affinity Peroxisome Proliferator-
Activated Receptor {beta}/{delta}-Specific Ligands with Pure 
Antagonistic or Inverse Agonistic Properties." Mol Pharmacol 80(5): 
828-838.
Nath, K. A. (1992). "Tubulointerstitial changes as a major determinant in the 
progression of renal damage." Am J Kidney Dis 20(1): 1-17.
National Collaborating Centre for Chronic Conditions (2008). "Chronic kidney 
disease: national clinical guideline for early identification and 
management in adults in primary and secondary care." London: Royal 
College of Physicians.
Niculescu-Duvaz, I., M. K. Phanish, et al. (2007). "The TGFbeta1-induced 
fibronectin in human renal proximal tubular epithelial cells is p38 MAP 
kinase dependent and Smad independent." Nephron Exp Nephrol 105
(4): e108-116.
Niederreither, K. and P. Dolle (2008). "Retinoic acid in development: towards 
an integrated view." Nat Rev Genet 9(7): 541-553.
Nishida, M., Y. Okumura, et al. (2007). "MMP-2 inhibition reduces renal 
macrophage infiltration with increased fibrosis in UUO." Biochem 
Biophys Res Commun 354(1): 133-139.
Norman, J. T. and L. G. Fine (1999). "Progressive renal disease: fibroblasts, 
extracellular matrix, and integrins." Exp Nephrol 7(2): 167-177.
Numaguchi, S., M. Okuno, et al. (1994). "Modulation of collagen synthesis 
and degradation by retinoids and cytokines in 3T3 L1 preadipocytes." 
Intern Med 33(6): 309-316.
Nunes, I., P. E. Gleizes, et al. (1997). "Latent transforming growth factor-beta 
binding protein domains involved in activation and transglutaminase-
dependent cross-linking of latent transforming growth factor-beta." J 
Cell Biol 136(5): 1151-1163.
Ochoa, W. F., A. Torrecillas, et al. (2003). "Retinoic acid binds to the C2-
domain of protein kinase C(alpha)." Biochemistry 42(29): 8774-8779.
Oda, T., Y. O. Jung, et al. (2001). "PAI-1 deficiency attenuates the fibrogenic 
response to ureteral obstruction." Kidney Int 60(2): 587-596.
Ohata, M., M. Lin, et al. (1997). "Diminished retinoic acid signaling in hepatic 
stellate cells in cholestatic liver fibrosis." Am J Physiol 272(3 Pt 1): 
G589-596.
Ohta, A. and J. Uitto (1987). "Procollagen gene expression by scleroderma 
fibroblasts in culture. Inhibition of collagen production and reduction of 
pro alpha 1(I) and pro alpha 1(III) collagen messenger RNA steady-
state levels by retinoids." Arthritis Rheum 30(4): 404-411.
Oikarinen, H., A. I. Oikarinen, et al. (1985). "Modulation of procollagen gene 
expression by retinoids. Inhibition of collagen production by retinoic 
acid accompanied by reduced type I procollagen messenger 
ribonucleic acid levels in human skin fibroblast cultures." J Clin Invest 
75(5): 1545-1553.
Okada, H., T. Danoff, et al. (1997). "Early role of Fsp1 in epithelial-
mesenchymal transformation." Am J Physiol Renal Physiol 273(4): 
F563-F574.
Okuda, S., L. R. Languino, et al. (1990). "Elevated expression of transforming 
growth factor-beta and proteoglycan production in experimental 
194
glomerulonephritis. Possible role in expansion of the mesangial 
extracellular matrix." J Clin Invest 86(2): 453-462.
Okuno, M., H. Moriwaki, et al. (1997). "Retinoids exacerbate rat liver fibrosis 
by inducing the activation of latent TGF-beta in liver stellate cells." 
Hepatology 26(4): 913-921.
Oldfield, M. D., L. A. Bach, et al. (2001). "Advanced glycation end products 
cause epithelial-myofibroblast transdifferentiation via the receptor for 
advanced glycation end products (RAGE)." J Clin Invest 108(12): 
1853-1863.
Oliverio, S., A. Amendola, et al. (1999). "Inhibition of "tissue" transglutaminase 
increases cell survival by preventing apoptosis." J Biol Chem 274(48): 
34123-34128.
Oseto, S., T. Moriyama, et al. (2003). "Therapeutic effect of all-trans retinoic 
acid on rats with anti-GBM antibody glomerulonephritis." Kidney Int 64
(4): 1241-1252.
Ozer, E. A., A. Kumral, et al. (2005). "Effect of retinoic acid on oxygen-induced 
lung injury in the newborn rat." Pediatr Pulmonol 39(1): 35-40.
Palczewski, K. (2010). "Retinoids for treatment of retinal diseases." Trends 
Pharmacol Sci 31(6): 284-295.
Pan, J., Y. L. Kao, et al. (2005). "Activation of Rac1 by phosphatidylinositol 3-
kinase in vivo: role in activation of mitogen-activated protein kinase 
(MAPK) pathways and retinoic acid-induced neuronal differentiation of 
SH-SY5Y cells." J Neurochem 93(3): 571-583.
Panabiere-Castaings, M. H. (1988). "Retinoic acid in the treatment of keloids." 
J Dermatol Surg Oncol 14(11): 1275-1276.
Pares, X., J. Farres, et al. (2008). "Medium- and short-chain dehydrogenase/
reductase gene and protein families : Medium-chain and short-chain 
dehydrogenases/reductases in retinoid metabolism." Cell Mol Life Sci 
65(24): 3936-3949.
Pendaries, V., F. Verrecchia, et al. (2003). "Retinoic acid receptors interfere 
with the TGF-beta/Smad signaling pathway in a ligand-specific 
manner." Oncogene 22(50): 8212-8220.
Peng, X., T. Maruo, et al. (2004). "A novel RARbeta isoform directed by a 
distinct promoter P3 and mediated by retinoic acid in breast cancer 
cells." Cancer Res 64(24): 8911-8918.
Perez, J. R., S. Shull, et al. (1992). "Glucocorticoid and retinoid regulation of 
alpha-2 type I procollagen promoter activity." J Cell Biochem 50(1): 
26-34.
Perlmann, T., P. N. Rangarajan, et al. (1993). "Determinants for selective RAR 
and TR recognition of direct repeat HREs." Genes Dev 7(7B): 
1411-1422.
Perlmann, T., K. Umesono, et al. (1996). "Two distinct dimerization interfaces 
differentially modulate target gene specificity of nuclear hormone 
receptors." Mol Endocrinol 10(8): 958-966.
Pfahl, M. and F. Chytil (1996). "Regulation of metabolism by retinoic acid and 
its nuclear receptors." Annu Rev Nutr 16: 257-283.
Phanish, M. K., N. A. Wahab, et al. (2006). "The differential role of Smad2 and 
Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human 
proximal-tubule epithelial cells." Biochem J 393(Pt 2): 601-607.
195
Picard, N., O. Baum, et al. (2008). "Origin of renal myofibroblasts in the model 
of unilateral ureter obstruction in the rat." Histochem Cell Biol 130(1): 
141-155.
Pignatello, M. A., F. C. Kauffman, et al. (1997). "Multiple factors contribute to 
the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding 
affinities and disposition." Toxicol Appl Pharmacol 142(2): 319-327.
Pignatello, M. A., F. C. Kauffman, et al. (1999). "Multiple factors contribute to 
the toxicity of the aromatic retinoid TTNPB (Ro 13-7410): interactions 
with the retinoic acid receptors." Toxicol Appl Pharmacol 159(2): 
109-116.
Pino-Lagos, K., M. J. Benson, et al. (2008). "Retinoic acid in the immune 
system." Ann N Y Acad Sci 1143: 170-187.
Poncelet, A. C. and H. W. Schnaper (1998). "Regulation of human mesangial 
cell collagen expression by transforming growth factor-beta1." Am J 
Physiol 275(3 Pt 2): F458-466.
Popov, Y., D. Y. Sverdlov, et al. (2011). "Tissue transglutaminase does not 
affect fibrotic matrix stability or regression of liver fibrosis in mice." 
Gastroenterology 140(5): 1642-1652.
Predki, P. F., D. Zamble, et al. (1994). "Ordered binding of retinoic acid and 
retinoid-X receptors to asymmetric response elements involves 
determinants adjacent to the DNA-binding domain." Mol Endocrinol 8
(1): 31-39.
Qin, Y. H., F. Y. Lei, et al. (2009). "Effect of all-trans retinoic acid on renal 
expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 
and tissue inhibitor of metalloproteinase-1 in rats with 
glomerulosclerosis." Pediatr Nephrol 24(8): 1477-1486.
Redfern, C. P. and C. Todd (1992). "Retinoic acid receptor expression in 
human skin keratinocytes and dermal fibroblasts in vitro." J Cell Sci 
102 ( Pt 1): 113-121.
Redlich, C. A., H. M. Delisser, et al. (1995). "Retinoic acid inhibition of 
transforming growth factor-beta-induced collagen production by human 
lung fibroblasts." Am J Respir Cell Mol Biol 12(3): 287-295.
Reeves, W. B., B. B. Rawal, et al. (2012). "Therapeutic Modalities in Diabetic 
Nephropathy: Future Approaches." Open J Nephrol 2(2): 5-18.
Rieck, M., W. Meissner, et al. (2008). "Ligand-mediated regulation of 
peroxisome proliferator-activated receptor (PPAR) beta/delta: a 
comparative analysis of PPAR-selective agonists and all-trans retinoic 
acid." Mol Pharmacol 74(5): 1269-1277.
Risdon, R. A., J. C. Sloper, et al. (1968). "Relationship between renal function 
and histological changes found in renal-biopsy specimens from 
patients with persistent glomerular nephritis." Lancet 2(7564): 363-366.
Roberts, A. B., M. A. Anzano, et al. (1981). "New class of transforming growth 
factors potentiated by epidermal growth factor: isolation from non-
neoplastic tissues." Proc Natl Acad Sci U S A 78(9): 5339-5343.
Roberts, A. B., M. A. Anzano, et al. (1985). "Type beta transforming growth 
factor: a bifunctional regulator of cellular growth." Proc Natl Acad Sci U 
S A 82(1): 119-123.
Roberts, A. B., M. B. Sporn, et al. (1986). "Transforming growth factor type 
beta: rapid induction of fibrosis and angiogenesis in vivo and 
196
stimulation of collagen formation in vitro." Proc Natl Acad Sci U S A 83
(12): 4167-4171.
Rochette-Egly, C. and P. Germain (2009). "Dynamic and combinatorial control 
of gene expression by nuclear retinoic acid receptors (RARs)." Nucl 
Recept Signal 7: e005.
Rochette-Egly, C., Y. Lutz, et al. (1994). "Detection of retinoid X receptors 
using specific monoclonal and polyclonal antibodies." Biochem Biophys 
Res Commun 204(2): 525-536.
Rodemann, H. P. and G. A. Muller (1991). "Characterization of human renal 
fibroblasts in health and disease: II. In vitro growth, differentiation, and 
collagen synthesis of fibroblasts from kidneys with interstitial fibrosis." 
Am J Kidney Dis 17(6): 684-686.
Rojiani, M. V., J. Alidina, et al. (2010). "Expression of MMP-2 correlates with 
increased angiogenesis in CNS metastasis of lung carcinoma." Int J 
Clin Exp Pathol 3(8): 775-781.
Ronco, P. and C. Chatziantoniou (2008). "Matrix metalloproteinases and 
matrix receptors in progression and reversal of kidney disease: 
therapeutic perspectives." Kidney Int 74(7): 873-878.
Ronco, P., B. Lelongt, et al. (2007). "Matrix metalloproteinases in kidney 
disease progression and repair: a case of flipping the coin." Semin 
Nephrol 27(3): 352-362.
Rossin, F., M. D'Eletto, et al. (2011). "TG2 transamidating activity acts as a 
reostat controlling the interplay between apoptosis and autophagy." 
Amino Acids.
Rubenstein, R., H. H. Roenigk, Jr., et al. (1986). "Atypical keloids after 
dermabrasion of patients taking isotretinoin." J Am Acad Dermatol 15(2 
Pt 1): 280-285.
Salbert, G., A. Fanjul, et al. (1993). "Retinoic acid receptors and retinoid X 
receptor-alpha down-regulate the transforming growth factor-beta 1 
promoter by antagonizing AP-1 activity." Mol Endocrinol 7(10): 
1347-1356.
Sanchez, M., E. Gionti, et al. (1993). "Alpha 2(I) collagen gene expression is 
up-regulated in quail chondrocytes pretreated with retinoic acid." 
Biochem J 295 ( Pt 1): 115-119.
Sanderson, N., V. Factor, et al. (1995). "Hepatic expression of mature 
transforming growth factor beta 1 in transgenic mice results in multiple 
tissue lesions." Proc Natl Acad Sci U S A 92(7): 2572-2576.
Sato, M., Y. Muragaki, et al. (2003). "Targeted disruption of TGF-beta1/Smad3 
signaling protects against renal tubulointerstitial fibrosis induced by 
unilateral ureteral obstruction." J Clin Invest 112(10): 1486-1494.
Satre, M. A., K. E. Ugen, et al. (1992). "Developmental changes in 
endogenous retinoids during pregnancy and embryogenesis in the 
mouse." Biol Reprod 46(5): 802-810.
Schaier, M., T. Jocks, et al. (2003). "Retinoid agonist isotretinoin ameliorates 
obstructive renal injury." J Urol 170(4 Pt 1): 1398-1402.
Schaier, M., I. Lehrke, et al. (2001). "Isotretinoin alleviates renal damage in rat 
chronic glomerulonephritis." Kidney Int 60(6): 2222-2234.
197
Schaier, M., S. Liebler, et al. (2004). "Retinoic acid receptor alpha and retinoid 
X receptor specific agonists reduce renal injury in established chronic 
glomerulonephritis of the rat." J Mol Med 82(2): 116-125.
Schainuck, L. I., G. E. Striker, et al. (1970). "Structural-functional correlations 
in renal disease. II. The correlations." Hum Pathol 1(4): 631-641.
Schmierer, B. and C. S. Hill (2007). "TGFbeta-SMAD signal transduction: 
molecular specificity and functional flexibility." Nat Rev Mol Cell Biol 8
(12): 970-982.
Schnaper, H. W., T. Hayashida, et al. (2003). "TGF-beta signal transduction 
and mesangial cell fibrogenesis." Am J Physiol Renal Physiol 284(2): 
F243-252.
Schug, T. T., D. C. Berry, et al. (2007). "Opposing effects of retinoic acid on 
cell growth result from alternate activation of two different nuclear 
receptors." Cell 129(4): 723-733.
Schug, T. T., D. C. Berry, et al. (2008). "Overcoming retinoic acid-resistance of 
mammary carcinomas by diverting retinoic acid from PPARbeta/delta to 
RAR." Proc Natl Acad Sci U S A 105(21): 7546-7551.
Scott, W. J., Jr., R. Walter, et al. (1994). "Endogenous status of retinoids and 
their cytosolic binding proteins in limb buds of chick vs mouse 
embryos." Dev Biol 165(2): 397-409.
Sharma, A. K., S. M. Mauer, et al. (1995). "Altered expression of matrix 
metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy." J 
Lab Clin Med 125(6): 754-761.
Sharma, K., F. N. Ziyadeh, et al. (1997). "Increased renal production of 
transforming growth factor-beta1 in patients with type II diabetes." 
Diabetes 46(5): 854-859.
Shaw, N., M. Elholm, et al. (2003). "Retinoic acid is a high affinity selective 
ligand for the peroxisome proliferator-activated receptor beta/delta." J 
Biol Chem 278(43): 41589-41592.
Shearer, B. G., D. J. Steger, et al. (2008). "Identification and characterization 
of a selective peroxisome proliferator-activated receptor beta/delta 
(NR1C2) antagonist." Mol Endocrinol 22(2): 523-529.
Shi, Y. and J. Massague (2003). "Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus." Cell 113(6): 685-700.
Shigematsu, T. and S. Tajima (1995). "Modulation of collagen synthesis and 
cell proliferation by retinoids in human skin fibroblasts." J Dermatol Sci 
9(2): 142-145.
Shweke, N., N. Boulos, et al. (2008). "Tissue transglutaminase contributes to 
interstitial renal fibrosis by favoring accumulation of fibrillar collagen 
through TGF-beta activation and cell infiltration." Am J Pathol 173(3): 
631-642.
Singh, R., R. H. Song, et al. (2001). "High glucose decreases matrix 
metalloproteinase-2 activity in rat mesangial cells via transforming 
growth factor-beta1." Exp Nephrol 9(4): 249-257.
Skill, N. J., M. Griffin, et al. (2001). "Increases in renal epsilon-(gamma-
glutamyl)-lysine crosslinks result from compartment-specific changes in 
tissue transglutaminase in early experimental diabetic nephropathy: 
pathologic implications." Lab Invest 81(5): 705-716.
198
Skill, N. J., T. S. Johnson, et al. (2004). "Inhibition of transglutaminase activity 
reduces extracellular matrix accumulation induced by high glucose 
levels in proximal tubular epithelial cells." J Biol Chem 279(46): 
47754-47762.
Somerville, R. P., S. A. Oblander, et al. (2003). "Matrix metalloproteinases: old 
dogs with new tricks." Genome Biol 4(6): 216.
Starkey, J. M., Y. Zhao, et al. (2010). "Altered retinoic acid metabolism in 
diabetic mouse kidney identified by O isotopic labeling and 2D mass 
spectrometry." PLoS One 5(6): e11095.
Stehlin-Gaon, C., D. Willmann, et al. (2003). "All-trans retinoic acid is a ligand 
for the orphan nuclear receptor ROR beta." Nat Struct Biol 10(10): 
820-825.
Stevens, P. E., D. J. O'Donoghue, et al. (2007). "Chronic kidney disease 
management in the United Kingdom: NEOERICA project results." 
Kidney Int 72(1): 92-99.
Sun, S. Z., Y. Wang, et al. (2006). "Effects of benazepril on renal function and 
kidney expression of matrix metalloproteinase-2 and tissue inhibitor of 
metalloproteinase-2 in diabetic rats." Chin Med J (Engl) 119(10): 
814-821.
Surendran, K., T. C. Simon, et al. (2004). "Matrilysin (MMP-7) expression in 
renal tubular damage: association with Wnt4." Kidney Int 65(6): 
2212-2222.
Sutton, A. B., A. E. Canfield, et al. (1991). "The response of endothelial cells 
to TGF beta-1 is dependent upon cell shape, proliferative state and the 
nature of the substratum." J Cell Sci 99 ( Pt 4): 777-787.
Suzui, M., M. Shimizu, et al. (2004). "Acyclic retinoid activates retinoic acid 
receptor beta and induces transcriptional activation of p21(CIP1) in 
HepG2 human hepatoma cells." Mol Cancer Ther 3(3): 309-316.
Suzuki, S., I. Ebihara, et al. (1993). "Transcriptional activation of matrix genes 
by transforming growth factor beta 1 in mesangial cells." Exp Nephrol 1
(4): 229-237.
Suzuki, Y., J. Shimada, et al. (1999). "Physical interaction between retinoic 
acid receptor and Sp1: mechanism for induction of urokinase by 
retinoic acid." Blood 93(12): 4264-4276.
Sznaidman, M. L., C. D. Haffner, et al. (2003). "Novel selective small molecule 
agonists for peroxisome proliferator-activated receptor delta 
(PPARdelta)--synthesis and biological activity." Bioorg Med Chem Lett 
13(9): 1517-1521.
Tabata, C., Y. Kadokawa, et al. (2006). "All-trans-retinoic acid prevents 
radiation- or bleomycin-induced pulmonary fibrosis." Am J Respir Crit 
Care Med 174(12): 1352-1360.
Tan, N. S., N. S. Shaw, et al. (2002). "Selective cooperation between fatty acid 
binding proteins and peroxisome proliferator-activated receptors in 
regulating transcription." Mol Cell Biol 22(14): 5114-5127.
Taneja, R., C. Rochette-Egly, et al. (1997). "Phosphorylation of activation 
functions AF-1 and AF-2 of RAR alpha and RAR gamma is 
indispensable for differentiation of F9 cells upon retinoic acid and 
cAMP treatment." EMBO J 16(21): 6452-6465.
199
Tang, X. H. and L. J. Gudas (2011). "Retinoids, Retinoic Acid Receptors, and 
Cancer." Annu Rev Pathol 28(6): 345-364.
ten Dijke, P., P. Hansen, et al. (1988). "Identification of another member of the 
transforming growth factor type beta gene family." Proc Natl Acad Sci U 
S A 85(13): 4715-4719.
Theodosiou, M., V. Laudet, et al. (2010). "From carrot to clinic: an overview of 
the retinoic acid signaling pathway." Cell Mol Life Sci 67(9): 1423-1445.
Tomooka, S., W. A. Border, et al. (1992). "Glomerular matrix accumulation is 
linked to inhibition of the plasmin protease system." Kidney Int 42(6): 
1462-1469.
Tsou, H. C., X. Lee, et al. (1994). "Regulation of retinoic acid receptor 
expression in dermal fibroblasts." Exp Cell Res 211(1): 74-81.
Tsou, H. C., X. X. Xie, et al. (1997). "Expression of retinoid X receptors in 
human dermal fibroblasts." Exp Cell Res 236(2): 493-500.
Turgut, F. and W. K. Bolton (2010). "Potential new therapeutic agents for 
diabetic kidney disease." Am J Kidney Dis 55(5): 928-940.
Uchida, G., K. Yoshimura, et al. (2003). "Tretinoin reverses upregulation of 
matrix metalloproteinase-13 in human keloid-derived fibroblasts." Exp 
Dermatol 12 Suppl 2: 35-42.
Urbach, J. and R. R. Rando (1994). "Isomerization of all-trans-retinoic acid to 
9-cis-retinoic acid." Biochem J 299 ( Pt 2): 459-465.
Varani, J., R. S. Mitra, et al. (1990). "All-trans retinoic acid stimulates growth 
and extracellular matrix production in growth-inhibited cultured human 
skin fibroblasts." J Invest Dermatol 94(5): 717-723.
Vasios, G. W., J. D. Gold, et al. (1989). "A retinoic acid-responsive element is 
present in the 5' flanking region of the laminin B1 gene." Proc Natl 
Acad Sci U S A 86(23): 9099-9103.
Verderio, E., B. Nicholas, et al. (1998). "Regulated expression of tissue 
transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of 
fibronectin, cell attachment, and cell death." Exp Cell Res 239(1): 
119-138.
Verrecchia, F., M. L. Chu, et al. (2001). "Identification of novel TGF-beta /
Smad gene targets in dermal fibroblasts using a combined cDNA 
microarray/promoter transactivation approach." J Biol Chem 276(20): 
17058-17062.
Villa, R., L. Morey, et al. (2006). "The methyl-CpG binding protein MBD1 is 
required for PML-RARalpha function." Proc Natl Acad Sci U S A 103(5): 
1400-1405.
Visse, R. and H. Nagase (2003). "Matrix metalloproteinases and tissue 
inhibitors of metalloproteinases: structure, function, and biochemistry." 
Circ Res 92(8): 827-839.
Vollmar, B., C. Heckmann, et al. (2002). "High, but not low, dietary retinoids 
aggravate manifestation of rat liver fibrosis." J Gastroenterol Hepatol 
17(7): 791-799.
Vuligonda, V., S. M. Thacher, et al. (2001). "Enantioselective syntheses of 
potent retinoid X receptor ligands: differential biological activities of 
individual antipodes." J Med Chem 44(14): 2298-2303.
200
Wagner, J., C. Dechow, et al. (2000). "Retinoic acid reduces glomerular injury 
in a rat model of glomerular damage." J Am Soc Nephrol 11(8): 
1479-1487.
Wang, H., Z. Dan, et al. (2008). "Effect of all-trans retinoic acid on liver fibrosis 
induced by common bile duct ligation in rats." J Huazhong Univ Sci 
Technolog Med Sci 28(5): 553-557.
Wang, L., J. J. Potter, et al. (2007). "Effects of retinoic acid on the 
development of liver fibrosis produced by carbon tetrachloride in mice." 
Biochim Biophys Acta 1772(1): 66-71.
Wang, L., L. R. Tankersley, et al. (2002). "Regulation of the murine alpha(2)(I) 
collagen promoter by retinoic acid and retinoid X receptors." Arch 
Biochem Biophys 401(2): 262-270.
Wang, L., L. R. Tankersley, et al. (2004). "Regulation of alpha 2(I) collagen 
expression in stellate cells by retinoic acid and retinoid X receptors 
through interactions with their cofactors." Arch Biochem Biophys 428
(1): 92-98.
Wang, Z., J. Xu, et al. (2011). "Effect of the regulation of retinoid X receptor-
alpha gene expression on rat hepatic fibrosis." Hepatol Res 41(5): 
475-483.
Watanabe, A., H. Kanai, et al. (2002). "Retinoids induce the PAI-1 gene 
expression through tyrosine kinase-dependent pathways in vascular 
smooth muscle cells." J Cardiovasc Pharmacol 39(4): 503-512.
Weiner, F. R., W. S. Blaner, et al. (1992). "Ito cell expression of a nuclear 
retinoic acid receptor." Hepatology 15(2): 336-342.
Wells, D. J. (2010). "Electroporation and ultrasound enhanced non-viral gene 
delivery in vitro and in vivo." Cell Biol Toxicol 26(1): 21-28.
Wen, X., Y. Li, et al. (2005). "Hepatocyte growth factor receptor signaling 
mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular 
mesangial cells." Am J Pathol 167(4): 947-957.
Wotton, D., R. S. Lo, et al. (1999). "Multiple modes of repression by the Smad 
transcriptional corepressor TGIF." J Biol Chem 274(52): 37105-37110.
Wozel, G., A. Chang, et al. (1991). "The effect of topical retinoids on the 
leukotriene-B4-induced migration of polymorphonuclear leukocytes into 
human skin." Arch Dermatol Res 283(3): 158-161.
Wu, L. N., Y. Ishikawa, et al. (1997). "Retinoic acid stimulates matrix 
calcification and initiates type I collagen synthesis in primary cultures of 
avian weight-bearing growth plate chondrocytes." J Cell Biochem 65
(2): 209-230.
Xu, Q., B. M. Hendry, et al. (2010). "Kidneys of Alb/TGF-beta1 transgenic 
mice are deficient in retinoic acid and exogenous retinoic acid shows 
dose-dependent toxicity." Nephron Exp Nephrol 114(4): e127-132.
Xu, Q., J. Lucio-Cazana, et al. (2004). "Retinoids in nephrology: promises and 
pitfalls." Kidney Int 66(6): 2119-2131.
Xu, Q., J. T. Norman, et al. (2007). "In vitro models of TGF-beta-induced 
fibrosis suitable for high-throughput screening of antifibrotic agents." 
Am J Physiol Renal Physiol 293(2): F631-640.
Yamaguchi, I., J. M. Lopez-Guisa, et al. (2007). "Endogenous urokinase lacks 
antifibrotic activity during progressive renal injury." Am J Physiol Renal 
Physiol 293(1): F12-19.
201
Yamamoto, T., N. A. Noble, et al. (1996). "Expression of transforming growth 
factor-beta isoforms in human glomerular diseases." Kidney Int 49(2): 
461-469.
Yamamoto, T., N. A. Noble, et al. (1994). "Sustained expression of TGF-beta 1 
underlies development of progressive kidney fibrosis." Kidney Int 45(3): 
916-927.
Yamane, A., N. Tsukamoto, et al. (2009). "Successful treatment by all-trans 
retinoic acid in a patient with acute promyelocytic leukemia complicated 
by liver cirrhosis and polycystic kidney." Intern Med 48(18): 1691-1694.
Yan, Z. H., S. Noonan, et al. (1996). "Retinoic acid induction of the tissue 
transglutaminase promoter is mediated by a novel response element." 
Mol Cell Endocrinol 120(2): 203-212.
Yang, J., R. W. Shultz, et al. (2002). "Disruption of tissue-type plasminogen 
activator gene in mice reduces renal interstitial fibrosis in obstructive 
nephropathy." J Clin Invest 110(10): 1525-1538.
Yoshioka, K., T. Takemura, et al. (1993). "Transforming growth factor-beta 
protein and mRNA in glomeruli in normal and diseased human 
kidneys." Lab Invest 68(2): 154-163.
Yu, V. C., C. Delsert, et al. (1991). "RXR beta: a coregulator that enhances 
binding of retinoic acid, thyroid hormone, and vitamin D receptors to 
their cognate response elements." Cell 67(6): 1251-1266.
Zechel, C., X. Q. Shen, et al. (1994). "The dimerization interfaces formed 
between the DNA binding domains of RXR, RAR and TR determine the 
binding specificity and polarity of the full-length receptors to direct 
repeats." EMBO J 13(6): 1425-1433.
Zeisberg, E. M., S. E. Potenta, et al. (2008). "Fibroblasts in kidney fibrosis 
emerge via endothelial-to-mesenchymal transition." J Am Soc Nephrol 
19(12): 2282-2287.
Zelent, A., C. Mendelsohn, et al. (1991). "Differentially expressed isoforms of 
the mouse retinoic acid receptor beta generated by usage of two 
promoters and alternative splicing." EMBO J 10(1): 71-81.
Zhang, G. and A. A. Eddy (2008). "Urokinase and its receptors in chronic 
kidney disease." Front Biosci 13: 5462-5478.
Zhang, G., K. A. Kernan, et al. (2007). "Plasmin(ogen) promotes renal 
interstitial fibrosis by promoting epithelial-to-mesenchymal transition: 
role of plasmin-activated signals." J Am Soc Nephrol 18(3): 846-859.
Zhang, W., J. Ou, et al. (2000). "Synergistic cooperation between Sp1 and 
Smad3/Smad4 mediates transforming growth factor beta1 stimulation 
of alpha 2(I)-collagen (COL1A2) transcription." J Biol Chem 275(50): 
39237-39245.
Zhang, Y. E. (2009). "Non-Smad pathways in TGF-beta signaling." Cell Res 
19(1): 128-139.
Zhong, H., H. R. Wang, et al. (2010). "Targeting Smad4 links microRNA-146a 
to the TGF-beta pathway during retinoid acid induction in acute 
promyelocytic leukemia cell line." Int J Hematol 92(1): 129-135.
Zhong, Y., Y. Wu, et al. (2011). "Novel retinoic acid receptor alpha agonists for 
treatment of kidney disease." PLoS One 6(11): e27945.
202
Zhou, T. B., Y. H. Qin, et al. (2012). "All-trans retinoic Acid treatment is 
associated with prohibitin expression in renal interstitial fibrosis rats." 
Int J Mol Sci 13(3): 2769-2782.
Zhou, T. B., Y. H. Qin, et al. (2011). "All-trans retinoic acid can regulate the 
expressions of gelatinases and apolipoprotein E in glomerulosclerosis 
rats." Vascul Pharmacol 55(5-6): 167-177.
203
Chapter 10. Appendix
Appendix A. Supplementary figures
Supplementary figure 1. RXRγ (Y-20):sc-555 antibody datasheet from Santa Cruz 
Biotechnology, INC. with enlarged picture of RXRγ immunoblot. Western blot analysis of 
RXRγ protein expression in non-transfected :sc-117752 (A) and human RXRγ transfected: 
sc-177886 (B) 293T whole cell  lysates. Website address: http://www.scbt.com/datasheet-555-
rxrgamma-y-20-antibody.html.
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Appendix B. Supplementary tables
Supplementary table 1. PCR array dataset showing fold change of tRA-treated group 
compared to vehicle.
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments Fold Change 95% CI Comments
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 ) OKAY
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 ) OKAY
A03 Adamts8 0.5106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 ) B
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 ) OKAY
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A06 Cd44 0.7571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 ) B
A07 Cdh1 0.4761 ( 0.00001, 0.98 ) B 0.5756 ( 0.06, 1.09 ) B
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 ) OKAY
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 ) OKAY
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A11 Cntn1 0.1183 ( 0.06, 0.18 ) OKAY 0.3036 ( 0.10, 0.51 ) OKAY
A12 Col1a1 0.9333 ( 0.16, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 ) OKAY
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
B02 Col3a1 1.3306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 ) OKAY
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 ) OKAY
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 ) OKAY
B05 Col4a3 0.5068 ( 0.32, 0.70 ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0.8534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 ) OKAY
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 ) OKAY
B08 Col8a1 0.5523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 ) OKAY
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( 0.39, 0.63 ) OKAY
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 ) OKAY
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 ) OKAY
B12 Ecm1 0.4708 ( 0.00001, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 ) OKAY
C01 Emilin1 1.9568 ( 0.08, 3.84 ) OKAY 1.606 ( 0.00001, 3.51 ) OKAY
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 ) OKAY
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 ) OKAY
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 ) OKAY
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 ) OKAY
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 ( 2.02, 15.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 ) OKAY
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 ) B
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 ) OKAY
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C12 Itgae 0.6312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 ) OKAY
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 ) OKAY
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D06 Itgb3 1.6009 ( 0.00001, 3.21 ) OKAY 2.1995 ( 0.04, 4.36 ) OKAY
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0.327 ( 0.20, 0.45 ) A
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( 0.04, 1.23 ) B 0.2574 ( 0.00001, 0.54 ) B
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 ) OKAY
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, 0.35 ) OKAY
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335.4897 ( 0.00001, 769.29 ) A
E01 Lamc1 1.6337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 ) OKAY
E02 Mmp10 0.1952 ( 0.00001, 0.41 ) B 1.8539 ( 0.67, 3.04 ) B
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 ) OKAY
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 ) OKAY
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY 0.8518 ( 0.63, 1.08 ) OKAY
E06 Mmp14 1.1015 ( 0.00001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 ) OKAY
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 ) OKAY
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 ) B
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 ) OKAY
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY 0.1408 ( 0.08, 0.20 ) OKAY
Fold Change (comparing to control group)
Group 1 tRA Group 2 TGF
205
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments Fold Change 95% CI Comments
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 ) OKAY
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 ) OKAY
A03 Adamts8 0.5106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 ) B
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 ) OKAY
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A06 Cd44 0.7571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 ) B
A07 Cdh1 0.4761 ( 0.00001, 0.98 ) B 0.5756 ( 0.06, 1.09 ) B
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 ) OKAY
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 ) OKAY
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A11 Cntn1 0.1183 ( 0.06, 0.18 ) OKAY 0.3036 ( 0.10, 0.51 ) OKAY
A12 Col1a1 0.9333 ( 0.16, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 ) OKAY
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
B02 Col3a1 1.3306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 ) OKAY
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 ) OKAY
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 ) OKAY
B05 Col4a3 0.5068 ( 0.32, 0.70 ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0.8534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 ) OKAY
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 ) OKAY
B08 Col8a1 0.5523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 ) OKAY
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( 0.39, 0.63 ) OKAY
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 ) OKAY
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 ) OKAY
B12 Ecm1 0.4708 ( 0.00001, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 ) OKAY
C01 Emilin1 1.9568 ( 0.08, 3.84 ) OKAY 1.606 ( 0.00001, 3.51 ) OKAY
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 ) OKAY
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 ) OKAY
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 ) OKAY
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 ) OKAY
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 ( 2.02, 15.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 ) OKAY
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 ) B
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 ) OKAY
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C12 Itgae 0.6312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 ) OKAY
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 ) OKAY
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D06 Itgb3 1.6009 ( 0.00001, 3.21 ) OKAY 2.1995 ( 0.04, 4.36 ) OKAY
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0.327 ( 0.20, 0.45 ) A
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( 0.04, 1.23 ) B 0.2574 ( 0.00001, 0.54 ) B
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 ) OKAY
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, 0.35 ) OKAY
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335.4897 ( 0.00001, 769.29 ) A
E01 Lamc1 1.6337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 ) OKAY
E02 Mmp10 0.1952 ( 0.00001, 0.41 ) B 1.8539 ( 0.67, 3.04 ) B
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 ) OKAY
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 ) OKAY
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY 0.8518 ( 0.63, 1.08 ) OKAY
E06 Mmp14 1.1015 ( 0.00001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 ) OKAY
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 ) OKAY
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 ) B
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 ) OKAY
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY 0.1408 ( 0.08, 0.20 ) OKAY
Fold Change (comparing to control group)
Group 1 tRA Group 2 TGF
206
Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test Sample
divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample.
Fold-Regulation represents fold-change results in a biologically meaningful way. Fold-change values greater
than one indicate a positive- or an up-regulation, and the fold-regulation is equal to the fold-change.
Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the
negative inverse of the fold-change.
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-change values less than 0.5
and fold-regulation values less than -2 are indicated in blue.
Fold Change & Fold Regulation: 
E12 Mmp7 13.663 ( 8. 1, 19.32 ) OKAY 0.6386 ( 0.29, 0.9  ) C
F0 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Peca 1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
l    l  l i  
Supplementary Table 2. PCR array dataset showing fold change of TGF-β1-treated 
group compared to vehicle. 
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments Fold Change 95% CI Comments
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 ) OKAY
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 ) OKAY
A03 Adamts8 0.5106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 ) B
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 ) OKAY
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A06 Cd44 0.7571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 ) B
A07 Cdh1 0.4761 ( 0.00001, 0.98 ) B 0.5756 ( 0.06, 1.09 ) B
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 ) OKAY
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 ) OKAY
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A11 Cntn1 0.1183 ( 0.06, 0.18 ) OKAY 0.3036 ( 0.10, 0.51 ) OKAY
A12 Col1a1 0.9333 ( 0.16, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 ) OKAY
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
B02 Col3a1 1.3306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 ) OKAY
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 ) OKAY
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 ) OKAY
B05 Col4a3 0.5068 ( 0.32, 0.70 ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0.8534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 ) OKAY
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 ) OKAY
B08 Col8a1 0.5523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 ) OKAY
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( 0.39, 0.63 ) OKAY
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 ) OKAY
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 ) OKAY
B12 Ecm1 0.4708 ( 0.00001, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 ) OKAY
C01 Emilin1 1.9568 ( 0.08, 3.84 ) OKAY 1.606 ( 0.00001, 3.51 ) OKAY
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 ) OKAY
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 ) OKAY
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 ) OKAY
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 ) OKAY
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 ( 2.02, 15.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 ) OKAY
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 ) B
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 ) OKAY
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C12 Itgae 0.6312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 ) OKAY
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 ) OKAY
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D06 Itgb3 1.6009 ( 0.00001, 3.21 ) OKAY 2.1995 ( 0.04, 4.36 ) OKAY
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0.327 ( 0.20, 0.45 ) A
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( 0.04, 1.23 ) B 0.2574 ( 0.00001, 0.54 ) B
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 ) OKAY
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, 0.35 ) OKAY
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335.4897 ( 0.00001, 769.29 ) A
E01 Lamc1 1.6337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 ) OKAY
E02 Mmp10 0.1952 ( 0.00001, 0.41 ) B 1.8539 ( 0.67, 3.04 ) B
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 ) OKAY
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 ) OKAY
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY 0.8518 ( 0.63, 1.08 ) OKAY
E06 Mmp14 1.1015 ( 0.00001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 ) OKAY
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 ) OKAY
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 ) B
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 ) OKAY
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY 0.1408 ( 0.08, 0.20 ) OKAY
Fold Change (comparing to control group)
Group 1 tRA Group 2 TGF
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0 99 C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 )
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 )
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 69 29
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 )
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 )
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 )
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 )
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 )
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 )
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0. 0001, 11.82 )
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 )
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 )
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 )
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 )
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0. 01, 20
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( .46, 0.87 )
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 )
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 )
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 )
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 )
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 )
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( .51, .70 )
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1 1467 ( 0.51, 1.78 )
H09 RTC 0.6593 ( 0.41, 0.9  ) OKAY 0.8815 ( 0.49, 1.27 )
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 )
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 )
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 )
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sampl , and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and re sonably detected i the
other sample suggesting that the actual fold-change value is at least as large as the calc lat d and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; t erefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that it relative expression leve is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to ve a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater t an the defin d cut-off value
(default 35), in both samples meaning that its expression was undetecte , making this f ld-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments l   I e ts
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 )
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 )
A03 Adamts8 0.5106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 )
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 )
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
A06 Cd44 0.7571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 )
A07 Cdh1 0.4761 ( 0.00001, 0.98 ) B 0.5756 ( 0. 6, 1.0  )
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 )
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 )
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
A11 Cntn1 0.1183 ( 0.06, 0.18 ) OKAY .3036 ( 0.10, 0.51 )
A12 Col1a1 0.9333 ( 0.16, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 )
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
B02 Col3a1 1.3306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 )
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 )
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 )
B05 Col4a3 0.5068 ( 0.32, 0.7  ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0.8534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 )
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 )
B08 Col8a1 0.5523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 )
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( .39, 0.63 )
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 )
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 )
B12 Ecm1 0.4708 ( 0.00001, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 )
C01 Emilin1 1.9568 ( 0.08, 3.84 ) OKAY 1.606 ( 0.0 001, 3.51 )
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 )
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 )
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 )
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 )
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 2 02 5.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 )
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 )
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 )
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
C12 Itgae 0.6312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 )
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 )
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
D06 Itgb3 1.6009 ( 0.00001, 3.21 ) OKAY 2.1995 ( 0. 4, 4.36 )
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0. 27 ( 0.20, 0.45 )
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( 0.04, 1.23 ) B 0.2574 ( 0.0 00 , 0.54 )
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 )
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, .35 )
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335. 897 ( 0.00 01, 769.29 ) A
E01 Lamc1 1.6337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 )
E02 Mmp10 0.1952 ( 0.00001, 0.41 ) B 1.8539 ( 0.67, 3.0  )
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 )
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 )
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY .85 8 ( 0.63, 1.08 )
E06 Mmp14 1.1015 ( 0.00001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 )
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 )
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 )
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 )
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 )
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY .1408 ( 0.08, 0.20 )
Fold Change (comparing to control group)
Group 1 tRA 2 TGF
2
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments Fold Change 95% CI Comments
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 ) OKAY
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 ) OKAY
A03 Adamts8 0.5106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 ) B
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 ) OKAY
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A06 Cd44 0.7571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 ) B
A07 Cdh1 0.4761 ( 0.00001, 0.98 ) B 0.5756 ( 0.06, 1.09 ) B
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 ) OKAY
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 ) OKAY
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A11 Cntn1 0.1183 ( 0.06, 0.18 ) OKAY 0.3036 ( 0.10, 0.51 ) OKAY
A12 Col1a1 0.9333 ( 0.16, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 ) OKAY
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
B02 Col3a1 1.3306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 ) OKAY
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 ) OKAY
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 ) OKAY
B05 Col4a3 0.5068 ( 0.32, 0.70 ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0.8534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 ) OKAY
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 ) OKAY
B08 Col8a1 0.5523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 ) OKAY
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( 0.39, 0.63 ) OKAY
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 ) OKAY
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 ) OKAY
B12 Ecm1 0.4708 ( 0.00001, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 ) OKAY
C01 Emilin1 1.9568 ( 0.08, 3.84 ) OKAY 1.606 ( 0.00001, 3.51 ) OKAY
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 ) OKAY
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 ) OKAY
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 ) OKAY
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 ) OKAY
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 ( 2.02, 15.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 ) OKAY
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 ) B
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 ) OKAY
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C12 Itgae 0.6312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 ) OKAY
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 ) OKAY
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D06 Itgb3 1.6009 ( 0.00001, 3.21 ) OKAY 2.1995 ( 0.04, 4.36 ) OKAY
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0.327 ( 0.20, 0.45 ) A
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( 0.04, 1.23 ) B 0.2574 ( 0.00001, 0.54 ) B
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 ) OKAY
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, 0.35 ) OKAY
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335.4897 ( 0.00001, 769.29 ) A
E01 Lamc1 1.6337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 ) OKAY
E02 Mmp10 0.1952 ( 0.00001, 0.41 ) B 1.8539 ( 0.67, 3.04 ) B
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 ) OKAY
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 ) OKAY
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY 0.8518 ( 0.63, 1.08 ) OKAY
E06 Mmp14 1.1015 ( 0.00001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 ) OKAY
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 ) OKAY
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 ) B
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 ) OKAY
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY 0.1408 ( 0.08, 0.20 ) OKAY
Fold Change (comparing to control group)
Group 1 tRA Group 2 TGF
E12 Mmp7 13. 639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0. 025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0. 0001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2. 045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0. 2, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0. 758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0. 000 , 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0. 896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0. 357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0. 3, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0. 6, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10. 021 ( .00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0. 018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0. 0, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0. 492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0. 0001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s averag threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
Thes data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result m y also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average thr shold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-ch nge resul may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
Fold Change 95% CI Comments Fold Change 95% CI Comments
A01 Adamts1 0.9463 ( 0.60, 1.29 ) OKAY 1.8948 ( 0.98, 2.80 ) OKAY
A02 Adamts5 0.8375 ( 0.42, 1.26 ) OKAY 0.4675 ( 0.29, 0.65 ) OKAY
A03 Adamts8 0. 106 ( 0.18, 0.84 ) B 0.5255 ( 0.20, 0.85 ) B
A04 Catna1 1.1402 ( 0.89, 1.39 ) OKAY 0.6053 ( 0.42, 0.79 ) OKAY
A05 Ctnna2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A06 Cd44 0. 571 ( 0.15, 1.36 ) B 2.6187 ( 0.93, 4.31 ) B
A07 Cdh1 0.4761 ( .000 1, 0.98 ) B 0.5756 ( 0.06, 1.09 ) B
A08 Cdh2 1.0256 ( 0.44, 1.61 ) OKAY 0.7254 ( 0.36, 1.09 ) OKAY
A09 Cdh3 1.044 ( 0.50, 1.59 ) OKAY 0.2541 ( 0.11, 0.40 ) OKAY
A10 Cdh4 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
A11 Cntn1 0.1183 ( 0. 6, 0.18 ) OKAY 0.3036 ( 0.10, 0.51 ) OKAY
A12 Col1a1 0.9333 ( 0. 6, 1.70 ) OKAY 0.9764 ( 0.36, 1.59 ) OKAY
B01 Col2a1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
B02 Col3a1 1. 306 ( 0.85, 1.81 ) OKAY 3.7563 ( 2.79, 4.72 ) OKAY
B03 Col4a1 1.125 ( 0.76, 1.49 ) OKAY 2.1044 ( 1.43, 2.78 ) OKAY
B04 Col4a2 1.4434 ( 0.63, 2.25 ) OKAY 1.5535 ( 0.58, 2.52 ) OKAY
B05 Col4a3 0.5068 ( 0.32, 0.70 ) OKAY 0.5742 ( 0.19, 0.96 ) B
B06 Col5a1 0. 534 ( 0.36, 1.34 ) OKAY 1.848 ( 1.44, 2.26 ) OKAY
B07 Col6a1 0.6072 ( 0.38, 0.83 ) OKAY 0.5475 ( 0.21, 0.89 ) OKAY
B08 Col8a1 0. 523 ( 0.27, 0.83 ) OKAY 1.0965 ( 0.44, 1.75 ) OKAY
B09 Vcan 0.8921 ( 0.67, 1.11 ) OKAY 0.5109 ( 0.39, 0.63 ) OKAY
B10 Ctgf 0.4991 ( 0.25, 0.75 ) OKAY 1.0759 ( 0.50, 1.65 ) OKAY
B11 Ctnnb1 1.1814 ( 0.20, 2.16 ) OKAY 0.4026 ( 0.09, 0.72 ) OKAY
B12 Ecm1 0.4708 ( 0. 00 1, 1.13 ) OKAY 0.1905 ( 0.00001, 0.41 ) OKAY
C01 Emilin1 1.9568 ( .08, 3.84 ) OKAY 1.606 ( 0.00001, 3.51 ) OKAY
C02 Entpd1 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C03 Fbln1 2.7423 ( 1.84, 3.64 ) OKAY 3.5942 ( 2.21, 4.98 ) OKAY
C04 Fn1 0.6504 ( 0.19, 1.11 ) OKAY 2.0625 ( 1.31, 2.81 ) OKAY
C05 Hapln1 0.1715 ( 0.00001, 0.39 ) OKAY 0.3609 ( 0.24, 0.48 ) OKAY
C06 Icam1 0.8271 ( 0.10, 1.56 ) OKAY 0.1737 ( 0.05, 0.30 ) OKAY
C07 Itga2 0.7606 ( 0.35, 1.18 ) B 8.6921 ( 2.02, 15.37 ) A
C08 Itga3 1.6376 ( 0.84, 2.44 ) OKAY 0.5092 ( 0.25, 0.77 ) OKAY
C09 Itga4 0.6933 ( 0.26, 1.12 ) B 0.6554 ( 0.30, 1.01 ) B
C10 Itga5 0.9508 ( 0.56, 1.34 ) OKAY 1.8212 ( 1.08, 2.56 ) OKAY
C11 Itgad 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
C12 Itgae 0. 312 ( 0.18, 1.09 ) B 0.6386 ( 0.29, 0.99 ) C
D01 Itgal 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D02 Itgam 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D03 Itgav 1.2746 ( 0.62, 1.93 ) OKAY 1.6384 ( 0.92, 2.36 ) OKAY
D04 Itgb1 1.7988 ( 0.18, 3.42 ) OKAY 2.5893 ( 1.40, 3.78 ) OKAY
D05 Itgb2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
D06 Itgb3 1.6009 ( .00001, 3.21 ) OKAY 2.1995 ( 0.04, 4.36 ) OKAY
D07 Itgb4 0.4349 ( 0.25, 0.62 ) A 0.327 ( 0.20, 0.45 ) A
D08 Lama1 1.0885 ( 0.52, 1.66 ) B 4.3578 ( 1.97, 6.75 ) A
D09 Lama2 0.6356 ( .04, 1.23 ) B 0.2574 ( 0.00001, 0.54 ) B
D10 Lama3 0.4812 ( 0.31, 0.65 ) OKAY 5.6291 ( 3.39, 7.87 ) OKAY
D11 Lamb2 0.695 ( 0.43, 0.96 ) OKAY 0.2332 ( 0.11, 0.35 ) OKAY
D12 Lamb3 0.4931 ( 0.04, 0.94 ) B 335.4897 ( 0.00001, 769.29 ) A
E01 Lamc1 1. 337 ( 0.54, 2.73 ) OKAY 1.9206 ( 0.58, 3.26 ) OKAY
E02 Mmp10 0.1952 ( 0.000 1, 0.41 ) B 1.8539 ( 0.67, 3.04 ) B
E03 Mmp11 1.1807 ( 0.82, 1.54 ) OKAY 0.3727 ( 0.29, 0.45 ) OKAY
E04 Mmp12 0.4312 ( 0.19, 0.67 ) OKAY 0.3375 ( 0.19, 0.49 ) OKAY
E05 Mmp13 0.0411 ( 0.02, 0.06 ) OKAY 0.8518 ( 0.63, 1.08 ) OKAY
E06 Mmp14 1.1015 ( 0. 0001, 2.38 ) OKAY 1.0058 ( 0.00001, 2.27 ) OKAY
E07 Mmp15 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
E08 Mmp16 0.7768 ( 0.39, 1.16 ) OKAY 0.971 ( 0.50, 1.44 ) OKAY
E09 Mmp1a 0.5132 ( 0.07, 0.96 ) B 0.6537 ( 0.09, 1.22 ) B
E10 Mmp2 1.4998 ( 0.95, 2.05 ) OKAY 0.6656 ( 0.42, 0.91 ) OKAY
E11 Mmp3 0.2116 ( 0.14, 0.29 ) OKAY 0.1408 ( 0.08, 0.20 ) OKAY
Fold Change (comparing to control group)
Group 1 tRA Group 2 TGF
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Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test Sample
divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample.
Fold-Regulation represents fold-change results in a biologically meaningful way. Fold-change values greater
than one indicate a positive- or an up-regulation, and the fold-regulation is equal to the fold-change.
Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the
negative inverse of the fold-change.
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-change values less than 0.5
and fold-regulation values less than -2 are indicated in blue.
Fold Change & Fold Regulation: 
E12 Mmp7 13.6639 ( 8.01, 19.32 ) OKAY 0.6386 ( 0.29, 0.99 ) C
F01 Mmp8 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F02 Mmp9 0.3025 ( 0.07, 0.54 ) OKAY 2.6053 ( 0.92, 4.29 ) B
F03 Ncam1 2.175 ( 1.30, 3.05 ) OKAY 1.2809 ( 1.06, 1.50 ) OKAY
F04 Ncam2 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F05 Pecam1 0.3475 ( 0.00001, 0.72 ) B 1.27 ( 0.00001, 2.68 ) B
F06 Postn 2.1045 ( 0.00001, 4.35 ) OKAY 86.2131 ( 3.13, 169.29 ) OKAY
F07 Adamts2 0.9556 ( 0.35, 1.56 ) OKAY 0.7716 ( 0.25, 1.29 ) OKAY
F08 Sele 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F09 Sell 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
F10 Selp 0.5936 ( 0.12, 1.07 ) C 0.9263 ( 0.09, 1.76 ) B
F11 Sgce 0.5758 ( 0.15, 1.00 ) OKAY 0.2735 ( 0.06, 0.48 ) OKAY
F12 Sparc 42.6872 ( 0.00001, 383.00 ) OKAY 67.9995 ( 0.00001, 610.82 ) OKAY
G01 Spock1 0.8628 ( 0.37, 1.36 ) A 0.6405 ( 0.33, 0.95 ) B
G02 Spp1 0.6896 ( 0.51, 0.87 ) OKAY 2.4626 ( 1.64, 3.28 ) OKAY
G03 Syt1 0.3357 ( 0.01, 0.66 ) A 0.7953 ( 0.12, 1.47 ) OKAY
G04 Tgfbi 0.4401 ( 0.23, 0.65 ) OKAY 2.8865 ( 2.17, 3.61 ) OKAY
G05 Thbs1 0.3962 ( 0.24, 0.55 ) OKAY 0.7108 ( 0.44, 0.98 ) OKAY
G06 Thbs2 2.2811 ( 0.12, 4.44 ) OKAY 5.8709 ( 0.00001, 11.82 ) OKAY
G07 Timp1 0.5726 ( 0.23, 0.92 ) OKAY 1.4481 ( 0.23, 2.67 ) OKAY
G08 Timp2 0.5553 ( 0.29, 0.82 ) OKAY 0.3106 ( 0.16, 0.46 ) OKAY
G09 Timp3 0.7366 ( 0.66, 0.81 ) OKAY 3.8951 ( 1.69, 6.10 ) OKAY
G10 Tnc 0.7611 ( 0.26, 1.26 ) OKAY 53.0506 ( 16.22, 89.88 ) OKAY
G11 Vcam1 10.2021 ( 0.00001, 20.71 ) OKAY 0.1012 ( 0.00001, 0.20 ) A
G12 Vtn 0.5936 ( 0.12, 1.07 ) C 0.6386 ( 0.29, 0.99 ) C
H01 Rplp1 0.7018 ( 0.29, 1.11 ) OKAY 0.6607 ( 0.46, 0.87 ) OKAY
H02 Hprt1 1.2145 ( 1.00, 1.43 ) OKAY 1.3396 ( 1.19, 1.49 ) OKAY
H03 Rpl13a 1.5083 ( 0.96, 2.06 ) OKAY 1.568 ( 0.65, 2.49 ) OKAY
H04 Ldha 0.9453 ( 0.77, 1.12 ) OKAY 0.7706 ( 0.45, 1.09 ) OKAY
H05 Actb 0.8229 ( 0.10, 1.54 ) OKAY 0.935 ( 0.75, 1.12 ) OKAY
H06 RGDC 0.6492 ( 0.21, 1.09 ) B 0.6256 ( 0.27, 0.98 ) B
H07 RTC 0.7834 ( 0.46, 1.11 ) OKAY 1.1031 ( 0.51, 1.70 ) OKAY
H08 RTC 0.8111 ( 0.45, 1.18 ) OKAY 1.1467 ( 0.51, 1.78 ) OKAY
H09 RTC 0.6593 ( 0.41, 0.90 ) OKAY 0.8815 ( 0.49, 1.27 ) OKAY
H10 PPC 19.868 ( 0.00001, 155.85 ) OKAY 21.9409 ( 0.00001, 171.58 ) OKAY
H11 PPC 0.5718 ( 0.10, 1.04 ) OKAY 0.666 ( 0.37, 0.96 ) OKAY
H12 PPC 0.6292 ( 0.13, 1.13 ) OKAY 0.5398 ( 0.18, 0.90 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
l    l  l i  
Supplementary Table 3. PCR array dataset showing fold change of the dual-treated 
group compared to the TGF-β1-treated group. 
Fold Change 95% CI Comments
A01 Adamts1 0.1876 ( 0.07, 0.31 ) OKAY
A02 Adamts5 1.3789 ( 0.83, 1.93 ) OKAY
A03 Adamts8 0.6887 ( 0.34, 1.03 ) B
A04 Catna1 1.0327 ( 0.72, 1.34 ) OKAY
A05 Ctnna2 0.9647 ( 0.26, 1.66 ) B
A06 Cd44 0.4985 ( 0.26, 0.74 ) B
A07 Cdh1 0.6857 ( 0.34, 1.03 ) B
A08 Cdh2 1.2062 ( 1.02, 1.39 ) OKAY
A09 Cdh3 0.9636 ( 0.51, 1.42 ) OKAY
A10 Cdh4 0.7708 ( 0.42, 1.13 ) C
A11 Cntn1 0.1338 ( 0.06, 0.21 ) OKAY
A12 Col1a1 0.9903 ( 0.58, 1.40 ) OKAY
B01 Col2a1 0.7708 ( 0.42, 1.13 ) C
B02 Col3a1 0.9061 ( 0.75, 1.06 ) OKAY
B03 Col4a1 0.8118 ( 0.58, 1.04 ) OKAY
B04 Col4a2 0.6426 ( 0.23, 1.06 ) OKAY
B05 Col4a3 2.5618 ( 0.00001, 5.42 ) B
B06 Col5a1 0.755 ( 0.57, 0.94 ) OKAY
B07 Col6a1 0.4663 ( 0.16, 0.77 ) OKAY
B08 Col8a1 0.2295 ( 0.10, 0.36 ) OKAY
B09 Vcan 1.4914 ( 1.13, 1.85 ) OKAY
B10 Ctgf 0.2054 ( 0.13, 0.28 ) OKAY
B11 Ctnnb1 1.5039 ( 0.72, 2.29 ) OKAY
B12 Ecm1 0.5055 ( 0.36, 0.65 ) OKAY
C01 Emilin1 0.4488 ( 0.00001, 0.93 ) OKAY
C02 Entpd1 0.7708 ( 0.42, 1.13 ) C
C03 Fbln1 1.8752 ( 1.15, 2.60 ) OKAY
C04 Fn1 0.8744 ( 0.55, 1.19 ) OKAY
C05 Hapln1 0.3641 ( 0.27, 0.46 ) OKAY
C06 Icam1 1.2736 ( 0.77, 1.78 ) OKAY
C07 Itga2 1.3085 ( 0.52, 2.09 ) OKAY
C08 Itga3 1.4985 ( 0.84, 2.16 ) OKAY
C09 Itga4 0.8661 ( 0.34, 1.39 ) B
C10 Itga5 1.0695 ( 0.80, 1.34 ) OKAY
C11 Itgad 0.7708 ( 0.42, 1.13 ) C
C12 Itgae 0.7708 ( 0.42, 1.13 ) C
D01 Itgal 0.7781 ( 0.43, 1.13 ) B
D02 Itgam 0.7708 ( 0.42, 1.13 ) C
D03 Itgav 0.5509 ( 0.31, 0.80 ) OKAY
D04 Itgb1 0.7025 ( 0.53, 0.87 ) OKAY
D05 Itgb2 1.0141 ( 0.20, 1.83 ) B
D06 Itgb3 0.5937 ( 0.11, 1.08 ) OKAY
D07 Itgb4 0.8391 ( 0.46, 1.22 ) B
D08 Lama1 0.6083 ( 0.39, 0.82 ) OKAY
D09 Lama2 0.8038 ( 0.19, 1.42 ) B
D10 Lama3 0.3984 ( 0.22, 0.57 ) OKAY
D11 Lamb2 1.2126 ( 0.59, 1.84 ) OKAY
D12 Lamb3 0.856 ( 0.00001, 1.92 ) OKAY
E01 Lamc1 0.7047 ( 0.25, 1.16 ) OKAY
E02 Mmp10 0.6454 ( 0.51, 0.78 ) OKAY
E03 Mmp11 1.6439 ( 1.36, 1.93 ) OKAY
E04 Mmp12 1.2478 ( 0.65, 1.85 ) B
E05 Mmp13 0.2724 ( 0.20, 0.34 ) OKAY
E06 Mmp14 0.4132 ( 0.09, 0.73 ) OKAY
E07 Mmp15 0.7708 ( 0.42, 1.13 ) C
E08 Mmp16 0.6528 ( 0.54, 0.76 ) OKAY
E09 Mmp1a 1.1303 ( 0.11, 2.16 ) B
E10 Mmp2 0.6106 ( 0.34, 0.88 ) OKAY
E11 Mmp3 0.5144 ( 0.29, 0.74 ) OKAY
Group 3 dual
Fold Change (comparing to control group)- TGF !1
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Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test Sample
divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample.
Fold-Regulation represents fold-change results in a biologically meaningful way. Fold-change values greater
than one indicate a positive- or an up-regulation, and the fold-regulation is equal to the fold-change.
Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the
negative inverse of the fold-change.
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-change values less than 0.5
and fold-regulation values less than -2 are indicated in blue.
Fold Change & Fold Regulation: 
E12 Mmp7 3.506 ( 1.41, 5.61 ) OKAY
F01 Mmp8 0.7708 ( 0.42, 1.13 ) C
F02 Mmp9 1.295 ( 0.50, 2.09 ) B
F03 Ncam1 1.6203 ( 1.26, 1.98 ) OKAY
F04 Ncam2 0.7708 ( 0.42, 1.13 ) C
F05 Pecam1 0.5979 ( 0.00001, 1.24 ) B
F06 Postn 0.0218 ( 0.01, 0.04 ) OKAY
F07 Adamts2 0.4678 ( 0.21, 0.73 ) OKAY
F08 Sele 0.7708 ( 0.42, 1.13 ) C
F09 Sell 0.7708 ( 0.42, 1.13 ) C
F10 Selp 2.0933 ( 0.35, 3.84 ) B
F11 Sgce 1.2613 ( 0.74, 1.78 ) OKAY
F12 Sparc 0.4527 ( 0.08, 0.82 ) OKAY
G01 Spock1 1.2025 ( 0.67, 1.74 ) A
G02 Spp1 0.7527 ( 0.54, 0.97 ) OKAY
G03 Syt1 0.5644 ( 0.16, 0.97 ) OKAY
G04 Tgfbi 0.2818 ( 0.22, 0.34 ) OKAY
G05 Thbs1 0.3343 ( 0.20, 0.47 ) OKAY
G06 Thbs2 0.31 ( 0.03, 0.59 ) OKAY
G07 Timp1 0.3997 ( 0.13, 0.67 ) OKAY
G08 Timp2 0.4675 ( 0.36, 0.57 ) OKAY
G09 Timp3 0.1167 ( 0.04, 0.19 ) OKAY
G10 Tnc 0.0607 ( 0.03, 0.09 ) OKAY
G11 Vcam1 51.1681 ( 14.42, 87.91 ) A
G12 Vtn 0.7708 ( 0.42, 1.13 ) C
H01 Rplp1 0.9726 ( 0.80, 1.14 ) OKAY
H02 Hprt1 1.1873 ( 1.07, 1.31 ) OKAY
H03 Rpl13a 0.809 ( 0.29, 1.33 ) OKAY
H04 Ldha 1.3536 ( 0.64, 2.07 ) OKAY
H05 Actb 0.7907 ( 0.55, 1.03 ) OKAY
H06 RGDC 0.7708 ( 0.42, 1.13 ) C
H07 RTC 0.7663 ( 0.39, 1.14 ) OKAY
H08 RTC 0.7158 ( 0.35, 1.08 ) OKAY
H09 RTC 0.7705 ( 0.48, 1.06 ) OKAY
H10 PPC 0.7001 ( 0.34, 1.06 ) OKAY
H11 PPC 0.8023 ( 0.48, 1.12 ) OKAY
H12 PPC 0.9054 ( 0.31, 1.50 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
ld Change & Fold Regulation: 
E12 Mmp7 3.506 ( 1.41, 5.61 ) OKAY
F01 Mmp8 0.7708 ( 0.42, 1.13 ) C
F02 Mmp9 1.295 ( 0.50, 2.09 ) B
F03 Ncam1 1.6203 ( 1.26, 1.98 ) OKAY
F04 Ncam2 0.7708 ( 0.42, 1.13 ) C
F05 Pecam1 0.5979 ( 0.00001, 1.24 ) B
F06 Postn 0.0218 ( 0.01, 0.04 ) OKAY
F07 Adamts2 0.4678 ( 0.21, 0.73 ) OKAY
F08 Sele 0.7708 ( 0.42, 1.13 ) C
F09 Sell 0.7708 ( 0.42, 1.13 ) C
F10 Selp 2.0933 ( 0.35, 3.84 ) B
F11 Sgce 1.2613 ( 0.74, 1.78 ) OKAY
F12 Sparc 0.4527 ( 0.08, 0.82 ) OKAY
G01 Spock1 1.2025 ( 0.67, 1.74 ) A
G02 Spp1 0.7527 ( 0.54, 0.97 ) OKAY
G03 Syt1 0.5644 ( 0.16, 0.97 ) OKAY
G04 Tgfbi 0.2818 ( 0.22, 0.34 ) OKAY
G05 Thbs1 0.3343 ( 0.20, 0.47 ) OKAY
G06 Thbs2 0.31 ( 0.03, 0.59 ) OKAY
G07 Timp1 0.3997 ( 0.13, 0.67 ) OKAY
G08 Timp2 0.4675 ( 0.36, 0.57 ) OKAY
G09 Timp3 0.1167 ( 0.04, 0.19 ) OKAY
G10 Tnc 0.0607 ( 0.03, 0.09 ) OKAY
G11 Vcam1 51.1681 ( 14.42, 87.91 ) A
G12 Vtn 0.7708 ( 0.42, 1.13 ) C
H01 Rplp1 0.9726 ( 0.80, 1.14 ) OKAY
H02 Hprt1 1.1873 ( 1.07, 1.31 ) OKAY
H03 Rpl13a 0.809 ( 0.29, 1.33 ) OKAY
H04 Ldha 1.3536 ( 0.64, 2.07 ) OKAY
H05 Actb 0.7907 ( 0.55, 1.03 ) OKAY
H06 RGDC 0.7708 ( 0.42, 1.13 ) C
H07 RTC 0.7663 ( 0.39, 1.14 ) OKAY
H08 RTC 0.7158 ( 0.35, 1.08 ) OKAY
H09 RTC 0.7705 ( 0.48, 1.06 ) OKAY
H10 PPC 0.7001 ( 0.34, 1.06 ) OKAY
H11 PPC 0.8023 ( 0.48, 1.12 ) OKAY
H12 PPC 0.9054 ( 0.31, 1.50 ) OKAY
Comments: 
A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test sample, and is
reasonably low in the other sample (< 30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected in the
other sample suggesting that the actual fold-change value is at least as large as the calculated and reported
fold-change result.
This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a
sufficient number of biological replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is
low, in both control and test samples, and the p-value for the fold-change is either unavailable or relatively
high (p > 0.05).
This fold-change result may also have greater variations; therefore, it is important to have a sufficient number
of biological replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cut-off value
(default 35), in both samples meaning that its expression was undetected, making this fold-change result
erroneous and un-interpretable.
Fold Change & Fold Regulation: 
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Supplementary Table 4. LC/MS/MS analysis of 1D polyacrylamide gel bands of interest 
in NRK-49F total cell lysate. AR2_1 and AR2_2 represent bands of interest corresponding 
to the TG2 immunoblot (see Figure 3.12); AR3_1, AR3_2 and AR3_3 represent bands of 
interest corresponding to the CRABP-II immunoblot (see Figure 4.9).
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                49.0 49.9   VYEGERPLTK 
  Stress-70 protein, mitochondrial Rat P48721  73812 5.97 44 23 57.2 49.8 41% AQFEGIVTDLIK 
                59.3 49.9   AQFEGIVTDLIKR 
                84.1 49.8   ASNGDAWVEAHGK 
                63.8 49.8   DAGQISGLNVLR 
                63.9 50.0   EQQIVIQSSGGLSK 
                43.8 49.8   EQQIVIQSSGGLSKDDIENMVK 
                82.8 49.8   ERVEAVNMAEGIIHDTETK 
                91.5 49.9   ETAENYLGHTAK 
                47.8 49.9   ETGVDLTKDNMALQR 
                47.5 50.3   LFEMAYK 
                55.7 49.5   LLGQFTLIGIPPAPR 
                45.0 49.4   MEEFKDQLPADECNK 
                69.2 49.6   MKETAENYLGHTAK 
                55.3 49.8   NAVITVPAYFNDSQR 
                93.8 50.1   QAASSLQQASLK 
                101.2 49.8   QAVTNPNNTFYATK 
                61.7 49.7   RYDDPEVQKDTK 
                63.3 50.0   SDIGEVILVGGMTR 
                92.4 49.6   STNGDTFLGGEDFDQALLR 
                74.6 49.9   TTPSVVAFTPDGER 
                95.1 49.8   VEAVNMAEGIIHDTETK 
                63.7 49.8   VINEPTAAALAYGLDKSEDK 
                62.6 50.0   VQQTVQDLFGR 
  Heat shock cognate 71 kDa protein Rat P63018  70827 5.37 32 15 72.1 49.7 32% ARFEELNADLFR 
                75.9 49.4   FEELNADLFR 
                53.2 49.8   HWPFMVVNDAGRPK 
                73.7 49.9   IINEPTAAAIAYGLDKK 
                47.1 49.0   LLQDFFNGK 
                55.4 50.3   LSKEDIER 
                80.0 49.4   MKEIAEAYLGK 
                52.5 49.4   MVNHFIAEFK 
                38.7 49.8   MVQEAEKYKAEDEK 
                100.3 49.7   NQVAMNPTNTVFDAK 
                57.5 50.0   NSLESYAFNMK 
                118.2 49.5   QTQTFTTYSDNQPGVLIQVYEGER 
                69.4 49.6   RFDDAVVQSDMK 
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Table 2: LC/MS/MS analysis of 1D SDS gel bands of a rat cell lysate. 
 
   
Band Protein I.D. Species Accession MW pI No. No. Peptide Peptide Percentage Sequence 
No.     No. (Da)   Peptides Unique Identity Identity Coverage   
            Matched Peptides Score Threshold     
AR2_1 78 kDa glucose-regulated protein Rat P06761  72302 5.07 53 30 62.1 49.9 48% AKFEELNMDLFR 
                80.4 49.7   AVEEKIEWLESHQDADIEDFK 
                60.0 50.0   DAGTIAGLNVMR 
                117.0 49.8   DNHLLGTFDLTGIPPAPR 
                42.8 49.7   ELEEIVQPIISK 
                68.1 50.0   FEELNMDLFR 
                75.4 49.7   IEIESFFEGEDFSETLTR 
                84.4 49.7   IEWLESHQDADIEDFK 
                71.8 49.8   IEWLESHQDADIEDFKAK 
                68.8 49.9   IINEPTAAAIAYGLDK 
                93.1 49.8   IINEPTAAAIAYGLDKR 
                54.6 49.6   ITPSYVAFTPEGER 
                50.0 49.4   KKELEEIVQPIISK 
                102.1 50.0   KSDIDEIVLVGGSTR 
                74.1 49.9   KTKPYIQVDIGGGQTK 
                64.8 49.8   KVTHAVVTVPAYFNDAQR 
                34.1 50.1   LTPEEIER 
                86.0 49.9   MKETAEAYLGK 
                52.3 49.6   MVNDAEKFAEEDKK 
                50.6 50.1   NELESYAYSLK 
                39.8 49.9   NGRVEIIANDQGNR 
                95.2 49.8   NQLTSNPENTVFDAK 
                56.1 49.9   NQLTSNPENTVFDAKR 
                76.0 49.8   SQIFSTASDNQPTVTIK 
                66.6 49.7   TFAPEEISAMVLTK 
                59.9 49.9   TKPYIQVDIGGGQTK 
                63.7 50.0   TWNDPSVQQDIK 
                57.8 50.3   VLEDSDLK 
                51.9 50.2   VLEDSDLKK 
                58.8 49.8   VTHAVVTVPAYFNDAQR 
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LETM1 and EF-hand domain-
containing protein 1, mitochondrial Rat Q5XIN6  83008 6.22 5 3 80.1 49.5 6% AKLEATLQEEAAIQQEHLEELKR 
                40.9 49.6   FLQDTIEEMALK 
                46.0 49.8   STLQTLPEIVAK 
  Septin-9 Rat Q9QZR6  63752 8.65 4 2 50.2 50.1 5% QVESTASTPGPSR 
                56.8 48.7   RTEITIVKPQESGLR 
  Sorting nexin-1 Rat Q99N27  59008 5.15 4 2 65.4 49.9 5% AVGTQALSGAGLLK 
                57.9 50.0   ELALNTALFAK 
  Zyxin Mouse Q62523  60751 6.47 3 2 50.3 49.8 4% GPLSQAPTPAPK 
                67.0 49.1   SPGGPGPLTLK 
  Protein phosphatase 1G Mouse Q61074  58691 4.27 2 2 65.4 50.0 4% ALQDAFLAIDAK 
                83.1 50.0   QLIVANAGDSR 
  
Dihydropyrimidinase-related 
protein 3 Rat Q62952  61928 6.04 3 2 37.6 49.4 4% QIGDNLIVPGGVK 
                45.2 50.1   SAADLISQAR 
  Glucosidase 2 subunit beta Mouse O08795  58756 4.41 2 1 50.1 50.1 4% ESLQQLAEVTR 
                50.3 50.0   KLWEEQQAAAK 
  
Eukaryotic translation initiation 
factor 4B Mouse Q8BGD9  68799 5.47 3 1 46.5 50.1 2% RGDDSFGDKYR 
  
Far upstream element-binding 
protein 1 Rat Q32PX7  67155 7.18 1 1 81.7 49.7 2% IGGNEGIDVPIPR 
  Splicing factor 1 Mouse Q64213  70363 8.98 2 1 52.5 49.9 2% AYIVQLQIEDLTR 
  Calnexin Rat P35565  67213 4.49 1 1 62.5 49.8 3% APVPTGEVYFADSFDR 
  
Peptidyl-prolyl cis-trans isomerase 
FKBP9 Rat Q66H94  63086 4.93 1 1 48.5 49.8 2% LAPGFNAEMIVK 
  Neuroplastin Rat P97546  43904 8.6 1 1 47.7 50.1 3% IVTSEEVIIR 
AR2_2 Cytoskeleton-associated protein 4 Mouse Q8BMK4  63654 5.46 30 17 68.6 52.1 27% DFTSLENTVEER 
                44.6 51.7   DLSDGIHVVK 
                66.0 52.1   ERDFTSLENTVEER 
                53.7 53.0   ERDIEALK 
                38.2 53.3   ISEVLQK 
                57.3 52.9   LALQALTEK 
                43.6 53.0   LQNEILK 
                60.1 52.4   LQNEILKDLSDGIHVVK 
                64.2 52.3   MKVASLEESKGDR 
                42.9 53.0   QIEGLGAR 
                63.1 52.5   QRDELGQGLQGVEQK 
                54.4 52.6   RLEEELQQLK 
                75.5 52.5   SINDNIAIFTDVQK 
                108.6 52.2   SSLQTMESDVYTEVR 
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                79.9 49.6   STAGDTHLGGEDFDNR 
                50.7 50.0   TTPSYVAFTDTER 
                55.9 49.7   TVTNAVVTVPAYFNDSQR 
  Non-muscle caldesmon Rat Q62736  60548 6.34 15 8 59.5 49.9 22% ASGDKEAEGAPQVEAGKR 
                67.1 49.6   GSVFSSPSASGTPNK 
                86.5 49.5   LEQYTNAIEGTK 
                96.6 49.8   QKEFDPTITDGSLSVPSR 
                40.1 50.0   QQEAALELEELK 
                49.4 49.5   QTENAFSPSR 
                69.1 49.6   RGETESEEFEKLK 
                44.1 49.6   SGRYEMEETEVVITSYQK 
  Src substrate cortactin Mouse Q60598  61222 5.24 13 8 39.7 49.9 15% CALGWDHQEK 
                56.2 50.0   ENVFQEHQTLK 
                40.7 50.0   LQLHESQKDYK 
                56.6 49.8   LRENVFQEHQTLK 
                62.4 49.8   NASTFEEVVQVPSAYQK 
                97.6 50.1   QDSSAVGFDYK 
                62.7 49.8   SAVGFEYQGK 
                38.4 49.3   YGIDKDKVDK 
  Protein disulfide-isomerase A4 Rat P38659 72721 5.16 11 7 54.9 49.4 12% FDVSGYPTIK 
                45.0 50.1   FIDEHATKR 
                47.0 49.7   IASTLKDNDPPIAVAK 
                59.5 49.4   RFDVSGYPTLK 
                27.9 49.7   TFDAIVMDPK 
                60.7 49.2   VDATEQTDLAK 
  
Peptidyl-prolyl cis-trans isomerase 
FKBP10 Mouse Q61576  64628 5.38 13 7 58.6 49.0 16% EVQMGDFVR 
                56.2 50.0   GGTYDTYIGSGWLIK 
                68.8 49.1   GLMGMCVNER 
                39.8 49.7   GLQGMCVGER 
                38.9 49.9   IIIPPFLAYGEK 
                100.0 49.8   LFSSHDYEAPQEITLGANK 
                45.1 49.8   QLIVPPHLAHGENGAR 
  Prelamin-A/C Rat P48679  74279 6.54 7 4 46.5 50.0 8% AQHEDQVEQYKK 
                62.8 49.9   ITESEEVVSR 
                69.3 49.8   MQQQLDEYQELLDIK 
                48.6 50.0   SGAQASSTPLSPTR 
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                53.6 52.0   VNVPGSQAQLK 
                50.3 51.9   YLESLGEEQR 
  
Prolyl 4-hydroxylase subunit alpha-
1 Rat P54001  60860 5.63 8 6 52.5 52.5 14% FILAPAKQEDEWDKPR 
                51.9 52.7   GIAVDYLPER 
                52.1 51.9   HAACPVLVGNK 
                68.0 52.3   LLELDPEHQR 
                56.2 52.3   LQDTYNLDTNTISK 
                44.0 52.0   QYFPNDEDQVGAAK 
  Prelamin-A/C Rat P48679  P48679  6.54 10 5 42.5 52.6 9% AQHEDQVEQYKK 
                56.8 52.7   LADALQELR 
                46.6 52.7   LKDLEALLNSK 
                38.7 52.6   LQEKEDLQELNDR 
                45.0 52.7   SGAQASSTPLSPTR 
  
Dihydropyrimidinase-related 
protein 2 Rat P47942  62239 5.95 9 4 48.3 52.4 11% IVLEDGTLHVTEGSGR 
                45.0 52.3   NLHQSGFSLSGAQIDDNIPR 
                49.6 52.1   QIGENLIVPGGVK 
                82.8 52.5   SITIANQTNCPLYVTK 
  
Protein kinase C and casein kinase 
substrate in neurons 2 protein Rat Q9QY17  55943 5.04 8 4 62.5 51.6 10% AGDELTKIEDEDEQGWCK 
                66.1 52.2   AYAQQLTEWAR 
                67.4 52.7   HLDLSNVASYK 
                49.7 51.6   VSELHLEVK 
  Vimentin Rat P31000  53700 5.06 5 2 59.2 52.5 5% KVESLQEEIAFLKK 
                58.3 51.9   LGDLYEEEMR 
  RNA-binding protein FUS Mouse P56959  52642 9.4 6 2 45.4 52.3 6% AAIDWFDGKEFSGNPIK 
                50.2 52.5   LKGEATVSFDDPPSAK 
  Sulfated glycoprotein 1 Rat P10960  61084 5.13 4 2 56.8 52.8 4% LVTDIQTAVR 
                39.6 52.6   QLESNKIPEVDLAR 
  Gamma-glutamyltranspeptidase 1 Rat P07314  61571 7.21 3 2 49.8 52.7 4% LFQPSIQLAR 
                44.0 52.5   VLQEGETVTMPK 
  Brain acid soluble protein 1 Mouse Q91XV3  22074 4.5 2 2 54.5 52.7 16% ETPAASEAPSSAAK 
                49.8 52.1   SDAAPAASDSKPSSAEPAPSSK 
  Abl interactor 1 Rat Q9QZM5  51673 6.57 1 1 62.7 52.5 3% KPIDYTVLDDVGHGVK 
AR3_1 Vinculin Rat P85972  116542 5.83 51 30 67.9 52.3 37% AGEVINQPMMMAAR 
                67.5 52.7   ALASQLQDSLK 
                94.2 52.6   AQQVSQGLDVLTAK 
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                52.8 52.3   SSVSQVESDLK 
                101.3 51.9   TAVDSLVAYSVK 
                78.6 52.6   VASLEESKGDR 
  Stress-induced-phosphoprotein 1 Rat O35814  62530 6.4 32 15 54.5 52.3 26% AAALEFLNRFEEAK 
                52.9 51.7   ALDLDSSCK 
                65.4 52.7   EGLQNMEAR 
                61.4 52.5   ELIEQLQNKPSDLGTK 
                94.6 52.6   IGNSYFKEER 
                47.1 52.5   KAAALEAMKDYTK 
                75.6 52.7   KAAALEFLNR 
                55.6 52.4   KAAALEFLNRFEEAK 
                84.7 52.7   LAYINPDLALEEK 
                66.3 52.8   LMDVGLIAIR 
                51.9 52.7   MEQVNELKEK 
                58.6 52.5   RTYEEGLKHEANNLQLK 
                45.7 51.8   TLLSDPTYR 
                46.1 52.5   TYEEGLKHEANNLQLK 
                40.4 52.5   YKDAIHFYNK 
  
Heterogeneous nuclear 
ribonucleoprotein K Rat P61980  50944 5.39 19 13 53.8 52.2 35% GGDLMAYDR 
                41.5 52.1   GGDLMAYDRR 
                37.6 51.6   GSDFDCELR 
                69.3 52.5   GSYGDLGGPIITTQVTIPK 
                74.8 52.6   IDEPLEGSEDR 
                97.6 52.4   IITITGTQDQIQNAQYLLQNSVK 
                51.1 51.7   LFQECCPHSTDR 
                52.7 52.5   LLIHQSLAGGIIGVK 
                44.2 51.9   NLPLPPPPPPR 
                54.9 51.7   NTDEMVELR 
                72.4 52.2   RPAEDMEEEQAFKR 
                71.8 51.9   TDYNASVSVPDSSGPER 
                52.8 51.6   VVLIGGKPDR 
  Nucleobindin-1 Rat Q63083  53474 5.04 11 7 54.1 52.7 18% DLELLIQTATR 
                41.6 52.6   ELQQAVLQMEQR 
                50.0 52.4   KVPEQPPVLPQLDSQHL 
                51.2 52.8   LQAANAEDIK 
                67.3 52.7   LSQETEALGR 
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                59.8 52.3   AVAGNISDPGLQK 
                65.3 52.3   CDRVDQLAAQLADLAAR 
                69.1 51.5   EAFQPQEPDFPPPPPDLEQLR 
                59.3 52.5   ELLPVLISAMK 
                64.5 52.5   ETVQTTEDQILK 
                101.4 51.8   GILEYLTVAEVVETMEDLVTYTK 
                93.0 51.9   GWLRDPNASPGDAGEQAIR 
                42.0 52.8   IPTISTQLK 
                59.2 52.5   KIAELCDDPKER 
                105.7 51.6   KIDAAQNWLADPNGGPEGEEQIR 
                109.8 52.2   LVQAAQMLQSDPYSVPAR 
                64.8 52.0   MALLMAEMSR 
                92.6 51.8   MLGQMTDQVADLR 
                89.3 52.5   MSAEINEIIR 
                85.3 51.9   MTGLVDEAIDTK 
                45.6 53.0   NQGIEEALK 
                48.0 51.5   QILDEAGK 
                79.1 52.7   QVATALQNLQTK 
                47.1 53.0   SFLDSGYR 
                57.9 52.7   SLGEIAALTSK 
                92.2 52.7   SLLDASEEAIKK 
                48.2 52.1   TISPMVMDAK 
                106.8 50.9   TQMQEAMTQEVSDVFSDTTTPIK 
                71.0 52.5   VDQLAAQLADLAAR 
                64.1 52.7   VGELCAGKER 
                93.4 52.0   VLQLTSWDEDAWASK 
                67.0 52.4   WIDNPTVDDR 
  Endoplasmin Rat Q66HD0  92713 4.72 47 27 50.0 52.4 36% DISTNYYASQK 
                85.0 52.1   EATEKEFEPLLNWMK 
                35.8 52.2   EFEPLLNWMK 
                46.9 50.9   EGSRTDDEVVQREEEAIQLDGLNASQIR 
                67.3 51.5   EGVKFDESEK 
                67.1 52.0   EGVKFDESEKSK 
                84.4 52.6   ELISNASDALDK 
                88.8 52.7   ELISNASDALDKIR 
                43.6 51.5   FAFQAEVNR 
                116.8 51.4   FQSSHHSTDITSLDQYVER 
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                33.8 52.8   GLFDEYGSK 
                80.9 52.4   GVVDSDDLPLNVSR 
                50.6 50.8   GYEVIYLTEPVDEYCIQALPEFDGKR 
                43.2 52.6   IYFMAGSSR 
                84.8 52.1   KEAESSPFVER 
                79.9 50.9   KGYEVIYLTEPVDEYCIQALPEFDGK 
                59.8 50.9   KGYEVIYLTEPVDEYCIQALPEFDGKR 
                41.4 52.8   KTFEINPR 
                42.8 52.6   KTLDMIK 
                75.2 51.6   LGVIEDHSNR 
                127.8 52.3   LISLTDENALAGNEELTVK 
                97.1 51.1   LTESPCALVASQYGWSGNMER 
                40.9 52.3   NLLHVTDTGVGMTREELVK 
                58.0 51.2   SGTSEFLNK 
                55.6 51.9   SGYLLPDTK 
                51.7 52.8   SILFVPTSAPR 
                90.1 51.5   TDDEVVQREEEAIQLDGLNASQIR 
  Alpha-actinin-4 Rat Q9QXQ0  104849 5.27 37 17 68.8 51.9 26% ACLISLGYDVENDR 
                64.1 51.9   AGTQIENIDEDFRDGLK 
                67.2 51.5   ASFNHFDKDHGGALGPEEFK 
                57.8 52.3   DGLAFNALIHR 
                122.6 51.7   ETTDTDTADQVIASFK 
                65.1 51.7   GISQEQMQEFR 
                67.3 52.3   HRDYETATLSDIK 
                77.2 51.9   ICDQWDNLGSLTHSR 
                45.8 52.1   KAGTQIENIDEDFRDGLK 
                124.6 52.2   KDDPVTNLNNAFEVAEK 
                137.4 52.4   LSGSNPYTSVTPQIINSK 
                111.5 51.9   MAPYQGPDAAPGALDYK 
                85.1 52.5   QLETIDQLHLEYAK 
                74.7 52.2   RDHALLEEQSK 
                102.2 52.6   VLAGDKNFITAEELR 
                68.1 51.5   VLAVNQENEHLMEDYER 
                32.4 50.4   VQQLVPK 
  Alpha-actinin-1 Rat Q9Z1P2  102896 5.23 39 17 92.0 51.1 31% ACLISLGYDIGNDPQGEAEFAR 
                49.0 52.0   AGTQIENIEEDFRDGLK 
                64.5 51.7   GISQEQMNEFR 
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                50.7 52.5   HRPELIDYGK 
                96.2 52.2   ICDQWDNLGALTQK 
                64.9 52.0   IDQLEGDHQLIQEALIFDNK 
                68.4 52.4   ILAGDKNYITGDELR 
                44.6 52.8   IMSIVDPNR 
                80.4 52.1   ISIEMHGTLEDQLSHLR 
                118.0 52.1   KDDPLTNLNTAFDVAER 
                71.6 52.1   LAILGIHNEVSK 
                38.5 49.8   MDHYDSQQTNDYMQPEEDWDRDLLLDPAWEK 
                47.4 52.1   MLDAEDIVGTARPDEK 
                70.4 51.3   MVSDINNAWGCLEQAEK 
                113.0 52.5   QFGAQANVIGPWIQTK 
                68.8 52.2   QKDYETATLSEIK 
                55.2 51.5   VLAVNQENEQLMEDYEK 
  
Transitional endoplasmic reticulum 
ATPase Rat P46462  89293 5.14 18 12 130.3 52.4 23% ASGADSKGDDLSTAILK 
                63.2 52.0   ETVVEVPQVTWEDIGGLEDVKR 
                54.0 52.6   EVDIGIPDATGR 
                46.4 52.6   IVSQLLTLMDGLK 
                48.2 52.8   KGDIFLVR 
                63.9 50.4   LADDVDLEQVANETHGHVGADLAALCSEAALQAIR 
                69.7 52.7   LAGESESNLR 
                101.1 52.2   LIVDEAINEDNSVVSLSQPK 
                50.9 51.4   MDELQLFR 
                106.1 52.5   NAPAIIFIDELDAIAPK 
                55.5 52.1   VINQILTEMDGMSTK 
                63.9 52.6   WALSQSNPSALR 
  Nucleolin  Rat P13383  77101 4.67 13 11 40.3 51.0 18% ALVPTPGKK 
                51.1 52.2   ATFIKVPQNPHGK 
                45.4 52.3   EVFEDAVEIR 
                82.9 51.6   FGYVDFESAEDLEK 
                64.7 51.9   GYAFIEFASFEDAK 
                113.6 52.0   KFGYVDFESAEDLEK 
                59.5 52.1   NLSFNITEDELK 
                100.9 52.1   QKIEGSEPTTPFNLFIGNLNPNK 
                43.4 52.3   SKGIAYIEFK 
                51.0 52.7   SVSLYYTGEK 
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                52.2 52.5   VAISELFAK 
  Calnexin Rat P35565  67213 4.49 21 10 82.9 51.5 19% APVPTGEVYFADSFDR 
                50.1 52.7   GSLSGWILSK 
                53.1 51.1   KDDTDDEIAKYDGKWEVDEMK 
                96.6 52.2   KIPNPDFFEDLEPFR 
                54.2 52.4   KPEDWDERPK 
                73.8 51.8   VTYKAPVPTGEVYFADSFDR 
                88.3 52.2   VVDDWANDGWGLK 
                47.8 52.1   WKPPMIDNPNYQGIWKPR 
                43.2 52.0   YDGKWEVDEMK 
                67.6 51.6   YDGKWEVDEMKETK 
  Glucosidase 2 subunit beta Mouse O08795  58756 4.41 13 10 67.4 52.6 18% EKESLQQLAEVTR 
                78.0 52.7   ESLQQLAEVTR 
                63.0 52.2   ETVVTSTTEPSR 
                42.4 52.9   KILIEEWK 
                82.0 52.7   KLWEEQQAAAK 
                40.9 52.8   LLELQAGK 
                43.3 52.7   LWEEQQAAAK 
                101.9 51.4   MPPYDEETQAIIDAAQEAR 
                51.5 52.1   SLKEMEESIR 
                67.8 51.3   YEQGTGCWQGPNR 
  Heat shock protein HSP 90-beta Rat P34058  83229 4.97 13 9 71.1 52.6 16% ADLINNLGTIAK 
                49.7 52.2   EQVANSAFVER 
                75.9 52.6   GVVDSEDLPLNISR 
                76.3 52.4   HLEINPDHPIVETLR 
                97.9 51.3   NPDDITQEEYGEFYK 
                76.3 52.3   TLTLVDTGIGMTK 
                56.0 52.4   VILHLKEDQTEYLEER 
                40.9 51.9   YESLTDPSKLDSGK 
                51.8 51.8   YIDQEELNK 
  
Transcription intermediary factor 
1-beta Rat O08629  88900 5.52 10 8 46.3 51.9 17% FQWDLNAWTK 
                55.2 52.2   IVAERPGTNSTGPGPMAPPR 
                75.8 50.3   LASPSGSTSSGLEVVAPEVTSAPVSGPGILDDSATICR 
                96.2 52.5   LDLDLTSDSQPPVFK 
                96.4 52.0   LSPPYSSPQEFAQDVGR 
                110.7 52.6   LTEDKADVQSIIGLQR 
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                75.2 52.0   SGEGEVSGLMR 
                79.2 52.2   VFPGSTTEDYNLIVIER 
  Kinesin-1 heavy chain Rat Q2PQA9  109463 6.06 10 8 49.9 51.7 11% HVAVTNMNEHSSR 
                42.9 52.6   ILQDSLGGNCR 
                66.9 52.5   ISFLENNLEQLTK 
                73.9 52.0   QAVEQQIQSHR 
                72.1 51.8   QLDDKDEEINQQSQLVEK 
                102.1 52.2   QLEESVDSLGEELVQLR 
                68.0 52.7   SATLASIDAELQK 
                63.3 52.7   TGAEGAVLDEAK 
  
Splicing factor, proline- and 
glutamine-rich Mouse Q8VIJ6  75394 9.45 13 8 69.3 51.4 18% DKLESEMEDAYHEHQANLLR 
                86.1 52.3   FGQGGAGPVGGQGPR 
                50.4 52.7   GIVEFASKPAAR 
                70.7 52.2   LFVGNLPADITEDEFKR 
                44.9 51.6   MPGGPKPGGGPGMGAPGGHPKPPHR 
                56.3 51.8   RMEELHSQEMQK 
                49.0 52.0   SPPPGMGLNQNR 
                59.1 51.8   YGEPGEVFINK 
  Catenin alpha-1 Mouse P26231  100044 5.91 11 7 61.8 52.1 11% AHVLAASVEQATENFLEKGDK 
                83.2 52.3   IAEQVASFQEEK 
                91.3 52.1   LIEVANLACSISNNEEGVK 
                90.9 52.5   LLEPLVTQVTTLVNTNSK 
                55.7 52.2   LLILADMADVYK 
                57.8 52.6   QDLLAYLQR 
                65.3 52.5   QIIVDPLSFSEER 
  Calpastatin Rat P27321  77266 5.09 12 5 54.0 51.7 9% DKELDDALDELSDSLGQR 
                46.2 52.5   GVVPDDAVETLAR 
                83.6 52.4   QPDPQSHLR 
                54.9 52.6   SLTPTLPMESTLNK 
                53.2 52.0   SQSSEPPVIHEK 
  Importin-5 Mouse Q8BKC5  123511 4.82 9 5 53.7 51.7 7% HIVENAVQK 
                61.6 52.1   LLSSAFDEVYPALPSDVQTAIK 
                81.2 52.1   STACQMLVCYAK 
                64.8 52.5   VAAAESMPLLLECAR 
                85.8 52.4   VIAALLQTMEDQGNQR 
  Caprin-1 Rat Q5M9G3  78073 5.14 7 5 55.0 52.4 13% QILGVIDKK 
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                66.3 52.1   SFMALSQDIQK 
                122.6 51.1   SSFSNTPNSGYTQSQFNAPR 
                44.2 50.2   SSGPPPPSGSSGSEAAAGAAAPASQHPATGTGAVQTEAMK 
                51.9 52.3   YQEVTNNLEFAK 
  Drebrin Rat Q07266  77424 4.46 6 5 54.2 52.1 11% KSESEVEEAAAIIAQRPDNPR 
                61.0 51.9   LAASGEGGLQELSGHFENQK 
                65.1 52.0   LREDENAEPVGTTYQK 
                53.8 51.6   LSSPVLHR 
                78.1 52.4   YVLINWVGEDVPDAR 
  78 kDa glucose-regulated protein Rat P06761  72302 5.07 6 4 92.0 52.6 9% IINEPTAAAIAYGLDKR 
                81.7 52.6   KSDIDEIVLVGGSTR 
                49.0 52.3   TFAPEEISAMVLTK 
                69.1 52.4   TWNDPSVQQDIK 
  
Heterogeneous nuclear 
ribonucleoprotein U Mouse Q8VEK3  87863 5.92 5 4 40.5 51.3 7% DIDIHEVR 
                41.5 52.3   DLPEHAVLK 
                53.6 51.2   EKPYFPIPEDCTFIQNVPLEDR 
                108.8 52.5   SSGPTSLFAVTVAPPGAR 
  Integrin beta-1 Rat P49134  88436 5.77 5 4 48.6 51.6 6% IGFGSFVEK 
                52.5 52.5   LRPEDITQIQPQQLLLK 
                74.6 51.6   SLGTDLMNEMR 
                61.4 51.8   WDTGENPIYK 
  
Ubiquitin-like modifier-activating 
enzyme 1 Rat Q5U300  117713 5.36 2 2 69.1 52.4 3% LAGTQPLEVLEAVQR 
                159.2 52.0   NEEDATELVTLAQAVNAR 
  Heat shock protein 105 kDa Rat Q66HA8  96357 5.4 3 2 52.6 52.0 3% DLLNMYIETEGK 
                81.2 52.3   GCALQCAILSPAFK 
 Catenin delta-1 Mouse P30999  104860 6.41 3 2 41.8 52.6 2% QDVYGPQPQVR 
  
Lon protease homolog, 
mitochondrial Rat Q924S5  105726 6.17 2 1 92.1 52.4 2% VLFICTANVTDTIPEPLR 
  
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 Mouse Q00PI9  84948 4.83 2 1 67.8 52.3 2% YNVLGAETVLTQMR 
  Transmembrane glycoprotein NMB Rat Q6P7C7  63691 6.67 1 1 92.6 50.9 3% GWSSDENEWDEQLYPVWR 
  Ankycorbin Rat Q5U312  109066 5.81 2 1 58.1 52.7 1% EKENIQTLLK 
  Src substrate cortactin Mouse Q60598  61222 5.24 2 1 50.1 52.5 2% YGLFPANYVELR 
  Gelsolin Rat Q68FP1  86014 5.76 1 1 65.3 52.6 2% AGALNSNDAFVLK 
  Lysosome membrane protein 2 Rat P27615  54056 4.91 1 1 66.0 52.3 3% KLDDFVETGNIR 
  Importin subunit beta-1 Rat P52296  97062 4.66 1 1 54.3 52.1 1% VLANPGNSQVAR 
  
LIM domain and actin-binding 
protein 1 Mouse Q9ERG0  84038 6.18 1 1 49.5 52.5 1% LSETSIKDR 
216
 KCL Proteomics Facility, Institute of Psychiatry www.iop.kcl.ac.uk/proteomics 17 
AR3_2 Actin, cytoplasmic 1 Rat P60711  41710 5.29 40 15 72.2 52.5 59% AGFAGDDAPR 
                60.5 52.5   AVFPSIVGRPR 
                65.7 50.9   DDDIAALVVDNGSGMCK 
                36.2 51.6   DLTDYLMK 
                120.4 51.0   DLYANTVLSGGTTMYPGIADR 
                44.9 51.4   DSYVGDEAQSK 
                56.1 52.7   EITALAPSTMK 
                52.2 52.1   GYSFTTTAER 
                79.0 52.3   HQGVMVGMGQK 
                61.5 52.1   IWHHTFYNELR 
                101.8 51.6   KDLYANTVLSGGTTMYPGIADR 
                124.0 50.8   LCYVALDFEQEMATAASSSSLEK 
                98.3 51.5   QEYDESGPSIVHR 
                89.8 52.0   SYELPDGQVITIGNER 
                81.7 50.8   TTGIVMDSGDGVTHTVPIYEGYALPHAILR 
  Fructose-bisphosphate aldolase A Rat P05065  39327 8.31 19 14 85.1 51.9 52% AAQEEYIKR 
                44.8 52.5   ADDGRPFPQVIK 
                63.7 52.6   ALANSLACQGK 
                52.4 51.1   ELADIAHR 
                122.9 51.8   FSNEEIAMATVTALR 
                73.9 52.5   GILAADESTGSIAK 
                82.8 51.4   GVVPLAGTNGETTTQGLDGLSER 
                103.4 51.8   IGEHTPSSLAIMENANVLAR 
                80.5 51.8   LQSIGTENTEENR 
                53.4 51.9   LQSIGTENTEENRR 
                42.9 52.3   PHPYPALTPEQK 
                51.9 51.9   RLQSIGTENTEENRR 
                61.4 50.8   YASICQQNGIVPIVEPEILPDGDHDLK 
                65.6 50.9   YTPSGQSGAAASESLFISNHAY 
  Phosphoglycerate kinase 1 Rat P16617  44510 8.02 19 13 59.2 52.1 40% AHSSMVGVNLPQK 
                81.4 52.5   ALESPERPFLAILGGAK 
                46.0 50.8   FCLDNGAK 
                47.1 52.8   FHVEEEGK 
                97.2 51.2   GCITIIGGGDTATCCAK 
                88.3 51.7   ITLPVDFVTADKFDENAK 
                45.6 52.1   KYAEAVAR 
                84.1 51.5   LGDVYVNDAFGTAHR 
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                52.7 52.9   LTLDKLDVK 
                117.0 51.0   VLNNMEIGTSLYDEEGAK 
                97.6 52.2   VSHVSTGGGASLELLEGK 
                87.7 51.3   WNTEDKVSHVSTGGGASLELLEGK 
                55.9 52.5   YSLEPVAAELK 
  Annexin A2 Rat Q07936  38654 7.55 15 13 123.7 51.1 41% AEDGSVIDYELIDQDAR 
                55.5 52.8   DALNIETAIK 
                43.2 51.6   DIISDTSGEFR 
                101.4 51.8   GLGTDEDSLIEIICSR 
                93.5 52.5   GVDEVTIVNILTNR 
                57.4 51.5   KLLVALAK 
                67.3 51.2   RAEDGSVIDYELIDQDAR 
                68.2 52.5   SALSGHLETVMLGLLK 
                57.6 52.5   STVHEILCK 
                45.7 51.8   SYSPYDMLESIR 
                77.4 51.6   TDLEKDIISDTSGEFR 
                70.8 52.5   TNQELQEINR 
                79.7 51.6   TPAQYDASELK 
  
Glyceraldehyde-3-phosphate 
dehydrogenase Rat P04797  35805 8.14 17 8 60.5 52.1 41% GAAQNIIPASTGAAK 
                107.3 51.8   IVSNASCTTNCLAPLAK 
                77.9 50.7   LISWYDNEYGYSNR 
                104.5 51.6   VIHDNFGIVEGLMTTVHAITATQK 
                44.2 51.7   VIISAPSADAPMFVMGVNHEK 
                91.9 51.7   VPTPNVSVVDLTCR 
                70.5 52.0   VVDLMAYMASKE 
                99.5 50.9   WGDAGAEYVVESTGVFTTMEK 
  Annexin A1 Rat P07150  38805 6.97 10 8 61.7 52.3 25% AAYLQETGKPLDETLKK 
                46.9 51.9   CATSTPAFFAEK 
                110.7 52.5   GLGTDEDTLIEILTTR 
                81.8 52.2   GTDVNVFNTILTTR 
                89.6 52.3   KGTDVNVFNTILTTR 
                39.1 51.3   KVFQNYR 
                72.6 52.0   QEQEYVQAVK 
                101.6 52.2   TPAQFDADELR 
  Nucleophosmin Rat P13084  32540 4.62 9 7 63.6 50.9 35% ADKDYHFKVDNDENEHQLSLR 
                47.8 52.4   DLKPSTPR 
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                43.2 53.0   GPSSVEDIK 
                73.1 52.3   MSVQPTVSLGGFEITPPVVLR 
                125.4 51.2   MTDQEAIQDLWQWR 
                112.7 51.0   TVSLGAGAKDELHIVEAEAMNYEGSPIK 
                103.0 51.4   VDNDENEHQLSLR 
  Macrophage-capping protein Rat Q6AYC4  38775 6.11 11 7 47.7 51.9 37% AQVEIITDGEEPAEMIQVLGPKPALK 
                58.4 52.6   EGGVESAFHK 
                109.5 50.8   EGNPEEDITADQTNAQAAALYK 
                99.4 51.0   EVQGNESDLFMSYFPQGLK 
                46.3 51.0   MYTPIPQSGSPFPASVQDPGLHIWR 
                82.0 51.9   VSDATGQMNLTK 
                87.5 52.4   YSPNTQVEILPQGR 
  
Malate dehydrogenase, 
mitochondrial Rat P04636  35661 8.93 8 6 40.9 51.7 25% EGVIECSFVQSK 
                74.5 51.9   ETECTYFSTPLLLGK 
                46.5 52.3   GYLGPEQLPDCLK 
                55.2 52.6   IFGVTTLDIVR 
                55.0 52.8   IQEAGTEVVK 
                116.2 51.9   LTLYDIAHTPGVAADLSHIETR 
  Poly(rC)-binding protein 1 Mouse P60335  37474 6.66 6 6 69.7 52.5 24% AITIAGVPQSVTECVK 
                95.0 51.1   ESTGAQVQVAGDMLPNSTER 
                65.1 52.7   IITLTGPTNAIFK 
                71.1 52.1   INISEGNCPER 
                64.5 52.7   QGANINEIR 
                109.3 51.9   QICLVMLETLSQSPQGR 
  Elongation factor 1-delta Rat Q68FR9  31311 4.94 8 6 46.4 51.6 25% ATAPQTQHVSPMR 
                46.6 52.3   ATNFLMHEK 
                83.8 51.5   FYEQMNGPVTAGSR 
                70.0 52.6   GVVQDLQQAISK 
                41.1 52.8   QENGASVILR 
                61.6 52.7   SIQLDGLVWGASK 
  
Heterogeneous nuclear 
ribonucleoprotein A3 Rat Q6URK4  39628 9.1 8 5 64.5 52.1 19% EDSVKPGAHLTVK 
                55.0 52.2   IETIEVMEDR 
                43.7 52.0   IFVGGIKEDTEEYNLR 
                145.2 50.8   SSGSPYGGGYGSGGGSGGYGSR 
                45.9 51.5   YHTINGHNCEVK 
  Alcohol dehydrogenase [NADP+]  Rat P51635  36483 6.84 7 5 50.5 51.6 16% ALGLSNFSSR 
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                64.0 52.1   AWRHPDEPVLLEEPVVLALAEK 
                62.4 52.3   HPDEPVLLEEPVVLALAEK 
                52.3 52.8   MPLIGLGTWK 
                54.8 51.9   YIVPMITVDGK 
  
Thioredoxin domain-containing 
protein 5 Mouse Q91W90  46386 5.51 7 4 61.6 52.1 15% ALAPTWEQLALGLEHSETVK 
                62.3 52.6   DLDSLHSFVLR 
                82.0 52.2   SFEDTIAQGITFVK 
                93.5 50.9   VDCTADSDVCSAQGVR 
  LIM and SH3 domain protein 1 Rat Q99MZ8  29951 6.61 5 4 63.0 52.4 18% GFSVVADTPELQR 
                78.4 52.6   LKQQSELQSQVR 
                63.0 51.8   QSFTMVADTPENLR 
                51.0 52.8   TQDQISNIK 
  
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial Rat Q99NA5  39588 6.47 6 4 48.4 52.6 14% APIQWEER 
                72.6 51.2   ENTEGEYSGIEHVIVDGVVQSIK 
                60.6 52.6   IAEFAFEYAR 
                65.4 52.4   TPYTDVNIVTIR 
  
Alpha-2-macroglobulin receptor-
associated protein Rat Q99068  42006 6.85 4 4 89.8 52.1 14% HVESIGDPEHISR 
                46.5 52.6   IHEYNVLLDTLSR 
                78.5 51.4   KVSHQGYGPATEFEEPR 
                53.2 51.4   LAELHSDLK 
  PDZ and LIM domain protein 1 Rat P52944  35562 6.79 5 4 50.1 52.6 18% DFEQPLAISR 
                55.1 51.8   MNLASEPQEVLHIGSAHNR 
                59.5 52.1   SAMPFTASPAPGTR 
                49.8 52.1   TTQQIVLQGPGPWGFR 
  Poly(rC)-binding protein 2 Mouse Q61990  38197 6.33 5 3 54.8 52.5 12% AITIAGIPQSIIECVK 
                51.7 52.7   IITLAGPTNAIFK 
                65.0 52.6   LVVPASQCGSLIGK 
  
Nascent polypeptide-associated 
complex subunit alpha Mouse Q60817  23370 4.52 3 3 74.5 52.2 19% DIELVMSQANVSR 
                124.8 52.3   IEDLSQQAQLAAAEK 
                73.9 52.4   NILFVITKPDVYK 
  Reticulocalbin-1 Mouse Q05186  38090 4.7 5 3 76.0 51.5 14% HWILPQDYDHAQAEAR 
                84.2 51.8   IVDRIDSDGDGLVTTEELK 
                67.2 51.5   TFDQLSPDESK 
  60S acidic ribosomal protein P0 Rat P19945  34194 5.91 5 3 54.0 52.0 11% GHLENNPALEK 
                48.6 52.6   GTIEILSDVQLIK 
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DnaJ homolog subfamily B 
member 1  Mouse Q9QYJ3  38143 8.75 2 1 62.8 51.9 5% EGDQTSNNIPADIVFVLK 
  
Isocitrate dehydrogenase [NADP] 
cytoplasmic Rat P41562  46705 6.53 1 1 83.3 52.1 3% TVEAEAAHGTVTR 
  L-lactate dehydrogenase A chain Rat P04642  36427 8.45 2 1 60.7 52.0 3% QVVDSAYEVIK 
  UBX domain-containing protein 1 Rat Q499N6  33561 5.22 2 1 78.3 52.3 5% AELTALESLIEMGFPR 
  Aldose reductase Rat P07943  35774 6.26 3 1 51.9 52.5 4% AIGVSNFNPLQIER 
  
Protein kinase C delta-binding 
protein Rat Q9Z1H9  27894 5.79 1 1 68.4 52.4 6% KGSEAAQPTPVKPPR 
  
Transcriptional activator protein 
Pur-alpha (Fragments) Rat P86252  15313 4.69 1 1 67.8 52.1 17% GPGLGSTQGQTIALPAQGLIEFR 
  
Peroxisomal 3,2-trans-enoyl-CoA 
isomerase Rat Q5XIC0  42994 9.11 1 1 65.0 52.5 3% WDAWNALGSLPK 
  Calponin-3 Rat P37397  36412 5.47 1 1 62.4 51.9 3% GPSYGLSAEVK 
  
3-ketoacyl-CoA thiolase B, 
peroxisomal Rat P07871  43793 8.53 1 1 62.2 52.4 4% IAQFLSGIPETVPLSAVNR 
  Brain acid soluble protein 1 Mouse Q91XV3  22074 4.5 1 1 61.4 52.3 6% ETPAASEAPSSAAK 
  Protein disulfide-isomerase Rat P04785  56916 4.82 1 1 59.3 51.5 2% YKPESDELTAEK 
  Malate dehydrogenase, cytoplasmic Rat O88989  36460 6.16 1 1 59.0 52.1 4% FVEGLPINDFSR 
  
Isocitrate dehydrogenase [NADP], 
mitochondrial Rat P56574  50935 8.88 1 1 83.3 52.1 3% GKLDGNQDLIR 




protein alph Rat O70593  34136 5.05 1 1 46.1 51.6 3% HAEAVAYYK 
AR3_3 
Peptidyl-prolyl cis-trans isomerase 
A Mouse P17742  17960 7.74 26 12 52.4 48.3 71% EGMNIVEAMER 
                48.6 48.7   FEDENFILK 
                111.7 48.0   HTGPGILSMANAGPNTNGSQFFICTAK 
                68.8 48.4   IIPGFMCQGGDFTR 
                54.2 49.8   KITISDCGQL 
                70.7 48.2   MVNPTVFFDITADDEPLGR 
                87.1 48.5   SIYGEKFEDENFILK 
                36.8 50.1   TEWLDGK 
                77.0 49.2   VKEGMNIVEAMER 
                69.6 48.4   VNPTVFFDITADDEPLGR 
                52.1 48.9   VSFELFADK 
                47.9 49.4   VSFELFADKVPK 
  
Cellular retinoic acid-binding 
protein 1 Mouse P62965  15582 5.3 10 8 47.5 50.3 55% ALGVNAMLR 
                79.7 48.8   IHCTQTLLEGDGPK 
                101.2 49.9   KVAVAAASKPHVEIR 
                51.7 49.9   PNFAGTWK 
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                60.2 52.6   TSFFQALGITTK 
  
Leucine-rich repeat-containing 
protein 59 Rat Q5RJR8  34848 9.57 3 3 117.7 51.6 14% DKLDGNELDLSLSDLNEVPVK 
                57.8 52.7   LQQLPADFGR 
                43.2 52.8   LVTLPVSFAQLK 
  Tropomyosin beta chain Rat P58775  32817 4.66 3 3 78.9 52.2 15% ATDAEADVASLNR 
                57.8 51.8   LDKENAIDRAEQAEADKK 
                66.1 52.4   QLEEEQQALQK 
  
26S protease regulatory subunit 
10B Mouse P62334  44145 7.1 3 3 75.0 52.5 10% ALQSVGQIVGEVLK 
                69.2 52.4   EVIELPLTNPELFQR 
                42.8 51.8   IHAGPITK 
  Cathepsin L1 Rat P07154  37636 6.37 4 2 75.2 51.4 7% FDQTFNAQWHQWK 
        55.4 52.6   LFQEPLMLQIPK 
                    
  
Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial Mouse Q9Z2I8  46811 6.58 3 2 86.0 51.8 7% MAENLGFLGSLK 
                88.9 52.3   SSGLPITSAVDLEDAAK 
  
Heterogeneous nuclear 
ribonucleoprotein A/B Mouse Q99020  30812 7.68 4 2 45.6 52.8 8% DLKDYFTK 
                72.1 52.5   IFVGGLNPEATEEK 
  SPARC Rat P16975  34274 4.81 3 2 75.2 52.5 10% RLEAGDHPVELLAR 
                123.3 51.7   YIAPCLDSELTEFPLR 
  Vimentin Rat P31000  53700 5.06 3 2 57.9 51.7 4% FADLSEAANR 
                79.6 52.7   QDVDNASLAR 
  Septin-2 Rat Q91Y81  41566 6.15 2 2 75.2 52.5 8% ASIPFSVVGSNQLIEAK 
                48.8 52.2   TIISYIDEQFER 
  Alpha-enolase Rat P04764  47098 6.16 2 2 57.3 52.2 6% GNPTVEVDLYTAK 
                59.7 52.1   YITPDQLADLYK 
  Adenosine deaminase Rat Q920P6  39874 5.32 2 2 40.7 52.7 7% AQTPAFNKPK 
                63.8 52.4   GIDLPADTVEGLR 
  
Heterogeneous nuclear 
ribonucleoprotein D0 Rat Q9JJ54  38168 7.62 2 2 52.0 51.4 7% FGDVVDCTLK 
                54.2 52.5   IFVGGLSPDTPEEK 
  Ribonuclease inhibitor Rat P29315  49942 4.67 2 1 122.2 51.6 5% TNELGDAGVGLVLQGLQNPTCK 
  TAR DNA-binding protein 43 Mouse Q921F2  44519 6.26 1 1 120.2 51.2 4% FGGNPGGFGNQGGFGNSR 
  Cathepsin B Rat P00787  37446 5.36 1 1 104.5 51.5 5% VGFSEDINLPESFDAR 
  
Heterogeneous nuclear 
ribonucleoproteins A2/B1 Rat A7VJC2  37455 8.97 2 1 57.4 51.8 4% GGGGNFGPGPGSNFR 
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                48.6 48.7   QDGDQFYIK 
                46.7 49.2   SLPTWENENK 
                76.5 48.6   SSENFDELLK 
                70.3 49.9   VAVAAASKPHVEIR 
  Galectin-1 Mouse P16045  14856 5.32 16 7 97.0 48.8 60% ACGLVASNLNLKPGECLK 
                90.2 48.6   DSNNLCLHFNPR 
                112.4 48.5   FNAHGDANTIVCNTK 
                110.4 48.2   LNMEAINYMAADGDFK 
                36.3 49.0   LPDGHEFK 
                54.8 49.0   LPDGHEFKFPNR 
                46.9 50.1   SFVLNLGK 
  
Eukaryotic translation initiation 
factor 5A-1 Mouse P63242 16821 5.08 11 7 108.0 48.1 67% ADDLDFETGDAGASATFPMQCSALR 
                49.5 49.3   EDLRLPEGDLGK 
                80.2 48.9   EDLRLPEGDLGKEIEQK 
                48.4 49.0   IVEMSTSK 
                57.0 48.3   KYEDICPSTHNMDVPNIK 
                96.6 48.2   NDFQLIGIQDGYLSLLQDSGEVR 
                76.5 49.7   VHLVGIDIFTGK 
  
Histidine triad nucleotide-binding 
protein 1 Mouse P70349 13768 6.36 8 6 59.6 49.6 73% AQVAQPGGDTIFGK 
                53.8 50.3   CAADLGLK 
                71.9 48.8   CLAFHDISPQAPTHFLVIPK 
                63.0 50.3   KCAADLGLK 
                87.1 48.3   KHISQISVADDDDESLLGHLMIVGK 
                34.0 48.2   MVVNEGADGGQSVYHIHLHVLGGR 
  Actin, cytoplasmic 1 Mouse P607110 41710 5.29 8 5 65.5 48.2 19% DDDIAALVVDNGSGMCK 
                75.1 48.3   DLYANTVLSGGTTMYPGIADR 
                41.7 49.9   EITALAPSTMK 
                79.3 48.3   KDLYANTVLSGGTTMYPGIADR 
                113.4 48.0   LCYVALDFEQEMATAASSSSLEK 
  Profilin-1 Mouse P62962  14948 8.46 15 5 46.8 48.1 50% CYEMASHLR 
                64.0 49.3   DSPSVWAAVPGK 
                67.9 49.3   SSFFVNGLTLGGQK 
                55.0 48.7   STGGAPTFNVTVTMTAK 
                109.4 49.6   TFVSITPAEVGVLVGKDR 
  Nucleoside diphosphate kinase B Mouse Q01768  17352 6.97 10 5 81.0 49.0 44% EIHLWFKPEELIDYK 
                49.7 48.7   GDFCIQVGR 
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                86.7 48.8   NIIHGSDSVESAEK 
                75.0 50.1   TFIAIKPDGVQR 
                66.6 49.0   VMLGETNPADSKPGTIR 
  Myosin light polypeptide 6 Mouse Q60605  16919 4.56 7 5 72.3 49.4 42% ALGQNPTNAEVLK 
                61.8 48.9   HVLVTLGEK 
                48.2 48.7   ILYSQCGDVMR 
                98.5 48.4   NKDQGTYEDYVEGLR 
                44.2 48.6   VFDKEGNGTVMGAEIR 
  40S ribosomal protein S19  Mouse Q9CZX8  16076 10.4 8 5 42.1 49.6 30% DVNQQEFVR 
                62.7 48.4   ELAPYDENWFYTR 
                50.2 49.9   LKVPEWVDTVK 
                50.5 49.4   RVLQALEGLK 
                47.5 50.0   VPEWVDTVK 
  
Fatty acid-binding protein, 
epidermal Mouse Q05816  15127 6.14 10 4 63.2 50.3 33% ASLKDLEGK 
                51.1 49.3   ELGVGLALR 
                40.0 48.2   LMESHGFEEYMK 
                69.8 48.1   MIVECVMNNATCTR 
  40S ribosomal protein S14 Mouse P62264  16263 10.1 5 4 61.5 49.2 19% IEDVTPIPSDSTR 
                59.3 49.2   IGRIEDVTPIPSDSTR 
                76.7 49.4   TKTPGPGAQSALR 
                73.0 48.8   TPGPGAQSALR 
  40S ribosomal protein S25 Mouse P62852  13734 10.1 5 4 54.3 50.2 24% AALQELLSK 
                67.1 49.9   DKLNNLVLFDK 
                58.0 49.5   LITPAVVSER 
                50.2 50.1   LNNLVLFDK 
  Superoxide dismutase [Cu-Zn] Mouse P08228  15933 6.02 6 3 64.3 49.5 23% DGVANVSIEDR 
                85.6 48.8   HVGDLGNVTAGK 
                87.0 49.4   VISLSGEHSIIGR 
  40S ribosomal protein S13 Mouse P62301  17212 10.5 4 3 78.3 49.6 28% KGLTPSQIGVILR 
                97.3 49.1   LTSDDVKEQIYK 
                58.5 49.4   SKGLAPDLPEDLYHLIK 
  40S ribosomal protein S17 Mouse P63276  15514 9.85 5 3 66.8 48.1 41% DNYVPEVSALDQEIIEVDPDTK 
                97.2 48.4   LLDFGSLSNLQVTQPTVGMNFK 
                66.7 49.9   VCEEIAIIPSK 
  
Ubiquitin-conjugating enzyme E2 
N Mouse P61089  17127 6.13 6 3 58.4 49.4 27% LLAEPVPGIK 
                79.9 49.6   TNEAQAIETAR 
220
 KCL Proteomics Facility, Institute of Psychiatry www.iop.kcl.ac.uk/proteomics 25 
                44.2 48.5   YFHVVIAGPQDSPFEGGTFK 
  40S ribosomal protein S18 Mouse P62270  17708 11 8 2 43.2 49.7 16% SLVIPEKFQHILR 
                77.4 49.3   YSQVLANGLDNK 
  
Low molecular weight 
phosphotyrosine protein 
phosphatase Mouse Q9D358  18180 6.3 3 2 116.9 48.1 18% IDSAATSTYEVGNPPDYR 
                58.3 49.7   IELLGSYDPQK 
  
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial Mouse P19783  19518 9.25 4 2 61.5 48.3 12% SEDYAFPTYADR 
                44.7 48.3   WDYDKNEWK 
  
Glyceraldehyde-3-phosphate 
dehydrogenase Rat P04797  35805 8.14 3 2 41.1 49.4 11% GAAQNIIPASTGAAK 
                110.8 48.2   WGDAGAEYVVESTGVFTTMEK 
  
ATP synthase subunit delta, 
mitochondrial Mouse Q9D3D9  17589 5.03 2 2 79.9 49.2 14% AQSELSGAADEAAR 
                69.3 50.1   IEANEALVK 
  60S ribosomal protein L36 Rat P39032  12260 11.6 4 2 61.7 49.8 12% EELSNVLAAMR 
                42.1 49.6   KREELSNVLAAMR 
  Putative RNA-binding protein 3 Mouse O89086  16595 6.84 4 2 45.0 48.5 19% DYSGSQGGYDR 
                47.3 48.2   GFGFITFTNPEHASDAMR 
  
Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 Mouse Q9QUR7  18359 8.93 2 2 56.5 48.5 21% GQMQKPFEDASFALR 
                70.4 48.8   TGEMSGPVFTDSGIHIILR 
  Peroxiredoxin-5, mitochondrial Mouse P99029  21884 9.1 3 2 51.0 50.1 10% KVNLAELFK 
                59.6 50.0   LLADPTGAFGK 
  Prothymosin alpha Mouse P26350  12247 3.7 2 1 75.1 48.6 13% SDAAVDTSSEITTK 
  Thioredoxin Mouse P10639  11668 4.8 3 1 63.0 49.1 12% EAFQEALAAAGDK 
  
Ubiquitin-conjugating enzyme E2 
variant 1 Mouse Q9CZY3  16344 7.74 3 1 48.6 49.8 7% WTGMIIGPPR 
  Prefoldin subunit 2 Mouse O70591  16524 6.19 2 1 77.2 49.9 8% IIETLSQQLQAK 
  60S acidic ribosomal protein P1 Mouse P47955  11468 4.28 1 1 94.9 47.2 38% ALANVNIGSLICNVGAGGPAPAAGAAPAGGAAPSTAAAPAEEK 
  60S ribosomal protein L23  Muse P62830  14856 10.5 2 1 53.3 49.4 6% ECADLWPR 
221
